SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Unknown status,NCT00438217,CENTRAL PRECOCIOUS PUBERTY,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Center of Pediatric endocrinology, Department of Pediatrics, University of Pisa, Pisa, Italy",A61K38/09,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K38/09,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Recruiting,NCT04094467,PCOS,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ahmed Abbas, Assiut, Cairo, Egypt",A61K38/09,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,NCT00805935,POLYCYSTIC OVARIAN SYNDROME|INFERTILITY,Female,18 Years to 42 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States|Women's Medical Research Group LLC, Florida, Clearwater, Florida, United States|Fertility Center of Illinois, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Women & Infants' Hospital of RI, Providence, Rhode Island, United States|Center for Assisted Reproduction, Bedford, Texas, United States",A61K38/09,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Unknown status,NCT02974270,"PRECOCIOUS PUBERTY, CENTRAL",All,up to 9 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cheol Woo Ko, Daegu, Korea, Republic of",A61K38/09,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,NCT00349258,OVARIAN HYPERSTIMULATION SYNDROME,Female,20 Years to 39 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Center for Advanced Reproductive Services, UCHC, Farmington, Connecticut, United States",A61K38/09,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,NCT00337766,"HEMORRHAGE|BLOOD LOSS, SURGICAL|POSTOPERATIVE HEMORRHAGE",All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy|Istituto Policlinico S.Donato, Milano, Italy|Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia, Milan, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy",C07K7/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,,NOCTURIA,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,,NOCTURNAL ENURESIS,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Recruiting,NCT04094467,PCOS,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ahmed Abbas, Assiut, Cairo, Egypt",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Enrolling by invitation,NCT03763786,INFERTILITY,Female,18 Years to 42 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oxford Fertility, Oxford, United Kingdom",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Unknown status,NCT03477929,INFERTILITY/STERILITY,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale Bernabeo, Ortona, Chieti, Italy",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,OVARIAN HYPERSTIMULATION SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,ASSISTED REPRODUCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,FEMALE INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,FERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00067,__VASOPRESSIN,9375478,Completed,,HEMORRHAGE,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Terminated,NCT00463801,STAPHYLOCOCCAL SKIN INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Italy, Novartis Italy, Italy|Novartis Italy, Saronno, Italy",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00171496,KIDNEY TRANSPLANTATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00171717,MAINTENANCE LIVER TRANSPLANT PATIENTS WITH NEW ONSET DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00171743,LIVER TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Terminated,NCT00150085,TACROLIMUS-ASSOCIATED ABNORMAL GLUCOSE METABOLISM IN KIDNEY AND LIVER TRANSPLANT RECIPIENTS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,NCT01371643,PITUITARY ADENOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"New York University School of Medicine, New York, New York, United States",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00106,__ABARELIX,5843901,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.8242674387564,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,1416.09,424.98,16.0,13.0,6.0,149.31,373.91,38.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Recruiting,NCT04387201,GLUCOSE INTOLERANCE|OVERWEIGHT AND OBESITY|DRUG EFFECT|ADIPOSITY,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",A61K47/186,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C[N+](C)(C)CCO,1,DB00122,__CHOLINE,,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Not Yet Recruiting,,GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",C07K14/672,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Not yet recruiting,NCT04524442,GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Ospedale di Messina, Messina, ME, Italy|Istituto Oncologico Europero Milano, Milan, MI, Italy|Erasmus, Rotterdam, GD, Netherlands",C07K14/672,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Terminated,NCT00569465,TYPE 2 DIABETES MELLITUS|HYPERTENSION,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","""San Giovanni Battista"" Hospital of Turin, Turin, Italy",C07K14/672,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07K14/672,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Completed,,GESTATIONAL DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
NC(=O)CC[C@H](N)C(=O)O,1,DB00130,__L-GLUTAMINE,5288703,Not yet recruiting,NCT03782155,WOUND HEALING|DIABETIC,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital General de México, Mexico City, Mexico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT01768351,ANEMIA|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Terminated,NCT00664430,SECONDARY HYPERPARATHYROIDISM|DIALYSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 7118, Sao Paulo, Brazil|Site Reference ID/Investigator# 7114, Sao Paulo, Brazil",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT00823303,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Northshore University Health System, Evanston, Illinois, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University, St. Louis, Missouri, United States",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Terminated,NCT01725113,KIDNEY FAILURE|SECONDARY HYPERPARATHYROIDISM|HYPERPHOSPHATEMIA|HYPERCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Winthrop University Hospital, Mineola, New York, United States",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT01115543,SECONDARY HYPERPARATHYROIDISM|END STAGE RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Siriraj Medical School, Bangkok-noi, Bangkok, Thailand",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Unknown status,NCT01673204,DIABETIC NEPHROPATHY,All,"19 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening","Seoul National University Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Recruiting,NCT03012529,OSTEOMYELITIS|DIABETES|AMPUTATION,All,"18 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Northern California Health Care System, Mather, CA, Sacramento, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",G01N15/042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,1,DB00146,__CALCIFEDIOL,6582727,Completed,NCT01939977,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",A61K9/4816,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,19.4829462617302,571.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.71,400.6371,40.46,2.0,2.0,3.0,50.32,125.06,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,1,DB00146,__CALCIFEDIOL,6582727,Completed,NCT03588884,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES|VITAMIN D DEFICIENCY|CKD STAGE 3|CKD STAGE 4,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institute of Clinical Research, Inc., Garden Grove, California, United States|Research by Design, LLC, Chicago, Illinois, United States|Spaulding Clinical Research, West Bend, Wisconsin, United States",A61K9/4816,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,19.4829462617302,571.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.71,400.6371,40.46,2.0,2.0,3.0,50.32,125.06,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
CN(CC(=O)O)C(=N)N,1,DB00148,__CREATINE,,Recruiting,NCT03202095,MAJOR DEPRESSIVE DISORDER,Female,20 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Utah, Salt Lake City, Utah, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,131.1332,90.41,5.0,3.0,0.0,12.17,42.01,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
N[C@@H](CS)C(=O)O,1,DB00151,__CYSTEINE,10478453,Completed,NCT02239107,PCOS,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,11.0,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.6,121.15799999999999,63.32,3.0,3.0,0.0,11.41,28.22,2.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,1,DB00152,__THIAMINE,3946115,Unknown status,NCT01725412,DIABETIC NEPHROPATHY,All,30 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Royal University Hospital, Saskatoon, Saskatchewan, Canada",A23K20/158,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,3121.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,265.355,75.91,4.0,2.0,2.0,28.14,73.4,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Completed,NCT00958451,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA Medical Center, Salem, Virginia, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Completed,NCT00288873,VITAMIN D DEFICIENCY|SECONDARY HYPERPARATHYROIDISM|OBESITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Unknown status,NCT01153243,VITAMIN D DEFICIENCY|DIABETES,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K9/1075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Recruiting,NCT02344888,INFERTILITY|POLYCYSTIC OVARIAN SYNDROME,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Dakahlia, Egypt|Private practice settings, Mansourah, Dakahlia, Egypt",A61K9/1694,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Completed,NCT01540747,PCOS,Female,27 Years to 38 Years   (Adult),Other,,"Praxi Pro Vita Centro di Fertilità, Rome, Italy",A61K9/1694,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Completed,NCT01115140,PREGNANCY|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 38 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","""Pugliese"" Hospital, Catanzaro, Italy",A61K9/1694,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Recruiting,NCT03642600,PCOS|OBESITY|METABOLIC SYNDROME,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sharon Lie Fong, Leuven, Vlaams Brabant, Belgium",A61K9/1694,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Unknown status,NCT01921192,NON PROLIFERATIVE DIABETIC RETINOPATHY|PROLIFERATIVE DIABETIC RETINOPATHY,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Catania, Cannizzaro Hospital, Catania, Italy",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Unknown status,NCT01511835,GESTATIONAL DIABETES,Female,20 Years to 45 Years   (Adult),Other,,"AGUNCO, Rome, Italy",A61K9/1694,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,1,DB00159,__ICOSAPENT,4377526,Recruiting,NCT04562467,"CARDIOVASCULAR DISEASES|CARDIOVASCULAR RISK FACTOR|TRIGLYCERIDES HIGH|DIABETES MELLITUS, TYPE 2",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The Oshawa Clinic, Oshawa, Ontario, Canada|Langstaff Medical Clinic, Vaughan, Ontario, Canada",C07C67/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.310375983079698,4159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.53,302.45099999999996,37.3,2.0,1.0,0.0,35.93,101.07,13.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Completed,NCT03112382,"DIABETES MELLITUS, TYPE II",All,20 Years to 64 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,"theoutpatient clinics, department of internal medicine, Cairo University teaching hospitals,, Cairo, Egypt",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Completed,NCT01002547,NONALCOHOLIC STEATOHEPATITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Unknown status,NCT01720719,FATTY LIVER|DYSLIPIDEMIAS|DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Completed,NCT02019186,TYPE 1 DIABETES,All,8 Years to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Completed,NCT00817622,DIABETES,All,30 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Tehran University Of Medical Sciences, Tehran, Iran, Islamic Republic of",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
O=C(O)CCCC[C@@H]1CCSS1,1,DB00166,__LIPOIC_ACID,4100150,Completed,NCT03914404,DIABETIC NEUROPATHY,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Sejong hospital, Bucheon, Gyeonggi, Korea, Republic of|Obesity Research Center of Chonbuk National University, Jeonju, Jeollabuk-do, Korea, Republic of|Dongguk university gyeongju hospital, Gyeongju, North Gyeongsang-do, Korea, Republic of|Soon chun hyang university hospital cheonan, Cheonan, South Chungcheong Province, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Inje university sanggye paik hospital, Seoul, Korea, Republic of|Yonsei univesity severance hospital, Seoul, Korea, Republic of|The catholic university of korea seoul st. mary's hospital, Seoul, Korea, Republic of|The catholic university of korea Yeouido st. mary's hospital, Seoul, Korea, Republic of",C07K14/565,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
O=C(O)CCCC[C@@H]1CCSS1,1,DB00166,__LIPOIC_ACID,4100150,Unknown status,NCT01978405,ACUTE KIDNEY INJURY|THE CHANGES OF PLASMA CREATININE|THE CHANGES OF PLASMA FREE RADICALS|THE CHANGES OF ENDOTHELIUM-DEPENDENT ARTERIAL DILATION,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Wuhan General Hospital, Wuhan, Hubei, China",C07K14/565,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
O=C(O)CCCC[C@@H]1CCSS1,1,DB00166,__LIPOIC_ACID,4100150,Completed,NCT01056497,TYPE 2 DIABETES|PREDIABETES,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Toronto General Hospital, Toronto, Ontario, Canada",C07K14/565,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT03588884,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES|VITAMIN D DEFICIENCY|CKD STAGE 3|CKD STAGE 4,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institute of Clinical Research, Inc., Garden Grove, California, United States|Research by Design, LLC, Chicago, Illinois, United States|Spaulding Clinical Research, West Bend, Wisconsin, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00288873,VITAMIN D DEFICIENCY|SECONDARY HYPERPARATHYROIDISM|OBESITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01390480,TYPE 1 DIABETES,All,"6 Years to 60 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Medical University Graz, Graz, Austria",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01436916,PREDIABETES|VITAMIN D DEFICIENCY,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"PGIMER, Chandigarh, Chandigarh(UT), India",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01538485,IMMUNE TOLERANCE,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Medical university Graz, Graz, Austria",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01431430,RENAL TRANSPLANT CANDIDATE FOR RIGHT KIDNEY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Georges Pompidou European Hospital, Paris, France",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT03648528,VITAMIN D DEFICIENCY|HEMODIALYSIS PATIENT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT02305355,"DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT02754739,DIABETES MELLITUS|PREDIABETIC STATE,All,"20 Years to 79 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Recruiting,NCT01816997,DIABETES,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Taipei Veterans General Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Recruiting,NCT03938389,PREDIABETES|IMPAIRED GLUCOSE TOLERANCE|OBESITY|BLOOD PRESSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00241124,HYPERTENSION,All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Investigative Centers, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Terminated,NCT00171600,HYPERTENSION|EARLY DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00171574,HYPERTENSION|DIABETIC NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Unknown status,NCT01095822,DIABETES,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Dr. Pokov's Polyclinic. 6821 Reisterstown Road Suite 206, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Unknown status,NCT00407680,TYPE 2 DIABETES MELLITUS|HYPERTENSION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kitasato University, 1-15-1 Kitasato Sagamihara, Kanagawa, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00241085,PROTEINURIA|HYPERTENSION|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT01375322,"HYPERTENSION|DIABETES MELLITUS, TYPE 2|ALBUMINURIA",All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00982358,HYPERTENSION|TYPE 2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Ulm, Department of Internal Medicine II, Ulm, Baden-Wuerttemberg, Germany|Charité University Medicine Berlin, Center for Cardiovascular Research, Outpatient Clinic, Berlin, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00239538,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"30 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Green Hospital, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States|Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|Memorial Research Medical Clinic, Long Beach, California, United States|1200, Los Angeles, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|8615, Nuena Park, California, United States|Boehringer Ingelheim Investigational Site, Orange, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|595, San Francisco, California, United States|1805, Stockton, California, United States|Boehringer Ingelheim Investigational Site, Torrance, California, United States|2311, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|6448, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States|Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pinellas Park, Florida, United States|Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States|Herron Medical Center, Ltd., Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Orland Park, Illinois, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Shawnee, Kansas, United States|Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|200, Baltimore, Maryland, United States|Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|12401, St.Louis, Missouri, United States|Boehringer Ingelheim Investigational Site, Missoula, Montana, United States|Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|3, Buffalo, New York, United States|Comprehensive Clinical Research, Berlin, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston Salem, North Carolina, United States|Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|Boehringer Ingelheim Investigational Site, Marion, Ohio, United States|Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|Boehringer Ingelheim Investigational Site, Broomal, Pennsylvania, United States|6605, Bartlett, Tennessee, United States|108, Fayetteville, Tennessee, United States|Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|7777, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, El Paso, Texas, United States|Team Research of Texas, Harker Heights, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|420, Salt Lake City, Utah, United States|20901, Ettrick, Virginia, United States|Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|5000, Miwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, BsAs, Argentina|Boehringer Ingelheim Investigational Site, Coronel Suárez, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Sta. Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Emeritus Research, Malvern, Victoria, Australia|Boehringer Ingelheim Investigational Site, Prahran, Victoria, Australia|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Conquitlam, British Columbia, Canada|Dr. Hugh Tildesley, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, North York, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|Boehringer Ingelheim Investigational Site, Orleans, Ontario, Canada|Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Thunder Bay, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|91 Thomas-Chapais, Boucherville, Quebec, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|Pavillon St. Sacrement, Sainte-Foy, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|c/o Hemodynamics Offices, Saskatoon, Saskatchewan, Canada|Inje University Pusan Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Col. Del Valle, Mexico|Boehringer Ingelheim Investigational Site, Col. Magdalena de las Salinas, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección 16, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Zapopan, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|National Taiwan University Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00550095,MICROALBUMINURIA|PROTEINURIA,All,"35 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site ,, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Unknown status,NCT00202618,HYPERTENSION|DIABETES MELLITUS|ALBUMINURIA,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shiga University of Medical Science, Otsu, Shiga, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00129233,HYPERTENSION|TYPE 2 DIABETES,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00599885,HYPERTENSION|DIABETES|CORONARY ARTERY DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Korea University Anam Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00921570,DIABETES|HYPERTENSION|PROTEINURIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GATA Nephrology, Ankara, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00153023,DIABETIC NEPHROPATHIES|HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Hospital St. Anna, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|University Hospital Vihohrady, Prague 10, Czech Republic|General University Hospital, Prague 2, Czech Republic|District Hospital Tabor, Tabor, Czech Republic|Masaryk Hospital, Usti nad Labem, Czech Republic|Hospital Usti nad Orlici, Usti nad Orlici, Czech Republic|Medical Department, Copenhagen NV, Denmark|Medicinsk afdeling, Fredericia, Denmark|Medicinsk afdeling F, Endokrinologisk, Hiller?d, Denmark|Endokrinologisk afdeling, Hvidovre, Denmark|Medical Department, Roskilde, Denmark|Chu Sud, Amiens, France|Centre Hospitalier, Beauvais, France|Hopital Duchenne, Boulogne sur Mer cedex, France|Hopital Clemenceau, Caen cedex 5, France|Centre Hospitalier, Dunkerque, France|Hopital Albert Michalon, La Tronche, France|Hopital A.Mignot, Le Chesnay, France|Hopital Maison Blanche, Reims, France|Hopital Yves Le Foll, Saint Brieuc cedex 1, France|Hopital Saint Quentin, Saint Quentin, France|Centre Hospitalier, Valenciennes, France|Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|Diabetes Klinik Bad Mergentheim, Bad Mergentheim, Germany|Institut fur Klinische Forschung, Berlin, Germany|Charite Campus Buch, Berlin, Germany|KFH Dialysezentrum, Eberswalde, Germany|Universitatsklinik Heidelberg, Heidelberg, Germany|Boehringer Ingelheim Investigational Site, Karlsruhe, Germany|Institut fur Klinische Forschung, Mainz, Germany|Boehringer Ingelheim Investigational Site, Munster, Germany|Boehringer Ingelheim Investigational Site, Neuwied, Germany|Boehringer Ingelheim Investigational Site, Pirna, Germany|Boehringer Ingelheim Investigational Site, Riesa, Germany|Boehringer Ingelheim Investigational Site, Rosenheim, Germany|Boehringer Ingelheim Investigational Site, Saarbrucken, Germany|Boehringer Ingelheim Investigational Site, Saarlouis, Germany|Boehringer Ingelheim Investigational Site, Sinsheim, Germany|Boehringer Ingelheim Investigational Site, Speyer, Germany|Internist, Wurzburg, Germany|Azienda Ospedaliera Policlinico S. Orsola Malpighi, Bologna, Italy|Ospedali Riuniti di Livorno, Livorno, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Italy|Universita degli Studi ""Federico II"", Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IRCCS Policlinico S.Matteo, Pavia, Italy|Policlinico Monteluce, Perugia, Italy|Azienda Ospedaliera S. Maria degli Angeli, Pordenone, Italy|Ospedale ""S. Maria delle Croci"", Ravenna, Italy|Universita Tor Vergata, Roma, Italy|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Yonsei University Medical Center, Seoul, Korea, Republic of|Hospital Ipoh, Ipoh, Perak, Malaysia|University Sains Malaysia, Kelantan, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Penang General Hospital, Penang, Malaysia|Hospital Putrajaya, Selangor, Malaysia|Centro Hospitalar de Coimbra, Coimbra, Portugal|Hospital Distrital de Faro, Faro, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Hospital de Santa Marta, Lisboa, Portugal|Associac?o Protectora dos Diabeticos de Portugal, Lisboa, Portugal|Hospital Curry Cabral, Lisbon, Portugal|Hospital Pedro Hispano, Matosinhos, Portugal|Hospital de S. Jo?o, Porto, Portugal|Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Medical Academy named Sechenova I.M., Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|National Endocrinology Research Center of Russia, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|President's Medical Center, Moscow, Russian Federation|Russian Cardiology Research Center, Moscow, Russian Federation|Russian Academy for Advanced Medical Studies, Moscow, Russian Federation|Moscow President's Medical Center, Moscow, Russian Federation|Regional Clinical Scientific Research Institute, Moscow, Russian Federation|City Hospital of Saint Elizaveta, St. Petersburg, Russian Federation|Military Medical Academy, St. Petersburg, Russian Federation|NovaMed, Banska Bystrica, Slovakia|Ministry Hospital of Internal Affairs, Bratislava, Slovakia|Faculty Hospital, Bratislava, Slovakia|Faculty Hospital of L. Derer, Bratislava, Slovakia|Diabetologic and Internal Clinic, Lucenec, Slovakia|Faculty Hospital, Nitra, Slovakia|Hospital Nove Mesto, Nove Mesto, Slovakia|Regional Hospital Nove Zamky, Nove Zamky, Slovakia|MSP-DIAGNOSTIK, Ltd., Trencin, Slovakia|Faculty Hospital Trnava, Trnava, Slovakia|Hospital Torrecardenas, Almeria, Spain|Hospital Ntra. Sra de Sonsoles, Avila, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital de Cabuenes, Gijon, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Buddhist Tzu Chi Hospital, Hualien City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chi Mei Medical Center, Taiwan, Taiwan|Dnyepropyetrovsk Medical Academy, Dnyepropetrovsk, Ukraine|Kharkiv Medical State University, Kharkov, Ukraine|Institute of Diabetic pathology problems, Kharkov, Ukraine|Institute of Cardiology, Kiev, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism, Kiev, Ukraine|Kyiv Clinical Hospital No. 1, Kyiv, Ukraine|Zaporozhye Regional Clinical Hospital, Zaporozhye, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,NCT00240422,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Lyon, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Friedrich-Alexander-Universität, Erlangen, Germany|Boehringer Ingelheim Investigational Site, Nürnberg, Germany|Universität Erlangen-Nürnberg, Nürnberg, Germany|Edificio de Medicina Comunitaria, Madrid, Spain",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Unknown status,NCT01743014,DIABETES TYPE 2|DIABETIC NEPHROPATHY|VASCULAR DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AHEPA University Hospital, Thessaloniki, Greece|Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Unknown status,NCT01038895,HYPERTENSION|TYPE 2 DIABETES,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pavia, Pavia, PV, Italy",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,NCT00674596,DIABETES|PROTEINURIA|RENIN ANGIOTENSIN SYSTEM,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Prevention,"Gulhane School of Medicine, Ankara, Turkey",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,NCT01703234,PROTEINURIA|DIABETIC NEPHROPATHY|CHRONIC KIDNEY DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Gulhane School of Medicine, Ankara, Turkey",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,ALBUMINURIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Completed,NCT00365508,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States|Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Nashville General Hospital at Meharry, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(C)(N)Cc1ccccc1,1,DB00191,__PHENTERMINE,6071537,Recruiting,NCT04531176,TYPE 2 DIABETES|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,35.4504199264872,1351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.32,149.2328,26.02,1.0,1.0,1.0,17.87,48.34,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(N)Cc1ccccc1,1,DB00191,__PHENTERMINE,6071537,Completed,,"OBESITY, CHILDHOOD",,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,35.4504199264872,1351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.32,149.2328,26.02,1.0,1.0,1.0,17.87,48.34,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00634543,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Withdrawn,NCT01116531,DIABETIC POLYNEUROPATHY|POSTHERPETIC NEURALGIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,"Active, not recruiting",NCT03469310,THYROID CANCER|THYROID NODULE|THYROID NEOPLASMS|THYROID GOITRE|THYROID DISEASES|PARATHYROID DISEASES|PARATHYROID ADENOMA|PARATHYROID HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"GME General Surgery Clinic, Edinburg, Texas, United States",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02246712,NEUROPATHIC PAIN|TYPE 1 DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Estadual Paulista Julio de Mesquita Filho, Araraquara, SP, Brazil",A61K9/2081,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2081,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(O)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,1,DB00200,__HYDROXOCOBALAMIN,5834448,Completed,,VITAMIN B12 DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/19,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,23.8526458448838,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-14.0,1346.3551,437.23,14.0,10.0,12.0,135.56,340.03,16.0,1.0,0.0,0.0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Not yet recruiting,NCT04243850,"DIABETES MELLITUS, TYPE 2|CHRONIC KIDNEY DISEASES",All,"45 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00512707,ERECTILE DYSFUNCTION|TESTOSTERONE DEFICIENCY|DIABETES,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Boston University Medical Center, Boston, Massachusetts, United States",C07D487/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00645268,"ERECTILE DYSFUNCTION|DIABETES MELLITUS, TYPE 2",Male,"35 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Duarte, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Laguna Woods, California, United States|Pfizer Investigational Site, LaJolla, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, New Albany, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Richmond Heights, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Medford, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Calgary, Canada",C07D487/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00692237,"DIABETES MELLITUS, TYPE 2|ENDOTHELIAL DYSFUNCTION",Male,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dipartimento di Fisiopatologia Medica - Policlinico Umberto I, Rome, Italy",C07D487/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00194909,DIABETIC NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peripheral Neuropathy Center - Weill Cornell Medical College, New York, New York, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Active Not Recruiting,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,,LEFT VENTRICULAR DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Unknown status,NCT02649465,NON-ALCOHOLIC FATTY LIVER DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Disease Control and Homeostasis, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT01890629,TYPE 2 DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Severance hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT02471404,TYPE 2 DIABETES MELLITUS|INADEQUATE GLYCAEMIC CONTROL,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Prelouc, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Neuenahr-Ahrweiler, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Bünde, Germany|Research Site, Daaden, Germany|Research Site, Darmstadt, Germany|Research Site, Datteln, Germany|Research Site, Deggingen, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Gelnhausen, Germany|Research Site, Giengen, Germany|Research Site, Goch, Germany|Research Site, Grevesmühlen, Germany|Research Site, Grossheirath, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hameln, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildesheim, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Höhenkirchen, Germany|Research Site, Jerichow, Germany|Research Site, Kallstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köln, Germany|Research Site, Köthen, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lichtenfels, Germany|Research Site, Lingen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Löhne, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marl, Germany|Research Site, Meine, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf A. Inn, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Neuwied Am Rhein, Germany|Research Site, Oldenburg, Germany|Research Site, Papenburg, Germany|Research Site, Pirna, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Rehlingen Siersburg, Germany|Research Site, Reinfeld, Germany|Research Site, Remagen, Germany|Research Site, Rhaunen, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Saarlouis, Germany|Research Site, Schwabenheim, Germany|Research Site, Speyer, Germany|Research Site, Stadtbergen, Germany|Research Site, Stolberg, Germany|Research Site, Straubing, Germany|Research Site, Stuttgart, Germany|Research Site, Sulzbach, Germany|Research Site, Trier, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wahlstedt, Germany|Research Site, Wangen, Germany|Research Site, Weinheim, Germany|Research Site, Westerkappeln, Germany|Research Site, Wetzlar, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hatvan, Hungary|Research Site, Kisvárda, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza-Szentetornya, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ács, Hungary|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chrzanow, Poland|Research Site, Gdańsk, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Legnica, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznan, Poland|Research Site, Sobótka, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Vrutky, Slovakia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Unknown status,NCT02462369,MICROALBUMINURIA|MICROALBUMINURIA /CREATININE RATIOS ACR,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Not yet recruiting,NCT04528212,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tanta University Hospital, Tanta, El-Gharbia, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT00318656,NON-INSULIN-DEPENDENT DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Terminated,NCT02373865,DIABETES MELLITUS TYPE 2,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Terminated,NCT02985242,"DIABETES MELLITUS, TYPE II",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT01429818,ENDOTHELIAL DYSFUNCTION|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Unidad PET Ciclotrón. Facultad de Medicina. Universidad Nacional Autónoma de México, Mexico city, Distrito Federal, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT00619697,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Ebreichsdorf, Austria|Novo Nordisk Investigational Site, Feldkirch, Austria|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Horn, Austria|Novo Nordisk Investigational Site, Oberpullendorf, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Villach, Austria|Novo Nordisk Investigational Site, Waidhofen a.d. Thaya, Austria|Novo Nordisk Investigational Site, Brno, Czech Republic|Novo Nordisk Investigational Site, Liberec, Czech Republic|Novo Nordisk Investigational Site, Augsburg, Germany|Novo Nordisk Investigational Site, Castrop-Rauxel, Germany|Novo Nordisk Investigational Site, Deggingen, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Erlangen, Germany|Novo Nordisk Investigational Site, Eschweiler, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Fulda, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Herne, Germany|Novo Nordisk Investigational Site, Kippenheim, Germany|Novo Nordisk Investigational Site, Lauffen, Germany|Novo Nordisk Investigational Site, Leverkusen, Germany|Novo Nordisk Investigational Site, Ludwigsburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Mannheim, Germany|Novo Nordisk Investigational Site, Mannheim, Germany|Novo Nordisk Investigational Site, Marburg, Germany|Novo Nordisk Investigational Site, Marburg, Germany|Novo Nordisk Investigational Site, Mülheim, Germany|Novo Nordisk Investigational Site, Neunkirchen, Germany|Novo Nordisk Investigational Site, Ostercappeln, Germany|Novo Nordisk Investigational Site, Pritzwalk, Germany|Novo Nordisk Investigational Site, Rosenheim, Germany|Novo Nordisk Investigational Site, Viernheim, Germany|Novo Nordisk Investigational Site, Weil der Stadt, Germany|Novo Nordisk Investigational Site, Weiskirchen, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Eger, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Czestochowa, Poland|Novo Nordisk Investigational Site, Gdynia, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Otwock, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, L'ubochna, Slovakia|Novo Nordisk Investigational Site, Martin, Slovakia|Novo Nordisk Investigational Site, Celje, Slovenia|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Maribor, Slovenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT01812122,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Recruiting,NCT04183868,TYPE 2 DIABETES|CARDIOVASCULAR RISK FACTOR,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Universital Hospital Mater Domini, Catanzaro, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Unknown status,NCT01565096,DIABETES MELLITUS TYPE II,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ikfe GmbH, Mainz, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT02973477,TYPE2 DIABETES|CARDIOVASCULAR DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Michigan, Ann Arbor, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT00576784,TYPE 2 DIABETES MELLITUS|INSULIN RESISTANCE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IKFE, Mainz, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Unknown status,NCT02528019,EFFECTS OF THE DPP-4 INHIBITORS OR SGLT2 INHIBITORS ON THE PROTECTIVE ACTIONS FOR DIABETIC COMPLICATIONS,All,"30 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kurume University Hospital, Kurume city, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT00633425,DIABETES,All,"35 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis, Paris, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT03693560,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"25 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Pharmacy - Damanhour University., Damanhūr, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Completed,NCT02007278,TYPE 2 DIABETES|HYPOGLYCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Medellín, Antioquia, Colombia|Novartis Investigative Site, Manizales, Caldas, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Chía, Cundinamarca, Colombia|Novartis Investigative Site, Cali, Valle del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Monteria, Colombia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Recruiting,NCT04246619,PAINFUL DIABETIC PERIPHERAL NEUROPATHY,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Opća bolnica Karlovac, Karlovac, Croatia|Clinical Medical Center Osijek, Osijek, Croatia|KB Merkur, Sveučilišna klinika Vuk Vrhovac, Zagreb, Croatia|Klinička bolnica Sveti Duh, Zagreb, Croatia|JZU Univerzitetska klinika za endokrinologija, dijabetes I metabolicki bolesti - Skopje, Skopje, North Macedonia|JZU Univerzitetska klinika za nevrologija, Skopje, North Macedonia|Gabinet Neurologiczny, prof. Adam Stępień, Warszawa, Poland|Poradnia neurologiczna, Centrum terapii dzieci i Dorosłych FIMEDICA Sp. z o.o., Warszawa, Poland|Klinički centar Srbije, Belgrade, Serbia|Klinički centar Niš, Niš, Serbia|Klinički centar Vojvodine, Novi Sad, Serbia|Zdravstveni dom Koper, Koper, Slovenia|Clemenz Marjetka - Nevrološka Ordinacija, Ljubljana, Slovenia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT02417935,DIABETIC PERIPHERAL NEUROPATHIC PAIN,All,"20 Years to 79 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Withdrawn,NCT01116531,DIABETIC POLYNEUROPATHY|POSTHERPETIC NEURALGIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00385671,"DIABETIC NEUROPATHY, PAINFUL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cromwell, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midvale, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Terminated,NCT01768988,PANCREATIC CANCER|VISCERAL PAIN,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital del Mar, Barcelona, Spain",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Unknown status,NCT01770964,DIABETES MELLITUS|PAINFUL DISTAL SYMMETRIC SENSORIMOTOR POLYNEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","St. Elizabeth's Medica Center, Brighton, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Neuro Care Medical Associates, Johnson City, New York, United States|University of Rochester, Rochester, New York, United States|Blair Medical Associates, Inc., Altoona, Pennsylvania, United States|Clinical Partners, Johnston, Rhode Island, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00573261,DIABETIC NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Medical Center, Durham, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00159731,DIABETIC PERIPHERAL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Hot Springs, Arkansas, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Torrance, California, United States|Pfizer Investigational Site, Torrance, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Palm Beach Gardens, Florida, United States|Pfizer Investigational Site, Sunrise, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Englewood, New Jersey, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00629681,PAINFUL DIABETIC NEUROPATHY AND POST HERPETIC NEURALGIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Aachen, Germany|Pfizer Investigational Site, Albstadt, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bielefeld, Germany|Pfizer Investigational Site, Celle, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Duisburg, Germany|Pfizer Investigational Site, Erbach, Germany|Pfizer Investigational Site, Erfurt, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Gera, Germany|Pfizer Investigational Site, Goeppingen, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hemsbach, Germany|Pfizer Investigational Site, Hildesheim, Germany|Pfizer Investigational Site, Holle, Germany|Pfizer Investigational Site, Itzehoe, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Katzhuette, Germany|Pfizer Investigational Site, Leer, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Limburgerhof, Germany|Pfizer Investigational Site, Ludwigshafen, Germany|Pfizer Investigational Site, Ludwigshafen, Germany|Pfizer Investigational Site, Luebeck, Germany|Pfizer Investigational Site, Luenen, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Marl, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenster, Germany|Pfizer Investigational Site, Osnabrueck, Germany|Pfizer Investigational Site, Recklinghausen, Germany|Pfizer Investigational Site, Senftenberg, Germany|Pfizer Investigational Site, Sinsheim, Germany|Pfizer Investigational Site, Surwold, Germany|Pfizer Investigational Site, Unterhaching, Germany|Pfizer Investigational Site, Veitsbronn, Germany|Pfizer Investigational Site, Weimar, Germany|Pfizer Investigational Site, Wiesbaden, Germany|Pfizer Investigational Site, Witten, Germany|Pfizer Investigational Site, Zwoenitz, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,"Active, not recruiting",NCT03088410,HIV|INSULIN SENSITIVITY|DIABETES MELLITUS,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana",C07D471/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,1,DB00243,__RANOLAZINE,6303607,Withdrawn,NCT01334203,ANGINA PECTORIS|CORONARY ARTERY DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,1,DB00243,__RANOLAZINE,6303607,Terminated,NCT02156336,DIABETIC PERIPHERAL NEUROPATHIC PAIN,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cardiology Associates, Fairhope, Alabama, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Cardiovascular Institute of the South, Lafayette, Louisiana, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
Nc1ccc(O)c(C(=O)O)c1,1,DB00244,__MESALAZINE,5541170,Unknown status,NCT01789294,INTESTINAL LNH,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Departments of Pediatrics, Sapienza - University of Rome, Rome, Italy",A61K9/2846,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.690281114601902,1899.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.75,153.1354,83.55,4.0,3.0,1.0,14.26,40.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,1,DB00246,__ZIPRASIDONE,5134127,Completed,NCT01714011,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University Malaya Medical Centre, Kuala Lumpur, Malaysia",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,121.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.64,412.936,48.47,4.0,1.0,5.0,44.96,116.72,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1
O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,1,DB00246,__ZIPRASIDONE,5134127,Completed,NCT01185743,SCHIZOPHRENIA|DIABETES,Male,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Medical University of Vienna, Vienna, Austria",B82Y5/00,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,121.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.64,412.936,48.47,4.0,1.0,5.0,44.96,116.72,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,Recruiting,,FEMALE INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01798225,PERIODONTAL DISEASE|TYPE 2 DIABETES MELLITUS,All,"13 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01375491,TYPE 2 DIABETES|OBESITY,All,18 Years to 60 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California San Diego Clinical trials Research Institute, La Jolla, California, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1,DB00257,__CLOTRIMAZOLE,4073901,Unknown Status,,MELASMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,25.0354216719029,1845.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.48,344.837,17.82,1.0,0.0,4.0,36.25,103.76,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0
CC(=O)[O-].CC(=O)[O-].[Ca+2],1,DB00258,__CALCIUM_ACETATE,6576665,Completed,NCT00211939,"CALCINOSIS|ARTERIOSCLEROSIS|HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Sciences Center, San Antonio, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,26.2181974989219,5.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.24,158.166,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00744237,HYPERTENSION|TYPE 2 DIABETES,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Forest Investigative Site 15, Athens, Alabama, United States|Forest Investigative Site 16, Huntsville, Alabama, United States|Forest Investigative Site 35, Bell Gardens, California, United States|Forest Investigative Site, Buena Park, California, United States|Forest Investigative Site 54, Chino, California, United States|Forest Investigative Site 40, Fremont, California, United States|Forest Investigative Site, Palm Springs, California, United States|Forest Investigative Site, Pomona, California, United States|Forest Investigative Site 55, Sacramento, California, United States|Forest Investigative Site 11, San Diego, California, United States|Forest Investigative Site, Santa Monica, California, United States|Forest Investigative Site, Spring Valley, California, United States|Forest Investigative Site 49, Tustin, California, United States|Forest Investigative Site 47, Walnut Creek, California, United States|Forest Investigative Site 61, Golden, Colorado, United States|Forest Investigative Site, Wheat Ridge, Colorado, United States|Forest Investigative Site 3, Daytona Beach, Florida, United States|Forest Investigative Site 33, DeLand, Florida, United States|Forest Investigative Site 36, Hollywood, Florida, United States|Forest Investigative Site 62, Miami, Florida, United States|Forest Investigative Site 080, Miami, Florida, United States|Forest Investigative Site 59, Miami, Florida, United States|Forest Investigative Site 32, Pembroke Pines, Florida, United States|Forest Investigative Site 081, Pembroke Pines, Florida, United States|Forest Investigative Site 2, Tamarac, Florida, United States|Forest Investigative Site, Tampa, Florida, United States|Forest Investigative Site 19, West Palm Beach, Florida, United States|Forest Investigative Site 44, Atlanta, Georgia, United States|Forest Investigative Site 5, Augusta, Georgia, United States|Forest Investigative Site 56, Honolulu, Hawaii, United States|Forest Investigative Site 57, Meridian, Idaho, United States|Forest Investigative Site 39, Chicago, Illinois, United States|Forest Investigative Site 37, Wichita, Kansas, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site 20, Baltimore, Maryland, United States|Forest Investigative Site 50, Oxon Hill, Maryland, United States|Forest Investigative Site 21, St. Clair Shores, Michigan, United States|Forest Investigative Site, Kansas City, Missouri, United States|Forest Investigative Site, St. Louis, Missouri, United States|Forest Investigative Site, New Hyde Park, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site 7, Charlotte, North Carolina, United States|Forest Investigative Site 45, Charlotte, North Carolina, United States|Forest Investigative Site 24, Morehead City, North Carolina, United States|Forest Investigative Site 26, Salisbury, North Carolina, United States|Forest Investigative Site 18, Wilmington, North Carolina, United States|Forest Investigative Site 51, Centerville, Ohio, United States|Forest Investigative Site 48, Cincinnati, Ohio, United States|Forest Investigative Site 12, Wadsworth, Ohio, United States|Forest Investigative Site 17, Charleston, South Carolina, United States|Forest Investigative Site 46, Columbia, South Carolina, United States|Forest Investigative Site, North Charleston, South Carolina, United States|Forest Investigative Site, Simpsonville, South Carolina, United States|Forest Investigative Site 4, Sioux Falls, South Dakota, United States|Forest Investigative Site 10, New Tazewell, Tennessee, United States|Forest Investigative Site 52, Corpus Christi, Texas, United States|Forest Investigative Site 28, Dallas, Texas, United States|Forest Investigative Site 38, Hurst, Texas, United States|Forest Investigative Site 34, Salt Lake City, Utah, United States|Forest Investigative Site, St. George, Utah, United States|Forest Investigative Site, Norfolk, Virginia, United States|Forest Investigative Site 31, Virginia Beach, Virginia, United States|Forest Investigative Site 41, Ponce, Puerto Rico|Forest Investigative Site 60, Salinas, Puerto Rico|Forest Investigative Site 29, Santurce, Puerto Rico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00642434,DIABETES,All,"45 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","UNMHSC, Albquerque, New Mexico, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00060918,HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Burlingame, California, United States|GSK Investigational Site, Concord, California, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Hemet, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Pasadena, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Luis Obispo, California, United States|GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Golden, Colorado, United States|GSK Investigational Site, Panama City, Florida, United States|GSK Investigational Site, St. Petersburg, Florida, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Idaho Falls, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, O'Fallon, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Oak Park, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Oregon City, Oregon, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Georgetown, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Colony, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Renton, Washington, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Unknown status,NCT00732511,ENDOTHELIAL FUNCTION|DIABETES MELLITUS|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"SUNY Downstate Medical Center, Brooklyn, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00497003,ENDOTHELIAL FUNCTION|BETA BLOCKER,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Cardiology, University Hospital of Copenhagen, Bispebjerg, Copenhagen, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Enrolling by Invitation,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Recruiting,NCT04453306,OBESITY|POLYCYSTIC OVARY SYNDROME|HYPERANDROGENISM,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",3,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Recruiting,NCT04531176,TYPE 2 DIABETES|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT00454662,HYPERTENSION|CARDIOVASCULAR DISEASE|DIABETES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"COLM-Study Data Center, Kamiyacho MT Bld.14F, 4-3-20 Toranomon Minato-ku, Tokyo, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT00134160,HYPERTENSION|CARDIOVASCULAR DISEASES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University, 1-1-1 Honjyo, Kumamoto-City, Kumamoto, Japan|OSCAR-Study Data Center, ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT00654745,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Sylmar, California, United States|Tustin, California, United States|Aventura, Florida, United States|DeLand, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Las Vegas, Nevada, United States|New Windsor, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Taylors, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT00403481,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Mesa, Arizona, United States|Searcy, Arkansas, United States|Los Angeles, California, United States|Roseville, California, United States|Tustin, California, United States|Deland, Florida, United States|Pembroke Pines, Florida, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Jackson, Mississippi, United States|Florissant, Missouri, United States|Williamsville, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|New Talenwell, Tennessee, United States|New Tazewell, Tennessee, United States|Colleyville, Texas, United States|Corpus Christi, Texas, United States|Richardson, Texas, United States|Murray, Utah, United States|Norfolk, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT01684748,OVERWEIGHT|OBESE|PREHYPERTENSION|HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT04238208,DIABETIC NERVE PROBLEMS|DIABETIC NEUROPATHY|DIABETIC COMPLICATIONS NEUROLOGICAL,Male,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zainab Khan, Lahore, Punjab, Pakistan",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02479789,THYROIDECTOMY|NERVE MONITORING,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Health and Wellness Center- Bronx Lebanon Hospital Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT02500329,ENDOTHELIAL FUNCTION|TYPE 2 DIABETES|GEMIGLIPTIN|ACARBOSE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boramae medical center, Seoul, Korea, Republic of",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT02605772,TYPE 2 DIABETES,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Terminated,NCT02072096,"DIABETES MELLITUS, TYPE 2",All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Florida Hospital, Orlando, Florida, United States|Athens Primary Care, Athens, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iderc, P.L.C., Des Moines, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Mercy Health Research, Saint Louis, Missouri, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Carolina Health Specialists, Myrtle Beach, South Carolina, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Stefan Ob Stainz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dortmund, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stuttgart, Germany|Manati Medical Center, Manati, Puerto Rico|American Telemedicine Center, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dundee, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ipswich, Suffolk, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Not yet recruiting,NCT03602638,ATHEROSCLEROSIS TYPE 2 DIABETES MELLITUS DIPEPTIDYL PEPTIDASE-4 INHIBITOR GLP-1,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Completed,NCT01863147,NEWLY DIAGNOSED TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"55 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangda Xiang, Wuhan, Hubei, China|Wuhan General Hospital, Wuhan, Hubei, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Completed,NCT01279512,PCOS,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Royan Institute, Tehran, Iran, Islamic Republic of",7,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT03383068,PCOS|IMPAIRED GLUCOSE TOLERANCE,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China",7,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT01175486,DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Completed,NCT01244971,DIABETES MELLITUS TYPE 2,All,45 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital, Stockholm, Sweden",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT02999841,"DIABETES MELLITUS, TYPE 2|OBESITY",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Pinggu Hospital, Beijing, Beijing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Completed,NCT00437918,DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea, Republic of|Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT00858676,DIABETES MELLITUS|IMPAIRED GLUCOSE TOLERANCE|CORONARY ARTERY DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University, Nagoya, Japan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Completed,NCT00829660,CORONARY HEART DISEASE|ACUTE CORONARY SYNDROME|IMPAIRED GLUCOSE TOLERANCE|TYPE 2 DIABETES MELLITUS (T2DM),All,"50 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Chuiyangliu Hospital, Beijing, Beijing, China|China Meitan General Hospital, Beijing, Beijing, China|Beijing Anzhen Hospital of The Capital University of Medical Sciences, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Beijing Ji Shui Tan Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Fu Xing Hospital, Beijing, Beijing, China|Beijing Shijingshan Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Aerospace Central Hospital, Beijing, Beijing, China|Affiliated to The Capital University of Medical Sciences Beijing Friendship Hospital, Beijing, Beijing, China|Wangjing Hospital of CACMS, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|Beijing Healthy Palace Hospital, Beijing, Beijing, China|Aerospace 731 Hospital, Beijing, Beijing, China|General Hospital of Second Artillery PLA, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|PLA General Hospital, Beijing, Beijing, China|Anzhen Hospital of The Capital University of Medical Sciences 2nd., Beijing, Beijing, China|Beijing Pinggu Hospital, Beijing, Beijing, China|Beijing Yanhua Hospital, Beijing, Beijing, China|Chongqing Medical University Second Afflicated Hospital, Chongqing, Chongqing, China|Chongqing Zhongshan Hospital, Chongqing, Chongqing, China|Chongqing Third People's Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Da Ping Hospital, Chongqing, Chongqing, China|The Second People's Hospital of Chongqing, Chongqing, Chongqing, China|Fujian Provincial Hospital, Fuzhou, Fujian, China|Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China|The People's Hospital of Fujian Province, Fuzhou, Fujian, China|The First Hospital of Xiamen, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China|Wu Jing Zhong Dui Hospital of Guangdong Province, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Zhong Shan City People's Hospital, Zhongshan, Guangdong, China|The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China|Liuzhou Worker's Hospital, Liuzhou, Guangxi, China|Liuzhou People's Hospital, Liuzhou, Guangxi, China|Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|303 Hospital of People's Liberation Army, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Bethune International Peace Hospital, Shijiazhuang, Hebei, China|Tangshan Workers Hospital, Tangshan, Hebei, China|The Affiliated Hospital of North China Coal Medical University, Tangshan, Hebei, China|Yu Tian County Hospital, Tangshan, Hebei, China|The Third Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China|Da Qing Oilfield General Hospital, Da Qing, Heilongjiang, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan Science & Technology University, Luoyang, Henan, China|Luo Yang Central Hospital, Affiliated to Zhengzhou University, Luoyang, Henan, China|The First Affiliated Hospital of Henan College of TCM, Zhengzhou, Henan, China|The People's Hospital of Zhengzhou, Zhengzhou, Henan, China|The Second Affiliated Hospital of Zhengzhou University, ZhengZhou, Henan, China|Union Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Tongji Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Pu'ai Hospital of Wuhan City, Wuhan, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Fourth Hospital of Changsha, Changsha, Hunan, China|Xiangya Hospital Central-South University, Changsha, Hunan, China|The Third Hospital of Changsha, Changsha, Hunan, China|The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Baotou Central Hospital, Baotou, Inner Mongolia, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China|Inner Mongolia Hospital, Hohhot, Inner Mongolia, China|81st Hospital of Chinese PLA, NanJing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Nanjing Zhongda Hospital, Nanjing, Jiangsu, China|BENQ Hospital, Nanjing, Jiangsu, China|Jiangsu Province Official Hospital, NanJing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jiangsu Provincial Hospital of TCM, NanJing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Wuxi No.3 People's Hospital, Wuxi, Jiangsu, China|Hospital Affiliated Xuzhou Medical University, Xuzhou, Jiangsu, China|The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China|Jiujiang University Hospital, Jiujiang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|The Central Hospital of Anshan, Anshan, Liaoning, China|Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|The First Hospital of Dalian Medical University, Dalian, Liaoning, China|Dalian Central Hospital, Dalian, Liaoning, China|Xianyang Central Hospital, Shengyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The People's Hospital of Liaoning Province, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The Fourth Hospital of China Medical University, Shenyang, Liaoning, China|The First Hospital of Yinchuan, Yinchuan, Ningxia, China|Affiliated Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China|Xi'an Central Hospital, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Affiliated Hospital of Xi'an Medical college, Xi'an, Shaanxi, China|Affiliated Hospital of Yan'an University, Yan'an, Shaanxi, China|Yan'an People's Hospital, Yanan, Shaanxi, China|The First Hospital of Yulin, Yulin, Shaanxi, China|The Central Hospital of Jinan, Jinan, Shandong, China|The First People's Hospital of Jinan, Jinan, Shandong, China|The General Hospital of Jinan Military Region, Jinan, Shandong, China|Linyi People's Hospital, Linyi, Shandong, China|Hospital Affiliated of Medical School, Qingdao University, Qingdao, Shandong, China|The Qingdao Municiple Hospital, Qingdao, Shandong, China|Qingdao Fuwai Hospital, Shibei, Shandong, China|Taian City Central Hospital, Taian, Shandong, China|Shanghai Ninth People's Hospital, Shanghai, Shanghai, China|Ruijin Hospital Affiliated to the Shanghai Jiaotong University Medical School, Shanghai, Shanghai, China|Shanghai Central Hospital of Xuhui District, Shanghai, Shanghai, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China|Shanghai Huadong Hospital, Shanghai, Shanghai, China|Shanghai Putuo District People's Hospital, Shanghai, Shanghai, China|Putuo District Center Hospital, Shanghai, Shanghai, China|Tongji Hospital of Tongji University, Shanghai, Shanghai, China|Shanghai Tenth People's Hospital, Shanghai, Shanghai, China|Number 411 Hospital of PLA, Shanghai, Shanghai, China|Shanghai Central Hospital of Yangpu District, Shanghai, Shanghai, China|Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai East Hospital, Shanghai, Shanghai, China|Renji Hospital Affilicated to Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Pudong New Area Gongli Hospital, Shanghai, Shanghai, China|Changhai Hospital, Shanghai, Shanghai, China|Shanghai Zhabei District Shibei Hospital, Shanghai, Shanghai, China|Shanghai Jinshan Hospital, Shanghai, Shanghai, China|Shanghai Pudong New District People's Hospital, Shanghai, Shanghai, China|General Hospital of Tisco, Taiyuan, Shanxi, China|The Third Engineering Bureau Hospital of Ministry of Railway, Taiyuan, Shanxi, China|Taiyuan City Central Hospital, Taiyuan, Shanxi, China|Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China|PLA No.323 Hospital, Xi'an, Shanxi, China|Chengdu First People's Hospital, Chengdu, Sichuan, China|Chengdu Second People's Hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|The West China Hospital, Chengdu, Sichuan, China|Sichuan Mianyang 404 Hospital, Sichuan, Sichuan, China|Tianjin Union Hospital, Tianjin, Tianjin, China|Tianjin Chest Hospital, Tianjin, Tianjin, China|Tianjin Union Medicine Centre, Tianjin, Tianjin, China|Army Police's Medical College Affiliated Hospital, Tianjin, Tianjin, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|Tianjin First Center Hospital, Tianjin, Tianjin, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Dagang Oil-Field General Hospital, Tianjin, Tianjin, China|The Fifth Central Hospital of Tianjin, Tianjin, Tianjin, China|First Affiliated Hospital of the Medical College, Shihezi, Xinjiang, China|Xin Jiang Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China|General Hospital of Xinjiang Production and Construction Corps, Urumqi, Xinjiang, China|The 474th Hospital of PLA, Urumqi, Xinjiang, China|The First Teaching Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|The First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|People's Hospital of Yuxi City, Yuxi, Yunnan, China|Zhe Jiang Hospital, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital Affiliated With School of Medicine, Zhe Jiang University, Hangzhou, Zhejiang, China|Prince of Wales Hospital, Hong Kong, Hong Kong",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,Completed,NCT00451776,CARDIAC SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University hospital, Saint-Etienne, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,Completed,NCT00415701,CORONARY ARTERY DISEASE|MITRAL VALVE REGURGITATION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departments of Intensive Care Medicine and Anesthesiology, Bern, BE, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,Completed,NCT02027311,CHOLEDOCHOLITHIASIS|CHOLANGIOCARCINOMA|PANCREATITIS|PANCREATIC CANCER,All,"20 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital, Jeju-si, Jeju Special Self-Governing Province, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,1,DB00294,__ETONOGESTREL,5150718,Recruiting,NCT04257500,PCOS,Female,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,7.490913571120548,417.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,324.4565,37.3,2.0,1.0,4.0,37.77,96.35,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,1
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT01704612,DIABETES TYPE 2,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP Pitié-Sampetriere, Paris, France",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT04082676,MATERNAL HYPOTENSION AFTER SPINAL ANESTHESIA,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Koshi, Nepal",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT00740116,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dept of Obstetric and Gynecology, Ryhov Central Hospital, Jönköping, Sweden|Department of Obstetrics and Gynecology, Kalmar Central Hospital, Kalmar, Sweden|University Hospital, Department of Obsterics and Gynecology,, Linköping, Sweden",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl,1,DB00310,__CHLORTHALIDONE,7157584,Terminated,NCT01368536,HYPERTENSION|STAGE 2 HYPERTENSION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Athens, Alabama, United States|Novartis Investigative Site, Florence, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Montgomery, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Chandler, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Buena Park, California, United States|Novartis Investigative Site, Fair Oaks, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Healdsburg, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orangevale, California, United States|Novartis Investigative Site, Riverside, California, United States|Novartis Investigative Site, Roseville, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, West Covina, California, United States|Novartis Investigative Site, Shelton, Connecticut, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Ft. Lauderdale, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lauderdale Lakes, Florida, United States|Novartis Investigative Site, North Miami Beach, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Lansing, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Beltsville, Maine, United States|Novartis Investigative Site, Waltham, Massachusetts, United States|Novartis Investigative Site, Wellesley Hills, Massachusetts, United States|Novartis Investigative Site, Brooklyn Center, Minnesota, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Ozark, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Trenton, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Camillus, New York, United States|Novartis Investigative Site, Asheboro, North Carolina, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Shelby, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Lyndhurst, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Reading, Pennsylvania, United States|Novartis Investigative Site, Uniontown, Pennsylvania, United States|Novartis Investigative Site, Wallingford, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Easley, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mt. Pleasant, South Carolina, United States|Novartis Investigative Site, Summerville, South Carolina, United States|Novartis Investigative Site, Varnville, South Carolina, United States|Novartis Investigative Site, Fayetteville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Pasadena, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Richardson, Texas, United States|Novartis Investigative Site, St. George, Utah, United States|Novartis Investigative Site, Arlington, Virginia, United States|Novartis Investigative Site, Carolina, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico",C07D413/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,23.8197909608,564.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,338.76599999999996,109.49,4.0,3.0,3.0,31.29,81.3,2.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00634543,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,"Active, not recruiting",NCT03469310,THYROID CANCER|THYROID NODULE|THYROID NEOPLASMS|THYROID GOITRE|THYROID DISEASES|PARATHYROID DISEASES|PARATHYROID ADENOMA|PARATHYROID HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"GME General Surgery Clinic, Edinburg, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT02180334,"DIABETES MELLITUS, TYPE 2",All,"20 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Seoul National University Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Completed,NCT00044746,DIABETES MELLITUS|DIABETIC FOOT,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
N#C[Fe-2](C#N)(C#N)(C#N)(C#N)N=O,1,DB00325,__NITROPRUSSIDE,,Unknown status,NCT00636584,NITROPRUSSIDE|THYROID HORMONES,All,"30 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening,"Kavaklıdere Umut Hastanesi, Ankara, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.071,215.938,148.38,6.0,0.0,0.0,16.52,39.44,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,,HEMORRHAGE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT04010942,PCOS|VITAMIN D DEFICIENCY,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ain Shams University Maternity hospital, Cairo, Egypt",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Withdrawn,NCT00502229,POLYCYSTIC OVARY SYNDROME|INFERTILITY,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pugliese Hospital, Catanzaro, Catanzaro, CZ, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00795808,PCOS,Female,18 Years to 39 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Auckland, Auckland, New Zealand",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00558077,POLYCYSTIC OVARY SYNDROME|INFERTILITY|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Catanzaro/Italy, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00471523,INFERTILITY|POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 41 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese Hospital"", Catanzaro, CZ, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT00461643,ANOVULATORY INFERTILITY RELATED TO POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy|""Pugliese"" Hospital, Catanzaro, Italy|Pugliese-Ciaccio Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Terminated,NCT01486966,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00657943,TYPE 2 DIABETES|ATHEROSCLEROSIS|ARTERIOSCLEROSIS,All,"30 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rigshospitalet, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Gentofte Sygehus, Gentofte, Denmark|Steno Diabetes Center, Gentofte, Denmark|Herlev Hospital, Herlev, Denmark|Hillerod Sygehus, Hillerod, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Køge Sygehus, Koge, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01131182,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01206647,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetologische Schwerpunktpraxis Dr. Lorra / Dr. Bonnermann, Bochum, Germany|Zentrum für klinische Studien Dresden, GWT-TUD GmbH, Dresden, Germany|Gemeinschaftspraxis Partner der Gesundheit, Essen, Germany|IKFE Institute for Clinical Research and Development, Mainz, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Diabetes Zentrum Neuwied, Neuwied, Germany|ikfe Studiencenter Potsdam GmbH, Potsdam, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01267448,DIABETES MELLITUS TYPE 2|SEVERE HYPERGLYCEMIA - BLOOD GLUCOSE LEVEL >300MG/DL.,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Stroger Hospital of Cook County, Chicago, Illinois, United States|John Stroger Hospital of Cook County, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01960205,PRE-DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shandong Provincial Hospital, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00513630,TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"up to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Shanghai Jiao Tong University School of Medicine, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03514108,HEART FAILURE|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sygehus Sønderjylland, Aabenraa, Aabenraa, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Amager Hospital, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Copenhagen, Denmark|Glostrup Hospital, Copenhagen, Denmark|Herlev Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark|Herning Hospital, Herning, Denmark|Regionshospital Nordjylland, Hjørring, Hjørring, Denmark|Holbæk Hospital, Holbæk, Denmark|Horsens Hospital, Horsens, Denmark|Kolding Hospital, Kolding, Denmark|Nykøbing Falster Hospital, Nykøbing Falster, Denmark|Odense University Hospital, Odense, Denmark|Randers Hospital, Randers, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Vejle Hospital, Vejle, Denmark|Viborg Hospital, Viborg, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00318656,NON-INSULIN-DEPENDENT DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02526615,INSULIN SENSITIVITY|TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turku PET Centre, Turku, Finland|Turku university hospital, PET center, Turku, Finland|Turku PET Centre (Turku University Hospital), Turku, Finland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02941445,POLYCYSTIC OVARY SYNDROME|BODY WEIGHT,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Not yet recruiting,NCT04298684,"DIABETES MELLITUS, TYPE 2|THYROID NODULE (BENIGN)",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CHU Bordeaux, Bordeaux, France|CHU Limoges, Limoges, France|University Hospital Center of Guadeloupe, Pointe-à-Pitre, Guadeloupe|CHU de la Réunion, Saint-Pierre, Réunion",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02147925,NON-ALCOHOLIC FATTY LIVER DISEASE,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01856907,DISORDER OF GLUCOSE REGULATION,Female,18 Years to 42 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Woman's Hospital, Baton Rouge, Louisiana, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01718093,TYPE 1 DIABETES,All,"13 Years to 18 Years   (Child, Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00820573,DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Texas Diabetes Institute, San Antonio, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01099618,KETOSIS PRONE DIABETES|DIABETES KETOACIDOSIS|HYPERGLYCEMIA,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Grady Memorial Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01429818,ENDOTHELIAL DYSFUNCTION|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Unidad PET Ciclotrón. Facultad de Medicina. Universidad Nacional Autónoma de México, Mexico city, Distrito Federal, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01565096,DIABETES MELLITUS TYPE II,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ikfe GmbH, Mainz, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03693560,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"25 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Pharmacy - Damanhour University., Damanhūr, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02007278,TYPE 2 DIABETES|HYPOGLYCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Medellín, Antioquia, Colombia|Novartis Investigative Site, Manizales, Caldas, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Chía, Cundinamarca, Colombia|Novartis Investigative Site, Cali, Valle del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Monteria, Colombia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT04485845,METABOLIC SYNDROME|DIABETE TYPE 2|KIDNEY INSUFFICIENCY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Diabetes & Endocrinology Institute, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT03029390,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,31 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03383068,PCOS|IMPAIRED GLUCOSE TOLERANCE,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT03774108,PREDIABETES|HIV-1-INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02167620,"DIABETES MELLITUS, TYPE 2|SCHIZOPHRENIA",All,"17 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Center for Addiction and Mental Health, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03819127,MILD COGNITIVE IMPAIRMENT,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT00182494,DIABETES MELLITUS|SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"McMaster University, Hamilton, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Terminated,NCT03380091,PCOS|DEPRESSION|VITAMIN D DEFICIENCY|INSULIN RESISTANCE,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Center for Reproductive Health, San Francisco, California, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT02409238,"MILD COGNITIVE IMPAIRMENT|INSULIN RESISTANCE|DIABETES MELLITUS, TYPE 2",All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SingHealth Polyclinics - Marine Parade Polyclinic, Singapore, Singapore",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01115140,PREGNANCY|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 38 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","""Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00682448,METABOLIC DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Rush University Medical Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Withdrawn,NCT02719132,DIABETES MELLITUS TYPE 2,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02187250,PCOS|OBESITY,Female,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Ljubljana, Ljubljana, Slovenia",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01675310,PREGESTATIONAL OBESITY (BMI > 27KG/M2)|HISTORY OF POLYCYSTIC OVARY SYNDROME,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"National Institute of Perinatology, Mexico, Mexico",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03486626,POLYCYSTIC OVARY SYNDROME|ANOVULATORY,Female,20 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ain Shams University Maternity Hospital, Cairo, Egypt",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03352869,POLYCYSTIC OVARY SYNDROME|OVERWEIGHT AND OBESITY|DISORDER OF GLUCOSE REGULATION,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, China",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03151005,POLYCYSTIC OVARY SYNDROME (PCOS)|OVERWEIGHT|OBESITY,Female,"14 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02909933,POLYCYSTIC OVARY SYNDROME|OBESITY,Female,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Ljubljana, Ljubljana, Slovenia",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00953355,POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","""Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Suspended,NCT02500147,POLYCYSTIC OVARY SYNDROME|NON-ALCOHOLIC FATTY LIVER DISEASE|METABOLIC SYNDROME,Female,"13 Years to 25 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Columbia University Medical Center, New York, New York, United States",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Terminated,NCT00682890,POLYCYSTIC OVARY SYNDROME|PCOS|INSULIN SENSITIVITY,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","General Clinical Research Center, Richmond, Virginia, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT00883259,OBESITY|POLYCYSTIC OVARY SYNDROME|GESTATIONAL DIABETES,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pugliese Hospital, Catanzaro, Catanzaro, CZ, Italy|""Pugliese"" Hospital, Catanzaro, Italy|University of Catanzaro, Italy, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01233206,INFERTILITY|POLYCYSTIC OVARY SYNDROME (PCOS),Female,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Terminated,NCT01208740,INFERTILITY|PCOS|PROGNOSIS FOR POOR RESPONSE,Female,35 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01438190,INFERTILITY|PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"""Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03796975,TYPE 2 DIABETES MELLITUS|NON-ALCOHOLIC FATTY LIVER DISEASE|EFFICACY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03068065,NON-ALCOHOLIC FATTY LIVER DISEASE|TYPE2 DIABETES,All,"17 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02875821,TYPE 2 DIABETES WITH NON-ALCOHOLIC FATTY LIVER (NAFLD),All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT02394158,GESTATIONAL DIABETES,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Imperial College NHS Trust, London, United Kingdom|London North West Healthcare Trust, London, United Kingdom",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT02719756,DIABETES MELLITUS|HYPOGLYCEMIC EPISODES,All,"18 Years to 74 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Research Clinical Centre of the Russian Railways, JSC, Moscow, Russian Federation",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03570632,"DIABETES MELLITUS, TYPE 1|PREGNANCY IN DIABETES",Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01966978,"DIABETES MELLITUS, TYPE 2|DIABETES",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03513874,TYPE 1 DIABETES MELLITUS|AUTOIMMUNE DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03029702,"GESTATIONAL DIABETES|DIABETES, GESTATIONAL|PREGNANCY IN DIABETES",Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00035568,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Local Institution, Little Rock, Arkansas, United States|Local Institution, Los Angeles, California, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Brooklyn, New York, United States|Local Institution, Rochester, New York, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03590262,TYPE 1 DIABETES MELLITUS|METFORMIN,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shenzhen People's Hospital, Shenzhen, Guangdong, China",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03179254,DIABETES TYPE 2,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT02501616,ENDOTHELIAL FUNCTION|TYPE 2 DIABETES,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boramae medical center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02014740,TYPE 2 DIABETES|OVERWEIGHT|OBESITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Not yet recruiting,NCT04284722,HYPERGLYCEMIA|METFORMIN|TYPE 2 DIABETES|HYPERLACTATEMIA,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00474838,TYPE 2 DIABETES MELLITUS|PANCREATIC BETA CELL FUNCTION|GLUCOTOXICITY,All,"25 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hanyang University Medical Center, Kuri, Kyunggi-do, Korea, Republic of|The Catholic University of Korea Bucheon St.Mary's Hospital, Bucheon, Korea, Republic of|Inha University Hospital, In Cheon, Korea, Republic of|Jeju National University Hospital, Jeju-do, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyung Hee University East Weast Neo Medicalcenter, Seoul, Korea, Republic of|Ajou University Medical Center, Suwon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Withdrawn,NCT03078725,"GESTATIONAL DIABETES MELLITUS, CLASS A2",Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01280409,"DIABETES, GESTATIONAL",Female,18 Years to 49 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Memorial Hermann Hospital, Texas Medical Center, Houston, Texas, United States|University of Texas Health Science Center at Houston, Professional Building, Houston, Texas, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00934570,OBESITY|TYPE 2 DIABETES,All,10 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Children's Hospital, London Health Sciences Centre, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Withdrawn,NCT02881528,PREDIABETIC STATE,All,5 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NHS Ayrshire & Arran, Kilmarnock, Ayrshire, United Kingdom|NHS Grampian, Aberdeen, Grampian, United Kingdom|NHS Lanarkshire, Wishaw, Lanarkshire, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01729156,TYPE 2 DIABETES|DYSLIPIDEMIA,All,"50 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03361878,"DIABETES MELLITUS, TYPE 2|METFORMIN ADVERSE REACTION",All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03765359,DIABETIC PREGNANCY|INSULIN RESISTANCE|TYPE1DIABETES,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Helsinki University Hospital, Helsinki, Finland|Central Finland Health Care District, Jyväskylä, Finland|Oulu University hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01947790,LVM|TYPE 2 DIABETIC PATIENTS WITH IHD|ENDOTHELIAL FUNCTION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Wuhan City, Hubei, China|Xiang Guangda, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01001962,HYPERTENSION|TYPE II DIABETES,All,"45 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hypertension 24h ABPM center Papageorgiou Hospital, Thessaloniki, Greece",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT01035528,CORONARY ARTERY DISEASE|TYPE 2 DIABETES,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Staedt. Klinikum Muenchen Bogenhausen, Munich, Bavaria, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01604213,TYPE 2 DIABETES MELLITUS|ISCHEMIC HEART DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Sheba Medical Center, Cardiac Rehabilitation Institute, Tel Hashomer, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03639545,"VASCULAR STIFFNESS|HYPOGLYCEMIC AGENTS|DIABETES COMPLICATIONS|DIABETES MELLITUS, TYPE 1",All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Centre Ljubljana, Ljubljana, Slovenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT02915198,PREDIABETIC STATE|ATHEROSCLEROSIS|METFORMIN,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT02621489,ATHEROSCLEROSIS|DIABETES|RESTENOSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept of clinical science and education Karolinska Institutet Södersjukhuset, Stockholm, Other, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT02535299,GLP-1；METFORMIN；TELOMERE-TELOMERASE SYSTEM；PAR-4,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01090752,DIABETES|HYPERTENSION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pechère-Bertschi Antoinette, Geneva, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00108615,GLUCOSE METABOLISM DISORDERS|DIABETES,All,"35 Years to 65 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Central Arkansas Veterans HCS, Little Rock, Arkansas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03980990,ACUTE CORONARY SYNDROME|UNSTABLE ANGINA|DIABETES MELLITUS|METFORMIN ADVERSE REACTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal University Hospital, Saskatoon, Saskatchewan, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03312582,PERI-IMPLANTITIS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00546728,IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Diabetes Center at Park Nicollet, St. Louis Park, Minnesota, United States|St. Paul Heart Clinic, St. Paul, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01775813,OBESITY|INSULIN RESISTANCE|GONADAL DYSFUNCTION|TYPE 2 DIABETES,All,9 Years to 17 Years   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Children's Hospital Colorado, Aurora, Colorado, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00723307,CORONARY ARTERY DISEASE,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Glasgow Clinical Research Facility, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Not yet recruiting,NCT04523363,PREDIABETES; COMPLICATING PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03398356,PREDIABETES|IMPAIRED FASTING GLUCOSE (IFG)|IMPAIRED GLUCOSE TOLERANCE (IGT),All,"40 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,"NZOZ Nowy Dwór, Wroclaw, Lower Silesia, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01237522,"METFORMIN|ORGANIC CATION TRANSPORTER 2|POLYMORPHISM,SINGLE NUCLEOTIDE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Odense, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03004612,PREDIABETIC STATE|INSULIN RESISTANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT04088461,PREDIABETIC STATE|IMPAIRED GLUCOSE TOLERANCE|INSULIN RESISTANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT04549415,CHRONIC HEART FAILURE|CORONARY ARTERY DISEASE|PREDIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Centre of Cardiology and Internal Medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyzstan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT02744976,CORONARY ARTERY DISEASE|ATHEROSCLEROSIS|PREDIABETIC STATE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pauls Stradins Clinical University hospital, Riga, Latvia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01765946,INSULIN RESISTANCE|PREDIABETES|AGING|INFLAMMATION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University Hospital Diabetes Outpatient Clinic, Padova, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02226510,LEFT VENTRICULAR HYPERTROPHY|INSULIN RESISTANCE|CORONARY ARTERY DISEASE|PREDIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital & Medical School, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT03253562,REDUCING THE ELEVATED BLOOD PRESSURE FOR DIABETIC HYPERTENSIVE PATIENTS,Female,40 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"National institute of diabetes and endocrinology, Cairo, Egypt",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01400191,PHARMACOGENETICS OF METFORMIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","Clinical pharmacology, Institute og public health, University of Southern Denmark, Odense, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02432287,AGING,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Einstein College of Medicine of Yeshiva University, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT00245206,SCHIZOPHRENIA|ALZHEIMER'S DISEASE|DEMENTIA,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, San Diego, California, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT01411930,DIABETES,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"VA San Diego Healthcare System, San Diego, California, United States",C07D495/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT00236379,SCHIZOPHRENIA|DIABETES MELLITUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT01185743,SCHIZOPHRENIA|DIABETES,Male,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Medical University of Vienna, Vienna, Austria",C07D495/04,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT00287820,SCHIZOPHRENIA|DIABETES|METABOLIC SYNDROME|HYPERGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Psychaitric Center, New York, New York, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,NCT00133692,HYPERTENSION|CORONARY ARTERY DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Gainesville, Florida, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Terminated,NCT00925119,"DIABETES MELLITUS, TYPE 2",All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland, Baltimore, Maryland, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,NCT00263393,MYOCARDIAL INFARCTION|ANGINA PECTORIS|CEREBROVASCULAR ACCIDENTS|DIABETES MELLITUS,All,"30 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Byrraju Foundation Primary Healthcare Centres in rural West Godavari and East Godavari Dstricts, Bhimavaram, Andhra Pradesh, India",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown Status,,HEPATITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT03047278,"NEUROPATHIC PAIN|TYPE 2 DIABETES MELLITUS|DIABETIC NEUROPATHY, PAINFUL",All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,"DIABETIC NEUROPATHY, PAINFUL",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
Nc1ccc(C(=O)NCC(=O)O)cc1,1,DB00345,__AMINOHIPPURIC_ACID,4292154,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N27/44747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,194.1873,92.42,4.0,3.0,1.0,19.13,50.82,3.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00351,__MEGESTROL_ACETATE,5145684,Recruiting,NCT03963752,IDIOPATHIC PRECOCIOUS PUBERTY,Female,5 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",B82Y5/00,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,2187.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.71,384.51599999999996,60.44,3.0,0.0,4.0,43.51,108.66,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN2c3ncccc3Cc3ccccc3C2C1,1,DB00370,__MIRTAZAPINE,5178878,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Withdrawn,NCT01927406,THYROID EYE DISEASE|OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Stanford Hospital and Clinics, Stanford, California, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00454662,HYPERTENSION|CARDIOVASCULAR DISEASE|DIABETES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"COLM-Study Data Center, Kamiyacho MT Bld.14F, 4-3-20 Toranomon Minato-ku, Tokyo, Japan",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00654745,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Sylmar, California, United States|Tustin, California, United States|Aventura, Florida, United States|DeLand, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Las Vegas, Nevada, United States|New Windsor, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Taylors, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Terminated,NCT01368536,HYPERTENSION|STAGE 2 HYPERTENSION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Athens, Alabama, United States|Novartis Investigative Site, Florence, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Montgomery, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Chandler, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Buena Park, California, United States|Novartis Investigative Site, Fair Oaks, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Healdsburg, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orangevale, California, United States|Novartis Investigative Site, Riverside, California, United States|Novartis Investigative Site, Roseville, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, West Covina, California, United States|Novartis Investigative Site, Shelton, Connecticut, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Ft. Lauderdale, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lauderdale Lakes, Florida, United States|Novartis Investigative Site, North Miami Beach, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Lansing, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Beltsville, Maine, United States|Novartis Investigative Site, Waltham, Massachusetts, United States|Novartis Investigative Site, Wellesley Hills, Massachusetts, United States|Novartis Investigative Site, Brooklyn Center, Minnesota, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Ozark, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Trenton, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Camillus, New York, United States|Novartis Investigative Site, Asheboro, North Carolina, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Shelby, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Lyndhurst, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Reading, Pennsylvania, United States|Novartis Investigative Site, Uniontown, Pennsylvania, United States|Novartis Investigative Site, Wallingford, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Easley, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mt. Pleasant, South Carolina, United States|Novartis Investigative Site, Summerville, South Carolina, United States|Novartis Investigative Site, Varnville, South Carolina, United States|Novartis Investigative Site, Fayetteville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Pasadena, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Richardson, Texas, United States|Novartis Investigative Site, St. George, Utah, United States|Novartis Investigative Site, Arlington, Virginia, United States|Novartis Investigative Site, Carolina, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Withdrawn,NCT03978884,DIABETES MELLITUS|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tropical Metabolism Research Unit, Kingston, Other, Jamaica",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00237588,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,"Cardiovascular and Renal Research Center/ Department of Cardiology, Ullevaal University Hospital, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT01375322,"HYPERTENSION|DIABETES MELLITUS, TYPE 2|ALBUMINURIA",All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Unknown status,NCT00202618,HYPERTENSION|DIABETES MELLITUS|ALBUMINURIA,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shiga University of Medical Science, Otsu, Shiga, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00129233,HYPERTENSION|TYPE 2 DIABETES,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00921570,DIABETES|HYPERTENSION|PROTEINURIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GATA Nephrology, Ankara, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT03747978,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"25 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","National Obesity Centre, Yaounde Central Hospital, Yaounde, Centre, Cameroon",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00787605,HYPERTENSION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sites in USA, East Hanover, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00818779,CORONARY ARTERY DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Texas Tech University Health Sciences Center, Lubbock, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00847262,HYPERTENSION|OBESITY|DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The third hospital affiliated to the Third Military Medical University, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00136773,ALBUMINURIA,All,"21 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Recruiting,NCT03264352,"DIABETES MELLITUS, TYPE 2|STROKE|BLOOD PRESSURE|PREHYPERTENSION|CARDIOVASCULAR RISK FACTOR",All,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Withdrawn,NCT00987662,OBESITY|HYPERTENSION,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hypertension-24h ABPM Center Papageorgiou Hospital, Thessaloniki, Greece",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Completed,NCT00501878,DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Srinagarind Hospital Eye Clinic, Khon Kaen, Thailand",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Completed,NCT01500863,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Instituto Valenciano de Infertilidad, Madrid, Spain",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Completed,NCT00732693,PREMATURE OVARIAN FAILURE,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Completed,NCT00805935,POLYCYSTIC OVARIAN SYNDROME|INFERTILITY,Female,18 Years to 42 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States|Women's Medical Research Group LLC, Florida, Clearwater, Florida, United States|Fertility Center of Illinois, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Women & Infants' Hospital of RI, Providence, Rhode Island, United States|Center for Assisted Reproduction, Bedford, Texas, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01675089,RENAL OSTEODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT04085419,PRIMARY HYPERPARATHYROIDISM|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Endocrinology Department, Ljubljana, Slovenia",C07F9/65031,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],1,DB00401,__NISOLDIPINE,5422123,Completed,NCT00311870,DIABETIC NEPHROPATHY,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Steno Diabetes Center, Gentofte, Denmark",A61K9/2086,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,20.468592784246,168.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.63,388.4144,110.45,5.0,1.0,2.0,39.72,105.91,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,OBSTRUCTIVE SLEEP APNEA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,,CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00640224,PCOS,Female,"10 Years to 20 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D277/22,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00329225,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Fairfield, Alabama, United States|GSK Investigational Site, Fultondale, Alabama, United States|GSK Investigational Site, Montgomery, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Concord, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Garden Grove, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Pasadena, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Longmont, Colorado, United States|GSK Investigational Site, Hamden, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Deland, Florida, United States|GSK Investigational Site, Fort Meyers, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Blue Ridge, Georgia, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Idaho Falls, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Gurnee, Illinois, United States|GSK Investigational Site, Melrose Park, Illinois, United States|GSK Investigational Site, Orland Park, Illinois, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Vernon Hills, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Madison, Kentucky, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, Marrero, Louisiana, United States|GSK Investigational Site, Slidell, Louisiana, United States|GSK Investigational Site, Slidell, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Haverhill, Massachusetts, United States|GSK Investigational Site, Taunton, Massachusetts, United States|GSK Investigational Site, Cadillac, Michigan, United States|GSK Investigational Site, Troy, Michigan, United States|GSK Investigational Site, Picayune, Mississippi, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Butte, Montana, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Pahrump, Nevada, United States|GSK Investigational Site, Hillsborough, New Jersey, United States|GSK Investigational Site, Kenilworth, New Jersey, United States|GSK Investigational Site, Martinsville, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Cooperstown, New York, United States|GSK Investigational Site, Fulton, New York, United States|GSK Investigational Site, Johnson City, New York, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Staten Island, New York, United States|GSK Investigational Site, Cary, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Bismarck, North Dakota, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Franklin, Ohio, United States|GSK Investigational Site, Kettering, Ohio, United States|GSK Investigational Site, Maumee, Ohio, United States|GSK Investigational Site, Sidney, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Feasterville, Pennsylvania, United States|GSK Investigational Site, Lansdale, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Reading, Pennsylvania, United States|GSK Investigational Site, Scranton, Pennsylvania, United States|GSK Investigational Site, Cranston, Rhode Island, United States|GSK Investigational Site, Warick, Rhode Island, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Bartlett, Tennessee, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Cardova, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Galveston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Chesapeake, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Federal Way, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00121966,TYPE 2 DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,"Diabetes Research Center, Odense, Denmark",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00318656,NON-INSULIN-DEPENDENT DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT02526615,INSULIN SENSITIVITY|TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turku PET Centre, Turku, Finland|Turku university hospital, PET center, Turku, Finland|Turku PET Centre (Turku University Hospital), Turku, Finland",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00738023,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Grady Memorial Hospital, Atlanta, Georgia, United States",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Withdrawn,NCT00225342,"ANGINA PECTORIS|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Cardiology Department, Glasgow Royal Infirmary, Glasgow, United Kingdom",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00571506,"DIABETES MELLITUS, TYPE 2|VASCULAR DISEASES",All,"40 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00372086,TYPE 1 DIABETES|PUBERTY: >TANNER 2 BREAST DEVELOPMENT OR TESTIS >4ML,All,"10 Years to 18 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Sydney Children's Hospital, Sydney, New South Wales, Australia",C07D277/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00522470,TYPE 2 DIABETES MELLITUS|OBESITY,Female,"45 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Baskent University Hospital Department of Endocrinology, Ankara, Bahçelievler, Turkey",C07D277/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00306696,DIABETES,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Sint Gillis-Waas, Belgium|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Dommartin-Les Toul, France|GSK Investigational Site, Paris Cedex 18, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Blieskastel, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, N. Efkarpia, Thessaloniki, Greece|GSK Investigational Site, Nikaia Piraeus, Greece|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Acquavive delle Fonti (BA), Puglia, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Tromsoe, Norway|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Lubochna, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, United Kingdom|GSK Investigational Site, London, United Kingdom",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00440375,TYPE 2 DIABETES MELLITUS|OBESITY|MENOPAUSE,Female,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D277/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00675740,IMPAIRED GLUCOSE TOLERANCE,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,1,DB00419,__MIGLUSTAT,5472969,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,13.766196431138198,165.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.1,219.278,84.16,5.0,4.0,1.0,23.99,55.74,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,NCT00306696,DIABETES,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Sint Gillis-Waas, Belgium|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Dommartin-Les Toul, France|GSK Investigational Site, Paris Cedex 18, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Blieskastel, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, N. Efkarpia, Thessaloniki, Greece|GSK Investigational Site, Nikaia Piraeus, Greece|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Acquavive delle Fonti (BA), Puglia, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Tromsoe, Norway|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Lubochna, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, United Kingdom|GSK Investigational Site, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,NCT00335413,HYPERTENSION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,NCT02426099,"HYPERTENSION, RESISTANT TO CONVENTIONAL THERAPY|DIABETES MELLITUS",All,"21 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"National Obesity Centre, Yaounde Central Hospital, Yaounde, Centre, Cameroon",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Unknown status,NCT03597035,TYPE2 DIABETES|HYPERKALEMIA,All,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Recruiting,NCT03502031,"RENAL INSUFFICIENCY, CHRONIC|DIABETIC NEPHROPATHY TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgia Nephrology Research Institute, Lawrenceville, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Unknown status,NCT00870402,DIABETIC NEPHROPATHY,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Los Andes, Santiago, Chile",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Withdrawn,NCT00792662,DIABETES MELLITUS|ALZHEIMER'S DISEASE|APATHY|DEMENTIA,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Veterans Affairs Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",A61L15/585,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",A61L15/585,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Not yet recruiting,NCT03700645,DIABETES MELLITUS|ISCHEMIC HEART DISEASE|MULTI VESSEL CORONARY ARTERY DISEASE,All,"40 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02829177,TYPE 1 DIABETES|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Steno Diabetes Center, Gentofte, Denmark",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Unknown status,NCT03195153,DIABETES MELLITUS TYPE 2 PLATELETS REACTIVITY STATIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Policlinico Umberto I, Rome, Roma, Italy",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,1,DB00440,__TRIMETHOPRIM,5763449,Unknown status,NCT03014687,ANTIBIOTICS|PITUITARY ADENOMA,All,"18 Years to 84 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Barrow Brain and Spine, Phoenix, Arizona, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Terminated,NCT00642733,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Morelia, Mexico|Tijuana, Mexico",C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,"Active, not recruiting",NCT02812992,ADENOCARCINOMA PANCREAS,All,70 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitätsklinikum Mannheim II. Medizinische Klinik, Mannheim, Germany",C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Unknown status,NCT02652884,TRANSIENT HYPOPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT00204373,ZOLLINGER-ELLISON SYNDROME|MULTIPLE ENDOCRINE NEOPLASIA,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,1,DB00450,__DROPERIDOL,4246894,Terminated,NCT00445055,NAUSEA|VOMITING,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux, PESSAC Cedex, France",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,20.1728988274913,364.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.93,379.4274,52.65,3.0,1.0,4.0,40.31,109.52,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT03094416,HYPOTHYROIDISM;POSTABLATIVE,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Head and Neck Specialists, La Jolla, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|MedStar Union Memorial Hospital, Baltimore, Maryland, United States|NYC Health + Hospitals/ Queens, New York, New York, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Carolina Ear Nose and Throat Clinic, Orangeburg, South Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Stonesifer Endocrine Care & Clinical Research Inc., PS, Federal Way, Washington, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT01853579,SUBCLINICAL HYPOTHYROIDISM|DEPRESSION,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, Netherlands|Department of General Internal Medicine, Lausanne, Vaud, Switzerland|University Clinic for General Internal Medicine, Bern University Hospital, Bern, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT02500342,THYROID DYSFUNCTION|MENTAL FATIGUE|FATIGUE,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University College Cork, National University of Ireland, Cork, Ireland|Department of General Internal Medicine, Lausanne, Vaud, Switzerland|Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT01660126,SUBCLINICAL HYPOTHYROIDISM,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Terminated,NCT02946918,THYROID CANCER|POSTSURGICAL HYPOTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Terminated,NCT02577367,HYPOTHYROIDISM,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maimonides Medical Center, Brooklyn, New York, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Withdrawn,NCT02329379,GOITER,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Withdrawn,NCT02186405,SUBCLINICAL HYPOTHYROÏDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nephrology Department, Nice, France",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT00277589,"GOITER, NODULAR",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Frankfurt, Germany",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Unknown status,NCT03096613,HEART FAILURE|SUBCLINICAL HYPOTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing, Beijing, China",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Unknown status,NCT02316743,SYSTOLIC HEART FAILURE|SUB-CLINICAL HYPOTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT01631305,EUTHYROID SICK SYNDROME,All,1 Month to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sinaloa Pediatric Hospital, Culiacan, Sinaloa, Mexico",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT02491008,"THYROID DYSFUNCTION|BONE MINERAL DENSITY|OSTEOPOROSIS|FRACTURES, BONE",All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of General Internal Medicine, Lausanne, Vaud, Switzerland|Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT02832960,THYROID DYSFUNCTION|ATHEROSCLEROSIS|HEART FAILURE,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of General Internal Medicine, Lausanne, Vaud, Switzerland|Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland|Cardiology Division, Geneva University Hospitals, Geneva, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Unknown status,NCT02512978,MYOCARDIAL INFARCTION|HYPOTHYROIDISM,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fuwai Cardiovascular Hospital, Beijing, China",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Withdrawn,NCT01276782,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,18 Years to 45 Years   (Adult),Other,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Johns Hopkins University, Baltimore, Maryland, United States",A61K9/2009,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCOC(=O)C1(c2ccccc2)CCN(C)CC1,1,DB00454,__MEPERIDINE,4053604,Completed,NCT02027311,CHOLEDOCHOLITHIASIS|CHOLANGIOCARCINOMA|PANCREATITIS|PANCREATIC CANCER,All,"20 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital, Jeju-si, Jeju Special Self-Governing Province, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.505595597445502,1923.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.9,247.3327,29.54,2.0,0.0,2.0,28.09,72.48,4.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT01832311,CATARACT|TYPE 2 DIABETES MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Department of Ophtalmology, General Hospital ""Dr. J. Bencevic"", Slavonski brod, Brodsko-posavska zupanija, Croatia|Department of Physiology and Immunology, University of Zagreb School of Medicine, Zagreb, Grad Zagreb, Croatia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,1,DB00468,__QUININE,3960559,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",H01L23/291,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,1,DB00469,__TENOXICAM,4636498,Unknown Status,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,16.953120187272805,1159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,337.37,99.6,5.0,2.0,3.0,31.96,83.93,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Completed,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Not Yet Recruiting,,POST OPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,1,DB00472,__FLUOXETINE,5945416,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,29.2408468346372,587.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.09,309.3261,21.26,2.0,1.0,2.0,30.33,80.37,7.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,1,DB00474,__METHOHEXITAL,4126684,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,204.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.43,262.3043,66.48,3.0,1.0,1.0,27.4,71.51,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT00844194,"DIABETIC NEUROPATHIES|DEPRESSIVE DISORDER, MAJOR",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1208.34.49008 Boehringer Ingelheim Investigational Site, Achim bei Bremen, Germany|1208.34.49025 Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|1208.34.49001 Boehringer Ingelheim Investigational Site, Bad Mergentheim, Germany|1208.34.49018 Boehringer Ingelheim Investigational Site, Baesweiler, Germany|1208.34.49007 Boehringer Ingelheim Investigational Site, Berlin-Steglitz, Germany|1208.34.49002 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49009 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49021 Boehringer Ingelheim Investigational Site, Bremen, Germany|1208.34.49028 Boehringer Ingelheim Investigational Site, Frankfurt am Main, Germany|1208.34.49012 Boehringer Ingelheim Investigational Site, Gera, Germany|1208.34.49004 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49020 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49023 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49015 Boehringer Ingelheim Investigational Site, Hattingen, Germany|1208.34.49027 Boehringer Ingelheim Investigational Site, Heidenheim, Germany|1208.34.49016 Boehringer Ingelheim Investigational Site, Kelkheim, Germany|1208.34.49006 Boehringer Ingelheim Investigational Site, Limburgerhof, Germany|1208.34.49022 Boehringer Ingelheim Investigational Site, Münster, Germany|1208.34.49019 Boehringer Ingelheim Investigational Site, Neuwied, Germany|1208.34.49024 Boehringer Ingelheim Investigational Site, St. Ingberg, Germany|1208.34.49010 Boehringer Ingelheim Investigational Site, Stuhr, Germany|1208.34.49013 Boehringer Ingelheim Investigational Site, Unterhaching, Germany|1208.34.49029 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany|1208.34.49026 Boehringer Ingelheim Investigational Site, Wuppertal, Germany",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Recruiting,NCT04246619,PAINFUL DIABETIC PERIPHERAL NEUROPATHY,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Opća bolnica Karlovac, Karlovac, Croatia|Clinical Medical Center Osijek, Osijek, Croatia|KB Merkur, Sveučilišna klinika Vuk Vrhovac, Zagreb, Croatia|Klinička bolnica Sveti Duh, Zagreb, Croatia|JZU Univerzitetska klinika za endokrinologija, dijabetes I metabolicki bolesti - Skopje, Skopje, North Macedonia|JZU Univerzitetska klinika za nevrologija, Skopje, North Macedonia|Gabinet Neurologiczny, prof. Adam Stępień, Warszawa, Poland|Poradnia neurologiczna, Centrum terapii dzieci i Dorosłych FIMEDICA Sp. z o.o., Warszawa, Poland|Klinički centar Srbije, Belgrade, Serbia|Klinički centar Niš, Niš, Serbia|Klinički centar Vojvodine, Novi Sad, Serbia|Zdravstveni dom Koper, Koper, Slovenia|Clemenz Marjetka - Nevrološka Ordinacija, Ljubljana, Slovenia",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT00266643,"DIABETIC NEUROPATHY, PAINFUL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ft. Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tallahassee, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Peters, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT02417935,DIABETIC PERIPHERAL NEUROPATHIC PAIN,All,"20 Years to 79 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Withdrawn,NCT01116531,DIABETIC POLYNEUROPATHY|POSTHERPETIC NEURALGIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Terminated,NCT00619983,DIABETIC NEUROPATHIC PAIN|CHRONIC LOW BACK PAIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT00322621,DIABETIC NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Angers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Annecy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Narbonne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nevers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chemitz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schkeuditz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wurzburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,NEUROPATHIC PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00520338,POSTOPERATIVE PAIN|THYROIDECTOMY|CYCLOOXYGENASE 2 INHIBITORS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,1,DB00485,__DICLOXACILLIN,4199566,Recruiting,,BONE AND JOINT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,914.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,470.32599999999996,112.74,5.0,2.0,4.0,42.86,111.44,3.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,1,DB00486,__NABILONE,3944673,Completed,NCT00380913,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Florida Medical Research, Aventura, Florida, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Naples Anesthesia and Pain Associates, Naples, Florida, United States|Lazlo Mate, MD, West Palm Beach, Florida, United States",C07C49/747,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,"Active, not recruiting",NCT03088410,HIV|INSULIN SENSITIVITY|DIABETES MELLITUS,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana",C07D411/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,1,DB00507,__NITAZOXANIDE,5387598,Completed,NCT01770483,"HEPATITIS C, CHRONIC|DIABETES MELLITUS TYPE 2",All,35 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Endocrinology and Diabetes management centre, Lahore, Punjab, Pakistan",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,9.856465225158619,123.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.14,307.282,114.11,5.0,1.0,2.0,27.54,73.89,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Terminated,NCT01133600,DIABETIC FOOT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Alliance for Research & Education, Infectious Diseases, LlC, Annandale, Virginia, United States|Infuscience, Annandale, Virginia, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,1,DB00519,__TRANDOLAPRIL,5744496,Completed,NCT00235014,HYPERTENSION|DIABETES,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07K5/0222,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,40.247233002731,784.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.31,430.5372,95.94,5.0,2.0,3.0,46.79,115.79,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,1,DB00519,__TRANDOLAPRIL,5744496,Completed,NCT00234871,HYPERTENSION|DIABETES|PROTEINURIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07K5/0222,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,40.247233002731,784.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.31,430.5372,95.94,5.0,2.0,3.0,46.79,115.79,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Terminated,NCT00642733,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Morelia, Mexico|Tijuana, Mexico",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Unknown status,NCT03014687,ANTIBIOTICS|PITUITARY ADENOMA,All,"18 Years to 84 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Barrow Brain and Spine, Phoenix, Arizona, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Withdrawn,NCT03891979,PANCREATIC CANCER,All,"18 Months to 100 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Langone Health, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,NCT01603940,HYPERTENSION|DIABETES,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,ALBUMINURIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCCc1cc(=O)[nH]c(=S)[nH]1,1,DB00550,__PROPYLTHIOURACIL,4369172,Unknown status,NCT01056419,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department, Ankara, Turkey",A61K9/2054,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,13.010534097209305,202.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.53,170.232,41.13,1.0,2.0,1.0,17.79,48.9,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,1,DB00555,__LAMOTRIGINE,5698226,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,18.333025318795,193.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,256.091,90.71,5.0,2.0,2.0,23.1,66.62,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,NCT01779609,TYPE 2 DIABETES,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands",C07D409/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
NC(=O)N1c2ccccc2C=Cc2ccccc21,1,DB00564,__CARBAMAZEPINE,5284662,Completed,NCT01089855,NEUROPATHIC PAIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigational Site, Rabat, Morocco",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,25.7910840058317,220.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1,236.2686,46.33,1.0,1.0,3.0,25.0,71.89,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,1,DB00567,__CEPHALEXIN,3931404,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.0682765559867,1218.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.55,347.389,112.73,5.0,3.0,3.0,32.52,88.97,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT03379181,HYPERTHYROIDISM,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University Hospital Basel, Department of Endocrinology, Basel, BS, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB00581,__LACTULOSE,4057655,Completed,NCT03666546,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Clinical Research Center (CRC), Graz, Austria",C13K13/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,16.0988932010924,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,342.2965,189.53,11.0,8.0,2.0,31.49,68.77,5.0,1.0,0.0,0.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,1,DB00584,__ENALAPRIL,8568747,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.7291936179387,1303.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.19,376.4467,95.94,5.0,2.0,2.0,40.41,99.57,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,1,DB00584,__ENALAPRIL,8568747,Terminated,NCT00456963,DIABETES MELLITUS|HYPERTENSION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Istituto Auxologico Italiano., Milan, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.7291936179387,1303.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.19,376.4467,95.94,5.0,2.0,2.0,40.41,99.57,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,1,DB00584,__ENALAPRIL,8568747,Completed,NCT00419835,MACROALBUMINURIC DIABETIC NEPHROPATHY,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.7291936179387,1303.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.19,376.4467,95.94,5.0,2.0,2.0,40.41,99.57,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00546000,ATOPIC DERMATITIS,All,3 Months to 12 Months   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre for Health Care Medical Associates, Poway, California, United States|Rady Children's Hospital, San Diego, San Diego, California, United States|University of Miami, Dept. of Dermatology, Miami, Florida, United States|Adult & Pediatric Dermatology, Overland Park, Kansas, United States|Dermatology Center for Children and Young Adults, Eagan, Minnesota, United States|Central Dermatology, Saint Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Paddington Testing Company, Inc, Philadelphia, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,1,DB00590,__DOXAZOSIN,4188390,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.8360541284215,320.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,451.4751,112.27,9.0,1.0,5.0,47.17,121.64,4.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,1,DB00590,__DOXAZOSIN,4188390,Completed,NCT00295555,DIABETES MELLITUS|ESSENTIAL HYPERTENSION|RENAL FAILURE,All,"20 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yokohama City University Center Hospital, Yokohama, Japan",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.8360541284215,320.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,451.4751,112.27,9.0,1.0,5.0,47.17,121.64,4.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1
N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,1,DB00594,__AMILORIDE,4178374,Completed,NCT02122731,HYPERTENSION|TYPE 2 DIABETES MELLITUS|MICROALBUMINURIA,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sydvestjysk Hospital, Esbjerg, Esbjerg, Denmark|Sygehus Lillebaelt., Fredericia, Denmark|Steno Diabetes Center, Gentofte, Denmark|Odense University Hospital, Department of Endocrinology, Odense, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,20.041479291155802,2363.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.48,229.627,156.79,7.0,5.0,1.0,20.0,67.18,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,NCT02340013,INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"First Steps Fertility, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",A61K9/0019,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,NCT01286090,GASTROPARESIS|DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K8/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,1,DB00612,__BISOPROLOL,4258062,Completed,NCT01066039,"HYPERTENSION|DIABETES MELLITUS, TYPE II",All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul St. Mary´s Hospital, Seoul, Korea, Republic of",C07D303/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,21.8156430316844,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,325.443,59.95,5.0,2.0,1.0,38.5,92.15,12.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,1,DB00612,__BISOPROLOL,4258062,Completed,NCT01190436,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Manila, Philippines",C07D303/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,21.8156430316844,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,325.443,59.95,5.0,2.0,1.0,38.5,92.15,12.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,1,DB00618,__DEMECLOCYCLINE,3966922,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01599273,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Severance hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT00682539,DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Dept. of Ophthalmology, Medical University of Vienna, Vienna, Austria",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,,RETINAL DETACHMENT,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,1,DB00622,__NICARDIPINE,5164405,Recruiting,,"STROKE, ISCHEMIC",,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.871147251483606,1273.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.34,479.525,113.69,6.0,1.0,3.0,49.95,134.8,11.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00421460,HYPOGONADISM|ERECTILE DYSFUNCTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|Ramathibodi Hospital, Rajthevee, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Not yet recruiting,NCT03851627,"FATTY LIVER|OBESITY|TYPE2 DIABETES MELLITUS|HYPOGONADISM, MALE",Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT03792321,"HYPOGONADISM, MALE|DIABETES MELLITUS, TYPE 2|OBESITY",Male,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Not yet recruiting,NCT03721497,BARIATRIC SURGERY CANDIDATE|MALE HYPOGONADISM|MUSCLE LOSS,Male,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,A61K9/7084,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT03126656,HYPOGONADISM|CHRONIC HEART FAILURE,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00194675,HYPOGONADISM|BENIGN PROSTATIC HYPERPLASIA,Male,"50 Years and older   (Adult, Older Adult)",Other|Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VA Puget Sound Health Care System, Seattle, Washington, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT01601327,IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM,Male,18 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gulhane School of Medicine Dep. of Endocrine and Metabolism, Ankara, Turkey|Gulhane School of Medicine Dep. of Endocrinology and Metabolism, Ankara, Turkey",A61K9/7084,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00512707,ERECTILE DYSFUNCTION|TESTOSTERONE DEFICIENCY|DIABETES,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Boston University Medical Center, Boston, Massachusetts, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT01123278,HYPOGONADISM|METABOLIC SYNDROME|OBESITY|ERECTILE DYSFUNCTION,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dipartimento di Fisiopatologia Medica - Policlinico Umberto I, Rome, Italy|Policlinico Umberto I Hospital - Sapienza University, Rome, Italy",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Terminated,NCT01092858,HYPOGONADISM,Male,"60 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Köln, Nordrhein-Westfalen, Germany",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00287586,HYPOGONADISM|ATHEROSCLEROSIS,Male,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kronos Longevity Research Institute, Phoenix, Arizona, United States|Charles R. Drew University of Medicine and Science, Los Angeles, California, United States|Boston University / Boston Medical Center, Boston, Massachusetts, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT01454011,SECONDARY HYPOGONADISM,Male,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gulhane School of Medicine, Ankara, Turkey",A61K9/7084,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Recruiting,NCT03325647,KLINEFELTER SYNDROME,Male,31 Days to 90 Days   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Children's Hospital Colorado, Aurora, Colorado, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT01560546,TYPE 2 DIABETES MELLITUS|HYPOGONADISM,Male,"50 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Endocrinology, Odense University Hospital, Odense, Denmark",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00355537,DIABETES MELLITUS|PERIPHERAL VASCULAR DISEASE,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00349362,HYPOGONADISM|DIABETES,Male,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Terminated,NCT01084369,TYPE 2 DIABETES|HYPOGONADISM,Male,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tameside General Hospital, Ashton-under-Lyne, Lancashire, United Kingdom|Tameside Hospital NHS Foundatoin Trust, Ashton under Lyne, United Kingdom",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00504712,HYPOGONADISM|PERIPHERAL VASCULAR DISEASE|TYPE 2 DIABETES,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Recruiting,NCT04439799,"HYPOGONADISM, MALE",Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Miller School of Medicine, Miami, Florida, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Recruiting,NCT03518034,HYPOGONADISM|CARDIOVASCULAR DISEASES,Male,"45 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wright Clinical Research, LLC /ID# 210864, Alabaster, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 202982, Birmingham, Alabama, United States|Cahaba Research, Inc. /ID# 167928, Birmingham, Alabama, United States|Atlanta VAMC /ID# 170318, Decatur, Alabama, United States|G & L Research, LLC /ID# 170365, Foley, Alabama, United States|Fundamental Research /ID# 170504, Gulf Shores, Alabama, United States|Urology Centers of Alabama /ID# 206197, Homewood, Alabama, United States|Longwood Research /ID# 201754, Huntsville, Alabama, United States|Medical Affiliated Research Center, Inc. /ID# 170569, Huntsville, Alabama, United States|Mostellar Medical Center /ID# 170329, Irvington, Alabama, United States|Terence T. Hart, MD /ID# 201561, Tuscumbia, Alabama, United States|Alaska Urological Institute /ID# 167894, Anchorage, Alaska, United States|East Valley Family Physicians /ID# 170530, Chandler, Arizona, United States|Fountain Hills Family Practice P.C /ID# 170419, Fountain Hills, Arizona, United States|Horizon Clinical Research Asoc /ID# 202937, Gilbert, Arizona, United States|Lenzmeier Family Medicine /ID# 202945, Glendale, Arizona, United States|Desert Clinical Rsch, LLC /ID# 170428, Mesa, Arizona, United States|Phoenix Medical Group, PC /ID# 170516, Peoria, Arizona, United States|Phoenix VA Healthcare /ID# 202962, Phoenix, Arizona, United States|Elite Clinical Studies, LLC /ID# 168058, Phoenix, Arizona, United States|Family Practice Specialists /ID# 167859, Phoenix, Arizona, United States|Central Phoenix Medical Clinic /ID# 170333, Phoenix, Arizona, United States|Tatum Highlands Medical Assoc /ID# 208277, Phoenix, Arizona, United States|Fiel Family & Sports Medicine /ID# 203034, Tempe, Arizona, United States|Quality of Life Medical & Research Center /ID# 167915, Tucson, Arizona, United States|Arizona Research Assoc /ID# 170421, Tucson, Arizona, United States|Veterans Affairs (VA) Health Care System - Tucson /ID# 167600, Tucson, Arizona, United States|Verde Valley Medical Center /ID# 202955, Tucson, Arizona, United States|Eclipse Clinical Research /ID# 170381, Tucson, Arizona, United States|B.G. Clinical Research Center, LLC /ID# 170461, Little Rock, Arkansas, United States|Preferred Research Partners In /ID# 170539, Little Rock, Arkansas, United States|Applied Research Center of Arkansas /ID# 170487, Little Rock, Arkansas, United States|Pacific Oaks Medical Group /ID# 170540, Beverly Hills, California, United States|TriWest Research Associates /ID# 170498, El Cajon, California, United States|Diagnamics Inc. /ID# 205836, Encinitas, California, United States|Cedars-Sinai Medical Group (MGOE) /ID# 170383, Encino, California, United States|St. Jude Hospital Yorba Linda /ID# 170437, Fullerton, California, United States|Arizona Internal Medicine Specialists, LLC- Glendale /ID# 203011, Glendale, California, United States|Allied Clinical Research /ID# 170519, Gold River, California, United States|Marvel Clinical Research, LLC /ID# 170324, Huntington Beach, California, United States|Irvine Center for Clinical Research /ID# 170368, Irvine, California, United States|Clinical Trials Research /ID# 210862, Lincoln, California, United States|Torrance Clinical Research Institute, Inc. /ID# 170307, Lomita, California, United States|VA Long Beach Healthcare System /ID# 170374, Long Beach, California, United States|Tower Urology /ID# 170330, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System /ID# 167948, Los Angeles, California, United States|Facey Medical Foundation /ID# 203004, Mission Hills, California, United States|Catalina Research Institute, LLC /ID# 170501, Montclair, California, United States|NewportNativeMD, Inc. /ID# 168110, Newport Beach, California, United States|Translational Res Group, Inc. /ID# 168115, North Hollywood, California, United States|Valley Clinical Trials, Inc /ID# 201587, Northridge, California, United States|Amicis Research /Id# 170587, Northridge, California, United States|Diabetes Associates Medical Gr /ID# 170499, Orange, California, United States|Desert Oasis Healthcare Medica /ID# 170841, Palm Springs, California, United States|Saviers Medical Group /ID# 170327, Port Hueneme, California, United States|Center for Clinical Trials of Sacramento, Inc. /ID# 168108, Sacramento, California, United States|Integrated Research Center, Inc. /ID# 170391, San Diego, California, United States|Ritchken & First MD's /ID# 201341, San Diego, California, United States|San Diego Sexual Medicine /ID# 170457, San Diego, California, United States|San Diego Clinical Trials /ID# 170468, San Diego, California, United States|Comprehensive Oncology Centre - Vratsa EOOD /ID# 168252, San Diego, California, United States|West Coast Research LLC /ID# 167903, San Ramon, California, United States|Syrentis Clinical Research /ID# 168056, Santa Ana, California, United States|Care Access Research, Santa Clarita /ID# 167916, Santa Clarita, California, United States|Encompass Clinical Research /ID# 202203, Spring Valley, California, United States|Stanford University /ID# 167595, Stanford, California, United States|St. Joseph's Medical Associate /ID# 170424, Stockton, California, United States|Olive View UCLA Medical Center /ID# 206131, Sylmar, California, United States|Millennium Clinical Trials /ID# 210695, Thousand Oaks, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center /ID# 170400, Torrance, California, United States|Bayview Research Group LLC /ID# 203036, Valley Village, California, United States|Anthony Mills, MD, Inc. /ID# 170571, West Hollywood, California, United States|Lynn Institute of Denver /ID# 170312, Aurora, Colorado, United States|Colorado Springs Family Practice /ID# 168231, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies /ID# 170477, Colorado Springs, Colorado, United States|Urology Associates, P.C. /ID# 170484, Englewood, Colorado, United States|Foothills Urology /ID# 170406, Golden, Colorado, United States|New West Physicians /ID# 203032, Golden, Colorado, United States|Aventura Heart Center /ID# 170354, Aventura, Florida, United States|MB Clinical Research /ID# 202970, Boca Raton, Florida, United States|Imagine Research of Palm Beach County /ID# 212140, Boynton Beach, Florida, United States|Helix Biomedics, LLC /ID# 202310, Boynton Beach, Florida, United States|Meridien Research Inc. - Brooksville /ID# 170556, Brooksville, Florida, United States|Innovative Research /ID# 170360, Clearwater, Florida, United States|Tampa Bay Medical Res, Inc /ID# 170512, Clearwater, Florida, United States|ALL Medical Research /ID# 170493, Cooper City, Florida, United States|Century Clinical Research, Inc /ID# 167597, Daytona Beach, Florida, United States|Seidman Clinical Trials,Delray /ID# 170418, Delray Beach, Florida, United States|S&W Clinical Research /ID# 170311, Fort Lauderdale, Florida, United States|Invesclinic, U.S., LLC /ID# 202553, Fort Lauderdale, Florida, United States|Office of Sam N. Lerman, MD /ID# 170373, Fort Lauderdale, Florida, United States|University of Florida - Hull Rd /ID# 170518, Gainesville, Florida, United States|Malcom Randall VAMC /ID# 170645, Gainesville, Florida, United States|International Research Associates, LLC - Hialeah /ID# 170543, Hialeah, Florida, United States|Indago Research and Health Cen /ID# 170420, Hialeah, Florida, United States|The University of Florida Heal /ID# 170450, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research /ID# 170446, Jacksonville, Florida, United States|Solutions Through Adv Rch /ID# 201590, Jacksonville, Florida, United States|Care Partners Clinical Researc /ID# 202520, Jacksonville, Florida, United States|Care Research center Inc. /ID# 167924, Kendall, Florida, United States|Meridien Research /ID# 167846, Lakeland, Florida, United States|South Florida Wellness & Clinic /ID# 170510, Margate, Florida, United States|Panax Clinical Research /ID# 170525, Miami, Florida, United States|Veritas Research, Corp. /ID# 202975, Miami, Florida, United States|Pharmax Research Clinic /ID# 170403, Miami, Florida, United States|APF Research, LLC. /ID# 170412, Miami, Florida, United States|Well Pharma Med Res Corp /ID# 170337, Miami, Florida, United States|Floridian Research Institute LLC /ID# 167882, Miami, Florida, United States|Advanced Pharma CR, LLC /ID# 167840, Miami, Florida, United States|Applemed Research Inc. /ID# 170364, Miami, Florida, United States|Future Care Solution LLc /ID# 170361, Miami, Florida, United States|New Horizon Research Center /ID# 170574, Miami, Florida, United States|Office of Francisco G Miranda, /ID# 203184, Miami, Florida, United States|International Research Associates, LLC /ID# 170563, Miami, Florida, United States|Bravo Health Care Center /ID# 202201, North Bay Village, Florida, United States|Harmony Clinical Research, Inc. /ID# 201816, North Miami Beach, Florida, United States|Endocrine Associates of Florida, P.A. /ID# 167839, Ocoee, Florida, United States|Sensible Healthcare /ID# 170402, Ocoee, Florida, United States|Omega Research Maitland, LLC /ID# 170340, Orlando, Florida, United States|IMIC Inc. /ID# 167899, Palmetto Bay, Florida, United States|South Broward Research /ID# 170480, Pembroke Pines, Florida, United States|DBC Research USA /ID# 170332, Pembroke Pines, Florida, United States|South Florida Research Solutio /ID# 167972, Pembroke Pines, Florida, United States|DBC Research USA Corporation /ID# 170435, Pembroke Pines, Florida, United States|Synexus Clinical Research US, Inc /ID# 209955, Pinellas Park, Florida, United States|Synexus Clinical Research US, Inc /ID# 210249, Pinellas Park, Florida, United States|DMI Research, Inc. /ID# 170893, Pinellas Park, Florida, United States|Clinical Research Center FL /ID# 202979, Pompano Beach, Florida, United States|St. Johns Center /ID# 212654, Ponte Vedra, Florida, United States|Charlotte Heart & Vascular Institute /ID# 202965, Port Charlotte, Florida, United States|Health Awareness, Inc - Port St Lucie /ID# 170507, Port Saint Lucie, Florida, United States|Meridien Research - St Petersburg /ID# 170370, Saint Petersburg, Florida, United States|Prof Health Care of Pinellas /ID# 167895, Saint Petersburg, Florida, United States|Advance Medical Research /ID# 170532, Saint Petersburg, Florida, United States|Precision Clinical Research /ID# 170469, Sunrise, Florida, United States|Meridien Research Inc. - Tampa /ID# 170377, Tampa, Florida, United States|Winter Park Urology Center/Charter Research /ID# 210542, Winter Park, Florida, United States|Atlanta Vascular Research Foundation - Atlanta Clinical Research Centers /ID# 170894, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 167950, Augusta, Georgia, United States|Endocrine Consustants Research /ID# 168147, Columbus, Georgia, United States|Physicians Research Associates, LLC /ID# 170313, Lawrenceville, Georgia, United States|Atlanta Center for Clinical Research /ID# 202984, Roswell, Georgia, United States|Meridian Clinical Research, LLC /ID# 167854, Savannah, Georgia, United States|Meridian Clinical Research, LLC /ID# 170548, Savannah, Georgia, United States|Herman Clinical Research, LLC /ID# 170474, Suwanee, Georgia, United States|North Georgia Clin Res /ID# 170467, Woodstock, Georgia, United States|East-West Medical Research Institute /ID# 202959, Honolulu, Hawaii, United States|Institute of Arthritis Researc /ID# 170495, Idaho Falls, Idaho, United States|Solaris Clinical Research /ID# 202936, Meridian, Idaho, United States|Biofortis, Inc. /ID# 167856, Addison, Illinois, United States|Synexus Clinical Research US, Inc /ID# 209956, Chicago, Illinois, United States|Chicago Clinical Research Institute, Inc /ID# 203190, Chicago, Illinois, United States|Loretto Hospital.Affnity Clinical Research Institute /ID# 207262, Chicago, Illinois, United States|Midwest Endocrinology /ID# 202992, Crystal Lake, Illinois, United States|Dupage Medical Group /ID# 219039, Evergreen Park, Illinois, United States|Pharmakon Inc /ID# 206149, Evergreen Park, Illinois, United States|Clinical Investigation Specialists, Inc. /ID# 170631, Gurnee, Illinois, United States|Edward Hines Jr. VA Hospital /ID# 167944, Hines, Illinois, United States|Koch Family Medicine SC /ID# 202205, Morton, Illinois, United States|Affinity Clinical Research /ID# 202552, Oak Brook, Illinois, United States|American Health Network - Avon /ID# 170359, Avon, Indiana, United States|American Health Network Franklin /ID# 170483, Avon, Indiana, United States|Investigators Research Group, LLC /ID# 170557, Brownsburg, Indiana, United States|Investigative Clinical Research of Indiana, LLC /ID# 170473, Elwood, Indiana, United States|Deaconess Clinic Downtown /ID# 167855, Evansville, Indiana, United States|Clinical Research Advantage, Inc. /ID# 170656, Evansville, Indiana, United States|MediSphere Medical Research Center /ID# 170317, Evansville, Indiana, United States|Richard L. Roudebush VA Medical Center /ID# 203020, Indianapolis, Indiana, United States|Urology of Indiana /ID# 203469, Indianapolis, Indiana, United States|First Urology,PSC /ID# 167719, Jeffersonville, Indiana, United States|LaPorte County Institute for Clinical Research, Inc. /ID# 170331, Michigan City, Indiana, United States|American Health Network of Ind /ID# 170578, Muncie, Indiana, United States|West Broadway Clinic /ID# 202204, Council Bluffs, Iowa, United States|IA Diabetes & Endo Res Ctr /ID# 170462, West Des Moines, Iowa, United States|The Iowa Clinic, PC /ID# 202986, West Des Moines, Iowa, United States|Heartland Research Associates, LLC /ID# 203031, Augusta, Kansas, United States|PRN Professional Research Network of Kansas, LLC /ID# 170415, Wichita, Kansas, United States|Drs. Borders, Hood, and Assoc /ID# 170536, Lexington, Kentucky, United States|The Research Grp of Lexington /ID# 202900, Lexington, Kentucky, United States|University of Louisville /ID# 170607, Louisville, Kentucky, United States|Research Integrity, LLC /ID# 168264, Owensboro, Kentucky, United States|Alexandria Cardiology Clinic /ID# 170463, Alexandria, Louisiana, United States|Centex Studies, Inc - Lake Charles /ID# 170416, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC /ID# 206203, Marrero, Louisiana, United States|Natchitoches Internal Medicine /ID# 170343, Natchitoches, Louisiana, United States|Tulane School of Medicine /ID# 170472, New Orleans, Louisiana, United States|Maryland Cardiovascular Specialists /ID# 168057, Baltimore, Maryland, United States|Johns Hopkins University /ID# 203006, Baltimore, Maryland, United States|Centennial Medical Group /ID# 170568, Elkridge, Maryland, United States|Massachusetts General Hospital /ID# 167969, Boston, Massachusetts, United States|NECCR PrimaCare Research, LLC /ID# 170326, Fall River, Massachusetts, United States|Oakland Medical Research /ID# 170389, Troy, Michigan, United States|Arcturus Healthcare, PLC, Troy /ID# 170431, Troy, Michigan, United States|Olive Branch Family Med Ctr /ID# 170409, Olive Branch, Mississippi, United States|David M. Headley, MD, P.A. /ID# 205428, Port Gibson, Mississippi, United States|West Florissant Internists /ID# 170314, Bridgeton, Missouri, United States|Med Research One /ID# 167923, Florissant, Missouri, United States|Saint Louis University School of Medicine /ID# 170531, Saint Louis, Missouri, United States|Radiant Research, Inc. /ID# 209957, Saint Louis, Missouri, United States|Mercy Clinic Endocrinology, LLC /ID# 170367, Springfield, Missouri, United States|Montana Medical Research /ID# 170579, Missoula, Montana, United States|Skyline Medical Center /ID# 168234, Elkhorn, Nebraska, United States|VA Nebraska-Western Iowa Health Care System /ID# 167892, Omaha, Nebraska, United States|Heartland Clinical Research /ID# 170541, Omaha, Nebraska, United States|Meridian Clinical Research, LLC - Omaha /ID# 167836, Omaha, Nebraska, United States|Clinical Research Advantage, Inc. /ID# 202966, Omaha, Nebraska, United States|McGill Family Practice, P.C. /ID# 170560, Papillion, Nebraska, United States|Synexus Clinical Research US, Inc. /ID# 210232, Henderson, Nevada, United States|Palm Research Center, Inc. /ID# 168224, Las Vegas, Nevada, United States|AB Clinical Trials /ID# 170612, Las Vegas, Nevada, United States|Alas Science Clinical Research /ID# 170352, Las Vegas, Nevada, United States|Clinical Research of So Nevada /ID# 167594, Las Vegas, Nevada, United States|Advanced Biomedical Research of America /ID# 202202, Las Vegas, Nevada, United States|Sheldon Freedman MD, ltd /ID# 170434, Las Vegas, Nevada, United States|Allied Clinical Research /ID# 210859, Reno, Nevada, United States|Internal Medicine Associates /ID# 170538, Bridgeton, New Jersey, United States|Medicor Cardiology /ID# 170436, Bridgewater, New Jersey, United States|Cooper Health System /ID# 170417, Camden, New Jersey, United States|Union Square Medical Associates,PC /ID# 170346, Elizabeth, New Jersey, United States|Amici Clinical Research /ID# 170452, Warren, New Jersey, United States|NM Clin Res & Osteoporosis Center, Inc /ID# 170386, Albuquerque, New Mexico, United States|Albany VA Medical Center /ID# 167862, Albany, New York, United States|James J. Peters VA Medical Center /ID# 202980, Bronx, New York, United States|NY Total Medical Care, PC /ID# 170423, Brooklyn, New York, United States|AccuMed Research Associates /ID# 202200, Garden City, New York, United States|Office of Bruce R. Gilbert, MD /ID# 202963, Great Neck, New York, United States|Synexus Clinical Research US, Inc. /ID# 210293, Jamaica, New York, United States|Mid Hudson Medical Research, PLLC /ID# 170511, New Windsor, New York, United States|Manhattan Medical Research /ID# 167956, New York, New York, United States|DiGiovanna Institute for Medical Education & Research /ID# 170613, North Massapequa, New York, United States|Premier Medical Group of the Hudson Valley PC /ID# 170456, Poughkeepsie, New York, United States|Endocrine Assc Long Island PC /ID# 170425, Smithtown, New York, United States|Randolph Health Internal Medic /ID# 168227, Asheboro, North Carolina, United States|PMG Research of Charlotte /ID# 202985, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170349, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170634, Charlotte, North Carolina, United States|Rapha Institute for Clinical Research /ID# 170362, Fayetteville, North Carolina, United States|Bland Clinic, PA /ID# 204943, Greensboro, North Carolina, United States|Medication Management, LLC /ID# 205260, Greensboro, North Carolina, United States|Triad Clinical Trials /ID# 170376, Greensboro, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 170449, Hickory, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 202968, Hickory, North Carolina, United States|Northstate Clinical Research /ID# 170414, Lenoir, North Carolina, United States|Research Institute of the Caro /ID# 170341, Mooresville, North Carolina, United States|Carteret Medical Group LLC /ID# 170771, Morehead City, North Carolina, United States|Diabetes and Endo Consultants /ID# 201589, Morehead City, North Carolina, United States|Family Medical Associates of Raleigh /ID# 203979, Raleigh, North Carolina, United States|Goshen Medical Center - Vineland /ID# 170342, Whiteville, North Carolina, United States|PMG Research of Wilmington LLC /ID# 170492, Wilmington, North Carolina, United States|Radiant Research, Inc /ID# 202976, Akron, Ohio, United States|New Horizons Clinical Research /ID# 170460, Blue Ash, Ohio, United States|Diabetes and Endocrinology Associates of Stark County Inc /ID# 170356, Canton, Ohio, United States|Duplicate_Gabrail Cancer Center Research /ID# 170533, Canton, Ohio, United States|Cincinnati Veterans Affairs Medical Center /ID# 170385, Cincinnati, Ohio, United States|Synexus Research Cincinnati /ID# 209958, Cincinnati, Ohio, United States|Rapid Medical Research, INC /ID# 170513, Cleveland, Ohio, United States|Endocrinology Associates, Inc. /ID# 168113, Columbus, Ohio, United States|Synexus Clinical Research US, Inc. /ID# 210234, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center - Department of Urology /ID# 170551, Columbus, Ohio, United States|Aventiv Research, Inc. /ID# 170338, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 168111, Columbus, Ohio, United States|PriMed Clinical Research /ID# 170310, Dayton, Ohio, United States|Dayton VA Medical Center /ID# 168251, Dayton, Ohio, United States|WVVA Healthcare Alliance dba. /ID# 168246, Lewisburg, Ohio, United States|Awasty Research Network, LLC /ID# 210860, Marion, Ohio, United States|Advanced Medical Research, LLC /ID# 170488, Maumee, Ohio, United States|Cardiovascular Research Center, LLC /ID# 203035, Toledo, Ohio, United States|Intend Research /ID# 170581, Norman, Oklahoma, United States|IPS Research Company /ID# 168117, Oklahoma City, Oklahoma, United States|Oklahoma City Clinic /ID# 170497, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute (LHSI) /ID# 202973, Oklahoma City, Oklahoma, United States|Urologic Consultants of Southeastern Pennsylvania /ID# 170351, Bala-Cynwyd, Pennsylvania, United States|Heritage Valley Medical Group /ID# 170387, Beaver, Pennsylvania, United States|AJH/Feasterville Family Health /ID# 168235, Feasterville, Pennsylvania, United States|Indiana-Armstrong Endocrinolgy /ID# 168249, Indiana, Pennsylvania, United States|Richard M Kastelic, MD and Ass /ID# 170382, Johnstown, Pennsylvania, United States|Family Medical Associates /ID# 170396, Levittown, Pennsylvania, United States|Founders Research Corp /ID# 170610, Philadelphia, Pennsylvania, United States|Allegheny Health Network /ID# 210544, Pittsburgh, Pennsylvania, United States|VA Pittsburgh HealthcareSystem /ID# 205837, Pittsburgh, Pennsylvania, United States|SFM Clinical Trials /ID# 168250, Scotland, Pennsylvania, United States|Frontier Clinical Research, LLC - Scottdale /ID# 167864, Scottdale, Pennsylvania, United States|Frontier Clinical Research /ID# 167842, Smithfield, Pennsylvania, United States|Ocean State Clin Rese Part,LLC /ID# 170547, Lincoln, Rhode Island, United States|Synexus Clinical Research US, Inc. /ID# 210228, Anderson, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210230, Anderson, South Carolina, United States|Medical Research South, LLC /ID# 203068, Charleston, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210237, Greer, South Carolina, United States|DeGarmo Institute of Med Res /ID# 170528, Greer, South Carolina, United States|Self Medical Group - Advanced /ID# 170336, Hodges, South Carolina, United States|Main Street Physician's Care - Waterway /ID# 210441, Little River, South Carolina, United States|PMG Research of Charleston /ID# 170572, Mount Pleasant, South Carolina, United States|Palmetto Institute of Clinical Research, Inc. /ID# 170395, Pelzer, South Carolina, United States|Palmetto Clinical Research /ID# 170524, Summerville, South Carolina, United States|Monument Health Clinical Research /ID# 170576, Rapid City, South Dakota, United States|Holston Medical Group /ID# 170565, Bristol, Tennessee, United States|University Diabetes & Endocrine Consultants /ID# 170392, Chattanooga, Tennessee, United States|Consolidated Medical Practices of Memphis, PLLC /ID# 170328, Collierville, Tennessee, United States|PMG Research of Knoxville /ID# 170393, Jefferson City, Tennessee, United States|Holston Medical Group Clinical /ID# 168165, Kingsport, Tennessee, United States|New Phase Research & Developme /ID# 170526, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170451, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170514, Knoxville, Tennessee, United States|Baptist Memorial Medical Group /ID# 168061, Memphis, Tennessee, United States|Clinical Neuroscience Solutions - Memphis /ID# 170559, Memphis, Tennessee, United States|Methodist Medical Group /ID# 168148, Memphis, Tennessee, United States|University of Tennessee Health /ID# 170321, Memphis, Tennessee, United States|Trinity Clinical Research, LLC /ID# 170369, Tullahoma, Tennessee, United States|Arlington Family Research Center, Inc /ID# 170366, Arlington, Texas, United States|Premier Family Physicians /ID# 167946, Austin, Texas, United States|Texas Diabetes and Endocrinology /ID# 170517, Austin, Texas, United States|DiscoveResearch, Inc. /ID# 170320, Beaumont, Texas, United States|Pioneer Research Solutions, Inc. /ID# 168062, Beaumont, Texas, United States|Family Medicine Associates of Texas, PA /ID# 167849, Carrollton, Texas, United States|3rd Coast Research Associates /ID# 203091, Corpus Christi, Texas, United States|Dallas VA Medical Center /ID# 170325, Dallas, Texas, United States|Urology Clinics of North Texas /ID# 203033, Dallas, Texas, United States|North TX Endocrine Ctr /ID# 170552, Dallas, Texas, United States|Radiant Research Dallas /ID# 170319, Dallas, Texas, United States|San Gabriel Clinical Research /ID# 167929, Georgetown, Texas, United States|East Texas Cardiology /ID# 170638, Houston, Texas, United States|PrimeCare Medical Group /ID# 168146, Houston, Texas, United States|Associates in Medicine, P.A. /ID# 170439, Houston, Texas, United States|M.E. DeBakey VAMC /ID# 167598, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 170537, Houston, Texas, United States|Discovery MM Services, Inc - Houston - Broadway St /ID# 170558, Houston, Texas, United States|Memorial Clinical Associates R /ID# 170443, Houston, Texas, United States|The Endocrine Center /ID# 170653, Houston, Texas, United States|Texas Center for Drug Development, Inc. /ID# 170404, Houston, Texas, United States|Methodist Urology Associates /ID# 170575, Houston, Texas, United States|Endocrine and Psychiatry Cente /ID# 170520, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 170379, Houston, Texas, United States|Research Trials Wroldwide /ID# 210694, Humble, Texas, United States|Protenium Clinical Research /ID# 170397, Hurst, Texas, United States|Discovery MM Services, Inc - Katy /ID# 202958, Katy, Texas, United States|Texas Cardio Association of Ho /ID# 170494, Kingwood, Texas, United States|FMC Science /ID# 170407, Lampasas, Texas, United States|Centex Studies, Inc /ID# 203019, McAllen, Texas, United States|Discovery MM Services, Inc. /ID# 170562, Missouri City, Texas, United States|Hill Country Medical Assoc /ID# 170444, New Braunfels, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials /ID# 170394, Pflugerville, Texas, United States|ClinRx Research, LLC /ID# 203067, Plano, Texas, United States|Village Health Partners /ID# 170659, Plano, Texas, United States|DeLeon Research /ID# 210861, Plano, Texas, United States|Research Across America /ID# 168229, Plano, Texas, United States|South Texas Cardiovascular Consultants /ID# 203088, San Antonio, Texas, United States|Radiant Research, Inc. /ID# 202947, San Antonio, Texas, United States|Covenant Clinical Research, PA /ID# 170564, San Antonio, Texas, United States|VIP Trials /ID# 168112, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 200845, San Antonio, Texas, United States|ALM VA Hospital /ID# 167973, San Antonio, Texas, United States|Northeast Endocrinology Associates, PA /ID# 202951, Schertz, Texas, United States|Consano Clinical Research, LLC /ID# 167848, Shavano Park, Texas, United States|Spring Family Practice Associates, PA /ID# 203470, Spring, Texas, United States|Hillcroft Medical Clinic /ID# 170500, Sugar Land, Texas, United States|Northwest Houston Clinical Research PLLC /ID# 168223, Tomball, Texas, United States|Crossroads Clinical Research, /ID# 170372, Victoria, Texas, United States|Hillcrest Clinics /ID# 202961, Waco, Texas, United States|Physicians Research Options, L /ID# 170441, Draper, Utah, United States|Tanner Clinic /ID# 168145, Layton, Utah, United States|Wasatch Peak Family Practice / Synexus Clinical Research US, Inc. /ID# 210175, Layton, Utah, United States|Radiant Research, Inc. /ID# 168248, Murray, Utah, United States|Advanced Research Institute /ID# 170445, Ogden, Utah, United States|Optimum Clinical Research /ID# 170322, Salt Lake City, Utah, United States|VA Salt Lake City Health Care System-George E Wahlen /ID# 167971, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 167596, West Jordan, Utah, United States|Connecticut Clinical Research Center /ID# 207771, Middlebury, Vermont, United States|Burke Internal Medicine & Research /ID# 202981, Burke, Virginia, United States|Seven Corners Medical Center /ID# 170577, Falls Church, Virginia, United States|Manassas Clinical Research Center /ID# 201815, Manassas, Virginia, United States|Virginia Research Center /ID# 170471, Midlothian, Virginia, United States|Health Research of Hampton Roads, Inc. (HRHR) /ID# 204937, Newport News, Virginia, United States|Clinical Research Associates of Tidewater /ID# 170609, Norfolk, Virginia, United States|Clinical Research Partners, LLC - Family Medicine/ Internal Medicine /ID# 170490, Richmond, Virginia, United States|Hunter Holmes McGuire VA Medical Center /ID# 170630, Richmond, Virginia, United States|Salem VA Medical Center /ID# 167925, Salem, Virginia, United States|NW Clinical Research Ctr /ID# 201588, Bellevue, Washington, United States|Sound Medical Research /ID# 202938, Port Orchard, Washington, United States|VA Puget Sound Health Care System /ID# 170555, Seattle, Washington, United States|Universal Research Group, LLC /ID# 170442, Tacoma, Washington, United States|American Health Network - Family Medicine and Specialty Care Services in Greenfi /ID# 202987, Greenfield, Wisconsin, United States|Emanuelli Research & Development Center LLC /ID# 206202, Arecibo, Puerto Rico|Research & Cardiovascular Corp /ID# 170353, Ponce, Puerto Rico|GCM Medical Group, PSC /ID# 170466, San Juan, Puerto Rico|Centro de Endocrinologia Alcantara-Gonzalez /ID# 207260, San Juan, Puerto Rico|Advanced Clinical Research /ID# 170553, Toa Baja, Puerto Rico",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT03091348,"TESTOSTERONE DEFICIENCY|HYPOGONADISM, MALE",Male,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Men's Health Boston, Chestnut Hill, Massachusetts, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Withdrawn,NCT01689896,LOW TESTOSTERONE|HYPOGONADISM|PAIN,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT03619330,HYPOGONADISM|OBESITY,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Ljubljana, Ljubljana, Slovenia",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT02366975,PROSTATIC HYPERPLASIA|LOWER URINARY TRACT SYMPTOMS|HYPOGONADISM,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ambulatori Medicina della Sessualità e Andrologia, Florence, Italy|Clinica Urologica - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Withdrawn,NCT03176537,"PERIODONTITIS|HYPOGONADISM, MALE",Male,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clínica de Odontologia da Universidade Federal do Paraná, Curitiba, PR, Brazil",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT02171390,HYPOGONADOTROPHIC HYPOGONADISM,Male,18 Years to 26 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gulhane School of Medicine Department of Endocrinology and Metabolism, Ankara, NonUS, Turkey",A61K9/7084,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00487734,METABOLIC SYNDROME|HYPOGONADISM,Male,"20 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Terminated,NCT00240981,SARCOPENIA|HYPOGONADISM|MUSCULAR DISEASES,Male,65 Years and older   (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Boston University Medical Center, Boston, Massachusetts, United States|VA Boston Healthcare System (Jamaica Plain Campus), Boston, Massachusetts, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00144391,PANHYPOPITUITARISM,Female,18 Years to 55 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Charles Drew University of Medicine and Science, Los Angeles, California, United States",A61K9/7084,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Completed,NCT02153879,TYPE 2 DIABETES MELLITUS|DYSLIPIDEMIA,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitari Sant Joan, Reus, Tarragona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Completed,NCT00079638,DYSLIPIDEMIA|CORONARY HEART DISEASE|ATHEROSCLEROSIS|STROKE|DIABETES,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,INTRABONY PERIODONTAL DEFECT,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT03312413,ANESTHESIA COMPLICATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","China,Chongqing The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT02549768,PITUITARY NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Division de Anestesia - Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT02154074,PERIOPERATIVE BLOOD GLUCOSE AND INSULIN,All,"60 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SecondXianJiaotongU, Xi'an, Shanxi, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02044224,CANCER OF LIVER|CANCER OF PANCREAS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uppsala University Hospital, Uppsala, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT02510612,DIABETES,All,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02137863,RADIOGRAPHIC CONTRAST AGENT NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT03315052,ACUTE CELLULAR GRAFT REJECTION|LIVER TRANSPLANT REJECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02190994,PITUITARY NEOPLASMS|CRANIOPHARYNGIOMAS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"West China Hospital, Sichuan University, Chengdu, Sichuan, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04542278,THYROID DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01837433,SUBACUTE THYROIDITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00975078,ADRENAL GLAND HYPOFUNCTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Division of Endocrinology University Hospital Basel, Basel, Switzerland",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03153527,INFLAMMATORY DISORDER|AUTOIMMUNE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departement of Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Endocrinology/Diabetology/Metabolism; University Hospital Basel, Basel, Switzerland|Department of Rheumatology, Immunology, and Allergology, Inselspital, Bern, Switzerland|Center for Primary Health Care,University of Basel, Kantonsspital Baselland, Liestal, Switzerland|Internal Medicine, Kantonsspital Baselland/Liestal, Liestal, Switzerland|Stoffwechselzentrum, Kantonsspital Olten, Olten, Switzerland|Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland|GZO Spital Wetzikon, Wetzikon, Switzerland|Dept. of Endocrinology, Diabetology and Clinical Nutrition, University Hospital, Zürich, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Not yet recruiting,NCT04140201,DIABETIC RETINOPATHY,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT02015988,"ACUTE CORONARY SYNDROME|DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCERIDEMIA",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Institution ""Dnipropetrovsk Medical Academy of Health Ministry of Ukraine"", Dnipropetrovsk, Ukraine",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT02766803,"PCOS, INSULIN RESISTANCE",Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics, Poznan, Poland",C07D205/08 ,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT01021579,PCOS,Female,"16 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Zainabieh Hospital, Shiraz, Fars, Iran, Islamic Republic of",C07D205/08 ,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00522158,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR DISEASE|LDL CHOLESTEROL|COGNITION,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT01185236,TYPE 2 DIABETES MELLITUS WITHOUT INSULIN TREATMENT,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul national university hospital, Seoul, Korea, Republic of",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT01384058,DIABETES MELLITUS TYPE 2|HYPERCHOLESTEROLEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut für Stoffwechselforschung, Frankfurt, Germany|Stephan Jacob, MD, Villingen-.Schwenningen, Germany",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT02305355,"DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00699023,POSTPRANDIAL LIPEMIA|TYPE 2 DIABETES,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Clinical and Experimental Medicine, Federico II University Hospital,, Naples, Italy",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT02255682,CARDIOVASCULAR DISEASE|DIABETES MELLITUS,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of Copenhagen, Copenhagen, Denmark",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00506961,DIABETES MELLITUS|DYSLIPIDEMIA,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT00404599,DIABETES MELLITUS|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"VU University Medical Center, Amsterdam, Netherlands",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00157924,HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00079638,DYSLIPIDEMIA|CORONARY HEART DISEASE|ATHEROSCLEROSIS|STROKE|DIABETES,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CC(C)CC(NC(=O)CNC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,1,DB00644,__GONADORELIN,,Not yet recruiting,NCT03989024,POLYCYSTIC OVARY SYNDROME|INFERTILITY|OVULATION DISORDER,Female,24 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.09,1182.2901,474.63,17.0,16.0,6.0,121.19,302.51,31.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,1
CC(C)CC(NC(=O)CNC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,1,DB00644,__GONADORELIN,,Unknown status,NCT01278290,CENTRAL PRECOCIOUS PUBERTY|SEXUAL PRECOCITY,Female,3 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Ciudad Autónoma de Buenos Aires, Argentina",,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.09,1182.2901,474.63,17.0,16.0,6.0,121.19,302.51,31.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01225653,DIABETIC RETINOPATHY,All,20 Years to 36 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Ophthalmology, Århus University Hospital, Århus, Denmark",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
C=CCN.ClCC1CO1,1,DB00658,__SEVELAMER,5496545,Completed,NCT00211939,"CALCINOSIS|ARTERIOSCLEROSIS|HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Sciences Center, San Antonio, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,22.012772336187602,6.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.68,149.619,12.53,1.0,0.0,1.0,8.38,20.06,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,1,DB00661,__VERAPAMIL,5785994,Completed,NCT00235014,HYPERTENSION|DIABETES,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,1,DB00661,__VERAPAMIL,5785994,Completed,NCT00133692,HYPERTENSION|CORONARY ARTERY DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Gainesville, Florida, United States",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Completed,NCT01432015,OVARIAN CANCER|UTERINE CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Gynecologic Oncology Associates, Newport Beach, California, United States",B82Y5/00,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,NCT02479256,PCOS,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Ain Shams University Maternity Hospital, Cairo, Egypt",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00155064,HYPERALDOSTERONISM,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Taiwan University Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Terminated,NCT00456963,DIABETES MELLITUS|HYPERTENSION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Istituto Auxologico Italiano., Milan, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Not yet recruiting,NCT04238702,"DIABETES MELLITUS, TYPE 2|DIABETIC KIDNEY DISEASE",All,"35 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT01603940,HYPERTENSION|DIABETES,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00419835,MACROALBUMINURIC DIABETIC NEPHROPATHY,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT03006952,DIABETIC NEPHROPATHY,All,"38 Years to 76 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00168857,HYPERTENSION|DIABETIC NEPHROPATHY,All,"21 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Montgomery, Alabama, United States|Boehringer Ingelheim Investigational Site, Little Rock, Arkansas, United States|Boehringer Ingelheim Investigational Site, Lancaster, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|VA of Greater Los Angeles, Los Angeles, California, United States|UCI Medical Center, Orange, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Boehringer Ingelheim Investigational Site, Santa Ana, California, United States|UCLA Medical Center, Sylmar, California, United States|Torrance Clinical Research, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Boehringer Ingelheim Investigational Site, Wheatridge, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Largo, Florida, United States|Boehringer Ingelheim Investigational Site, Ocala, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Rush Presbyterian - St. Lukes Medical Center, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Demoine, Iowa, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States|Boehringer Ingelheim Investigational Site, Towson, Maryland, United States|Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Springfield, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Eatontown, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Boehringer Ingelheim Investigational Site, Flushing, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Harlem Hospital, New York, New York, United States|Northport VAMC - Medical Service (111), Northport, New York, United States|Wake Nephrology Associates, PA, Raleigh, North Carolina, United States|The Cleveland Foundation, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|University of Texas Health and Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Burlington, Vermont, United States|University of Virginia Health Science Center, Charlottesville, Virginia, United States|Boehringer Ingelheim Investigational Site, Gig Harbor, Washington, United States|Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, Buenos aIRES, Argentina|Clinica Coronel Suarez, Coronel Suarez, Argentina|Boehringer Ingelheim Investigational Site, Córdoba, Argentina|Boehringer Ingelheim Investigational Site, Paraná, Argentina|Boehringer Ingelheim Investigational Site, Provincia de Buenos Aires, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Santa Fé, Argentina|Hospital San Bernardo, Salta, Argentina|Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Lyell McEwin Hospital Department of medicine, Elizabeth, South Australia, Australia|Geelong Clinical Research Centre, Geelong, Victoria, Australia|Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia|Universidade Federal do Pará, Belém, Brazil|Boehringer Ingelheim Investigational Site, Botucatu, Brazil|Faculdade de Medicina Universidade Federal de Juiz de Fora, Juiz de Fora ¿ MG, Brazil|Boehringer Ingelheim Investigational Site, Vila Clementino, São Paulo, Brazil|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada|BC Endocrine Research Foundation, Vancouver, British Columbia, Canada|Endocrine Research Society, Vancouver, British Columbia, Canada|University of Manitoba, Diabetes Research Group, Winnipeg, Manitoba, Canada|Division of Respirology, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Credit Valley Hospital, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|The Ottawa Hospital - Riverside Campus, Ottawa, Ontario, Canada|LIfestyle Metabolism Centre - Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Timmins, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook & Woman's College Health Science Centre, Toronto, Ontario, Canada|Humber River Regional Hospital, Dialysis Unit, Weston, Ontario, Canada|Boehringer Ingelheim Investigational Site, Laval, Quebec, Canada|CHUM - Hote-Dieu, Montreal, Quebec, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Dongsan Medical Center, Daegu, Korea, Republic of|National Health Insurance Corporation, Ilsan Hospital, Gyunggido, Korea, Republic of|Yongdong Severance Hospital, Seoul, Korea, Republic of|Fracc. Magallanes, Acapulco Guerrero, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección XVI, Deleg. Tlalpan, Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Cardiology, Guadalajara, Mexico|Hospital Civil Nuevo de Guadalajara, Guadalajara, Mexico|Dep of Neurology, Metepec, Mexico|Cardiologia, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Hualien, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|Cathay General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Bumrungrad Hospital, Bangkok, Thailand|Pramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Division of Hypertension, Bangkok, Thailand|Thummasart University Hospital, Bangkok, Thailand|Maharaj Nakom Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00237588,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,"Cardiovascular and Renal Research Center/ Department of Cardiology, Ullevaal University Hospital, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Unknown status,NCT02935855,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Policlinico San Matteo, Pavia, Italy",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT02027311,CHOLEDOCHOLITHIASIS|CHOLANGIOCARCINOMA|PANCREATITIS|PANCREATIC CANCER,All,"20 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital, Jeju-si, Jeju Special Self-Governing Province, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT03474939,PREANESTHETIC MEDICATION|COPEPTIN,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","I Department of Anesthesiology and Intensive Care Medical University of Warsaw, Warsaw, Mazowieckie, Poland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00687,__FLUDROCORTISONE,4041055,Completed,,"SHOCK, SEPTIC",,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00687,__FLUDROCORTISONE,4041055,Withdrawn,,ADRENAL INSUFFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Withdrawn,NCT03315052,ACUTE CELLULAR GRAFT REJECTION|LIVER TRANSPLANT REJECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT03582878,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Clinical and Experimental Medicine, Prague, Czechia",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT01304836,KIDNEY TRANSPLANTATION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Perth, Australia|Sydney, Australia|Sydney, Australia|Brussels, Belgium|Bruxelles, Belgium|Leuven, Belgium|Liege, Belgium|Cali, Colombia|Brno, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Prague, Czechia|Tartu, Estonia|Helsinki, Finland|Bordeaux, France|Cite Nord, France|D'Angers, France|Le Puytren, France|Montpellier, France|Nantes, France|Nice, France|Paris, France|Rennes, France|Rouen, France|Strasbourg, France|Suresnes, France|Aachen, Germany|Bonn, Germany|Düsseldorf, Germany|Essen, Germany|Halle Saale, Germany|Kaiserslautern, Germany|Mannheim, Germany|Muenchen, Germany|Regensburg, Germany|Rostock, Germany|Debrecen, Hungary|Szeged, Hungary|Ancona, Italy|Bologna, Italy|Cagliari, Italy|L'Aquila, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Pisa, Italy|Roma, Italy|Salerno, Italy|Treviso, Italy|Vicenza, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Riga, Latvia|Vilnius, Lithuania|Cuernavaca, Mexico|Mexico City, Mexico|Maastricht, Netherlands|Olso, Norway|Bydgoszcz, Poland|Gdansk, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Bucharest, Romania|Lasi, Romania|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Omsk, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Vol'skiy, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Cordoba, Spain|Madrid, Spain|Madrid, Spain|Santa Cruz de Tenerife, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Valladolid, Spain|Goteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Bern, Switzerland",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT01742624,DE NOVO KIDNEY TRANSPLANTATION,All,"20 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul, Korea, Republic of|Suwon, Korea, Republic of|Ulsan, Korea, Republic of",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,1,DB00695,__FUROSEMIDE,3939713,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",G01N30/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,1,DB00700,__EPLERENONE,6410524,Completed,NCT02809963,DIABETES TYPE 2,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Herlev and Gentofte Hospital, Department of Endocrinology and Metabolism, Department of internal medicine,, Herlev, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,1,DB00700,__EPLERENONE,6410524,Unknown status,NCT00553722,HYPERTENSION|DIALYSIS|HYPERALDOSTERONISM,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","Shaare Zedek Medical Center, Jerusalem, Israel",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1,DB00704,__NALTREXONE,5792477,Recruiting,NCT04531176,TYPE 2 DIABETES|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,233.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,341.4009,70.0,5.0,2.0,6.0,35.97,91.5,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB00717,__NORETHISTERONE,6036976,Completed,NCT00732693,PREMATURE OVARIAN FAILURE,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom",A61K9/1647,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.905911825704802,1272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.72,298.4192,37.3,2.0,1.0,4.0,34.59,87.42,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Completed,NCT00311870,DIABETIC NEPHROPATHY,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Steno Diabetes Center, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Unknown status,NCT00430040,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetes - Endocrinology Center of Western New York, Buffalo, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Completed,NCT00241124,HYPERTENSION,All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Investigative Centers, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Terminated,NCT00171600,HYPERTENSION|EARLY DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Completed,NCT00171574,HYPERTENSION|DIABETIC NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT00858013,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Myongji Hospital, Ilsan, Kyounggi, Korea, Republic of|Hanyang University Medical Center, Guri-si, Kyunggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hallym University Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyung hee University Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon-si, Korea, Republic of",C07D213/82,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT01030952,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, China|Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai, China|Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai, China",C07D213/82,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT00437918,DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea, Republic of|Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of",C07D213/82,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT00369148,TYPE 2 DIABETS MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan|Hamamatsu Red Cross Hospital, Hamamatsu, Shizuoka, Japan|Saiseikai Central Hospital, Minato-ku, Tokyo, Japan|Kitasato Institute Hospital, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan",C07D213/82,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT00212290,INSULIN RESISTANCE|TYPE 2 DIABETES MELLITUS,All,"55 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, United States|VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, United States",C07D213/82,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,1,DB00731,__NATEGLINIDE,RE34878,Completed,NCT00319189,RENAL TRANSPLANT RECIPIENTS|POSTTRANSPLANT DIABETES MELLITUS|POSTTRANSPLANT IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rikshospitalet, Section of Nephrology, Oslo, Norway",C07D213/82,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.6389248239183,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,317.4290000000001,66.4,3.0,2.0,2.0,35.55,89.46,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Completed,NCT00245206,SCHIZOPHRENIA|ALZHEIMER'S DISEASE|DEMENTIA,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, San Diego, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Unknown status,NCT01742390,SEXUAL DYSFUNCTION|HYPERPROLACTINEMIA,All,"12 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of mental health, Peking University, Beijing, Beijing, China|The first hospital of Hebei Province University, Shijiazhuang, Hebei, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Completed,NCT00236379,SCHIZOPHRENIA|DIABETES MELLITUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Completed,NCT00287820,SCHIZOPHRENIA|DIABETES|METABOLIC SYNDROME|HYPERGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Psychaitric Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,"Active, not recruiting",NCT02775227,PANCREATIC FISTULA|PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT00415701,CORONARY ARTERY DISEASE|MITRAL VALVE REGURGITATION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departments of Intensive Care Medicine and Anesthesiology, Bern, BE, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Withdrawn,NCT00368381,SEPSIS|ADRENAL INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT01546922,ADRENAL INSUFFICIENCY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Medical Centre Groningen, Groningen, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Unknown status,NCT02190994,PITUITARY NEOPLASMS|CRANIOPHARYNGIOMAS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"West China Hospital, Sichuan University, Chengdu, Sichuan, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Unknown status,NCT00773058,ACUTE RESPIRATORY DISTRESS SYNDROME|ADRENAL INSUFFICIENCY,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Terminated,NCT01089075,PARTIAL CORTICOTROPE INSUFFICIENCY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Schön Klinik Bad Aibling, Bad Aibling, Bavaria, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT02044159,SHOCK,All,up to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Hospital St. Justine, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT00149123,BURN,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Sylvie TISSOT, Lyon, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB00742,__MANNITOL,3932678,Unknown status,NCT00677664,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of Sao Paulo, Sao Paulo, SP, Brazil",A23L27/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PERIODONTAL DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Unknown status,NCT02154074,PERIOPERATIVE BLOOD GLUCOSE AND INSULIN,All,"60 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SecondXianJiaotongU, Xi'an, Shanxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,1,DB00755,__TRETINOIN,5955109,Completed,,MELASMA,,,,,"FISABIO, Elche, Alicante, Spain",A61Q19/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,75.1391198997925,9501.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.66,300.442,37.3,2.0,1.0,1.0,36.85,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT01684813,DIABETES MELLITUS TYPE II|ACUTE CORONARY SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Virgen del Rocío, Seville, Spain",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Withdrawn,NCT02302508,DIABETES,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Unknown status,NCT01743014,DIABETES TYPE 2|DIABETIC NEPHROPATHY|VASCULAR DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AHEPA University Hospital, Thessaloniki, Greece|Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Unknown status,NCT02457130,CORONARY ARTERY DISEASE|DIABETES MELLITUS. TYPE 2,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Not yet recruiting,NCT04484259,"DIABETES MELLITUS, TYPE 2|CORONARY ARTERY DISEASE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Unknown status,NCT01643031,DIABETES MELLITUS|CORONARY DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rabin Medical Center, Petah-Tikva, Israel",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT02548650,MYOCARDIAL INFARCTION|DIABETES MELLITUS|PERIPHERAL ARTERIAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Recruiting,NCT03774394,CHRONIC KIDNEY DISEASE (CKD)|TYPE 2 DIABETES MELLITUS (T2DM)|CORONARY ARTERY DISEASE (CAD),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida Jacksonville, Jacksonville, Florida, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT02748330,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT00728156,TYPE 2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Newcastle Diabetes Centre, Newcastle General Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom|Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT02742987,CORONARY ARTERY DISEASE|DIABETES MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D495/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT03329261,"DIABETES MELLITUS, TYPE 2|NSTEMI - NON-ST SEGMENT ELEVATION MI|CORONARY ANGIOPLASTY",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HMPIT, Ben Arous, Tunisia",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Recruiting,NCT02983214,"ISCHEMIC STROKE|PERIPHERAL ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Epirus, Greece",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT01823510,TYPE-2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Completed,NCT02663713,MYOCARDIAL INFARCTION|DIABETES MELLITUS|RENAL DISEASE|CORONARY ARTERY DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Cardiology Department Patras University Hospital, Rio, Achaia, Greece",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150137,TOXIC NODULAR GOITRE|GRAVES DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150124,TOXIC NODULAR GOITRE|GRAVES' DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown status,NCT01722513,"KIDNEY DISEASES|DIABETES MELLITUS|ACUTE KIDNEY INJURY|KIDNEY FAILURE, CHRONIC|RENAL INSUFFICIENCY",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Department of Cardiology, Shanghai Tenth People's Hospital, Shanghai, Shanghai, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,1,DB00775,__TIROFIBAN,5658929,Unknown status,NCT00407771,CORONARY ARTERY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jordan Hospital, Amman, Jordan",C07C311/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,24.969711903735103,371.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,440.597,104.73,6.0,3.0,2.0,49.27,117.48,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,1,DB00775,__TIROFIBAN,5658929,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07C311/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,24.969711903735103,371.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,440.597,104.73,6.0,3.0,2.0,49.27,117.48,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NC(=O)N1c2ccccc2CC(=O)c2ccccc21,1,DB00776,__OXCARBAZEPINE,8119148,Completed,,NEURALGIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,134.080781946241,36.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.76,252.268,63.4,2.0,1.0,3.0,25.72,71.56,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT02352597,POLYCYSTIC OVARIES,Female,20 Years to 37 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Unknown status,NCT02186782,INFERTILITY|ANOVULATION,Female,20 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansoura, Dakahlia, Egypt|Private practice settings, Mansoura, Dakahlia, Egypt|Private practice settings, Mit Ghamr, Dakahlia, Egypt",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00640224,PCOS,Female,"10 Years to 20 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Not yet recruiting,NCT04002635,"INFERTILITY, FEMALE|POLYCYSTIC OVARY SYNDROME|IVF|OVULATION DISORDER",Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT01500863,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Instituto Valenciano de Infertilidad, Madrid, Spain",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT01511822,PCOS|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,,"Istituto di Patologia Ostetrica e Ginecologica, Catania, Italy",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Unknown status,NCT01103518,AMENORRHEA|DYSMENORRHEA|MENSTRUATION DISTURBANCES|HYPERANDROGENISM,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital das Clínicas de Teresópolis, Teresópolis, Rio de Janeiro, Brazil",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Withdrawn,NCT03724955,CYSTIC FIBROSIS RELATED BONE DISEASE,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Emory University Hospital, Atlanta, Georgia, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00837616,TURNER SYNDROME|HYPOGONADISM|PREMATURE OVARIAN FAILURE,Female,"13 Years to 20 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nemours Children's Clinic, Jacksonville, Florida, United States|Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Chile/Clinica las Condes, Santiago, Chile",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00134745,TURNER SYNDROME,Female,"10 Years to 25 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Unit, Hillerod Hospital, Hillerod, Frederiksborg County, Denmark",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00732693,PREMATURE OVARIAN FAILURE,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,1,DB00790,__PERINDOPRIL,5162362,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",C07K5/0222,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,106.482679315797,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.56,368.4678,95.94,5.0,2.0,2.0,39.99,95.69,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,1,DB00790,__PERINDOPRIL,5162362,Completed,NCT03393715,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07K5/0222,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,106.482679315797,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.56,368.4678,95.94,5.0,2.0,2.0,39.99,95.69,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Completed,NCT03006952,DIABETIC NEPHROPATHY,All,"38 Years to 76 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Recruiting,NCT03664414,CHRONIC KIDNEY DISEASE STAGE3 AND 4|TYPE 2 DIABETES MELLITUS,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cibimi - Hgz 83 Imss, Morelia, Michoacán, Mexico",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Completed,NCT01382303,TYPE 2 DIABETES,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ajou University Hospital, Suwon, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Recruiting,NCT03625648,DIABETIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,1,DB00808,__INDAPAMIDE,3962850,Completed,NCT00980187,HYPERTENSION|TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cardiology, University and Emergency Hospital, Bucharest, Romania",A01D45/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.47274071336161,323.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,365.835,92.5,4.0,2.0,3.0,36.34,103.31,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT01770483,"HEPATITIS C, CHRONIC|DIABETES MELLITUS TYPE 2",All,35 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Endocrinology and Diabetes management centre, Lahore, Punjab, Pakistan",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01308320,THYROID NEOPLASMS,Female,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Severance Hospital, Seoul, Korea, Republic of",A61N1/303,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02110745,"HERNIA, INGUINAL|CRYPTORCHIDISM",All,2 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Mustafa Kemal University Medicine Faculty Anesthesiology Department, Hatay, Turkey",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT04365686,SMOOTH EXTUBATION,Female,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Fayoum University hospital, Fayoum, Madīnat Al Fayyūm, Faiyum Governorate, Egypt, Egypt",0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00451776,CARDIAC SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University hospital, Saint-Etienne, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00415701,CORONARY ARTERY DISEASE|MITRAL VALVE REGURGITATION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departments of Intensive Care Medicine and Anesthesiology, Bern, BE, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Unknown status,NCT01189721,HYPERALGESIA,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gang Nam Severance Hospital, Yonsei University, Anesthesia and Pain Medicine Department,, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Withdrawn,NCT01326117,GASTROPARESIS|DIABETIC GASTROPARESIS|NAUSEA|VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT01803828,DIABETIC CARDIOMYOPATHY|DIABETES MELLITUS TYPE 2,All,"45 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dipartimento di Medicina Sperimentale - Sezione di Fisiopatologia Medica - Sapienza Università di Roma, Rome, Italy",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,1,DB00834,__MIFEPRISTONE,10500216,Completed,NCT01990560,MILD HYPERCORTISOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,85.0,242.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.33,429.5937,40.54,3.0,1.0,5.0,50.69,132.58,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00838,__CLOCORTOLONE,4376767,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",C07J71/0031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,129.0,26.3496170352573,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.73,410.907,74.6,4.0,2.0,4.0,41.8,105.74,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Suspended,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,1,DB00842,__OXAZEPAM,4028466,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,579.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,286.71299999999997,61.69,3.0,2.0,3.0,28.38,77.89,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Terminated,NCT00619983,DIABETIC NEUROPATHIC PAIN|CHRONIC LOW BACK PAIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT01743976,NEUROPATHIC PAIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,,SLEEP DEPRIVATION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,1,DB00857,__TERBINAFINE,5681849,Completed,,ONYCHOMYCOSIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,42.3499455840982,1651.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.51,291.4299,3.24,1.0,0.0,2.0,35.84,98.08,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT02344888,INFERTILITY|POLYCYSTIC OVARIAN SYNDROME,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Dakahlia, Egypt|Private practice settings, Mansourah, Dakahlia, Egypt",A61K9/0056,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01275638,SEPSIS,All,"17 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00312325,REGIONAL BLOOD FLOW|OPTIC DISK,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Pharmacology, Vienna, Austria",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Withdrawn,NCT03315052,ACUTE CELLULAR GRAFT REJECTION|LIVER TRANSPLANT REJECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Terminated,NCT01002339,"DIABETES MELLITUS, ADULT-ONSET",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Antonio Osuna, Granada, Andalucía, Spain|Domingo Hernández, Málaga, Andalucía, Spain|Carmen Díaz Corte, Oviedo, Asturias, Spain|Carlos Gómez Alamillo, Santander, Cantabria, Spain|Juan Manuel Díaz, Barcelona, Cataluña, Spain|Francisco Moreso, Barcelona, Cataluña, Spain|Francisco Valdés, La Coruña, Galicia, Spain|Armando Torres Ramírez, La Laguna, S/C de Tenerife, Spain|Roberto Gallego, Las Palmas de Gran Canaria, Spain|Luis Pallardo, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00296296,"KIDNEY TRANSPLANT|DIABETES MELLITUS, TYPE 2|DIABETIC NEPHROPATHY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford university Hospital and Clinics, Stanford, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01092806,POST TRANSPLANT DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Oslo univeristy hospital, Rikshospitalet, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00171496,KIDNEY TRANSPLANTATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Terminated,NCT00177138,DIABETES,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota-Fairview, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Unknown status,NCT01875224,NEW ONSET DIABETES AFTER TRANSPLANT|KIDNEY TRANSPLANTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"University of Arizona, Tucson, Arizona, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Unknown status,NCT02036554,"KIDNEY; COMPLICATIONS, ALLOGRAFT",All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"division of nephrology;Seoul St Mary's Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Not yet recruiting,NCT04496401,KIDNEY TRANSPLANTATION|PANCREAS TRANSPLANTATION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Nantes University Hospital, Nantes, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT01023919,CORONARY ARTERY DISEASE|DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The second Affiliated Hospital of Harbin Medical University, Harbin, Heilong jiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT01021930,CORONARY HEART DISEASE|DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The second Affiliated Hospital of Harbin Medical University, Harbin, Heilong jiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT03582878,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Clinical and Experimental Medicine, Prague, Czechia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Completed,NCT00497172,CORONARY ARTERY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Azienda USL Ravenna - Ospedale santa Maria delle Croci, Ravenna, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT02097615,SOFT TISSUE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Leon, Leon, Guanajuato, Mexico",A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT02062047,PERIODONTITIS|DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Recruiting,NCT03209466,DIABETIC FOOT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universidad de Guanajuato, Leon, Guanajuato, Mexico",A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,1,DB00881,__QUINAPRIL,5684016,Terminated,NCT00313547,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Heart Institute, Montreal, Quebec, Canada",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,29.4708310232242,575.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.39,438.5161,95.94,5.0,2.0,3.0,47.36,119.96,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,1,DB00881,__QUINAPRIL,5684016,Completed,NCT03031834,DIABETIC AUTONOMIC NEUROPATHY,All,"Child, Adult, Older Adult",Other,,,A61K38/556,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,29.4708310232242,575.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.39,438.5161,95.94,5.0,2.0,3.0,47.36,119.96,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Recruiting,NCT04306692,OVULATION INDUCTION|POLYCYSTIC OVARY SYNDROME|CLOMIPHENE|INOSITOL,Female,18 Years to 40 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Ghent, Belgium",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT04010942,PCOS|VITAMIN D DEFICIENCY,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ain Shams University Maternity hospital, Cairo, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT02352597,POLYCYSTIC OVARIES,Female,20 Years to 37 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Recruiting,NCT03806036,PCOS,Female,20 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kasr Alainy medical school, Cairo, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Not yet recruiting,NCT03989024,POLYCYSTIC OVARY SYNDROME|INFERTILITY|OVULATION DISORDER,Female,24 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT02802865,POLYCYSTIC OVARY SYNDROME|INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT01219101,INFERTILITY,Female,25 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royan Institute, Tehran, Iran, Islamic Republic of",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Recruiting,NCT02436226,INFERTILITY|POLYCYSTIC OVARIAN SYNDROME,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Egypt|Private practice settings, Mansourah, Egypt|Obstetrics and Gynecology Department in Port Said University, Port Said, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT01004068,POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT00558077,POLYCYSTIC OVARY SYNDROME|INFERTILITY|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Catanzaro/Italy, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT00471523,INFERTILITY|POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 41 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese Hospital"", Catanzaro, CZ, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Unknown status,NCT00461643,ANOVULATORY INFERTILITY RELATED TO POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy|""Pugliese"" Hospital, Catanzaro, Italy|Pugliese-Ciaccio Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Recruiting,NCT04157725,PCO - POLYCYSTIC OVARIES|INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"American University of Beirut Medical Center, Beirut, Lebanon",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Recruiting,NCT04302532,COENZYME Q10,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Aziz medical center, Karachi, Sindh, Pakistan",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Unknown status,NCT02186782,INFERTILITY|ANOVULATION,Female,20 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansoura, Dakahlia, Egypt|Private practice settings, Mansoura, Dakahlia, Egypt|Private practice settings, Mit Ghamr, Dakahlia, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],1,DB00883,__ISOSORBIDE_DINITRATE,6465463,Recruiting,NCT03514108,HEART FAILURE|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sygehus Sønderjylland, Aabenraa, Aabenraa, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Amager Hospital, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Copenhagen, Denmark|Glostrup Hospital, Copenhagen, Denmark|Herlev Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark|Herning Hospital, Herning, Denmark|Regionshospital Nordjylland, Hjørring, Hjørring, Denmark|Holbæk Hospital, Holbæk, Denmark|Horsens Hospital, Horsens, Denmark|Kolding Hospital, Kolding, Denmark|Nykøbing Falster Hospital, Nykøbing Falster, Denmark|Odense University Hospital, Odense, Denmark|Randers Hospital, Randers, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Vejle Hospital, Vejle, Denmark|Viborg Hospital, Viborg, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.199696092322196,1182.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.87,236.1363,123.2,8.0,0.0,2.0,18.15,42.76,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Unknown status,NCT01761149,NODULAR GOITER,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anesthesiology, The Second Xiangya Hospital, Changsha, Hunan, China",C07D211/58,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT02059655,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital of Wales, Cardiff, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01939977,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT03588884,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES|VITAMIN D DEFICIENCY|CKD STAGE 3|CKD STAGE 4,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institute of Clinical Research, Inc., Garden Grove, California, United States|Research by Design, LLC, Chicago, Illinois, United States|Spaulding Clinical Research, West Bend, Wisconsin, United States",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT00977080,CHRONIC KIDNEY DISEASE|SECONDARY HYPERPARATHYROIDISM|HEMODIALYSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 22781, Tempe, Arizona, United States|Site Reference ID/Investigator# 24342, Chula Vista, California, United States|Site Reference ID/Investigator# 21142, Los Angeles, California, United States|Site Reference ID/Investigator# 22762, Los Angeles, California, United States|Site Reference ID/Investigator# 22758, Riverside, California, United States|Site Reference ID/Investigator# 21442, San Diego, California, United States|Site Reference ID/Investigator# 23688, Arvada, Colorado, United States|Site Reference ID/Investigator# 21370, Coral Springs, Florida, United States|Site Reference ID/Investigator# 25902, Hudson, Florida, United States|Site Reference ID/Investigator# 21146, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 26743, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22788, Miami, Florida, United States|Site Reference ID/Investigator# 22722, Orlando, Florida, United States|Site Reference ID/Investigator# 23147, Tampa, Florida, United States|Site Reference ID/Investigator# 22778, Meridian, Idaho, United States|Site Reference ID/Investigator# 21369, Detroit, Michigan, United States|Site Reference ID/Investigator# 22786, Detroit, Michigan, United States|Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21443, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21145, Omaha, Nebraska, United States|Site Reference ID/Investigator# 22505, Flushing, New York, United States|Site Reference ID/Investigator# 22759, Toledo, Ohio, United States|Site Reference ID/Investigator# 22796, Lancaster, Pennsylvania, United States|Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22772, Aiken, South Carolina, United States|Site Reference ID/Investigator# 21147, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 22982, Houston, Texas, United States|Site Reference ID/Investigator# 21143, Houston, Texas, United States|Site Reference ID/Investigator# 22506, San Antonio, Texas, United States|Site Reference ID/Investigator# 22776, Bluefield, West Virginia, United States|Site Reference ID/Investigator# 22311, Brno, Czech Republic|Site Reference ID/Investigator# 22310, Jilemnice, Czech Republic|Site Reference ID/Investigator# 21624, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 22363, Aalborg, Denmark|Site Reference ID/Investigator# 23105, Copenhagen, Denmark|Site Reference ID/Investigator# 23909, Fredericia, Denmark|Site Reference ID/Investigator# 22462, Holstebro, Denmark|Site Reference ID/Investigator# 21748, Coburg, Germany|Site Reference ID/Investigator# 33268, Darmstadt, Germany|Site Reference ID/Investigator# 35903, Duesseldorf, Germany|Site Reference ID/Investigator# 21742, Frankfurt, Germany|Site Reference ID/Investigator# 21744, Heilbronn, Germany|Site Reference ID/Investigator# 21368, Luedenscheid, Germany|Site Reference ID/Investigator# 22362, Athens, Greece|Site Reference ID/Investigator# 38970, Thessaloniki, Greece|Site Reference ID/Investigator# 22322, Thessaloniki, Greece|Site Reference ID/Investigator# 22463, Thessaloniki, Greece|Site Reference ID/Investigator# 22323, Thessaloniki, Greece|Site Reference ID/Investigator# 39262, Thessaloniki, Greece|Site Reference ID/Investigator# 22312, Bergamo, Italy|Site Reference ID/Investigator# 21746, Genova, Italy|Site Reference ID/Investigator# 39180, Lucca, Italy|Site Reference ID/Investigator# 22314, Milan, Italy|Site Reference ID/Investigator# 21367, Pavia, Italy|Site Reference ID/Investigator# 21745, Pesaro, Italy|Site Reference ID/Investigator# 21842, Alkmaar, Netherlands|Site Reference ID/Investigator# 22309, Delft, Netherlands|Site Reference ID/Investigator# 21843, Dordrecht, Netherlands|Site Reference ID/Investigator# 38903, Beja, Portugal|Site Reference ID/Investigator# 38531, Faro, Portugal|Site Reference ID/Investigator# 22464, Lisbon, Portugal|Site Reference ID/Investigator# 23910, Vila Franca de Xira, Portugal|Site Reference ID/Investigator# 24643, Moscow, Russian Federation|Site Reference ID/Investigator# 24642, Moscow, Russian Federation|Site Reference ID/Investigator# 21361, Barcelona, Spain|Site Reference ID/Investigator# 21364, Cordoba, Spain|Site Reference ID/Investigator# 22366, L'Hospitalet, Barcelona, Spain|Site Reference ID/Investigator# 38343, Madrid, Spain|Site Reference ID/Investigator# 21362, Madrid, Spain|Site Reference ID/Investigator# 21363, Palma de Mallorca, Spain|Site Reference ID/Investigator# 22367, Pamplona, Spain|Site Reference ID/Investigator# 38462, Puerto de la Cruz, Spain|Site Reference ID/Investigator# 21365, Seville, Spain|Site Reference ID/Investigator# 23913, Linkoping, Sweden|Site Reference ID/Investigator# 23782, Stockholm, Sweden|Site Reference ID/Investigator# 22364, Uppsala, Sweden|Site Reference ID/Investigator# 23912, Birmingham, United Kingdom|Site Reference ID/Investigator# 21747, Coventry, United Kingdom|Site Reference ID/Investigator# 23102, London, United Kingdom|Site Reference ID/Investigator# 23104, London, United Kingdom|Site Reference ID/Investigator# 23103, Manchester, United Kingdom|Site Reference ID/Investigator# 41982, Omagh, Northern Ireland, United Kingdom|Site Reference ID/Investigator# 40222, Sheffield, United Kingdom",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT00958451,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA Medical Center, Salem, Virginia, United States",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01768351,ANEMIA|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT00307840,SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Terminated,NCT00664430,SECONDARY HYPERPARATHYROIDISM|DIALYSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 7118, Sao Paulo, Brazil|Site Reference ID/Investigator# 7114, Sao Paulo, Brazil",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Unknown status,NCT03023748,ENDSTAGE RENAL DISEASE|SECONDARY HYPERPARATHYROIDISM,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01506947,MODERATE TO SEVERE SECONDARY HYPERPARATHYROIDISM|STAGE 5 CHRONIC KIDNEY DISEASES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT00053547,SECONDARY HYPERPARATHYROIDISM|END STAGE RENAL DISEASE,All,"2 Years to 20 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States|Miami Children's Hospital, Miami, Florida, United States|The Children's Hospital of Buffalo, Buffalo, New York, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas at Houston, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",C07C401/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Terminated,NCT01725113,KIDNEY FAILURE|SECONDARY HYPERPARATHYROIDISM|HYPERPHOSPHATEMIA|HYPERCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Winthrop University Hospital, Mineola, New York, United States",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01331317,CARDIOVASCULAR DISEASE|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Steno Diabetes Center A/S, Gentofte, Denmark",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C401/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,NCT01709305,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,NCT02694263,"DIABETES MELLITUS, TYPE 2",All,"25 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,NCT00568984,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Ipoh, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Cebu City, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Marikina City, Philippines|Novo Nordisk Investigational Site, Pampanga, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Quezon, Philippines|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,NCT03824002,DIABETES,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Internal Medicine Ward, University of Palermo, Palermo, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
NC12CC3CC(CC(C3)C1)C2,1,DB00915,__AMANTADINE,RE39069,Terminated,NCT00975611,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Freedom Trail Clinic, Boston, Massachusetts, United States",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,54.0,52.4692498819277,1321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.53,151.2487,26.02,1.0,1.0,3.0,17.92,45.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Withdrawn,NCT03891979,PANCREATIC CANCER,All,"18 Months to 100 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Langone Health, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Active Not Recruiting,,PERI-IMPLANTITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0078,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,1,DB00929,__MISOPROSTOL,5601843,Completed,,HEMORRHAGE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,30.8507361547465,370.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,382.5341,83.83,4.0,2.0,1.0,45.38,107.88,14.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,"Active, not recruiting",NCT03794336,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHINA, China, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT02670304,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Not yet recruiting,NCT04484259,"DIABETES MELLITUS, TYPE 2|CORONARY ARTERY DISEASE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT02548650,MYOCARDIAL INFARCTION|DIABETES MELLITUS|PERIPHERAL ARTERIAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT02748330,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01823510,TYPE-2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT04307511,ACUTE CORONARY SYNDROME PATIENTS WITH DIABETES AFTER PCI,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"shanghai Tongren hospital, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT00793754,DIABETES,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT04352439,VENOUS THROMBOEMBOLISM|OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Duke University Hospital, Durham, North Carolina, United States",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT02520921,DIABETES MELLITUS|ACUTE CORONARY SYNDROME|CORONARY ARTERY DISEASE|OBESITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Cardiology - Lariboisiere Hospital, Paris, France",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT00427271,DIABETES MELLITUS|MICROALBUMINURIA,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital de Clínicas de Porto Aelgre, Porto Alegre, RS, Brazil",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01397513,"DIABETES MELLITUS, TYPE 1",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT03248401,TYPE 2 DIABETES MELLITUS|CAROTID ATHEROSCLEROSIS,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01201785,TYPE 2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Florida, Jacksonville, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT00110448,"CORONARY DISEASE|ARTERIOSCLEROSIS|DIABETES MELLITUS, TYPE 2",All,"30 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan|Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT00225849,HYPERTENSION|HYPERLIPIDEMIA|DIABETES MELLITUS,All,"60 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Keio University School of Medicine, Tokyo, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT03188471,OVARIAN HYPERSTIMULATION SYNDROME|GNRH ANTAGONIST|ASPIRIN|VASCULAR ENDOTHELIAL GROWTH FACTOR|PIGMENT EPITHELIUM DERIVED FACTOR,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The First Affiliated Hospital of Sun Yatsen University, Guangzhou, Guangdong, China",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Recruiting,NCT04224428,DIABETIC KIDNEY DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Pharmacy, Tanta University, Tanta, Egypt",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Withdrawn,NCT03498534,LATENT TUBERCULOSIS|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Completed,NCT03278483,DIABETES MELLITUS|TUBERCULIN (SKIN TEST) POSITIVE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Not yet recruiting,NCT03098225,THYROID ASSOCIATED OPHTHALMOPATHY,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT03948191,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years to 76 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00168857,HYPERTENSION|DIABETIC NEPHROPATHY,All,"21 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Montgomery, Alabama, United States|Boehringer Ingelheim Investigational Site, Little Rock, Arkansas, United States|Boehringer Ingelheim Investigational Site, Lancaster, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|VA of Greater Los Angeles, Los Angeles, California, United States|UCI Medical Center, Orange, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Boehringer Ingelheim Investigational Site, Santa Ana, California, United States|UCLA Medical Center, Sylmar, California, United States|Torrance Clinical Research, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Boehringer Ingelheim Investigational Site, Wheatridge, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Largo, Florida, United States|Boehringer Ingelheim Investigational Site, Ocala, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Rush Presbyterian - St. Lukes Medical Center, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Demoine, Iowa, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States|Boehringer Ingelheim Investigational Site, Towson, Maryland, United States|Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Springfield, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Eatontown, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Boehringer Ingelheim Investigational Site, Flushing, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Harlem Hospital, New York, New York, United States|Northport VAMC - Medical Service (111), Northport, New York, United States|Wake Nephrology Associates, PA, Raleigh, North Carolina, United States|The Cleveland Foundation, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|University of Texas Health and Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Burlington, Vermont, United States|University of Virginia Health Science Center, Charlottesville, Virginia, United States|Boehringer Ingelheim Investigational Site, Gig Harbor, Washington, United States|Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, Buenos aIRES, Argentina|Clinica Coronel Suarez, Coronel Suarez, Argentina|Boehringer Ingelheim Investigational Site, Córdoba, Argentina|Boehringer Ingelheim Investigational Site, Paraná, Argentina|Boehringer Ingelheim Investigational Site, Provincia de Buenos Aires, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Santa Fé, Argentina|Hospital San Bernardo, Salta, Argentina|Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Lyell McEwin Hospital Department of medicine, Elizabeth, South Australia, Australia|Geelong Clinical Research Centre, Geelong, Victoria, Australia|Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia|Universidade Federal do Pará, Belém, Brazil|Boehringer Ingelheim Investigational Site, Botucatu, Brazil|Faculdade de Medicina Universidade Federal de Juiz de Fora, Juiz de Fora ¿ MG, Brazil|Boehringer Ingelheim Investigational Site, Vila Clementino, São Paulo, Brazil|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada|BC Endocrine Research Foundation, Vancouver, British Columbia, Canada|Endocrine Research Society, Vancouver, British Columbia, Canada|University of Manitoba, Diabetes Research Group, Winnipeg, Manitoba, Canada|Division of Respirology, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Credit Valley Hospital, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|The Ottawa Hospital - Riverside Campus, Ottawa, Ontario, Canada|LIfestyle Metabolism Centre - Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Timmins, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook & Woman's College Health Science Centre, Toronto, Ontario, Canada|Humber River Regional Hospital, Dialysis Unit, Weston, Ontario, Canada|Boehringer Ingelheim Investigational Site, Laval, Quebec, Canada|CHUM - Hote-Dieu, Montreal, Quebec, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Dongsan Medical Center, Daegu, Korea, Republic of|National Health Insurance Corporation, Ilsan Hospital, Gyunggido, Korea, Republic of|Yongdong Severance Hospital, Seoul, Korea, Republic of|Fracc. Magallanes, Acapulco Guerrero, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección XVI, Deleg. Tlalpan, Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Cardiology, Guadalajara, Mexico|Hospital Civil Nuevo de Guadalajara, Guadalajara, Mexico|Dep of Neurology, Metepec, Mexico|Cardiologia, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Hualien, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|Cathay General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Bumrungrad Hospital, Bangkok, Thailand|Pramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Division of Hypertension, Bangkok, Thailand|Thummasart University Hospital, Bangkok, Thailand|Maharaj Nakom Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00240422,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Lyon, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Friedrich-Alexander-Universität, Erlangen, Germany|Boehringer Ingelheim Investigational Site, Nürnberg, Germany|Universität Erlangen-Nürnberg, Nürnberg, Germany|Edificio de Medicina Comunitaria, Madrid, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00239538,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"30 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Green Hospital, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States|Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|Memorial Research Medical Clinic, Long Beach, California, United States|1200, Los Angeles, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|8615, Nuena Park, California, United States|Boehringer Ingelheim Investigational Site, Orange, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|595, San Francisco, California, United States|1805, Stockton, California, United States|Boehringer Ingelheim Investigational Site, Torrance, California, United States|2311, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|6448, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States|Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pinellas Park, Florida, United States|Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States|Herron Medical Center, Ltd., Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Orland Park, Illinois, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Shawnee, Kansas, United States|Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|200, Baltimore, Maryland, United States|Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|12401, St.Louis, Missouri, United States|Boehringer Ingelheim Investigational Site, Missoula, Montana, United States|Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|3, Buffalo, New York, United States|Comprehensive Clinical Research, Berlin, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston Salem, North Carolina, United States|Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|Boehringer Ingelheim Investigational Site, Marion, Ohio, United States|Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|Boehringer Ingelheim Investigational Site, Broomal, Pennsylvania, United States|6605, Bartlett, Tennessee, United States|108, Fayetteville, Tennessee, United States|Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|7777, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, El Paso, Texas, United States|Team Research of Texas, Harker Heights, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|420, Salt Lake City, Utah, United States|20901, Ettrick, Virginia, United States|Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|5000, Miwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, BsAs, Argentina|Boehringer Ingelheim Investigational Site, Coronel Suárez, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Sta. Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Emeritus Research, Malvern, Victoria, Australia|Boehringer Ingelheim Investigational Site, Prahran, Victoria, Australia|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Conquitlam, British Columbia, Canada|Dr. Hugh Tildesley, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, North York, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|Boehringer Ingelheim Investigational Site, Orleans, Ontario, Canada|Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Thunder Bay, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|91 Thomas-Chapais, Boucherville, Quebec, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|Pavillon St. Sacrement, Sainte-Foy, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|c/o Hemodynamics Offices, Saskatoon, Saskatchewan, Canada|Inje University Pusan Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Col. Del Valle, Mexico|Boehringer Ingelheim Investigational Site, Col. Magdalena de las Salinas, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección 16, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Zapopan, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|National Taiwan University Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00599885,HYPERTENSION|DIABETES|CORONARY ARTERY DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Korea University Anam Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00153023,DIABETIC NEPHROPATHIES|HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Hospital St. Anna, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|University Hospital Vihohrady, Prague 10, Czech Republic|General University Hospital, Prague 2, Czech Republic|District Hospital Tabor, Tabor, Czech Republic|Masaryk Hospital, Usti nad Labem, Czech Republic|Hospital Usti nad Orlici, Usti nad Orlici, Czech Republic|Medical Department, Copenhagen NV, Denmark|Medicinsk afdeling, Fredericia, Denmark|Medicinsk afdeling F, Endokrinologisk, Hiller?d, Denmark|Endokrinologisk afdeling, Hvidovre, Denmark|Medical Department, Roskilde, Denmark|Chu Sud, Amiens, France|Centre Hospitalier, Beauvais, France|Hopital Duchenne, Boulogne sur Mer cedex, France|Hopital Clemenceau, Caen cedex 5, France|Centre Hospitalier, Dunkerque, France|Hopital Albert Michalon, La Tronche, France|Hopital A.Mignot, Le Chesnay, France|Hopital Maison Blanche, Reims, France|Hopital Yves Le Foll, Saint Brieuc cedex 1, France|Hopital Saint Quentin, Saint Quentin, France|Centre Hospitalier, Valenciennes, France|Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|Diabetes Klinik Bad Mergentheim, Bad Mergentheim, Germany|Institut fur Klinische Forschung, Berlin, Germany|Charite Campus Buch, Berlin, Germany|KFH Dialysezentrum, Eberswalde, Germany|Universitatsklinik Heidelberg, Heidelberg, Germany|Boehringer Ingelheim Investigational Site, Karlsruhe, Germany|Institut fur Klinische Forschung, Mainz, Germany|Boehringer Ingelheim Investigational Site, Munster, Germany|Boehringer Ingelheim Investigational Site, Neuwied, Germany|Boehringer Ingelheim Investigational Site, Pirna, Germany|Boehringer Ingelheim Investigational Site, Riesa, Germany|Boehringer Ingelheim Investigational Site, Rosenheim, Germany|Boehringer Ingelheim Investigational Site, Saarbrucken, Germany|Boehringer Ingelheim Investigational Site, Saarlouis, Germany|Boehringer Ingelheim Investigational Site, Sinsheim, Germany|Boehringer Ingelheim Investigational Site, Speyer, Germany|Internist, Wurzburg, Germany|Azienda Ospedaliera Policlinico S. Orsola Malpighi, Bologna, Italy|Ospedali Riuniti di Livorno, Livorno, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Italy|Universita degli Studi ""Federico II"", Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IRCCS Policlinico S.Matteo, Pavia, Italy|Policlinico Monteluce, Perugia, Italy|Azienda Ospedaliera S. Maria degli Angeli, Pordenone, Italy|Ospedale ""S. Maria delle Croci"", Ravenna, Italy|Universita Tor Vergata, Roma, Italy|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Yonsei University Medical Center, Seoul, Korea, Republic of|Hospital Ipoh, Ipoh, Perak, Malaysia|University Sains Malaysia, Kelantan, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Penang General Hospital, Penang, Malaysia|Hospital Putrajaya, Selangor, Malaysia|Centro Hospitalar de Coimbra, Coimbra, Portugal|Hospital Distrital de Faro, Faro, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Hospital de Santa Marta, Lisboa, Portugal|Associac?o Protectora dos Diabeticos de Portugal, Lisboa, Portugal|Hospital Curry Cabral, Lisbon, Portugal|Hospital Pedro Hispano, Matosinhos, Portugal|Hospital de S. Jo?o, Porto, Portugal|Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Medical Academy named Sechenova I.M., Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|National Endocrinology Research Center of Russia, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|President's Medical Center, Moscow, Russian Federation|Russian Cardiology Research Center, Moscow, Russian Federation|Russian Academy for Advanced Medical Studies, Moscow, Russian Federation|Moscow President's Medical Center, Moscow, Russian Federation|Regional Clinical Scientific Research Institute, Moscow, Russian Federation|City Hospital of Saint Elizaveta, St. Petersburg, Russian Federation|Military Medical Academy, St. Petersburg, Russian Federation|NovaMed, Banska Bystrica, Slovakia|Ministry Hospital of Internal Affairs, Bratislava, Slovakia|Faculty Hospital, Bratislava, Slovakia|Faculty Hospital of L. Derer, Bratislava, Slovakia|Diabetologic and Internal Clinic, Lucenec, Slovakia|Faculty Hospital, Nitra, Slovakia|Hospital Nove Mesto, Nove Mesto, Slovakia|Regional Hospital Nove Zamky, Nove Zamky, Slovakia|MSP-DIAGNOSTIK, Ltd., Trencin, Slovakia|Faculty Hospital Trnava, Trnava, Slovakia|Hospital Torrecardenas, Almeria, Spain|Hospital Ntra. Sra de Sonsoles, Avila, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital de Cabuenes, Gijon, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Buddhist Tzu Chi Hospital, Hualien City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chi Mei Medical Center, Taiwan, Taiwan|Dnyepropyetrovsk Medical Academy, Dnyepropetrovsk, Ukraine|Kharkiv Medical State University, Kharkov, Ukraine|Institute of Diabetic pathology problems, Kharkov, Ukraine|Institute of Cardiology, Kiev, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism, Kiev, Ukraine|Kyiv Clinical Hospital No. 1, Kyiv, Ukraine|Zaporozhye Regional Clinical Hospital, Zaporozhye, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Withdrawn,NCT03504566,DIABETIC NEPHROPATHY TYPE 2,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT02079805,ESSENTIAL HYPERTENSION COMPLICATED BY TYPE 2 DIABETES MELLITUS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kyoto-Shi, Kyoto, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Terminated,NCT00559286,ARTERIAL HYPERTENSION|DIABETES MELLITUS TYPE 2 IRC OR NIR,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital, Aachen, NRW, Germany",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT00153088,DIABETIC NEPHROPATHY,All,"30 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Adachi-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Amagasaki, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Arakawa-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Asaguchi-gun, Okayama, Japan|Boehringer Ingelheim Investigational Site, Asahi, Chiba, Japan|Boehringer Ingelheim Investigational Site, Asahikawa, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Asahikwa, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Atami, Shizuoka, Japan|Boehringer Ingelheim Investigational Site, Atsugi,Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Chikugo, Fukuoka, Japan|Boehringer Ingelheim Investigational Site, Chisagata-gun, Nagano, Japan|Boehringer Ingelheim Investigational Site, Chisagata-gun, Nagano, Japan|Boehringer Ingelheim Investigational Site, Chitose, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Chiyoda, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Ebina, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Fujisawa, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|Boehringer Ingelheim Investigational Site, Fukuyama, Hiroshima, Japan|Boehringer Ingelheim Investigational Site, Funabashi, Chiba, Japan|Boehringer Ingelheim Investigational Site, Furukawa, Miyagi, Japan|Boehringer Ingelheim Investigational Site, Gifu, Gifu, Japan|Boehringer Ingelheim Investigational Site, Gobo, Wakayama, Japan|Boehringer Ingelheim Investigational Site, Hachioji, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Hakodate, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Hanamaki, Iwate, Japan|Boehringer Ingelheim Investigational Site, Hannan, Osaka, Japan|Boehringer Ingelheim Investigational Site, Hashima-gun, Gifu, Japan|Boehringer Ingelheim Investigational Site, Hatsukaichi, Hiroshima, Japan|Boehringer Ingelheim Investigational Site, Hirakata, Osaka, Japan|Boehringer Ingelheim Investigational Site, Hitachiota, Ibaragi, Japan|Boehringer Ingelheim Investigational Site, Ichinomiya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Iida, Nagano, Japan|Boehringer Ingelheim Investigational Site, Ikeda, Osaka, Japan|Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaragi, Japan|Boehringer Ingelheim Investigational Site, Isehara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Isezaki, Gunma, Japan|Boehringer Ingelheim Investigational Site, Itami, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Izumisano, Osaka, Japan|Boehringer Ingelheim Investigational Site, Kamakura, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kamakura, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kamogawa, Chiba, Japan|Boehringer Ingelheim Investigational Site, Katsushika-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Kawagoe, Saitama, Japan|Boehringer Ingelheim Investigational Site, Kawaguchi, Saitama, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Kisarazu, Chiba, Japan|Boehringer Ingelheim Investigational Site, Kita-katushika-gun, Saitama, Japan|Boehringer Ingelheim Investigational Site, Kita-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Kitami, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Kobe, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Kobe, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Kochi, Kochi, Japan|Boehringer Ingelheim Investigational Site, Kochi, Kochi, Japan|Boehringer Ingelheim Investigational Site, Kodaira, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Kodaira, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Komaki, Aichi, Japan|Boehringer Ingelheim Investigational Site, Komatsushima, Tokushima, Japan|Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan|Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan|Boehringer Ingelheim Investigational Site, Koriyama,Fukushima, Japan|Boehringer Ingelheim Investigational Site, Kounan, Aichi, Japan|Boehringer Ingelheim Investigational Site, Kumagaya, Saitama, Japan|Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan|Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan|Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan|Boehringer Ingelheim Investigational Site, Matsuyama, Ehime, Japan|Boehringer Ingelheim Investigational Site, Matsuyama, Ehime, Japan|Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|Boehringer Ingelheim Investigational Site, Nakano-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Nangoku, Kochi, Japan|Boehringer Ingelheim Investigational Site, Nishinomiya, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Nishinomiya, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Nishinomiya, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Noda, Chiba, Japan|Boehringer Ingelheim Investigational Site, Nomi, Ishikawa, Japan|Boehringer Ingelheim Investigational Site, Obihiro, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Odawara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Oita, Oita, Japan|Boehringer Ingelheim Investigational Site, Okawa, Fukuoka, Japan|Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan|Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan|Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan|Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|Boehringer Ingelheim Investigational Site, Osaka-sayama, Osaka, Japan|Boehringer Ingelheim Investigational Site, Osaka, Japan|Boehringer Ingelheim Investigational Site, Otaru, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Oyama, Tochigi, Japan|Boehringer Ingelheim Investigational Site, Sagamihara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Sagamihara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Sakai, Osaka, Japan|Boehringer Ingelheim Investigational Site, Sakai, Osaka, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan|Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan|Boehringer Ingelheim Investigational Site, Setagaya-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Seto, Aichi, Japan|Boehringer Ingelheim Investigational Site, Shibetsu, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Shibuya-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Shibuya-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Shinagawa, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Shinjyuku-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Shiojiri, Nagano, Japan|Boehringer Ingelheim Investigational Site, Sunagawa, Hokkaido, Japan|Boehringer Ingelheim Investigational Site, Takamatsu, Kagawa, Japan|Boehringer Ingelheim Investigational Site, Takarazuka, Hyogo, Japan|Boehringer Ingelheim Investigational Site, Takasaki, Gunma, Japan|Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan|Boehringer Ingelheim Investigational Site, Tama, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Toride, Ibaraki, Japan|Boehringer Ingelheim Investigational Site, Tosu, Saga, Japan|Boehringer Ingelheim Investigational Site, Toyohashi, Aichi, Japan|Boehringer Ingelheim Investigational Site, Toyohashi, Aichi, Japan|Boehringer Ingelheim Investigational Site, Toyota, Aichi, Japan|Boehringer Ingelheim Investigational Site, Tsuchiura, Ibaraki, Japan|Boehringer Ingelheim Investigational Site, Tsuchiura,Ibaraki, Japan|Boehringer Ingelheim Investigational Site, Tsukuba, Ibaragi, Japan|Boehringer Ingelheim Investigational Site, Uji, Kyoto, Japan|Boehringer Ingelheim Investigational Site, Ushiku, Ibaraki, Japan|Boehringer Ingelheim Investigational Site, Uwajima, Ehime, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT02642159,DYSLIPIDEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840-163, Little Rock, Arkansas, United States|Investigational Site Number 840-141, Fresno, California, United States|Investigational Site Number 840-152, Huntington Beach, California, United States|Investigational Site Number 840-115, La Jolla, California, United States|Investigational Site Number 840-118, Los Angeles, California, United States|Investigational Site Number 840-106, Northridge, California, United States|Investigational Site Number 840-176, Port Hueneme, California, United States|Investigational Site Number 840-122, Tarzana, California, United States|Investigational Site Number 840-156, Tustin, California, United States|Investigational Site Number 840-160, Van Nuys, California, United States|Investigational Site Number 840-107, Boca Raton, Florida, United States|Investigational Site Number 840-170, Boynton Beach, Florida, United States|Investigational Site Number 840-114, Bradenton, Florida, United States|Investigational Site Number 840-132, Ocoee, Florida, United States|Investigational Site Number 840-179, Oviedo, Florida, United States|Investigational Site Number 840-123, Tampa, Florida, United States|Investigational Site Number 840-137, Bainbridge, Georgia, United States|Investigational Site Number 840-128, Columbus, Georgia, United States|Investigational Site Number 840-169, Stockbridge, Georgia, United States|Investigational Site Number 840-167, Idaho Falls, Idaho, United States|Investigational Site Number 840-161, Chicago, Illinois, United States|Investigational Site Number 840-184, Crystal Lake, Illinois, United States|Investigational Site Number 840-174, Evanston, Illinois, United States|Investigational Site Number 840-138, Springfield, Illinois, United States|Investigational Site Number 840-108, Louisville, Kentucky, United States|Investigational Site Number 840-183, Paducah, Kentucky, United States|Investigational Site Number 840-190, Metairie, Louisiana, United States|Investigational Site Number 840-151, Rockville, Maryland, United States|Investigational Site Number 840-113, Jefferson City, Missouri, United States|Investigational Site Number 840-120, Saint Louis, Missouri, United States|Investigational Site Number 840-148, Omaha, Nebraska, United States|Investigational Site Number 840-101, Las Vegas, Nevada, United States|Investigational Site Number 840-140, Las Vegas, Nevada, United States|Investigational Site Number 840-178, Albany, New York, United States|Investigational Site Number 840-181, New York, New York, United States|Investigational Site Number 840-157, New York, New York, United States|Investigational Site Number 840-188, Greensboro, North Carolina, United States|Investigational Site Number 840-131, Morehead City, North Carolina, United States|Investigational Site Number 840-158, Morganton, North Carolina, United States|Investigational Site Number 840-129, Fargo, North Dakota, United States|Investigational Site Number 840-104, Columbus, Ohio, United States|Investigational Site Number 840-105, Marion, Ohio, United States|Investigational Site Number 840-175, Maumee, Ohio, United States|Investigational Site Number 840-136, Bend, Oregon, United States|Investigational Site Number 840-187, Murrells Inlet, South Carolina, United States|Investigational Site Number 840-111, Summerville, South Carolina, United States|Investigational Site Number 840-147, Chattanooga, Tennessee, United States|Investigational Site Number 840-159, Knoxville, Tennessee, United States|Investigational Site Number 840-153, Dallas, Texas, United States|Investigational Site Number 840-143, Houston, Texas, United States|Investigational Site Number 840-168, Houston, Texas, United States|Investigational Site Number 840-142, Round Rock, Texas, United States|Investigational Site Number 840-133, Tomball, Texas, United States|Investigational Site Number 840-185, Orem, Utah, United States|Investigational Site Number 840-150, Salt Lake City, Utah, United States|Investigational Site Number 840-126, Chesapeake, Virginia, United States|Investigational Site Number 840-171, Richmond, Virginia, United States|Investigational Site Number 036102, Herston, Australia|Investigational Site Number 036104, Merewether, Australia|Investigational Site Number 036101, St Leonards, Australia|Investigational Site Number 076103, Campinas, Brazil|Investigational Site Number 076104, Fortaleza, Brazil|Investigational Site Number 076101, Sao Paulo, Brazil|Investigational Site Number 076105, São paulo, Brazil|Investigational Site Number 076106, São Paulo, Brazil|Investigational Site Number 076102, SãO Paulo, Brazil|Investigational Site Number 246102, Oulu, Finland|Investigational Site Number 246101, Oulu, Finland|Investigational Site Number 246104, Tampere, Finland|Investigational Site Number 276112, Berlin, Germany|Investigational Site Number 276109, Berlin, Germany|Investigational Site Number 276104, Dippoldiswalde, Germany|Investigational Site Number 276101, Dresden, Germany|Investigational Site Number 276110, Essen, Germany|Investigational Site Number 276108, Essen, Germany|Investigational Site Number 276111, Goch, Germany|Investigational Site Number 276107, Karlsruhe, Germany|Investigational Site Number 276103, Künzing, Germany|Investigational Site Number 276102, Oldenburg in Holstein, Germany|Investigational Site Number 376101, Beer Sheva, Israel|Investigational Site Number 376103, Petach Tikva, Israel|Investigational Site Number 376104, Petach tikva, Israel|Investigational Site Number 376102, Rehovot, Israel|Investigational Site Number 376106, Tel-Aviv, Israel|Investigational Site Number 380104, Bergamo, Italy|Investigational Site Number 380107, Catanzaro, Italy|Investigational Site Number 380103, Napoli, Italy|Investigational Site Number 380108, Padova, Italy|Investigational Site Number 380106, Partinico, Italy|Investigational Site Number 380101, Pisa, Italy|Investigational Site Number 380105, Roma, Italy|Investigational Site Number 380102, Torino, Italy|Investigational Site Number 414101, Kuwait, Kuwait|Investigational Site Number 422101, Beirut, Lebanon|Investigational Site Number 422102, Hazmieh, Lebanon|Investigational Site Number 578101, Oslo, Norway|Investigational Site Number 578102, Oslo, Norway|Investigational Site Number 752102, Göteborg, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 756101, Genève, Switzerland|Investigational Site Number 756102, Olten, Switzerland|Investigational Site Number 756103, Reinach, Switzerland|Investigational Site Number 792105, Adana, Turkey|Investigational Site Number 792106, Ankara, Turkey|Investigational Site Number 792102, Ankara, Turkey|Investigational Site Number 792108, Corum, Turkey|Investigational Site Number 792109, Hatay, Turkey|Investigational Site Number 792104, Izmir, Turkey|Investigational Site Number 792101, Izmir, Turkey|Investigational Site Number 792110, Izmir, Turkey|Investigational Site Number 792107, Kayseri, Turkey|Investigational Site Number 792103, Samsun, Turkey|Investigational Site Number 784101, Dubai, United Arab Emirates|Investigational Site Number 826104, Exeter, United Kingdom|Investigational Site Number 826106, Manchester, United Kingdom|Investigational Site Number 826105, Middlesborough, United Kingdom|Investigational Site Number 826103, Stevenage, United Kingdom|Investigational Site Number 826101, Torquay, United Kingdom|Investigational Site Number 826102, West Bromwich, United Kingdom",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT01384058,DIABETES MELLITUS TYPE 2|HYPERCHOLESTEROLEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut für Stoffwechselforschung, Frankfurt, Germany|Stephan Jacob, MD, Villingen-.Schwenningen, Germany",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT00699023,POSTPRANDIAL LIPEMIA|TYPE 2 DIABETES,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Clinical and Experimental Medicine, Federico II University Hospital,, Naples, Italy",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT00157924,HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT00079638,DYSLIPIDEMIA|CORONARY HEART DISEASE|ATHEROSCLEROSIS|STROKE|DIABETES,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT02682680,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"LMC Calgary, Calgary, Alberta, Canada|LMC Barrie, Barrie, Ontario, Canada|LMC Brampton, Brampton, Ontario, Canada|LMC Etobicoke, Etobicoke, Ontario, Canada|LMC Markham, Markham, Ontario, Canada|LMC Oakville, Oakville, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Manna Toronto, Toronto, Ontario, Canada|LMC Bayview, Toronto, Ontario, Canada",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT01035320,DIABETES MELLITUS|RENAL IMPAIRMENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), Stockholm, Sweden",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT01008345,CORONARY ARTERY DISEASE|DIABETES,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Terminated,NCT00651378,HYPERCHOLESTEROLEMIA|ATHEROSCLEROSIS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Unknown status,NCT00433823,CORONARY HEART DISEASE|DIABETES MELLITUS|NON-CORONARY ATHEROSCLEROTIC DISEASE|HYPERCHOLESTEROLEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Bolu Izzet Baysal School of Medicine, Bolu, Turkey",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Terminated,NCT00651014,HYPERCHOLESTEROLEMIA|ATHEROSCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,1,DB00975,__DIPYRIDAMOLE,6015577,Completed,NCT01613755,DIABETES,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,1101.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.52,504.6256,145.44,12.0,4.0,4.0,56.94,142.78,12.0,1.0,0.0,0.0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Completed,NCT02866786,PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Obstetrics & Gynecology, Cuttack, Odisha, India",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Completed,NCT01511822,PCOS|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,,"Istituto di Patologia Ostetrica e Ginecologica, Catania, Italy",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Unknown status,NCT01103518,AMENORRHEA|DYSMENORRHEA|MENSTRUATION DISTURBANCES|HYPERANDROGENISM,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital das Clínicas de Teresópolis, Teresópolis, Rio de Janeiro, Brazil",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Completed,NCT00732693,PREMATURE OVARIAN FAILURE,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Unknown status,NCT02027337,POLYCYSTIC OVARIAN SYNDROME|HYPERANDROGENISM|MENSTRUAL IRREGULARITIES,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Tyumen State Medical Academy, Tyumen, Russian Federation",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,1,DB00980,__RAMELTEON,6034239,Completed,NCT00595504,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|SCHIZOPHRENIFORM DISORDERS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Freedom Trail Clinic, Boston, Massachusetts, United States",C07D263/62,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,36.04180783999671,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,38.33,2.0,1.0,3.0,29.99,75.52,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,1,DB00982,__ISOTRETINOIN,7435427,Completed,NCT02855138,ADVERSE EFFECTS OF MEDICAL DRUGS,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science",,2,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,84.76560093636421,968.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.66,300.4351,37.3,2.0,1.0,1.0,36.15,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",C07D207/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Recruiting,NCT04107480,PROLACTINOMA|PROLACTIN-PRODUCING PITUITARY TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Amsterdam University Medical Center, loc. AMC, Amsterdam-Zuidoost, Noord-Holland, Netherlands|Reinier de Graaf Gasthuis, Delft, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands",C07D207/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,ESRD,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00634543,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Terminated,NCT00619983,DIABETIC NEUROPATHIC PAIN|CHRONIC LOW BACK PAIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00385671,"DIABETIC NEUROPATHY, PAINFUL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cromwell, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midvale, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT03047278,"NEUROPATHIC PAIN|TYPE 2 DIABETES MELLITUS|DIABETIC NEUROPATHY, PAINFUL",All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C229/28,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00904202,POSTHERPETIC NEURALGIA|DIABETIC NEUROPATHY|COMPLEX REGIONAL PAIN SYNDROME|CARPAL TUNNEL SYNDROME|HIV NEUROPATHY|IDIOPATHIC SENSORY NEUROPATHY|PERIPHERAL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Hueytown, Alabama, United States|Phoenix, Arizona, United States|Pembroke Pines, Florida, United States|New York, New York, United States|Rochester, New York, United States|Altoona, Pennsylvania, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT01364298,DIABETIC PERIPHERAL NEUROPATHIC PAIN,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Mexico City, Mexico",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Terminated,NCT02599701,SLEEP,Male,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto do Sono, Sao Paulo, Brazil",C07C229/28,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,NEUROPATHIC PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,NCT00727961,OVARIAN NEOPLASMS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/5537,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Recruiting,NCT03794778,EFFICACY AND SAFETY,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Women's Hospital School Of Medicine Zhejiang University, Zhejiang, Hangzhou, China",C07F9/5537,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,1,DB00998,__FROVATRIPTAN,5464864,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,22.47274071336161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,243.3043,70.91,2.0,3.0,3.0,27.55,71.84,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00306696,DIABETES,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Sint Gillis-Waas, Belgium|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Dommartin-Les Toul, France|GSK Investigational Site, Paris Cedex 18, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Blieskastel, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, N. Efkarpia, Thessaloniki, Greece|GSK Investigational Site, Nikaia Piraeus, Greece|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Acquavive delle Fonti (BA), Puglia, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Tromsoe, Norway|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Lubochna, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, United Kingdom|GSK Investigational Site, London, United Kingdom",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00654745,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Sylmar, California, United States|Tustin, California, United States|Aventura, Florida, United States|DeLand, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Las Vegas, Nevada, United States|New Windsor, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Taylors, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00403481,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Mesa, Arizona, United States|Searcy, Arkansas, United States|Los Angeles, California, United States|Roseville, California, United States|Tustin, California, United States|Deland, Florida, United States|Pembroke Pines, Florida, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Jackson, Mississippi, United States|Florissant, Missouri, United States|Williamsville, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|New Talenwell, Tennessee, United States|New Tazewell, Tennessee, United States|Colleyville, Texas, United States|Corpus Christi, Texas, United States|Richardson, Texas, United States|Murray, Utah, United States|Norfolk, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00239538,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"30 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Green Hospital, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States|Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|Memorial Research Medical Clinic, Long Beach, California, United States|1200, Los Angeles, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|8615, Nuena Park, California, United States|Boehringer Ingelheim Investigational Site, Orange, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|595, San Francisco, California, United States|1805, Stockton, California, United States|Boehringer Ingelheim Investigational Site, Torrance, California, United States|2311, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|6448, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States|Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pinellas Park, Florida, United States|Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States|Herron Medical Center, Ltd., Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Orland Park, Illinois, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Shawnee, Kansas, United States|Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|200, Baltimore, Maryland, United States|Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|12401, St.Louis, Missouri, United States|Boehringer Ingelheim Investigational Site, Missoula, Montana, United States|Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|3, Buffalo, New York, United States|Comprehensive Clinical Research, Berlin, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston Salem, North Carolina, United States|Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|Boehringer Ingelheim Investigational Site, Marion, Ohio, United States|Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|Boehringer Ingelheim Investigational Site, Broomal, Pennsylvania, United States|6605, Bartlett, Tennessee, United States|108, Fayetteville, Tennessee, United States|Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|7777, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, El Paso, Texas, United States|Team Research of Texas, Harker Heights, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|420, Salt Lake City, Utah, United States|20901, Ettrick, Virginia, United States|Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|5000, Miwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, BsAs, Argentina|Boehringer Ingelheim Investigational Site, Coronel Suárez, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Sta. Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Emeritus Research, Malvern, Victoria, Australia|Boehringer Ingelheim Investigational Site, Prahran, Victoria, Australia|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Conquitlam, British Columbia, Canada|Dr. Hugh Tildesley, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, North York, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|Boehringer Ingelheim Investigational Site, Orleans, Ontario, Canada|Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Thunder Bay, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|91 Thomas-Chapais, Boucherville, Quebec, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|Pavillon St. Sacrement, Sainte-Foy, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|c/o Hemodynamics Offices, Saskatoon, Saskatchewan, Canada|Inje University Pusan Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Col. Del Valle, Mexico|Boehringer Ingelheim Investigational Site, Col. Magdalena de las Salinas, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección 16, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Zapopan, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|National Taiwan University Hospital, Taipei, Taiwan",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT03254849,TYPE 2 DIABETES,All,"50 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00787605,HYPERTENSION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sites in USA, East Hanover, New Jersey, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Recruiting,NCT03264352,"DIABETES MELLITUS, TYPE 2|STROKE|BLOOD PRESSURE|PREHYPERTENSION|CARDIOVASCULAR RISK FACTOR",All,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,"Active, not recruiting",NCT04242758,RENAL FUNCTION DISORDER|GLUCOSE METABOLISM DISORDERS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Pisa, Pisa, Italy",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00980187,HYPERTENSION|TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cardiology, University and Emergency Hospital, Bucharest, Romania",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00263393,MYOCARDIAL INFARCTION|ANGINA PECTORIS|CEREBROVASCULAR ACCIDENTS|DIABETES MELLITUS,All,"30 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Byrraju Foundation Primary Healthcare Centres in rural West Godavari and East Godavari Dstricts, Bhimavaram, Andhra Pradesh, India",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Withdrawn,NCT00994253,HYPERTENSION|DIABETES TYPE 2,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"William Beaumont Hospital, Royal Oak, Michigan, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,GLUCOSE METABOLISM DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT02802865,POLYCYSTIC OVARY SYNDROME|INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Not yet recruiting,NCT04002635,"INFERTILITY, FEMALE|POLYCYSTIC OVARY SYNDROME|IVF|OVULATION DISORDER",Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT01999569,OVULATION DISORDER|ESTROGENS/RIFAMPIN [VA DRUG INTERACTION]|OVARIAN CYSTS,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Women's Institute at Carolinas Medical Center, Charlotte, North Carolina, United States",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Recruiting,NCT04069117,PCOS,Female,20 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine, Mansoura, Dakahlia, Egypt",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT00478504,INFERTILITY|POLYCYSTIC OVARIAN SYNDROME,Female,18 Years to 39 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Derby Hospital, Derby, Derbyshire, United Kingdom",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT01315912,INFERTILITY,Female,20 Years to 35 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bushehr university of medical science, Bushehr, Iran, Islamic Republic of",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Unknown status,NCT02137538,SHORT STATURE,Male,10 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lucile Packard Children's Hospital, Palo Alto, California, United States",C07D213/57,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Unknown status,NCT02703649,ANOVULATION,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada|TRIO Fertility, Toronto, Ontario, Canada",C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT02670304,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,C07D213/57,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Active Not Recruiting,,FERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)(C(=O)c1cccnc1)c1cccnc1,1,DB01011,__METYRAPONE,4490350,Recruiting,NCT03491696,DEPRESSIVE DISORDER|HORMONE DISTURBANCE,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopitaux Universitares de Strasbourg, Strasbourg, Bas Rhin, France|Centre Hospitalier de Rouffach, Rouffach, Haut Rhin, France",A61K51/0455,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,32.460625474855696,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,226.2738,42.85,3.0,0.0,2.0,23.98,65.94,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00431496,ANEMIA|SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT01181531,"HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Unknown status,NCT02338934,SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Centre, Penang Hospital, George Town, Penang, Malaysia|Penang Hospital, George Town, Penang, Malaysia",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT03123406,"HYPERPARATHYROIDISM; SECONDARY, RENAL",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nanjing Jinling Hospital, Nanjing, Jiangsu, China",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00803712,CHRONIC KIDNEY DISEASE|SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT01143987,HYPERPARATHYROIDISM|ARTERIAL STIFFNESS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00977080,CHRONIC KIDNEY DISEASE|SECONDARY HYPERPARATHYROIDISM|HEMODIALYSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 22781, Tempe, Arizona, United States|Site Reference ID/Investigator# 24342, Chula Vista, California, United States|Site Reference ID/Investigator# 21142, Los Angeles, California, United States|Site Reference ID/Investigator# 22762, Los Angeles, California, United States|Site Reference ID/Investigator# 22758, Riverside, California, United States|Site Reference ID/Investigator# 21442, San Diego, California, United States|Site Reference ID/Investigator# 23688, Arvada, Colorado, United States|Site Reference ID/Investigator# 21370, Coral Springs, Florida, United States|Site Reference ID/Investigator# 25902, Hudson, Florida, United States|Site Reference ID/Investigator# 21146, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 26743, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22788, Miami, Florida, United States|Site Reference ID/Investigator# 22722, Orlando, Florida, United States|Site Reference ID/Investigator# 23147, Tampa, Florida, United States|Site Reference ID/Investigator# 22778, Meridian, Idaho, United States|Site Reference ID/Investigator# 21369, Detroit, Michigan, United States|Site Reference ID/Investigator# 22786, Detroit, Michigan, United States|Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21443, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21145, Omaha, Nebraska, United States|Site Reference ID/Investigator# 22505, Flushing, New York, United States|Site Reference ID/Investigator# 22759, Toledo, Ohio, United States|Site Reference ID/Investigator# 22796, Lancaster, Pennsylvania, United States|Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22772, Aiken, South Carolina, United States|Site Reference ID/Investigator# 21147, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 22982, Houston, Texas, United States|Site Reference ID/Investigator# 21143, Houston, Texas, United States|Site Reference ID/Investigator# 22506, San Antonio, Texas, United States|Site Reference ID/Investigator# 22776, Bluefield, West Virginia, United States|Site Reference ID/Investigator# 22311, Brno, Czech Republic|Site Reference ID/Investigator# 22310, Jilemnice, Czech Republic|Site Reference ID/Investigator# 21624, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 22363, Aalborg, Denmark|Site Reference ID/Investigator# 23105, Copenhagen, Denmark|Site Reference ID/Investigator# 23909, Fredericia, Denmark|Site Reference ID/Investigator# 22462, Holstebro, Denmark|Site Reference ID/Investigator# 21748, Coburg, Germany|Site Reference ID/Investigator# 33268, Darmstadt, Germany|Site Reference ID/Investigator# 35903, Duesseldorf, Germany|Site Reference ID/Investigator# 21742, Frankfurt, Germany|Site Reference ID/Investigator# 21744, Heilbronn, Germany|Site Reference ID/Investigator# 21368, Luedenscheid, Germany|Site Reference ID/Investigator# 22362, Athens, Greece|Site Reference ID/Investigator# 38970, Thessaloniki, Greece|Site Reference ID/Investigator# 22322, Thessaloniki, Greece|Site Reference ID/Investigator# 22463, Thessaloniki, Greece|Site Reference ID/Investigator# 22323, Thessaloniki, Greece|Site Reference ID/Investigator# 39262, Thessaloniki, Greece|Site Reference ID/Investigator# 22312, Bergamo, Italy|Site Reference ID/Investigator# 21746, Genova, Italy|Site Reference ID/Investigator# 39180, Lucca, Italy|Site Reference ID/Investigator# 22314, Milan, Italy|Site Reference ID/Investigator# 21367, Pavia, Italy|Site Reference ID/Investigator# 21745, Pesaro, Italy|Site Reference ID/Investigator# 21842, Alkmaar, Netherlands|Site Reference ID/Investigator# 22309, Delft, Netherlands|Site Reference ID/Investigator# 21843, Dordrecht, Netherlands|Site Reference ID/Investigator# 38903, Beja, Portugal|Site Reference ID/Investigator# 38531, Faro, Portugal|Site Reference ID/Investigator# 22464, Lisbon, Portugal|Site Reference ID/Investigator# 23910, Vila Franca de Xira, Portugal|Site Reference ID/Investigator# 24643, Moscow, Russian Federation|Site Reference ID/Investigator# 24642, Moscow, Russian Federation|Site Reference ID/Investigator# 21361, Barcelona, Spain|Site Reference ID/Investigator# 21364, Cordoba, Spain|Site Reference ID/Investigator# 22366, L'Hospitalet, Barcelona, Spain|Site Reference ID/Investigator# 38343, Madrid, Spain|Site Reference ID/Investigator# 21362, Madrid, Spain|Site Reference ID/Investigator# 21363, Palma de Mallorca, Spain|Site Reference ID/Investigator# 22367, Pamplona, Spain|Site Reference ID/Investigator# 38462, Puerto de la Cruz, Spain|Site Reference ID/Investigator# 21365, Seville, Spain|Site Reference ID/Investigator# 23913, Linkoping, Sweden|Site Reference ID/Investigator# 23782, Stockholm, Sweden|Site Reference ID/Investigator# 22364, Uppsala, Sweden|Site Reference ID/Investigator# 23912, Birmingham, United Kingdom|Site Reference ID/Investigator# 21747, Coventry, United Kingdom|Site Reference ID/Investigator# 23102, London, United Kingdom|Site Reference ID/Investigator# 23104, London, United Kingdom|Site Reference ID/Investigator# 23103, Manchester, United Kingdom|Site Reference ID/Investigator# 41982, Omagh, Northern Ireland, United Kingdom|Site Reference ID/Investigator# 40222, Sheffield, United Kingdom",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT01100723,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lynchburg Nephrology Associates, P.L.L.C., Lynchburg, Virginia, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00379899,CHRONIC KIDNEY DISEASE|END STAGE RENAL DISEASE|CORONARY ARTERY CALCIFICATION|VASCULAR CALCIFICATION|CALCIFICATION|CARDIOVASCULAR DISEASE|CHRONIC RENAL FAILURE|HYPERPARATHYROIDISM|KIDNEY DISEASE|NEPHROLOGY|SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00110890,END STAGE RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT01103206,PARATHYROID HORMONE SUPPRESSION TEST WITH CINACALCET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University hospital, Rouen, Haute Normandie, France",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT02417389,"HYPERPARATHYROIDISM, PRIMARY|OSTEOPOROSIS",All,"50 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Auxologico Italiano IRCCS, Milano, Italy",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,,ARTERIAL STIFFNESS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/062,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT00347100,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT00123643,TYPE 2 DIABETES,All,"25 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","St. Paul Heart Clinic, St. Paul, Minnesota, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Recruiting,NCT03029702,"GESTATIONAL DIABETES|DIABETES, GESTATIONAL|PREGNANCY IN DIABETES",Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT00035568,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Local Institution, Little Rock, Arkansas, United States|Local Institution, Los Angeles, California, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Brooklyn, New York, United States|Local Institution, Rochester, New York, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Not yet recruiting,NCT03527537,GESTATIONAL DIABETES,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,"Active, not recruiting",NCT01107717,DIABETES,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Diabetes Institute, San Antonio, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Withdrawn,NCT03078725,"GESTATIONAL DIABETES MELLITUS, CLASS A2",Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT01605773,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT00494312,DIABETES MELLITUS|LIVER,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,NCT00744965,MILD GESTATIONAL DIABETES,Female,"16 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Parkland Memorial Hospital, Dallas, Texas, United States",6,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2,1,DB01024,__MYCOPHENOLIC_ACID,6025391,Unknown status,NCT02036554,"KIDNEY; COMPLICATIONS, ALLOGRAFT",All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"division of nephrology;Seoul St Mary's Hospital, Seoul, Korea, Republic of",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,20.632867204665306,755.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.36,320.3371,93.06,5.0,2.0,2.0,32.95,85.23,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00535925,DIABETIC NEPHROPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Advanced Medical and Surgical Sciences, Università della Campania ""Luigi Vanvitelli"", Naples, Italy, Naples, Italy",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00660309,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Novartis Investigator Site, Boston, Massachusetts, United States",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Withdrawn,NCT00987662,OBESITY|HYPERTENSION,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hypertension-24h ABPM Center Papageorgiou Hospital, Thessaloniki, Greece",C07D231/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00549133,HYPERTENSION|DIABETES MELLITUS TYPE 2,All,"40 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis, Istanbul, Turkey",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00320879,TYPE 2 DIABETES|MICROALBUMINURIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Steno Diabetes Center, Gentofte, Copenhagen, Denmark",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00334581,HYPERTENSION,All,"30 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Shanghai, China",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT03147677,TYPE 2 DIABETIC NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China|Hunan Yiyang Central Hospital, Yiyang, Hunan, China",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Not yet recruiting,NCT04140201,DIABETIC RETINOPATHY,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Completed,NCT01927315,DIABETES|DIABETIC RETINOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"University Hospital of Padova, Diabetes Outpatient Clinic, Padova, Italy",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Recruiting,NCT03829514,"DIABETES MELLITUS, TYPE II",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Medical University of South Carolina, Charleston, South Carolina, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Unknown status,NCT02015988,"ACUTE CORONARY SYNDROME|DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCERIDEMIA",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Institution ""Dnipropetrovsk Medical Academy of Health Ministry of Ukraine"", Dnipropetrovsk, Ukraine",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Completed,NCT02153879,TYPE 2 DIABETES MELLITUS|DYSLIPIDEMIA,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitari Sant Joan, Reus, Tarragona, Spain",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Not yet recruiting,NCT04528212,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tanta University Hospital, Tanta, El-Gharbia, Egypt",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Completed,NCT02642159,DYSLIPIDEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840-163, Little Rock, Arkansas, United States|Investigational Site Number 840-141, Fresno, California, United States|Investigational Site Number 840-152, Huntington Beach, California, United States|Investigational Site Number 840-115, La Jolla, California, United States|Investigational Site Number 840-118, Los Angeles, California, United States|Investigational Site Number 840-106, Northridge, California, United States|Investigational Site Number 840-176, Port Hueneme, California, United States|Investigational Site Number 840-122, Tarzana, California, United States|Investigational Site Number 840-156, Tustin, California, United States|Investigational Site Number 840-160, Van Nuys, California, United States|Investigational Site Number 840-107, Boca Raton, Florida, United States|Investigational Site Number 840-170, Boynton Beach, Florida, United States|Investigational Site Number 840-114, Bradenton, Florida, United States|Investigational Site Number 840-132, Ocoee, Florida, United States|Investigational Site Number 840-179, Oviedo, Florida, United States|Investigational Site Number 840-123, Tampa, Florida, United States|Investigational Site Number 840-137, Bainbridge, Georgia, United States|Investigational Site Number 840-128, Columbus, Georgia, United States|Investigational Site Number 840-169, Stockbridge, Georgia, United States|Investigational Site Number 840-167, Idaho Falls, Idaho, United States|Investigational Site Number 840-161, Chicago, Illinois, United States|Investigational Site Number 840-184, Crystal Lake, Illinois, United States|Investigational Site Number 840-174, Evanston, Illinois, United States|Investigational Site Number 840-138, Springfield, Illinois, United States|Investigational Site Number 840-108, Louisville, Kentucky, United States|Investigational Site Number 840-183, Paducah, Kentucky, United States|Investigational Site Number 840-190, Metairie, Louisiana, United States|Investigational Site Number 840-151, Rockville, Maryland, United States|Investigational Site Number 840-113, Jefferson City, Missouri, United States|Investigational Site Number 840-120, Saint Louis, Missouri, United States|Investigational Site Number 840-148, Omaha, Nebraska, United States|Investigational Site Number 840-101, Las Vegas, Nevada, United States|Investigational Site Number 840-140, Las Vegas, Nevada, United States|Investigational Site Number 840-178, Albany, New York, United States|Investigational Site Number 840-181, New York, New York, United States|Investigational Site Number 840-157, New York, New York, United States|Investigational Site Number 840-188, Greensboro, North Carolina, United States|Investigational Site Number 840-131, Morehead City, North Carolina, United States|Investigational Site Number 840-158, Morganton, North Carolina, United States|Investigational Site Number 840-129, Fargo, North Dakota, United States|Investigational Site Number 840-104, Columbus, Ohio, United States|Investigational Site Number 840-105, Marion, Ohio, United States|Investigational Site Number 840-175, Maumee, Ohio, United States|Investigational Site Number 840-136, Bend, Oregon, United States|Investigational Site Number 840-187, Murrells Inlet, South Carolina, United States|Investigational Site Number 840-111, Summerville, South Carolina, United States|Investigational Site Number 840-147, Chattanooga, Tennessee, United States|Investigational Site Number 840-159, Knoxville, Tennessee, United States|Investigational Site Number 840-153, Dallas, Texas, United States|Investigational Site Number 840-143, Houston, Texas, United States|Investigational Site Number 840-168, Houston, Texas, United States|Investigational Site Number 840-142, Round Rock, Texas, United States|Investigational Site Number 840-133, Tomball, Texas, United States|Investigational Site Number 840-185, Orem, Utah, United States|Investigational Site Number 840-150, Salt Lake City, Utah, United States|Investigational Site Number 840-126, Chesapeake, Virginia, United States|Investigational Site Number 840-171, Richmond, Virginia, United States|Investigational Site Number 036102, Herston, Australia|Investigational Site Number 036104, Merewether, Australia|Investigational Site Number 036101, St Leonards, Australia|Investigational Site Number 076103, Campinas, Brazil|Investigational Site Number 076104, Fortaleza, Brazil|Investigational Site Number 076101, Sao Paulo, Brazil|Investigational Site Number 076105, São paulo, Brazil|Investigational Site Number 076106, São Paulo, Brazil|Investigational Site Number 076102, SãO Paulo, Brazil|Investigational Site Number 246102, Oulu, Finland|Investigational Site Number 246101, Oulu, Finland|Investigational Site Number 246104, Tampere, Finland|Investigational Site Number 276112, Berlin, Germany|Investigational Site Number 276109, Berlin, Germany|Investigational Site Number 276104, Dippoldiswalde, Germany|Investigational Site Number 276101, Dresden, Germany|Investigational Site Number 276110, Essen, Germany|Investigational Site Number 276108, Essen, Germany|Investigational Site Number 276111, Goch, Germany|Investigational Site Number 276107, Karlsruhe, Germany|Investigational Site Number 276103, Künzing, Germany|Investigational Site Number 276102, Oldenburg in Holstein, Germany|Investigational Site Number 376101, Beer Sheva, Israel|Investigational Site Number 376103, Petach Tikva, Israel|Investigational Site Number 376104, Petach tikva, Israel|Investigational Site Number 376102, Rehovot, Israel|Investigational Site Number 376106, Tel-Aviv, Israel|Investigational Site Number 380104, Bergamo, Italy|Investigational Site Number 380107, Catanzaro, Italy|Investigational Site Number 380103, Napoli, Italy|Investigational Site Number 380108, Padova, Italy|Investigational Site Number 380106, Partinico, Italy|Investigational Site Number 380101, Pisa, Italy|Investigational Site Number 380105, Roma, Italy|Investigational Site Number 380102, Torino, Italy|Investigational Site Number 414101, Kuwait, Kuwait|Investigational Site Number 422101, Beirut, Lebanon|Investigational Site Number 422102, Hazmieh, Lebanon|Investigational Site Number 578101, Oslo, Norway|Investigational Site Number 578102, Oslo, Norway|Investigational Site Number 752102, Göteborg, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 756101, Genève, Switzerland|Investigational Site Number 756102, Olten, Switzerland|Investigational Site Number 756103, Reinach, Switzerland|Investigational Site Number 792105, Adana, Turkey|Investigational Site Number 792106, Ankara, Turkey|Investigational Site Number 792102, Ankara, Turkey|Investigational Site Number 792108, Corum, Turkey|Investigational Site Number 792109, Hatay, Turkey|Investigational Site Number 792104, Izmir, Turkey|Investigational Site Number 792101, Izmir, Turkey|Investigational Site Number 792110, Izmir, Turkey|Investigational Site Number 792107, Kayseri, Turkey|Investigational Site Number 792103, Samsun, Turkey|Investigational Site Number 784101, Dubai, United Arab Emirates|Investigational Site Number 826104, Exeter, United Kingdom|Investigational Site Number 826106, Manchester, United Kingdom|Investigational Site Number 826105, Middlesborough, United Kingdom|Investigational Site Number 826103, Stevenage, United Kingdom|Investigational Site Number 826101, Torquay, United Kingdom|Investigational Site Number 826102, West Bromwich, United Kingdom",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Unknown status,NCT02314533,MICROALBUMINURIA,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Completed,NCT03278483,DIABETES MELLITUS|TUBERCULIN (SKIN TEST) POSITIVE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Recruiting,NCT03012529,OSTEOMYELITIS|DIABETES|AMPUTATION,All,"18 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Northern California Health Care System, Mather, CA, Sacramento, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,1,DB01046,__LUBIPROSTONE,5317032,Completed,NCT01170039,CONSTIPATION|DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Atlanta Veterans Administration Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.9859750713566,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,390.468,83.83,5.0,2.0,2.0,42.35,95.6,11.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT02351700,PITUITARY TUMOR|PAIN,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,1,DB01065,__MELATONIN,4309415,Completed,NCT01540747,PCOS,Female,27 Years to 38 Years   (Adult),Other,,"Praxi Pro Vita Centro di Fertilità, Rome, Italy",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,1,DB01067,__GLIPIZIDE,5024843,Unknown status,NCT01267448,DIABETES MELLITUS TYPE 2|SEVERE HYPERGLYCEMIA - BLOOD GLUCOSE LEVEL >300MG/DL.,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Stroger Hospital of Cook County, Chicago, Illinois, United States|John Stroger Hospital of Cook County, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,21.3885295385942,1696.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.83,445.535,130.15,6.0,3.0,3.0,47.62,115.62,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,1,DB01067,__GLIPIZIDE,5024843,Completed,NCT01951651,TYPE 2 DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,21.3885295385942,1696.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.83,445.535,130.15,6.0,3.0,3.0,47.62,115.62,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,1,DB01067,__GLIPIZIDE,5024843,Completed,NCT00347100,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,21.3885295385942,1696.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.83,445.535,130.15,6.0,3.0,3.0,47.62,115.62,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,1,DB01067,__GLIPIZIDE,5024843,Completed,NCT00513630,TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"up to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Shanghai Jiao Tong University School of Medicine, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,21.3885295385942,1696.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.83,445.535,130.15,6.0,3.0,3.0,47.62,115.62,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,1,DB01067,__GLIPIZIDE,5024843,Not yet recruiting,NCT04167761,CARDIOVASCULAR DISEASES|ATHEROSCLEROSIS|TYPE 2 DIABETES|INSULIN RESISTANCE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Stanford University, Stanford, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,21.3885295385942,1696.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.83,445.535,130.15,6.0,3.0,3.0,47.62,115.62,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT01720719,FATTY LIVER|DYSLIPIDEMIAS|DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00522158,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR DISEASE|LDL CHOLESTEROL|COGNITION,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT01185236,TYPE 2 DIABETES MELLITUS WITHOUT INSULIN TREATMENT,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul national university hospital, Seoul, Korea, Republic of",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02305355,"DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00157924,HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00079638,DYSLIPIDEMIA|CORONARY HEART DISEASE|ATHEROSCLEROSIS|STROKE|DIABETES,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00211939,"CALCINOSIS|ARTERIOSCLEROSIS|HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Sciences Center, San Antonio, Texas, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Recruiting,NCT03532620,PREDIABETIC STATE|HYPERTENSION|DYSLIPIDEMIAS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fourth People's Hospital of Chongqing, Chongqing, Chongqing, China|First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|People's Hospital of Zhongshan City, Zhongshan, Guangdong, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Yichang Central Hospital, Yichang, Hubei, China|Taizhou Hospital of TCM, Taizhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China|Lanzhou University Second Hospital, Lanzhou, Qinghai, China|Yantaishan Hospital, Yantai, Yantai, Shandong, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00889226,HYPERCHOLESTEROLEMIA WITH TYPE2DM,All,"25 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT00651378,HYPERCHOLESTEROLEMIA|ATHEROSCLEROSIS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT00433823,CORONARY HEART DISEASE|DIABETES MELLITUS|NON-CORONARY ATHEROSCLEROTIC DISEASE|HYPERCHOLESTEROLEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Bolu Izzet Baysal School of Medicine, Bolu, Turkey",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT03195153,DIABETES MELLITUS TYPE 2 PLATELETS REACTIVITY STATIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Policlinico Umberto I, Rome, Roma, Italy",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02842359,TYPE 2 DIABETES,All,"19 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Korea, Seoul, Korea, Republic of",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Recruiting,NCT02099123,INDEPENDENT LIVING|DISABILITY FREE SURVIVAL|ELDERLY|HEALTHY,All,70 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Tasmania, Hobart, Tasmania, Australia|Victoria, Melbourne, Victoria, Australia|South Australia, Adelaide, Western Australia, Australia|Queensland, Brisbane, Australia|New South Wales, Newcastle, Australia|Western Australia, Perth, Australia",C07D405/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01448174,RENAL FAILURE CHRONIC REQUIRING HEMODIALYSIS|METABOLIC SYNDROME|DIABETES MELLITUS TYPE 2|HYPERLIPIDEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","BBraun Avitum Dialysis Center, Nowy Tomyśl, Wielkopolska, Poland",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT00640549,"HYPERLIPIDEMIA|DIABETES MELLITUS, TYPE 2|NON-INSULIN DEPENDENT DIABETES MELLITUS",All,"35 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Bad Muenster Am Stein, Germany|Pfizer Investigational Site, Bosenheim, Germany|Pfizer Investigational Site, Bretten, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Duisburg, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Goch, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Rain, Germany|Pfizer Investigational Site, Schwabenheim, Germany",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00141232,"DIABETES, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Irvine, Ayrshire, United Kingdom|Pfizer Investigational Site, Farnworth, Bolton, United Kingdom|Pfizer Investigational Site, Thornhill, Cardiff, United Kingdom|Pfizer Investigational Site, Fowey, Cornwall, United Kingdom|Pfizer Investigational Site, Launceston, Cornwall, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Saltash, Cornwall, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Darlington, County Durham, United Kingdom|Pfizer Investigational Site, Newton Aycliffe, County Durham, United Kingdom|Pfizer Investigational Site, Three Bridges, Crawley, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Bexhill-On-Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Bath, England, United Kingdom|Pfizer Investigational Site, Dronfield, Sheffield, England, United Kingdom|Pfizer Investigational Site, Surrey, England, United Kingdom|Pfizer Investigational Site, Halstead, Essex, United Kingdom|Pfizer Investigational Site, Stonehouse, Gloucestershire, United Kingdom|Pfizer Investigational Site, Southampton, Hampshire, United Kingdom|Pfizer Investigational Site, Hildenborough, Kent, United Kingdom|Pfizer Investigational Site, Thorneton-Clevely, Lancashire, United Kingdom|Pfizer Investigational Site, Balham, London, United Kingdom|Pfizer Investigational Site, Fulham, London, United Kingdom|Pfizer Investigational Site, Tooting, London, United Kingdom|Pfizer Investigational Site, Hayes, Middlesex, United Kingdom|Pfizer Investigational Site, Wellingborough, Northamptonshire, United Kingdom|Pfizer Investigational Site, Cookstown, Northern Ireland, United Kingdom|Pfizer Investigational Site, Frome, Somerset, United Kingdom|Pfizer Investigational Site, Fetcham, Surrey, United Kingdom|Pfizer Investigational Site, Woking, Surrey, United Kingdom|Pfizer Investigational Site, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Melksham, Wiltshire, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Bucks, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Cornwall, United Kingdom|Pfizer Investigational Site, County Antrim, Northern Ireland, United Kingdom|Pfizer Investigational Site, Darlington, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, East Sussex, United Kingdom|Pfizer Investigational Site, Isle of Wight, United Kingdom|Pfizer Investigational Site, Isle of Wight, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Westbury, United Kingdom",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT01239849,"DIABETES MELLITUS, HYPERCHOLESSTEROLEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sung Rae Kim, Bucheon, Kyeongki, Korea, Republic of",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01497912,TYPE 1 DIABETES MELLITUS|DYSLIPIDEMIA,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT03784703,DYSLIPIDEMIA ASSOCIATED WITH TYPE II DIABETES MELLITUS,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Tanta University Hospital, Tanta, El-Gharbia, Egypt",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02125682,DYSLIPIDEMIA IN PATIENTS WITH DIABETES MELLITUS,All,"21 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hotel Dieu de France Hospital, Beirut, Lebanon",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00793754,DIABETES,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00645424,HYPERLIPIDEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyuan Hsien, Taiwan",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT01322711,TYPE 2 DIABETES MELLITUS|HYPERCHOLESTEROLEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stefania Basili, Rome, Italy",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00327418,"MAJOR CORONARY EVENT|CEREBROVASCULAR ACCIDENT|CORONARY ARTERY BYPASS GRAFT|ANGINA, UNSTABLE|REVASCULARIZATION",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Pfizer Investigational Site, Fosterhill, Aberdeen, United Kingdom|Pfizer Investigational Site, Irvine, Ayrshire, United Kingdom|Pfizer Investigational Site, Midsomer Norton, Bath, United Kingdom|Pfizer Investigational Site, Reading, Berkshire, United Kingdom|Pfizer Investigational Site, Slough, Berkshire, United Kingdom|Pfizer Investigational Site, Maidenhead, Berskhire, United Kingdom|Pfizer Investigational Site, Edgbaston, Birmingham, United Kingdom|Pfizer Investigational Site, Frenchay, Bristol, United Kingdom|Pfizer Investigational Site, Llanishen, Cardiff, United Kingdom|Pfizer Investigational Site, Wrexham, Clwydd, United Kingdom|Pfizer Investigational Site, Bocastle, Cornwall, United Kingdom|Pfizer Investigational Site, Falmouth, Cornwall, United Kingdom|Pfizer Investigational Site, Fowey, Cornwall, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Redruth, Cornwall, United Kingdom|Pfizer Investigational Site, Saltash, Cornwall, United Kingdom|Pfizer Investigational Site, St. Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Truro, Cornwall, United Kingdom|Pfizer Investigational Site, Chesterfield, Derbyshire, United Kingdom|Pfizer Investigational Site, Crownhill, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Plympton, Devon, United Kingdom|Pfizer Investigational Site, Bournemouth, Dorset, United Kingdom|Pfizer Investigational Site, Bournemouth, Dorset, United Kingdom|Pfizer Investigational Site, Epping, Essex, United Kingdom|Pfizer Investigational Site, Southend on Sea, Essex, United Kingdom|Pfizer Investigational Site, Langside, Glasgow, United Kingdom|Pfizer Investigational Site, Portsmouth, Hampshire, United Kingdom|Pfizer Investigational Site, Southampton, Hampshire, United Kingdom|Pfizer Investigational Site, Titchfield, Hampshire, United Kingdom|Pfizer Investigational Site, Hemel Hempstead, Hertfordshire, United Kingdom|Pfizer Investigational Site, Watford, Hertfordshire, United Kingdom|Pfizer Investigational Site, Ryde, Isle of Wight, United Kingdom|Pfizer Investigational Site, Gillingham, Kent, United Kingdom|Pfizer Investigational Site, Hildenborough, Kent, United Kingdom|Pfizer Investigational Site, Tunbridge Wells, Kent, United Kingdom|Pfizer Investigational Site, Bolton, Lancashire, United Kingdom|Pfizer Investigational Site, Ormskirk, Lancashire, United Kingdom|Pfizer Investigational Site, Waterloo, Liverpool, United Kingdom|Pfizer Investigational Site, Manchester, M15 6sx, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Southall, Middlesex, United Kingdom|Pfizer Investigational Site, Scunthorpe, North Lincolnshire, United Kingdom|Pfizer Investigational Site, Harrogate, North Yorkshire, United Kingdom|Pfizer Investigational Site, Northallerton, North Yorkshire, United Kingdom|Pfizer Investigational Site, Sutton-in-Ashfield, Nottinghamshire, United Kingdom|Pfizer Investigational Site, Worksop, Nottinghamshire, United Kingdom|Pfizer Investigational Site, Huthwaite, Nottingham, United Kingdom|Pfizer Investigational Site, Headington, Oxford, United Kingdom|Pfizer Investigational Site, Haverfordwest, Pembrokeshire, United Kingdom|Pfizer Investigational Site, Haverfordwest, Pembrokeshire, United Kingdom|Pfizer Investigational Site, Shrewsbury, Shropshire, United Kingdom|Pfizer Investigational Site, Frome, Somerset, United Kingdom|Pfizer Investigational Site, Weston-Super-Mare, Somerset, United Kingdom|Pfizer Investigational Site, Sheffield, South Yorkshire, United Kingdom|Pfizer Investigational Site, Sheffield, South Yorkshire, United Kingdom|Pfizer Investigational Site, Sheffield, South Yorkshire, United Kingdom|Pfizer Investigational Site, Stirling, Stirlingshire, United Kingdom|Pfizer Investigational Site, Carshalton, Surrey, United Kingdom|Pfizer Investigational Site, Epsom, Surrey, United Kingdom|Pfizer Investigational Site, Pontarddulais, Swansea, United Kingdom|Pfizer Investigational Site, Dundee, Tayside, United Kingdom|Pfizer Investigational Site, Dundee, Tayside, United Kingdom|Pfizer Investigational Site, Hetton le Hole, Tyne & Wear, United Kingdom|Pfizer Investigational Site, Gateshead, Tyne and Wear, United Kingdom|Pfizer Investigational Site, Nuneaton, Warwickshire, United Kingdom|Pfizer Investigational Site, Rugby, Warwickshire, United Kingdom|Pfizer Investigational Site, Lyndon, West Bromwich, West Midlands, United Kingdom|Pfizer Investigational Site, Livingston, West Lothian, United Kingdom|Pfizer Investigational Site, Wolverhampton, West Midlands, United Kingdom|Pfizer Investigational Site, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Haywards Heath, West Sussex, United Kingdom|Pfizer Investigational Site, Corsham, Wiltshire, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom|Pfizer Investigational Site, Westbury, Wiltshire, United Kingdom|Pfizer Investigational Site, York, Yorkshire, United Kingdom|Pfizer Investigational Site, Ayr, United Kingdom|Pfizer Investigational Site, Ayr, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Cambridge, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Co. Dublin, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Derby, United Kingdom|Pfizer Investigational Site, Dewsbury, United Kingdom|Pfizer Investigational Site, Dublin 8, United Kingdom|Pfizer Investigational Site, Dumfries, United Kingdom|Pfizer Investigational Site, East Kilbride, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Hartlepool, United Kingdom|Pfizer Investigational Site, Hertfordshire, United Kingdom|Pfizer Investigational Site, Hertfordshire, United Kingdom|Pfizer Investigational Site, Inverness, United Kingdom|Pfizer Investigational Site, Leicester, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, Llantrisant, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom|Pfizer Investigational Site, Nottingham, United Kingdom|Pfizer Investigational Site, Oldham, United Kingdom|Pfizer Investigational Site, Paisley, United Kingdom|Pfizer Investigational Site, Pontefract, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Swansea, United Kingdom|Pfizer Investigational Site, Swansea, United Kingdom|Pfizer Investigational Site, Wakefield, United Kingdom|Pfizer Investigational Site, Wigan, United Kingdom|Pfizer Investigational Site, Wiltshire, United Kingdom|Pfizer Investigational Site, Wiltshire, United Kingdom|Pfizer Investigational Site, Wiltshire, United Kingdom|Pfizer Investigational Site, Wishaw, United Kingdom",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00442845,"CORONARY ARTERIOSCLEROSIS|DIABETES MELLITUS, TYPE 2|CEREBROVASCULAR ACCIDENT|DYSLIPIDEMIA|PERIPHERAL VASCULAR DISEASE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Mississauga, Ontario, Cameroon|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Red Deer, Alberta, Canada|Pfizer Investigational Site, Campbell River, British Columbia, Canada|Pfizer Investigational Site, Maple Ridge, British Columbia, Canada|Pfizer Investigational Site, Nanaimo, British Columbia, Canada|Pfizer Investigational Site, New Westminster, British Columbia, Canada|Pfizer Investigational Site, Richmond, British Columbia, Canada|Pfizer Investigational Site, Surrey, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vernon, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Brandon, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Ajax, Ontario, Canada|Pfizer Investigational Site, Brampton, Ontario, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Cambridge, Ontario, Canada|Pfizer Investigational Site, Cornwall, Ontario, Canada|Pfizer Investigational Site, Etobicoke, Ontario, Canada|Pfizer Investigational Site, Mississauga, Ontario, Canada|Pfizer Investigational Site, Niagara Falls, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, Orillia, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Rexdale, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Scarborough, Ontario, Canada|Pfizer Investigational Site, Simcoe, Ontario, Canada|Pfizer Investigational Site, Thunder Bay, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Weston, Ontario, Canada|Pfizer Investigational Site, Whitby, Ontario, Canada|Pfizer Investigational Site, Willowdale, Ontario, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Cowansville, Quebec, Canada|Pfizer Investigational Site, Drummondville, Quebec, Canada|Pfizer Investigational Site, Joliette, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Levis, Quebec, Canada|Pfizer Investigational Site, Maria, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Newport, Quebec, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Repentigny, Quebec, Canada|Pfizer Investigational Site, Saint Hyacinthe, Quebec, Canada|Pfizer Investigational Site, Sainte Foy, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-georges (beauce), Quebec, Canada|Pfizer Investigational Site, St. Lambert, Quebec, Canada|Pfizer Investigational Site, Thetford Mines, Quebec, Canada|Pfizer Investigational Site, Vaudreuil, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Tricase, (le), Italy|Pfizer Investigational Site, Vimercate, (mi), Italy|Pfizer Investigational Site, Somma Lombardo, (va), Italy|Pfizer Investigational Site, Asti, Italy|Pfizer Investigational Site, Bari, Italy|Pfizer Investigational Site, Belluno, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Bolzano, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Chieti, Italy|Pfizer Investigational Site, Ferrara, Italy|Pfizer Investigational Site, Firenze, Italy|Pfizer Investigational Site, Foggia, Italy|Pfizer Investigational Site, Grosseto, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Novara, Italy|Pfizer Investigational Site, Palermo, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Potenza, Italy|Pfizer Investigational Site, Prato, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Salerno, Italy|Pfizer Investigational Site, San Donato Milanese, Italy|Pfizer Investigational Site, Sassari, Italy|Pfizer Investigational Site, Savona, Italy|Pfizer Investigational Site, Siena, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Venezia, Italy|Pfizer Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Girona, Cataluna, Spain|Pfizer Investigational Site, Galdakao, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Granada, Spain|Pfizer Investigational Site, Huelva, Spain|Pfizer Investigational Site, Jerez de La Frontera, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Marbella, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Tarragona, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Newtonabbey, Belfast, United Kingdom|Pfizer Investigational Site, Aylesbury, Buckinghamshire, United Kingdom|Pfizer Investigational Site, ELY, Cambs, United Kingdom|Pfizer Investigational Site, Peterborough, Cambs, United Kingdom|Pfizer Investigational Site, Newtonabbey, Co Antrim, United Kingdom|Pfizer Investigational Site, Hastings, East Sussex, United Kingdom|Pfizer Investigational Site, High Valleyfield, Fife, United Kingdom|Pfizer Investigational Site, Rutherglen, Glasgow, United Kingdom|Pfizer Investigational Site, Leslie, Fife, Glenrotheshire, United Kingdom|Pfizer Investigational Site, Sunbury on Thames, Middlesex, United Kingdom|Pfizer Investigational Site, Frome, Somerset, United Kingdom|Pfizer Investigational Site, Barry, South Glamorgan, United Kingdom|Pfizer Investigational Site, Doncaster, South Yorkshire, United Kingdom|Pfizer Investigational Site, Stairfoot, Barnsley, South Yorkshire, United Kingdom|Pfizer Investigational Site, Addlestone, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Surrey, United Kingdom|Pfizer Investigational Site, Atherstone, Warks, United Kingdom|Pfizer Investigational Site, Balsall Common, West Midlands, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wilts, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(O)(P(=O)(O)O)P(=O)(O)O,1,DB01077,__ETIDRONIC_ACID,,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,206.0282,135.29,7.0,5.0,0.0,13.97,34.51,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,NCT00390975,GASTROPARESIS|DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Kansas Medical Center, Kansas City, Kansas, United States|The University of Louisville, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",C07D409/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Unknown status,NCT03383068,PCOS|IMPAIRED GLUCOSE TOLERANCE,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China",C12R1/465,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Recruiting,NCT04531176,TYPE 2 DIABETES|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",C12R1/465,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Unknown status,NCT01475019,OBESITY|POLYCYSTIC OVARIES SYNDROME,Female,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece",C12R1/465,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Terminated,NCT01597531,TYPE 2 DIABETES|GASTRIC BANDING,All,"25 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States",C12R1/465,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Active Not Recruiting,,TYPE II DIABETES IN SUBJECTS BMI 27 TO 32,,,,,"FISABIO, Elche, Alicante, Spain",C12R1/465,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Completed,,FATTY LIVER,,,,,"FISABIO, Elche, Alicante, Spain",C12R1/465,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CC(C)n1c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1,DB01095,__FLUVASTATIN,5354772,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,10.5464177909197,1359.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.69,411.4659,82.69,4.0,3.0,3.0,44.31,114.86,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT02305355,"DIABETES MELLITUS, TYPE 2|HYPERTRIGLYCEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00506961,DIABETES MELLITUS|DYSLIPIDEMIA,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00079638,DYSLIPIDEMIA|CORONARY HEART DISEASE|ATHEROSCLEROSIS|STROKE|DIABETES,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Terminated,NCT00651378,HYPERCHOLESTEROLEMIA|ATHEROSCLEROSIS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Recruiting,NCT01816997,DIABETES,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Taipei Veterans General Hospital, Taipei, Taiwan",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT03784703,DYSLIPIDEMIA ASSOCIATED WITH TYPE II DIABETES MELLITUS,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Tanta University Hospital, Tanta, El-Gharbia, Egypt",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT03074630,"DIABETES MELLITUS, TYPE 2|HYPERCHOLESTEROLEMIA",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Academic Medical Center, Amsterdam, North Holland, Netherlands",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Withdrawn,NCT00913562,GLAUCOMA|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT03217409,DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA,All,"19 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Soon Chun Hyang University Hospital Gumi, Gumi, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon, Gyeonggi-do, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00262548,"DIABETES MELLITUS, TYPE 2",Female,"45 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research site, Cuernavaca, Morelos, Mexico",C07D239/42 ,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00786136,DIABETES MELLITUS|CHRONIC KIDNEY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"The Armed Police General Hospital, BeiJing, Beijing, China|The Chinese people's liberation army general hospital affiliated hospitals, BeiJing, Beijing, China|Peking University first hospital, Beijing, Beijing, China|General Hospital Of The Second Artillery Force of the PLA, BeiJing, Beijing, China|The General Hospital of the People's Liberation Army (PLAGH) ( Hospital 301), BeiJing, Beijing, China|The Third Military Medical University, Chongqing Xinqiao Hospital, ChongQing, Chongqing, China|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, ChongQing, Chongqing, China|First Hospital of Lanzhou University, LanZhou, Gansu, China|Dongguan Kanghua Hospital, DongGuan, Guangdong, China|General Hospital of Guangzhou Military Command of PLA, GuangZhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical College, GuangZhou, Guangdong, China|Chinese People's Liberation Army 252th Hostipal, BaoDing, Hebei, China|CanZhou Central Hospital, CangZhou, Hebei, China|Shijiazhuang International Peace Hospital, ShiJiaZhuang, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|HeNan Provincial People's Hospital, ZhengZhou, Henan, China|WuHan Asia Heart Hosital, WuHan, Hubei, China|WuHan Union Hospital Of China, WuHan, Hubei, China|TongJi Medical College HuaZhong University Of Science & Technology, WuHan, Hubei, China|Renmin Hospital Of Wuhan University, WuHan, Hubei, China|Wuhan General Hospital of Guangzhou Military Area Command of Chinese PLA, WuHan, Hubei, China|Nanjing First Hospital, NanJing, Jiangsu, China|NanJing Drum Tower Hospital, NanJing, Jiangsu, China|FAW subsidiary of the General Hospital of Jilin University (Jilin University, Fourth Hospital), ChangChun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Changchun Central Hospital, ChangChun, Jilin, China|General Hospital of Liaoning Anshan Iron and Steel Group Corporation, AnShan, Liaoning, China|Affiliated Zhongshan Hospital of Dalian University, DaLian, Liaoning, China|Fushun central hospital, FuShun, Liaoning, China|The First Affiliated Hospital of Liaoning Medical College, Jinzhou, Liaoning, China|ShenZhou Hopital Of ShenYang Medical College, ShengYang, Liaoning, China|PLA 202 Hospital, ShenYang, Liaoning, China|Shenyang Nortern Hospital, Shenyang, Liaoning, China|Affiliated Hospital of LiaoNing University of Traditional Chinese Medicine, ShenYang, Liaoning, China|The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China|The 463th Hospital Of PLA, ShenYang, Liaoning, China|Affiliated Hospital of Ningxia Medical College, Yinchuan, Ningxia, China|General Hospital of Jinan Military Area Command of Chinese PLA, JiNan, Shandong, China|88th Hospital of the Chinese PLA, TaiAn, Shandong, China|Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University, ShangHai, Shanghai, China|Xijing Hospital of the Fourth Military Medical University, XiAn, Shanxi, China|Chengdu Military General Hospital, ChengDu, Sichuan, China|PLA 254 Hosipital, TianJin, Tianjin, China|Affiliated Hospital Of Medical College Of The Chinese People's Armed Polic Forces, TianJin, Tianjin, China|WuluMuqi General Hospital of PLA Lanzhou Military Area Command, WuLuMuQI, Xinjiang, China|The First Affilliated Hospital Of Xinjiang Medical University, Wulumuqi, Xinjiang, China|The First Affiliated Hospital of Kunming Medical College, KunMing, Yunnan, China|Kunming General Hospital of PLA, KunMing, Yunnan, China|The First Affiliated Hospital of Wenzhou Medical College, WenZhou, Zhejiang, China|Baotou city central hospital, BaoTou, China|Baotou iron and steel group company worker hospital, BaoTou, China",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00747149,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Red Deer, Alberta, Canada|Research Site, Spruce Grove, Alberta, Canada|Research Site, St Albert, Alberta, Canada|Research Site, Chilliwack, British Columbia, Canada|Research Site, Coquitlam, British Columbia, Canada|Research Site, Delta, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Maple Ridge, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Portage La Prairie, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Bathurst, New Brunswick, Canada|Research Site, Woodstock, New Brunswick, Canada|Research Site, Carbonear, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kentville, Nova Scotia, Canada|Research Site, Pubnico, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Truro, Nova Scotia, Canada|Research Site, Aylmer, Ontario, Canada|Research Site, Bolton, Ontario, Canada|Research Site, Chatham, Ontario, Canada|Research Site, Fort Erie, Ontario, Canada|Research Site, Georgetown, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Morrisburg, Ontario, Canada|Research Site, Nepean, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scaborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smith Falls, Ontario, Canada|Research Site, St Catherines, Ontario, Canada|Research Site, St. Catharines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Thorold, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Welland, Ontario, Canada|Research Site, Willowdale, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Charlottetown, Prince Edward Island, Canada|Research Site, Kensington, Prince Edward Island, Canada|Research Site, Montague, Prince Edward Island, Canada|Research Site, Anjou, Quebec, Canada|Research Site, Dolbeau-mistassini, Quebec, Canada|Research Site, Drummondville, Quebec, Canada|Research Site, Forestville, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Joliette, Quebec, Canada|Research Site, L'ile- Perrot, Quebec, Canada|Research Site, La Sarre, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Roberval, Quebec, Canada|Research Site, Roxton Pond, Quebec, Canada|Research Site, Saint-bruno-lac-saint-jean, Quebec, Canada|Research Site, Saint-charles-borromee, Quebec, Canada|Research Site, Saint-leonard, Quebec, Canada|Research Site, Saint-marc-des-carrieres, Quebec, Canada|Research Site, Saint-pie, Quebec, Canada|Research Site, Sainte Gedeon-de-beauce, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Trois-rivieres, Quebec, Canada|Research Site, Moose Jaw, Saskatchewan, Canada|Research Site, Porcupine Plain, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Yorkton, Saskatchewan, Canada|Research Site, Quebec, Canada",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Unknown status,NCT02418884,CORONARY ARTERY DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT02612714,SEXUAL DYSFUNCTION,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Chang Gung, Kaohsiung, Taiwan",C07D239/42 ,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,Completed,NCT03978286,DEPRESSION|TYPE 2 DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,Completed,NCT00208702,MAJOR DEPRESSIVE DISORDER,All,18 Years to 60 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Emory University, Atlanta, Georgia, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,Completed,NCT00624013,DIABETES|DEPRESSION,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Charles Drew University, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,Completed,NCT00374426,MAJOR DEPRESSION|DIABETES,All,"18 Years to 80 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,1,DB01105,__SIBUTRAMINE,5436272,Completed,NCT00463112,OBESITY|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hippocratio General Hospital, Thessaloniki, Greece",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,33.2819975769523,330.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.05,279.848,3.24,1.0,0.0,2.0,32.9,83.92,5.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,1,DB01105,__SIBUTRAMINE,5436272,Unknown status,NCT01475019,OBESITY|POLYCYSTIC OVARIES SYNDROME,Female,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,33.2819975769523,330.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.05,279.848,3.24,1.0,0.0,2.0,32.9,83.92,5.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Withdrawn,NCT02779257,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D225/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Suspended,NCT03608163,"DIABETES MELLITUS, TYPE 1|HYPOGLYCEMIA|HYPOGLYCEMIA UNAWARENESS",All,21 Years to 55 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Albert Einstein College of Medicine, Bronx, New York, United States",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Completed,NCT00131755,"DIABETES MELLITUS, TYPE 1",All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University Hospital of Trondheim, Trondheim, Norway",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Completed,NCT01488136,TYPE 1 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NHS Tayside, Dundee, United Kingdom",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT00367055,TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Withdrawn,NCT00225342,"ANGINA PECTORIS|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Cardiology Department, Glasgow Royal Infirmary, Glasgow, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT00780715,"DIABETES MELLITUS, TYPE 2",All,"36 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ninewells Hospital & Medical School, Dundee, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT03068065,NON-ALCOHOLIC FATTY LIVER DISEASE|TYPE2 DIABETES,All,"17 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT01022762,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT02682563,"DIABETES MELLITUS, TYPE 2|DIABETIC NEPHROPATHIES",All,"35 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT02610088,DIABETES,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT01679899,TYPE 2 DIABETES MELLITUS|MENOPAUSE|OSTEOPOROSIS|OSTEOPENIA,Female,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Diabetes Curitiba, Curitiba, Parana, Brazil",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,1,DB01126,__DUTASTERIDE,5565467,Completed,NCT00752869,HYPOGONADISM,Male,"40 Years to 85 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Men's Health Boston, Boston, Massachusetts, United States|The Miriam Hospital, Providence, Rhode Island, United States",C07J73/005,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,19.022977884556106,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.45,528.5297,58.2,2.0,2.0,5.0,50.13,127.9,4.0,1.0,0.0,0.0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,1,DB01126,__DUTASTERIDE,5565467,Completed,NCT00194675,HYPOGONADISM|BENIGN PROSTATIC HYPERPLASIA,Male,"50 Years and older   (Adult, Older Adult)",Other|Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VA Puget Sound Health Care System, Seattle, Washington, United States",C07J73/005,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,19.022977884556106,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.45,528.5297,58.2,2.0,2.0,5.0,50.13,127.9,4.0,1.0,0.0,0.0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01002547,NONALCOHOLIC STEATOHEPATITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT00879970,"DIABETES MELLITUS, TYPE 2",All,"50 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Tucker, Georgia, United States|GSK Investigational Site, Pocatella, Idaho, United States|GSK Investigational Site, Pocatello, Idaho, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Haverhill, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Kalispell, Montana, United States|GSK Investigational Site, Westfield, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Coronel Suarez, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, San Nicolas, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Salta, Argentina|GSK Investigational Site, San Miguel de Tucuman, Argentina|GSK Investigational Site, Zárate, Argentina|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Cambridge, Ontario, Canada|GSK Investigational Site, Hamilton., Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Ohsweken, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Thornhill, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Rimouski, Quebec, Canada|GSK Investigational Site, Saint-Georges, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Temuco, Región De La Araucania, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Osorno, Chile|GSK Investigational Site, Valdivia, Chile|GSK Investigational Site, Victoria, Chile|GSK Investigational Site, Armenia, Colombia|GSK Investigational Site, Barrangquilla, Colombia|GSK Investigational Site, Barranquilla, Colombia|GSK Investigational Site, Bogotac, Colombia|GSK Investigational Site, Bogota, Colombia|GSK Investigational Site, Cali, Colombia|GSK Investigational Site, Cartagena, Colombia|GSK Investigational Site, Cartagena, Colombia|GSK Investigational Site, Espinal, Colombia|GSK Investigational Site, Floridablanca, Colombia|GSK Investigational Site, Manizales, Colombia|GSK Investigational Site, Medellín, Colombia|GSK Investigational Site, Pereira, Colombia|GSK Investigational Site, Havirov, Czech Republic|GSK Investigational Site, Jihlava, Czech Republic|GSK Investigational Site, Mestec Kralove, Czech Republic|GSK Investigational Site, Ostrava, Czech Republic|GSK Investigational Site, Prague, Czech Republic|GSK Investigational Site, Praha 4, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Praha 6, Czech Republic|GSK Investigational Site, Praha, Czech Republic|GSK Investigational Site, Pribram 8, Czech Republic|GSK Investigational Site, Rakovnik, Czech Republic|GSK Investigational Site, Uherske Hradiste, Czech Republic|GSK Investigational Site, Aarhus-N, Denmark|GSK Investigational Site, Frederiksberg, Denmark|GSK Investigational Site, Glostrup, Denmark|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, København NV, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Viborg, Denmark|GSK Investigational Site, Helsinski, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Deggingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Weinheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Gars am Inn, Bayern, Germany|GSK Investigational Site, Haag, Bayern, Germany|GSK Investigational Site, Kuenzing, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Vilshofen, Bayern, Germany|GSK Investigational Site, Wallerfing, Bayern, Germany|GSK Investigational Site, Angermuende, Brandenburg, Germany|GSK Investigational Site, Elsterwerda, Brandenburg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Grossalmerode, Hessen, Germany|GSK Investigational Site, Kelkheim, Hessen, Germany|GSK Investigational Site, Winsen/Lohe, Niedersachsen, Germany|GSK Investigational Site, Bad Oeynhausen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergkamen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dorsten, Nordrhein-Westfalen, Germany|GSK Investigational Site, Eschweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Goch, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Witten, Nordrhein-Westfalen, Germany|GSK Investigational Site, Ingelheim, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, Germany|GSK Investigational Site, Neunkirchen, Saarland, Germany|GSK Investigational Site, Koethen, Sachsen-Anhalt, Germany|GSK Investigational Site, Schoenebeck, Sachsen-Anhalt, Germany|GSK Investigational Site, Wolmirstedt, Sachsen-Anhalt, Germany|GSK Investigational Site, Zerbst, Sachsen-Anhalt, Germany|GSK Investigational Site, Borna, Sachsen, Germany|GSK Investigational Site, Delitzsch, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzg, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Oschatz, Sachsen, Germany|GSK Investigational Site, Pirna, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Banjara Hills PO, Hyderabad, India|GSK Investigational Site, Belgaum, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Cochin, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Karnal, India|GSK Investigational Site, Kerala, India|GSK Investigational Site, Kochi, India|GSK Investigational Site, Kochi, India|GSK Investigational Site, Kottyam, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nasik, India|GSK Investigational Site, Nellore, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Tamil Nadu, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Vijayawada, India|GSK Investigational Site, Milano (Milan), Lombardia, Italy|GSK Investigational Site, Sesto San Giovanni (MI), Lombardia, Italy|GSK Investigational Site, Pozzilli (IS), Molise, Italy|GSK Investigational Site, Chieri (Torino), Italy|GSK Investigational Site, Cesis, Latvia|GSK Investigational Site, Daugavpils, Latvia|GSK Investigational Site, Jekabpils, Latvia|GSK Investigational Site, Liepaja, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Tukums, Latvia|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Morelia, Michoacán, Mexico|GSK Investigational Site, San Luis Potosi, San Luis Potosí, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Guadalajara, Mexico|GSK Investigational Site, Tampico, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Hoofddorp, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Bodø, Norway|GSK Investigational Site, Hoenefoss, Norway|GSK Investigational Site, Kløfta, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Skedsmokorset, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Tromsø, Norway|GSK Investigational Site, Trondheim, Norway|GSK Investigational Site, Faisalabad, Pakistan|GSK Investigational Site, Islamabad, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Arequipa, Peru|GSK Investigational Site, Laoag City, Philippines|GSK Investigational Site, Bacau, Romania|GSK Investigational Site, Baia Mare, Romania|GSK Investigational Site, Bistrita, Romania|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Buzau, Romania|GSK Investigational Site, Deva, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Pitesti, Romania|GSK Investigational Site, Sibiu, Romania|GSK Investigational Site, Arkhangelsk, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Kirov, Russian Federation|GSK Investigational Site, Kursk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Nizhny Novgorod, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St Pertersburg, Russian Federation|GSK Investigational Site, St Petersberg, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Syktyvkar, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Vladivostok, Russian Federation|GSK Investigational Site, Vladivostok, Russian Federation|GSK Investigational Site, Volgograd, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Nitra, Slovakia|GSK Investigational Site, Port Elizabeth, Eastern Cape, South Africa|GSK Investigational Site, Meyerspark, Gauteng, South Africa|GSK Investigational Site, Parktown, Gauteng, South Africa|GSK Investigational Site, Chatsworth, KwaZulu- Natal, South Africa|GSK Investigational Site, Umhlanga Rocks, KwaZulu- Natal, South Africa|GSK Investigational Site, Bellville, South Africa|GSK Investigational Site, Benoni, South Africa|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Durban, South Africa|GSK Investigational Site, Newton, South Africa|GSK Investigational Site, Observatory, South Africa|GSK Investigational Site, Parktown, South Africa|GSK Investigational Site, Pretoria, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Soweto, South Africa|GSK Investigational Site, Soweto, South Africa|GSK Investigational Site, Worcester, South Africa|GSK Investigational Site, Eksjö, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Härnösand, Sweden|GSK Investigational Site, Karlshamn, Sweden|GSK Investigational Site, Kristianstad, Sweden|GSK Investigational Site, Ljungby, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Oskarshamn, Sweden|GSK Investigational Site, Skene, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Vällingby, Sweden|GSK Investigational Site, Växjö, Sweden|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Chippenham, United Kingdom|GSK Investigational Site, Doncaster, United Kingdom|GSK Investigational Site, Harrogate, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00571506,"DIABETES MELLITUS, TYPE 2|VASCULAR DISEASES",All,"40 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00953498,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service Endocrinologie-diabétologie, Hôpital du Bocage CHU, Dijon, France",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00576784,TYPE 2 DIABETES MELLITUS|INSULIN RESISTANCE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IKFE, Mainz, Germany",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT03796975,TYPE 2 DIABETES MELLITUS|NON-ALCOHOLIC FATTY LIVER DISEASE|EFFICACY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT02875821,TYPE 2 DIABETES WITH NON-ALCOHOLIC FATTY LIVER (NAFLD),All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00770445,DIABETES,All,"30 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lichtenfels, Bavaria, Germany|Frankfurt, Hessen, Germany|Kassel, Hessen, Germany|Wiesbaden, Hessen, Germany|Bad Oeynhausen, North Rhine-Westphalia, Germany|Dinslaken, North Rhine-Westphalia, Germany|Duisburg, North Rhine-Westphalia, Germany|Essen, North Rhine-Westphalia, Germany|Münster, North Rhine-Westphalia, Germany|Wuppertal, North Rhine-Westphalia, Germany|Mainz, Rheinland-Pfalz, Germany|Diez, Rhineland-Palatinate, Germany|Landau, Rhineland-Palatinate, Germany|Dresden, Saxony, Germany|Leipzig, Saxony, Germany|Jena, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01947790,LVM|TYPE 2 DIABETIC PATIENTS WITH IHD|ENDOTHELIAL FUNCTION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Wuhan City, Hubei, China|Xiang Guangda, Wuhan, Hubei, China",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01090752,DIABETES|HYPERTENSION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pechère-Bertschi Antoinette, Geneva, Switzerland",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00108615,GLUCOSE METABOLISM DISORDERS|DIABETES,All,"35 Years to 65 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Central Arkansas Veterans HCS, Little Rock, Arkansas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",C07D213/30,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Not yet recruiting,NCT03646292,NAFLD - NONALCOHOLIC FATTY LIVER DISEASE|TYPE2 DIABETES,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00845182,TYPE 2 DIABETES|HEALTHY|IMPAIRED GLUCOSE TOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Barter Research Center, ALM VA Hospital, San Antonio, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Not yet recruiting,NCT03950505,NON-ALCOHOLIC STEATOHEPATITIS|TYPE2 DIABETES,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Recruiting,NCT04473274,CORONAVIRUS INFECTION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00231894,DIABETES|SCHIZOPHRENIA|INSULIN RESISTANCE|COGNITIVE IMPAIRMENT,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nathan Kline Institute for Psychiatric Research, New York, New York, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00819325,CORONARY ARTERY DISEASE|ANGINA PECTORIS|TYPE 2 DIABETES MELLITUS|PERCUTANEOUS CORONARY INTERVENTION,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00145340,PCOS,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",C07D213/30,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00609856,TYPE 2 DIABETES|SECONDARY DRUG FAILURE,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Malmö University Hospital, Malmö, Sweden",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Enrolling by invitation,NCT03910361,TYPE2 DIABETES|NON-ALCOHOLIC FATTY LIVER DISEASE,All,"19 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00994682,NONALCOHOLIC STEATOHEPATITIS|NONALCOHOLIC FATTY LIVER DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bartter Research Unit, Audie L Murphy VA Hospital, San Antonio, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT02365233,TYPE II DIABETES|NONALCOHOLIC FATTY LIVER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Medical Branch -Galveston, Galveston, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00479986,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR DISEASE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Dr. Michael Morcos, Heidelberg, Germany|IKFE, Mainz, Germany",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Unknown status,NCT01339143,DIABETES MELLITUS|OXIDATIVE STRESS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Korea University Anam Hospital, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01799850,DIABETES TYPE 2,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ETSU Quillen College of Medicine, Johnson City, Tennessee, United States",C07D213/30,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT00212004,DIABETES MELLITUS|MYOCARDIAL INFARCTION,All,"20 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"National Cardiovascular Center, Suita, Osaka, Japan",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01588470,TYPE 2 DIABETES|CORONARY HEART DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00494312,DIABETES MELLITUS|LIVER,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Recruiting,NCT03878459,TYPE 1 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Health System Texas Diabetic Institute, San Antonio, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00212290,INSULIN RESISTANCE|TYPE 2 DIABETES MELLITUS,All,"55 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, United States|VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Unknown status,NCT02429232,OSTEOPOROSIS|DIABETES MELLITUS,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00494559,DIABETES MELLITUS|CORONARY ARTERY STENOSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Korea University Anam Hospital, Seoul, Korea, Republic of",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00579813,METABOLIC SYNDROME|INSULIN RESISTANCE|PREDIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Kentucky, Lexington, Kentucky, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00708175,BONE METABOLISM,Female,"up to 70 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Greenbrae, California, United States|Los Banos, California, United States|San Diego, California, United States|Walnut Creek, California, United States|West Hills, California, United States|Lakewood, Colorado, United States|Longmont, Colorado, United States|Boynton Beach, Florida, United States|Hialeah, Florida, United States|Jupiter, Florida, United States|Dunwoody,, Georgia, United States|Gainesville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Des Moines, Iowa, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Metarie, Louisiana, United States|Scarborough, Maine, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|Mineola, New York, United States|West Haverstraw, New York, United States|Pinehurst, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Aiken, South Carolina, United States|Greenville, South Carolina, United States|Brentwood, Tennessee, United States|Denton, Texas, United States|Houston, Texas, United States",C07D213/30,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT00352287,OBESITY|METABOLIC SYNDROME|IMPAIRED GLUCOSE TOLERANCE,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,"Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Unknown status,NCT00430040,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetes - Endocrinology Center of Western New York, Buffalo, New York, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT00123604,HYPERTENSION|TYPE 2 DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","St. Paul Heart Clinic, St. Paul, Minnesota, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT00642434,DIABETES,All,"45 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","UNMHSC, Albquerque, New Mexico, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT00060918,HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Burlingame, California, United States|GSK Investigational Site, Concord, California, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Hemet, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Pasadena, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Luis Obispo, California, United States|GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Golden, Colorado, United States|GSK Investigational Site, Panama City, Florida, United States|GSK Investigational Site, St. Petersburg, Florida, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Idaho Falls, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, O'Fallon, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Oak Park, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Oregon City, Oregon, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Georgetown, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Colony, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Renton, Washington, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Unknown status,NCT00732511,ENDOTHELIAL FUNCTION|DIABETES MELLITUS|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"SUNY Downstate Medical Center, Brooklyn, New York, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT00497003,ENDOTHELIAL FUNCTION|BETA BLOCKER,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Cardiology, University Hospital of Copenhagen, Bispebjerg, Copenhagen, Denmark",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Active Not Recruiting,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,SPINAL ANAESTHESIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,1,DB01162,__TERAZOSIN,5212176,Completed,NCT02046395,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Tulane University Health Sciences Center, New Orleans, Louisiana, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.629047824390604,855.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,387.4329,103.04,8.0,1.0,4.0,41.26,105.18,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Recruiting,NCT02983214,"ISCHEMIC STROKE|PERIPHERAL ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Epirus, Greece",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,NCT00823849,TYPE 2 DIABETES MELLITUS|ARTERIOSCLEROSIS OBLITERANS,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University First Hospital, Beijing, China",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,NCT01252056,DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Universuty First Hospital, Beijng, Beijing, China",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,NCT03248401,TYPE 2 DIABETES MELLITUS|CAROTID ATHEROSCLEROSIS,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Unknown status,NCT00886574,TYPE 2 DIABETES,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Inha University Hospital, In Cheon, Korea, Republic of|Hallym University Hospital, Pyungcheon, Korea, Republic of|Hallym University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyung hee University Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Unknown status,NCT00573950,"DIABETES MELLITUS, TYPE 2|METABOLIC SYNDROME X",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Korea Univerisity Anam Hospital, Seoul, Korea, Republic of",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,NCT00272831,"DIABETES MELLITUS, TYPE 2|DIABETES COMPLICATIONS",All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,NCT01076478,POLYNEUROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Santo Tomas Hospital, Manila, Philippines",C12N9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Unknown status,NCT00650897,MAJOR DEPRESSION|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sheba Medical Center, Tel Hashomer, Israel",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT00209170,DIABETES|DEPRESSION,All,"18 Years to 81 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Grady Hospital Diabetes Clinic, Atlanta, Georgia, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,1,DB01183,__NALOXONE,6159498,Suspended,NCT03608163,"DIABETES MELLITUS, TYPE 1|HYPOGLYCEMIA|HYPOGLYCEMIA UNAWARENESS",All,21 Years to 55 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Albert Einstein College of Medicine, Bronx, New York, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,27.3681184418571,1213.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,327.3743,70.0,5.0,2.0,5.0,33.83,88.72,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT02335151,ADENOCARCINOMA|CIRCULATING TUMOR CELLS|PANCREATIC NEOPLASMS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|University Hospital Zurich, Zurich, Switzerland|Stadtspital Triemli, Zürich, Switzerland",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,1,DB01197,__CAPTOPRIL,5238924,Completed,NCT00660309,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Novartis Investigator Site, Boston, Massachusetts, United States",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,21.3556746545103,1584.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,217.285,57.61,3.0,2.0,1.0,21.72,54.63,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,1,DB01197,__CAPTOPRIL,5238924,Recruiting,NCT04485845,METABOLIC SYNDROME|DIABETE TYPE 2|KIDNEY INSUFFICIENCY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Diabetes & Endocrinology Institute, Cairo, Egypt",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,21.3556746545103,1584.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,217.285,57.61,3.0,2.0,1.0,21.72,54.63,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,1,DB01197,__CAPTOPRIL,5238924,Completed,NCT00155064,HYPERALDOSTERONISM,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Taiwan University Hospital, Taipei, Taiwan",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,21.3556746545103,1584.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,217.285,57.61,3.0,2.0,1.0,21.72,54.63,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,1,DB01200,__BROMOCRIPTINE,5468755,Unknown status,NCT00451672,HYPERALDOSTERONISM|HYPERTENSION,All,20 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan Univserty Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Unknown status,NCT02137538,SHORT STATURE,Male,10 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lucile Packard Children's Hospital, Palo Alto, California, United States",C07D239/26,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Recruiting,NCT03490513,"HYPOGONADISM, HYPOGONADOTROPIC|OBESITY",Male,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Michael E. DeBakey VAMC, Houston, Texas, United States",C07D239/26,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01220,__RIFAXIMIN,6861053,Not Yet Recruiting,,WEIGHT LOSS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Withdrawn,NCT03315052,ACUTE CELLULAR GRAFT REJECTION|LIVER TRANSPLANT REJECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2,1,DB01226,__MIVACURIUM,4761418,Completed,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D217/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,36.53463110125461,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,1029.2608,144.9,12.0,0.0,6.0,116.68,308.74,30.0,1.0,0.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Recruiting,NCT03794778,EFFICACY AND SAFETY,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Women's Hospital School Of Medicine Zhejiang University, Zhejiang, Hangzhou, China",A61K47/6925,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Unknown status,NCT01023919,CORONARY ARTERY DISEASE|DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The second Affiliated Hospital of Harbin Medical University, Harbin, Heilong jiang, China",A61K47/6925,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Unknown status,NCT01021930,CORONARY HEART DISEASE|DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The second Affiliated Hospital of Harbin Medical University, Harbin, Heilong jiang, China",A61K47/6925,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Unknown status,NCT01706120,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"A.S.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Centro di Riferimento Oncologico, Aviano, Italy|Ospedale Fatebenefratelli, Benevento, Italy|Spedali Civili - Università di Brescia, Brescia, Italy|Ospedale Senatore Antonio Perrino, Brindisi, Italy|Fondazione del Piemonte per l'Oncologia, Candiolo, Italy|Ospedale Ramazzini di Carpi /Ospedale di Mirandola, Carpi, Italy|Azienda Ospedaliera Garibaldi Nesimadi Catania, Catania, Italy|Ospedale Cannizzaro, Catania, Italy|Ospedale Mater Domini, Catanzaro, Italy|Ospedale Civile di Faenza, Faenza, Italy|Ospedale Santa Croce, Fano, Italy|A.O.U. Arcispedale Sant'Anna di Ferrara, Ferrara, Italy|Ospedale Fabrizio Spaziani di Frosinone / Osp. SS Trinità di Sora, Frosinone, Italy|E.O. Ospedali Galliera, Genova, Italy|IRCCS San Martino IST, Genova, Italy|Ospedale di Guastalla, Guastalla, Italy|Ospedale A. Manzoni, Lecco, Italy|Ospedale Mater Salutis, Legnago, Italy|Presidio Ospedaliero Manerbio, Manerbio, Italy|A.O. C. Poma, Mantova, Italy|Istituto Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale Tumori, MIlano, Italy|Ospedale San Raffaele, Milano, Italy|U.L.S.S. 13, Mirano, Italy|A.O.U. Policlinico Modena, Modena, Italy|Ospedale S. Gerardo, Monza, Italy|AOU Policlinico Federico II, Napoli, Italy|Istituto Nazionale dei Tumori, Napoli, Italy|Istituto Sacro Cuore Don Calabria, Negrar, Italy|Istituto Oncologico Veneto, Padova, Italy|Fondazione IRCCS S. Matteo, Pavia, Italy|Ospedale Silvestrini, Perugia, Italy|Ospedale Santa Chiara, Pisa, Italy|A.O. Santa Maria degli Angeli, Pordenone, Italy|Ospedale S. Maria delle Croci, Ravenna, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Ospedale degli Infermi / Ospedale Civile, Rimini, Italy|Istituto Regina Elena, Roma, Italy|Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore, Roma, Italy|A.O. Ordine Mauriziano, Torino, Italy|A.O.U. OIRM-S. Anna, Torino, Italy|ASS N 1 Triestina, Trieste, Italy|A.O. di Udine S. Maria delle Misericordia, Udine, Italy|Ospedale del Ponte, Varese, Italy",A61K47/6925,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Not yet recruiting,NCT04217096,ADVANCED PANCREATIC CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China",A61K47/6925,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,ADENOCARCINOMA OF THE PANCREAS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00817479,OVARIAN CANCER,Female,18 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago, Chicago, Illinois, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04025840,PANCREATIC CANCER|SURGERY|EPIDURAL BLOCK|DEXAMETHASONE|OVERALL SURVIVAL,All,"45 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Peking University First Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04412694,HYPOCALCEMIA|VITAMIN D DEFICIENCY|POSTOPERATIVE COMPLICATIONS|POSTOPERATIVE NAUSEA|POSTOPERATIVE PAIN|VOICE HOARSENESS|HYPOPARATHYROIDISM POSTPROCEDURAL,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Department of General and Oncological Surgery, Medical University of Lodz, Łódź, Łódzkie, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT03361709,DIABETES MELLITUS|CORNEAL ENDOTHELIAL CELL LOSS|DEXAMETHASONE ADVERSE REACTION|CORNEAL ENDOTHELIAL DECOMPENSATION,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04448496,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dong-A University Hospital, Busan, Korea, Republic of|Maryknoll Medical Center, Busan, Korea, Republic of|Gyeongsang National University Changwon Hospital, Changwon, Korea, Republic of|Yeungnam university hospital, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02399657,DIABETES MELLITUS|MACULAR EDEMA|RETINAL EXUDATES AND DEPOSITS,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Dong-A University hospital, Busan, Korea, Republic of|Pusan national university hospital, Busan, Korea, Republic of|Inje University Haeundae Paik hospital, Busan, Korea, Republic of|Inje University Busan Paik hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT03646916,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Genesys Regional Medical Center, Grand Blanc, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT02844907,INSULIN SECRETION,All,"18 Years to 65 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT01045876,ADRENAL INSUFFICIENCY,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","St Paul's Hospital, Vancouver, British Columbia, Canada",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT03210545,ADDISON DISEASE,All,20 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital, Gothenburg, Sweden",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Active Not Recruiting,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Unknown status,NCT01189721,HYPERALGESIA,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gang Nam Severance Hospital, Yonsei University, Anesthesia and Pain Medicine Department,, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,NCT01085383,HYPERPROLACTINEMIA,All,"16 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Dept. of Psychiatry, Oxford, Oxfordshire, United Kingdom",C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,NCT00351936,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Freedom Trail Clinic, Boston, Massachusetts, United States",C07D215/227,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,NCT00245206,SCHIZOPHRENIA|ALZHEIMER'S DISEASE|DEMENTIA,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, San Diego, California, United States",C07D215/227,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Unknown status,NCT01742390,SEXUAL DYSFUNCTION|HYPERPROLACTINEMIA,All,"12 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of mental health, Peking University, Beijing, Beijing, China|The first hospital of Hebei Province University, Shijiazhuang, Hebei, China",C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,NCT01411930,DIABETES,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"VA San Diego Healthcare System, San Diego, California, United States",C07D215/227,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,1,DB01241,__GEMFIBROZIL,4126637,Withdrawn,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/235,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,1026.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,250.3334,46.53,3.0,1.0,1.0,28.9,71.82,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,1,DB01242,__CLOMIPRAMINE,5008262,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,35.8775334195774,561.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,314.8520000000001,6.48,2.0,0.0,3.0,35.73,95.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01249,__IODIXANOL,5366722,Terminated,NCT00209417,RENAL INSUFFICIENCY|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","GE Healthcare, Princeton, New Jersey, United States|GE Healthcare, Amersham, United Kingdom",A61K49/0447,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,11.9263229224419,154.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1550.1819,339.09,15.0,13.0,2.0,111.56,277.16,22.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01249,__IODIXANOL,5366722,Terminated,NCT00782639,CHRONIC RENAL IMPAIRMENT|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","Bracco Diagnostics Inc., Princeton, New Jersey, United States",A61K49/0447,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,11.9263229224419,154.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1550.1819,339.09,15.0,13.0,2.0,111.56,277.16,22.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01249,__IODIXANOL,5366722,Withdrawn,NCT00335101,CORONARY ARTERY DISEASE (CAD)|RENAL IMPAIRMENT|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,"GE Healthcare, Princeton, New Jersey, United States|GE Healthcare, Munich, Germany",A61K49/0447,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,11.9263229224419,154.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1550.1819,339.09,15.0,13.0,2.0,111.56,277.16,22.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01249,__IODIXANOL,5366722,Not yet recruiting,NCT03631771,HYPOTHYROIDISM,All,up to 3 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,A61K49/0447,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,11.9263229224419,154.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1550.1819,339.09,15.0,13.0,2.0,111.56,277.16,22.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,1,DB01252,__MITIGLINIDE,EP-0507534-B1,Completed,NCT02143765,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First People's Hospital of Changzhou, Changzhou, Jiangsu, China|The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China|Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University, Nanjing, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|Yancheng City No.1 People's Hospital, Yancheng, Jiangsu, China|Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China",C07D409/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,46.98248423992271,60.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,315.413,57.61,3.0,1.0,3.0,34.98,88.31,5.0,0.0,1.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,1,DB01252,__MITIGLINIDE,EP-0507534-B1,Completed,NCT04349696,TYPE 2 DIABETES MELLITUS|LIVER DYSFUNCTION,All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chiayi Chang Gung Memorial Hospital, Chiayi City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",C07D409/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,46.98248423992271,60.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,315.413,57.61,3.0,1.0,3.0,34.98,88.31,5.0,0.0,1.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,1,DB01252,__MITIGLINIDE,EP-0507534-B1,Completed,NCT00663884,"DIABETES MELLITUS, TYPE 2",All,"30 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital, Seoul, Korea, Republic of",C07D409/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,46.98248423992271,60.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,315.413,57.61,3.0,1.0,3.0,34.98,88.31,5.0,0.0,1.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,1,DB01252,__MITIGLINIDE,EP-0507534-B1,Completed,NCT00369148,TYPE 2 DIABETS MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan|Hamamatsu Red Cross Hospital, Hamamatsu, Shizuoka, Japan|Saiseikai Central Hospital, Minato-ku, Tokyo, Japan|Kitasato Institute Hospital, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan",C07D409/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,46.98248423992271,60.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,315.413,57.61,3.0,1.0,3.0,34.98,88.31,5.0,0.0,1.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,1,DB01255,__LISDEXAMFETAMINE,7223735,Recruiting,NCT03187353,COGNITIVE IMPAIRMENT|RRSO,Female,35 Years to 58 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3535 Market Street, Philadelphia, Pennsylvania, United States",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,35.8775334195774,7.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.01,263.3785,81.14,3.0,3.0,1.0,31.28,78.31,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00847080,REACTIVE HYPOGLYCEMIA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00833027,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02917031,TYPE 2 DIABETES MELLITUS|HEART FAILURE,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site 1, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chicoutimi, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Viña del Mar, Chile|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kisvárda, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Rivne, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02294084,"NEOPLASMS, ADIPOSE TISSUE",Male,35 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT03122041,PCOS,Female,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02941445,POLYCYSTIC OVARY SYNDROME|BODY WEIGHT,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Not yet recruiting,NCT04298684,"DIABETES MELLITUS, TYPE 2|THYROID NODULE (BENIGN)",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CHU Bordeaux, Bordeaux, France|CHU Limoges, Limoges, France|University Hospital Center of Guadeloupe, Pointe-à-Pitre, Guadeloupe|CHU de la Réunion, Saint-Pierre, Réunion",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Withdrawn,NCT02263677,TYPE 2 DIABETES|NON-ALCOHOLIC FATTY LIVER DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02147925,NON-ALCOHOLIC FATTY LIVER DISEASE,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01186562,PANCREATITIS|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Minnesota, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Unknown status,NCT01337440,TYPE 2 DIABETES MELLITUS|CHRONIC LIVER DISEASE,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Internal medicine, Kanazawa university hospital, Kanazawa, Ishikawa, Japan",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00627744,MYOCARDIAL INFARCTION|UNSTABLE ANGINA PECTORIS|DIABETES MELLITUS|IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Karolinska Institutet, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01856907,DISORDER OF GLUCOSE REGULATION,Female,18 Years to 42 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Woman's Hospital, Baton Rouge, Louisiana, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT03267576,"DIABETES MELLITUS, TYPE 2",All,19 Years to 54 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Consultorio Privado, Guadalajara, Mexico|Investigación Clínica Especializada, Guadalajara, Mexico|Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,"Active, not recruiting",NCT01928199,POSTTRANSPLANT DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Washington University, Saint Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01235819,TYPE 1 DIABETES,All,"12 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Command Hospital, Lucknow, UP, India",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT02373865,DIABETES MELLITUS TYPE 2,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT00832624,DIABETES MELLITUS NON-INSULIN-DEPENDENT,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02008682,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Dalian, Liaoning, China|Novo Nordisk Investigational Site, Shenyang, Liaoning, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01530178,"DIABETES MELLITUS, TYPE 1",All,"13 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Albert Einstein College of Medicine CRC, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT01970462,"DIABETES MELLITUS, TYPE 2|HYPERGLYCEMIA",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02920918,"HEART FAILURE, SYSTOLIC|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01099618,KETOSIS PRONE DIABETES|DIABETES KETOACIDOSIS|HYPERGLYCEMIA,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Grady Memorial Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT00766441,DIABETES|HYPOGLYCEMIA,All,"18 Years to 78 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wellcome Trust Clinical Research Facility, Manchester, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT00936663,TYPE 2 DIABETES|END STAGE RENAL DISEASE,All,"19 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Nebraska Medical Center, Omaha, Nebraska, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01859793,DIABETES|ATHEROSCLEROSIS,All,"21 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Not yet recruiting,NCT03602638,ATHEROSCLEROSIS TYPE 2 DIABETES MELLITUS DIPEPTIDYL PEPTIDASE-4 INHIBITOR GLP-1,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Recruiting,NCT03959501,TYPE 2 DIABETES|KETONEMIA,All,"21 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"L2 Diabetes Centre, Queen Mary Hospital, Hong Kong, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01785043,DIABETES MELLITUS TYPE 2 NOT WELL CONTROLLED,All,"45 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínic de Barcelona, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01378117,TYPE 2 DIABETES MELLITUS|HOSPITALIZATION|HYPERGLYCEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02655757,ATHEROSCLEROSIS|TYPE 2 DIABETES MELLITUS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The General Hospital of PLA, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT02048904,TYPE 2 DIABETES|MICROALBUMINURIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02330406,DIPEPTIDYL-PEPTIDASE 4 INHIBITORS|LDL CHOLESTEROL|GLYCOSYLATED HEMOGLOBIN|DIABETES MELLITUS|CORONARY DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Cardiovascular Medicine, Tomishiro Central Hospital, Tomishiro, Okinawa, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Unknown status,NCT02802644,"ACUTE CORONARY SYNDROME|DIABETES MELLITUS, TYPE 2",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keimyung University Hospital, Daegu, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Jeju National University Hospital, Jeju, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Recruiting,NCT04323189,GENETICS DISEASE|TYPE2 DIABETES|HEART FAILURE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","University of Pennsylvania, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00364377,PRE-DIABETES,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic, Rochester, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01863147,NEWLY DIAGNOSED TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"55 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangda Xiang, Wuhan, Hubei, China|Wuhan General Hospital, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT03208465,DIABETES MELLITUS|CORONARY DISEASE,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT03717688,DIABETES|HEART FAILURE,Male,18 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Copenhagen, Copenhagen, Denmark",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00885638,HEALTHY|TYPE 2 DIABETES,Male,20 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Department of Clinical Sciences Lund, Lund University, Lund, Sweden",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02556918,HYPERGLYCEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Grady Health System, Atlanta, Georgia, United States|Emory Univeristy Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Recruiting,NCT03101930,OBESITY|PREDIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT00740363,GLUCOSE INTOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rikshospitalet Medical Center, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,1,DB01267,__PALIPERIDONE,5254556,Unknown status,NCT01742390,SEXUAL DYSFUNCTION|HYPERPROLACTINEMIA,All,"12 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of mental health, Peking University, Beijing, Beijing, China|The first hospital of Hebei Province University, Shijiazhuang, Hebei, China",C07D471/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,13.996180619725196,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,426.4839,82.17,5.0,1.0,5.0,45.95,116.04,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,1,DB01268,__SUNITINIB,6573293,Completed,NCT01525550,WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMOR,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: None (Open Label)|Primary Purpose: Other,"Univeristy of California, Orange, California, United States|Columbia University Medical Center, New York, New York, United States|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Cliniques Universitaires Saint-Luc, Gastroenterologie, Bruxelles, Brussels Gewest, Belgium|China-Japan Friendship Hospital, Beijing, Beijing, China|307 Hospital of PLA, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni poliklinika, Praha 2, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Hôpital Beaujon, Clichy Cedex, France|Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika, Budapest, Hungary|Tata Memorial Hospital, Mumbai, Maharashtra, India|IEO Istituto Europeo di Oncologia, IRCCS, Milano, Italy|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania|Narodny Onkologicky ustav, Bratislava, Slovakia|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
NNc1nncc2ccccc12,1,DB01275,__HYDRALAZINE,6465463,Recruiting,NCT03514108,HEART FAILURE|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sygehus Sønderjylland, Aabenraa, Aabenraa, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Amager Hospital, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Copenhagen, Denmark|Glostrup Hospital, Copenhagen, Denmark|Herlev Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark|Herning Hospital, Herning, Denmark|Regionshospital Nordjylland, Hjørring, Hjørring, Denmark|Holbæk Hospital, Holbæk, Denmark|Horsens Hospital, Horsens, Denmark|Kolding Hospital, Kolding, Denmark|Nykøbing Falster Hospital, Nykøbing Falster, Denmark|Odense University Hospital, Odense, Denmark|Randers Hospital, Randers, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Vejle Hospital, Vejle, Denmark|Viborg Hospital, Viborg, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.199696092322196,868.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,160.1759,63.83,4.0,2.0,2.0,16.06,50.23,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
NNc1nncc2ccccc12,1,DB01275,__HYDRALAZINE,6465463,Completed,NCT02046395,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Tulane University Health Sciences Center, New Orleans, Louisiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.199696092322196,868.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,160.1759,63.83,4.0,2.0,2.0,16.06,50.23,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00240253,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Phoenix, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Salinas, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00690235,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|DIABETES|WEIGHT GAIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","The University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00442767,TYPE 1 DIABETES,All,"12 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00502138,IDDM,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,1,DB01284,__TETRACOSACTIDE,4127537,Completed,NCT01371526,ADRENAL FAILURE,All,"16 Years to 66 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom",C07K14/6755,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.4130885644469,168.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.95,2933.49,1158.72,46.0,42.0,9.0,309.35,790.98,93.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,1,1,1
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",C12Q1/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not yet recruiting,NCT03631771,HYPOTHYROIDISM,All,up to 3 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,A61K49/0452,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Terminated,,RETINAL DETACHMENT,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,1,DB01380,__CORTISONE_ACETATE,3960757,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,483.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.35,402.4807,97.74,5.0,1.0,4.0,43.06,105.63,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1
O=C([O-])O.[Na+],1,DB01390,__SODIUM_BICARBONATE,5840737,Completed,NCT02502071,TYPE 1 DIABETES|DIABETIC NEPHROPATHY|DIABETIC KIDNEY DISEASE,All,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])O.[Na+],1,DB01390,__SODIUM_BICARBONATE,5840737,Unknown status,NCT00950079,CONTRAST INDUCED NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|Busan Saint Mary Hospital, Busan, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Cheonan, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gangneung Asan Hospital, Gangneung, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C,1,DB01395,__DROSPIRENONE,5798338,Completed,NCT00640224,PCOS,Female,"10 Years to 20 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,16.7559908827696,641.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.36,366.4932,43.37,2.0,0.0,7.0,41.81,101.68,0.0,0.0,1.0,0.0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C,1,DB01395,__DROSPIRENONE,5798338,Completed,NCT01511822,PCOS|POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,,"Istituto di Patologia Ostetrica e Ginecologica, Catania, Italy",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,641.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.36,366.4932,43.37,2.0,0.0,7.0,41.81,101.68,0.0,0.0,1.0,0.0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C,1,DB01395,__DROSPIRENONE,5798338,Unknown status,NCT02027337,POLYCYSTIC OVARIAN SYNDROME|HYPERANDROGENISM|MENSTRUAL IRREGULARITIES,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Tyumen State Medical Academy, Tyumen, Russian Federation",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,641.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.36,366.4932,43.37,2.0,0.0,7.0,41.81,101.68,0.0,0.0,1.0,0.0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,1,DB01399,__SALSALATE,3954533,Completed,NCT00339833,TYPE 2 DIABETES|DIABETES,All,18 Years to 45 Years   (Adult),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NIDDK, Phoenix, Phoenix, Arizona, United States",C06B23/007,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,1,DB01406,__DANAZOL,4055562,Completed,NCT01779232,ENDOMETRIOSIS|OVARIAN CYSTS|INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"CERM, Rome, Italy",C07J71/0063,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT03147677,TYPE 2 DIABETIC NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China|Hunan Yiyang Central Hospital, Yiyang, Hunan, China",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT01115543,SECONDARY HYPERPARATHYROIDISM|END STAGE RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Siriraj Medical School, Bangkok-noi, Bangkok, Thailand",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Recruiting,,NEPHROTIC SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown Status,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB01586,__URSODEOXYCHOLIC_ACID,3969503,Not yet recruiting,NCT04407650,GESTATIONAL DIABETES,Female,"16 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,9.363641963900688,359.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,392.57199999999995,77.76,4.0,3.0,4.0,46.33,109.27,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Unknown status,NCT02036554,"KIDNEY; COMPLICATIONS, ALLOGRAFT",All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"division of nephrology;Seoul St Mary's Hospital, Seoul, Korea, Republic of",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,"Active, not recruiting",NCT02842749,PANCREATIC NEUROENDOCRINE TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Unknown status,NCT01510509,DIABETES MELLITUS|PERCUTANEOUS CORONARY INTERVENTION,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Heart Center, Satakunta Hospital, Pori, Finland, Satakunta, Pori, Finland|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Puerto Real de Cádiz, Puerto Real, Cadiz, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Cristina, Badajoz, Spain|Hospital Juan Ramón Jiménez de Huelva, Huelva, Spain|Hospital Virgen de la Salud de Toledo, Toledo, Spain|Hospital General Universitario de Valencia, Valencia, Spain",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,1,DB01597,__CILASTATIN,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,358.45300000000015,129.72,6.0,4.0,1.0,38.28,92.85,11.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,NCT00823849,TYPE 2 DIABETES MELLITUS|ARTERIOSCLEROSIS OBLITERANS,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University First Hospital, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,NCT01252056,DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Universuty First Hospital, Beijng, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,,HYPERLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT01326533,PRE-DIABETES,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of Pittsburgh, Montefiore Hospital, Pittsburgh, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00565682,LAPAROSCOPIC SURGERY FOR APPENDICITIS|LAPAROSCOPIC SURGERY FOR CHOLECYSTITIS|LAPAROSCOPIC SURGERY FOR OVARIAN CYSTS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Unknown status,NCT00935116,ACUTE PAIN,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Completed,NCT02187250,PCOS|OBESITY,Female,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Ljubljana, Ljubljana, Slovenia",C07C235/56,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Unknown status,NCT01595750,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"55 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Spanish Research Center for Respiratory Diseases, Bunyola, Balearic Island, Spain",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(O)/C=C/C(=O)O,1,DB01677,__FUMARIC_ACID,,Unknown status,NCT01088165,"PSORIASIS|CARDIOVASCULAR DISEASES|DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Medical University Vienna Dpt. of Dermatology, Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.21,116.0722,74.6,4.0,2.0,0.0,9.35,24.61,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT00415701,CORONARY ARTERY DISEASE|MITRAL VALVE REGURGITATION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departments of Intensive Care Medicine and Anesthesiology, Bern, BE, Switzerland",C07C51/377,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT01371526,ADRENAL FAILURE,All,"16 Years to 66 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom",C07C51/377,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,1,DB02709,__RESVERATROL,5747536,Unknown status,NCT01997762,GESTATIONAL DIABETES,Female,18 Years to 40 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada",0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,1,DB03336,__BIA,,Completed,NCT00118963,"DIABETES MELLITUS, TYPE 2",All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Steno Diabetes Center, Gentofte, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,1,DB03336,__BIA,,Completed,NCT01889095,DIABETES TYPE 2,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(C)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,1,DB03614,__MECOBALAMIN,,Completed,NCT01192113,PERIPHERAL NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The 1st Hospital of Anhui Medical University, Hefei, Anhui, China|The General Hospital of the People's Liberation Army, Beijing, Beijing, China|The institute of rehabilitation medicine, Beijing, Beijing, China|Nanfang Hospital of Nanfang Medical Unversity, Guangzhou, Guangdong, China|The 1st People Hospital of Guangzhou, Guangzhou, Guangdong, China|the 1st Hospital affliated to Guangxi Medical University, Nanning, Guangxi, China|The 3rd Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|the people Hospital, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China|Xiehe Hospital, Wuhan, Hubei, China|the 1st Hospital of Nanjing, Nanjing, Jiangsu, China|Zhong Xi Yi Jie He Hospital of Jiangsu, Nanjing, Jiangsu, China|the 2nd Hospital of Suzhou University, Suzhou, Jiangsu, China|Subei People Hospital, Yangzhou, Jiangsu, China|The 1st People Hospital of Yangzhou, Yangzhou, Jiangsu, China|the Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|Changhai Hospital, Shanghai, Shanghai, China|Ruijing Hospital, Shanghai, Shanghai, China|the 10th People Hospital of Shanghai, Shanghai, Shanghai, China|the 10th People Hospital, Shanghai, Shanghai, China|The 1st Center Hospital of Tianjin, Tianjin, Tianjin, China|The institute of rehabilitation medicine, Beijing, China|Rui Jin Hospital, Shanghai, China|Shenzhen Hospital of Beijing University, Shenzhen, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-14.0,1344.3823,417.0,13.0,9.0,12.0,135.93,342.79,16.0,1.0,0.0,0.0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,1,DB04115,__BERBERINE,3943251,Recruiting,NCT02808351,DIABETES MELLITUS|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Nanjing First Hospital, Nanjing, Jiangsu, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,13.3719378221318,596.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.18,336.3612,40.8,4.0,0.0,5.0,36.92,93.52,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,1,DB04115,__BERBERINE,3943251,"Active, not recruiting",NCT03029390,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,31 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,13.3719378221318,596.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.18,336.3612,40.8,4.0,0.0,5.0,36.92,93.52,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,1,DB04173,__FRUCTOSE,WO-2006138705-A1,Completed,NCT03003507,CRITICAL ILLNESS,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",,A23L7/1963 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,110.38,6.0,5.0,1.0,16.29,36.36,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT00902616,TYPE 2 DIABETES,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tameside General Hospital, Ashton-under-Lyne, Cheshire, United Kingdom",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB04540,__CHOLESTEROL,,Completed,NCT00147251,CARDIOVASCULAR DISEASE|HYPERTENSION|HYPERLIPIDEMIA|DIABETES|CAROTID ATHEROSCLEROSIS,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Chinle Comprehensive Health Care, Chinle, Arizona, United States|Phoenix Indian Medical Center, Phoenix, Arizona, United States|USPHS Indian Hospital, Lawton, Oklahoma, United States|Black Hills Center for American Indian Health, Rapid City, South Dakota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,7.02,386.6535,20.23,1.0,1.0,4.0,50.64,120.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,1,DB04839,__CYPROTERONE_ACETATE,3957982,Completed,NCT02866786,PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Obstetrics & Gynecology, Cuttack, Odisha, India",A61K45/06,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,16.8217006509373,458.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,416.93800000000016,60.44,3.0,0.0,5.0,44.64,111.81,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,1,DB04839,__CYPROTERONE_ACETATE,3957982,Unknown status,NCT01103518,AMENORRHEA|DYSMENORRHEA|MENSTRUATION DISTURBANCES|HYPERANDROGENISM,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital das Clínicas de Teresópolis, Teresópolis, Rio de Janeiro, Brazil",A61K45/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,16.8217006509373,458.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,416.93800000000016,60.44,3.0,0.0,5.0,44.64,111.81,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02344602,TYPE 1 DIABETES,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renal Physiology Laboratory, University Health Network, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,NCT00744237,HYPERTENSION|TYPE 2 DIABETES,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Forest Investigative Site 15, Athens, Alabama, United States|Forest Investigative Site 16, Huntsville, Alabama, United States|Forest Investigative Site 35, Bell Gardens, California, United States|Forest Investigative Site, Buena Park, California, United States|Forest Investigative Site 54, Chino, California, United States|Forest Investigative Site 40, Fremont, California, United States|Forest Investigative Site, Palm Springs, California, United States|Forest Investigative Site, Pomona, California, United States|Forest Investigative Site 55, Sacramento, California, United States|Forest Investigative Site 11, San Diego, California, United States|Forest Investigative Site, Santa Monica, California, United States|Forest Investigative Site, Spring Valley, California, United States|Forest Investigative Site 49, Tustin, California, United States|Forest Investigative Site 47, Walnut Creek, California, United States|Forest Investigative Site 61, Golden, Colorado, United States|Forest Investigative Site, Wheat Ridge, Colorado, United States|Forest Investigative Site 3, Daytona Beach, Florida, United States|Forest Investigative Site 33, DeLand, Florida, United States|Forest Investigative Site 36, Hollywood, Florida, United States|Forest Investigative Site 62, Miami, Florida, United States|Forest Investigative Site 080, Miami, Florida, United States|Forest Investigative Site 59, Miami, Florida, United States|Forest Investigative Site 32, Pembroke Pines, Florida, United States|Forest Investigative Site 081, Pembroke Pines, Florida, United States|Forest Investigative Site 2, Tamarac, Florida, United States|Forest Investigative Site, Tampa, Florida, United States|Forest Investigative Site 19, West Palm Beach, Florida, United States|Forest Investigative Site 44, Atlanta, Georgia, United States|Forest Investigative Site 5, Augusta, Georgia, United States|Forest Investigative Site 56, Honolulu, Hawaii, United States|Forest Investigative Site 57, Meridian, Idaho, United States|Forest Investigative Site 39, Chicago, Illinois, United States|Forest Investigative Site 37, Wichita, Kansas, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site 20, Baltimore, Maryland, United States|Forest Investigative Site 50, Oxon Hill, Maryland, United States|Forest Investigative Site 21, St. Clair Shores, Michigan, United States|Forest Investigative Site, Kansas City, Missouri, United States|Forest Investigative Site, St. Louis, Missouri, United States|Forest Investigative Site, New Hyde Park, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site 7, Charlotte, North Carolina, United States|Forest Investigative Site 45, Charlotte, North Carolina, United States|Forest Investigative Site 24, Morehead City, North Carolina, United States|Forest Investigative Site 26, Salisbury, North Carolina, United States|Forest Investigative Site 18, Wilmington, North Carolina, United States|Forest Investigative Site 51, Centerville, Ohio, United States|Forest Investigative Site 48, Cincinnati, Ohio, United States|Forest Investigative Site 12, Wadsworth, Ohio, United States|Forest Investigative Site 17, Charleston, South Carolina, United States|Forest Investigative Site 46, Columbia, South Carolina, United States|Forest Investigative Site, North Charleston, South Carolina, United States|Forest Investigative Site, Simpsonville, South Carolina, United States|Forest Investigative Site 4, Sioux Falls, South Dakota, United States|Forest Investigative Site 10, New Tazewell, Tennessee, United States|Forest Investigative Site 52, Corpus Christi, Texas, United States|Forest Investigative Site 28, Dallas, Texas, United States|Forest Investigative Site 38, Hurst, Texas, United States|Forest Investigative Site 34, Salt Lake City, Utah, United States|Forest Investigative Site, St. George, Utah, United States|Forest Investigative Site, Norfolk, Virginia, United States|Forest Investigative Site 31, Virginia Beach, Virginia, United States|Forest Investigative Site 41, Ponce, Puerto Rico|Forest Investigative Site 60, Salinas, Puerto Rico|Forest Investigative Site 29, Santurce, Puerto Rico",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C[C@H]1CNCCc2ccc(Cl)cc21,1,DB04871,__LORCASERIN,6953787,Completed,NCT02019264,CARDIOVASCULAR DISEASE|HIGH CARDIOVASCULAR RISK|OBESITY|OVERWEIGHT|TYPE 2 DIABETES,All,"40 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|UAB Medical Center, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Mobile Heart Specialists, PC, Mobile, Alabama, United States|Alaska Heart Institute, Anchorage, Alaska, United States|Connect Clinical Research Center, LCC, Chandler, Arizona, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Heart, PLLC, Glendale, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Clinical Research Alliance, Alhambra, California, United States|Central Cardiology, Bakersfield, California, United States|Cardiovascular Research Foundation of Southern Cal, Beverly Hills, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|San Diego Costal Endocrinology Group AMC, Chula Vista, California, United States|John Muir Physician Network Clinical Research Cent, Concord, California, United States|Medical Group of Encino, Encino, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|California Heart Specialists, Huntington Beach, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|La Mesa Cardiac Center, La Mesa, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Metabolic Clinic and Research Center, Los Angeles, California, United States|Beverly Hills Cardiology, Los Angeles, California, United States|VA Greater Los Angeles Health Care System, Los Angeles, California, United States|Clinical Interventions Research Institute, Mission Viejo, California, United States|Brigid Freyne MD Inc, Murrieta, California, United States|Valley Clinical Trials Inc, Northridge, California, United States|Carr Cardiology, Oceanside, California, United States|Northern California Clinical Research Center, Redding, California, United States|Sharp Rees-Stealy Medical Group, Inc., San Diego, California, United States|University of California San Diego, San Diego, California, United States|Ritchken and First MD's, San Diego, California, United States|West Coast Research LLC, San Ramon, California, United States|Coastal Multi-Specialty Research, Santa Ana, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Ronald Chochinov, MD, Ventura, California, United States|Ventura Cardiology Consultants, Ventura, California, United States|Infosphere Clinical Research, West Hills, California, United States|UCH-MHS Cardiac Research, Colorado Springs, Colorado, United States|Creekside Endocrine Associates PC, Denver, Colorado, United States|New West Physicians, PC, Golden, Colorado, United States|University of Colorado Health, Loveland, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Clinical Research Works, Bristol, Bristol, Connecticut, United States|Cardiology Associates of Fairfield County, Norwalk, Norwalk, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Trumbull, Connecticut, United States|Connecticut Heart and Vascular Center, Trumbull, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Red Clay Research, Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Aventura Heart Center, Aventura, Florida, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Meridien Research, Bradenton, Florida, United States|NOVA Southeastern University, Bradenton, Florida, United States|Bay Area Cardiology, Brandon, Florida, United States|Meridien Research, Brooksville, Brooksville, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Holy Cross Medical Group, Coral Springs, Florida, United States|Cardiology Research Associates, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Asclepius Medical Research, Doral, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Integrative Research Associates, Inc., Fort Lauderdale, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|George E. Platt, M.D., Green Cove Springs, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Larry K. Levinson, D.O., P.A., Hollywood, Florida, United States|Research Physicians Network Alliance, Hollywood, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Florida- Jacksonville, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Pharmax Research Clinic, Inc, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|United Clinical Research Corp., Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|South Florida Research Group LLC, Miami, Florida, United States|South Florida Research Solutions, Miramar, Florida, United States|Southwest Florida Research, Naples, Florida, United States|Ocala Research Institute, Inc, Ocala, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Cardiology Partners Clinical Research Institute, Palm Beach Gardens, Florida, United States|Palm Beach Gardens Research Center, Palm Beach Gardens, Florida, United States|Research Physicians Network Alliance, Pembrok, Pembroke Pines, Florida, United States|South Florida Research Solutions, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Columbia Primary Care, LLC d/b/a Heart and Health Institute, Plantation, Florida, United States|St Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Brevard Cardiovascular Research Associates Inc, Rockledge, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Safety Harbor, Florida, United States|Bayfront Health St. Petersburg, Research, Saint Petersburg, Florida, United States|Meridien Research - St. Petersburg, Saint Petersburg, Florida, United States|Professional Health Care of Pinellas, INC, Saint Petersburg, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Springfield Medical Center, Springfield, Florida, United States|Advanced Clinical Research Group, Stuart, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Healthpoint Medical Group, Inc, Tampa, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Lovelace Scientific Research, Venice, Florida, United States|Indian River Medical Center-Cardiology, Vero Beach, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cleveland Clinic Foundation, West Palm Beach, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Endocrinology, Atlanta, Georgia, United States|Rockdale Medical-Research Associates, Conyers, Georgia, United States|Atlanta Heart Specialists, Cumming, Georgia, United States|Urban Family Practice Associates/Clinical Research Advantage, Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Herman Clinical Research LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, Tucker, Georgia, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Consultants in Cardiovascular Medicine, Elmhurst, Illinois, United States|Clinical Investigation Specialists, Inc. in Gurnee, Gurnee, Illinois, United States|Advanced CardioVascular Consultants, SC, Rock Island, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of IN, LLC, Avon, Avon, Indiana, United States|Premier Healthcare, LLC, Bloomington, Indiana, United States|Deaconess Clinic, Inc., Evansville, Indiana, United States|American Health Network of IN, LLC, Franklin, Franklin, Indiana, United States|American Health Network of IN, LLC, Greenfield, Greenfield, Indiana, United States|American Health Network - Thomas Moretto, MD, Indianapolis, Indiana, United States|Medical Consultants PC, Muncie, Indiana, United States|American Health Network of IN, LLC, Muncie, Indiana, United States|Cardiology Associates of Northwest Indiana, P.C, Munster, Indiana, United States|The University of Iowa, College of Public Health, Iowa City, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Norton Heart Specialists, Louisville, Kentucky, United States|Norton Heart Specialists, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Central Maine Medical Center, Auburn, Maine, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Eastern Maine Medical Center Northeast Cardiology Associates, Bangor, Maine, United States|Southern Maine Health Care/Maine Medical Center Research Ins, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Medstar Cardiology Associates, Annapolis, Maryland, United States|Chesapeake Cardiovascular Associates, GBMC, Baltimore, Maryland, United States|Clinical Research, Inc, Baltimore, Maryland, United States|Medstar Union Memorial Heart Specialists, Baltimore, Maryland, United States|Medstar Union Memorial Hospital, Baltimore, Maryland, United States|Spectrum Clinical Research, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Shahid Saeed MD, PC, Baltimore, Maryland, United States|Maryland Heart Associates, LLC, Glen Burnie, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Lutherville Personal Physicians, Lutherville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Endocrine & Metabolic Consultants, Rockville, Maryland, United States|Lutherville Personal Physicians, Towson, Maryland, United States|Overlea Personal Physicians, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|MGH Weight Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New England Center for Clinical Research, IMCA, Fall River, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|ActivMed Practices, Methuen, Massachusetts, United States|Partners Community Physicians Organization, Natick, Massachusetts, United States|Partners Community Physicians Organization, Needham, Massachusetts, United States|Endeavor Medical Research PLC, Alpena, Michigan, United States|Cadillac Clinical Research, LLC, Cadillac, Michigan, United States|Westside Family Medical Center, PC, Kalamazoo, Michigan, United States|Cardiology Consultants of East Michigan, Lapeer, Michigan, United States|Marquette General Heart and Vascular Institute, Marquette, Michigan, United States|MidMichigan Medical Center, Midland, Michigan, United States|Nisus Research at McLaren Northern Michigan Hospital, Petoskey, Michigan, United States|Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States|Remedica LLC, Rochester, Michigan, United States|Michigan CardioVascular Institute, Saginaw, Michigan, United States|American Center for Clinical Trials, Southfield, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Minneapolis Heart Institute Foundation, Baxter, Minnesota, United States|Essentia Institute of Rural Health, Duluth, Minnesota, United States|MNCOME Clinic, Eagan, Minnesota, United States|Radiant Research, Inc., Edina, Minnesota, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Coast Cardiovascular Consultants PLLC, Gulfport, Mississippi, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|Diabetes & Endocrinology Specialists, Inc., Chesterfield, Missouri, United States|BodyAesthetic Research Center, Washington, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Montana Health Research Institute, Inc., Billings, Montana, United States|Glacier View Cardiology PC, Kalispell, Montana, United States|Internal Medical Associates of Grand Island, PC, Grand Island, Nebraska, United States|Clinical Research Advantage / Rita Chuang, M.D., Henderson, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Medicor Cardiology, PA, Bridgewater, New Jersey, United States|Advanced Heart Care, Bridgewater, New Jersey, United States|UmiMed Center LLC, East Brunswick, New Jersey, United States|Cardiovascular Associates of the Delaware Valley, Elmer, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Cardiovascular Associates of the Delaware Valley P, Haddon Heights, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|Rutgers New Jersey Medical School, Mine Hill, New Jersey, United States|Cardiovascular Associates Delaware Valley Sewell, Sewell, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|New Mexico Heart Institute, PA, Albuquerque, New Mexico, United States|Albany College of Medicine, Division of Endocrinology, Albany, New York, United States|Capital Cardiology Associates, Albany, New York, United States|United Medical Associates, PC, Binghamton, New York, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Long Island Heart Associates, Mineola, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Weill Cornell Medical College, New York, New York, United States|DiGiovanna Institute for Medical Education, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Northwell Health Physician Partners Cardiology, Southampton, New York, United States|Capital Cardiology Associates, Troy, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|Clinical Trials of America Inc., Cary, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Clinical Trials of America Inc. Hickory, Hickory, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Clinical Trials of America, Inc., Lenoir, North Carolina, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aultman Hospital, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research, Cincinnati, Ohio, United States|Delaware Research Group, LLC, Delaware, Ohio, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Community Health Care, Massillon, Ohio, United States|Apex Medical Research Inc., Springfield, Ohio, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Oklahoma Heart Institute, Tulsa, Oklahoma, United States|Vital Prospects Clinical Research Institute PC, Tulsa, Oklahoma, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Geisinger Health Clinic, Danville, Pennsylvania, United States|Geisinger Health System, Danville, Pennsylvania, United States|Doylestown Health Cardiology a Division of Doylestown Health, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Liberty Family Practice, Erie, Pennsylvania, United States|Endocrine Clinical Research LLC, Feasterville, Pennsylvania, United States|Joseph Lamantia, DO, Indiana, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Lycoming Internal Medicine, Inc., Jersey Shore, Pennsylvania, United States|Berkley Hills Clinicals, Johnstown, Pennsylvania, United States|Ilumina Clinical Associates, Johnstown, Johnstown, Pennsylvania, United States|Joseph Lamantia, DO, Johnstown, Pennsylvania, United States|Comprehensive Cardiology Consultants, Langhorne, Pennsylvania, United States|Detweiler Family Medicine and Associates PC, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Capital Area Research LLC, Newport, Pennsylvania, United States|Endocrine Metabolic Associates, Philadelphia, Pennsylvania, United States|Pottstown Medical Specialists, Inc. (PMSI), Pottstown, Pennsylvania, United States|Geisinger Clinic, Scranton, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Radiant Research, Inc., Greer, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Brown Clinic, PLLP, Watertown, South Dakota, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Research Associates of Jackson, Jackson, Tennessee, United States|Kore Cardiovascular Research, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Wellmont CVA Heart Institute, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Wellmont CVA Heart Institute, Kingsport, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Cardiology Wellness Center, Nashville, Tennessee, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Adriana Pop-Moody MD Clinic, PA, Corpus Christi, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Odilon Alvarado, M.D., Fort Worth, Texas, United States|Texas Health Physicians Group Fort Worth, Fort Worth, Texas, United States|Tand R Clinic, PA, Fort Worth, Texas, United States|San Gabriel Clinical Research, LLC, Georgetown, Texas, United States|Angiocardiac Care of Texas PA, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|West Houston Area Clinical Trial Consultants, LLC, Houston, Texas, United States|Endocrine and Psychiatry Center, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|Texas Cardiology Associates of Houston, Kingwood, Texas, United States|Jalil Aziz Khan M.D., P.A., Lewisville, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Medical Clinic of North Texas, Plano, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|Texas Diabetes, Round Rock, Texas, United States|Physician PrimeCare Research Institute, PLLC, San Antonio, Texas, United States|Cardiology Clinic of San Antonio, San Antonio, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Cardiovascular Associates of East Texas, Tyler, Texas, United States|Bay Area Total Health Medical Group, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Alexandria Clinical Research, LLC, Alexandria, Virginia, United States|Washington Center for Weight Management and Resear, Arlington, Virginia, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Cardiology Consultants of Danville, Inc., Danville, Virginia, United States|Danville Internal Medicine, Inc, Danville, Virginia, United States|Virginia Heart, Falls Church, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|INOVA Health Care Services, Manassas, Virginia, United States|Burke Internal Medicine and Research, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Health Research of Hampton Roads - Norfolk, Inc., Norfolk, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Clinical Research Partners, Richmond, Virginia, United States|Virginia Cardiovascular Specialists, Richmond, Virginia, United States|National Clinical Research-Richmond, Inc, Richmond, Virginia, United States|Selma Medical Associates, Winchester, Virginia, United States|Larry D. Stonesifer, MD, Inc PS, Federal Way, Washington, United States|Seattle Women's, Seattle, Washington, United States|Rowan Research Inc., Spokane, Washington, United States|MultiCare Research Institute, Tacoma, Washington, United States|Universal Research Group, Tacoma, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Prevea Clinic, Inc, Green Bay, Wisconsin, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Meriter hospital Inc., DBA: UnityPoint Health-Meriter Heart, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Gosford Hospital, Cardiology Clinical Trials, Gosford, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Illawarra Shoalhaven Local Health District, Clinical Trial and Research Unit, Wollongong, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Core Research Group, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Cardiology Research Department, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Endocrinology Department, Herston, Queensland, Australia|HeartCare Partners Clinical Research Unit, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Gold Coast Hospital, Cardiovascular Research Centre, Southport, Queensland, Australia|New Royal Adelaide Hospital, Cardiology Department, Adelaide, South Australia, Australia|Adelaide Medical Research, Ashford, South Australia, Australia|Lyell McEwin Hospital, Department of Cardiology, Elizabeth Vale, South Australia, Australia|Heart and Vascular Institute, Fullarton, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Geelong Cardiology Research Unit, Barwon Health, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Department of Medicine, Boronia Centre, Heidelberg Heights, Victoria, Australia|Avenue Cardiovascular Centre, Saint Kilda East, Victoria, Australia|Joondalup Cardiovascular Trials Foundation Inc, Joondalup, Western Australia, Australia|Fiona Stanley Hospital, Cardiology Research Department,CDO11, Murdoch, Western Australia, Australia|South Australian Medical Research Inst, Centre for Clinical Research, Adelaide, Australia|The Partners Clinical Research Centre, Nassau, Bahamas|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Nova Scotia Health Authority /QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|LMC Diabetes & Endocrinology - Brampton, Brampton, Ontario, Canada|McMaster University, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Aviva Clinical Trial Group In., Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Joanne F. Liutkus Medicine Professional Corp., Cambridge, Ontario, Canada|Saul Vizel Professional Medicine Corporation, Vizel Cardiac Research, Cambridge, Ontario, Canada|LMC Diabetes & Endocrinology (Etobicoke), Etobicoke, Ontario, Canada|Wharton Medical Clinic Clinical Trials Group Inc., Hamilton, Ontario, Canada|Saint Josephs Health Care London, London, Ontario, Canada|LMC Diabetes & Endocrinoly, Markham, Ontario, Canada|New Market Cardiology Research Group, Newmarket, Ontario, Canada|Dr. Michael Heffernan, Oakville, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|Dr. Cha, Oshawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Dr. Dinkar Shukla Professional Medicine Corporation, Sudbury, Ontario, Canada|Dr Roger Labonte Professional Medicine Corp, Sudbury, Ontario, Canada|LMC Diabetes & Endocrinology (Thornhill), Thornhill, Ontario, Canada|JJ DIG Research Ltd., Toronto, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St Michael's Hospital Health Centre, Toronto, Ontario, Canada|ViaCar Recherche Clinique, Brossard, Quebec, Canada|Q&T Research Outaouais Inc., Gatineau, Quebec, Canada|ViaCar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|Manna Research Inc, Levis, Quebec, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Centre hospitalier régional de Lanaudière, Saint-Charles-Borromee, Quebec, Canada|Recherche Clinique London, Sherbrooke, Quebec, Canada|CardioVasc HR, Inc., St Jean sur Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc., St-Lambert, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Ville Saint-Laurent, Quebec, Canada|Biomedica Research Group, Providencia, Santiago, Chile|Sociedad Medica Cardiologica El Llano, San Miguel, Santiago, Chile|Hospital Regional Concepcion, Concepcion, Chile|Cardiocob, Santiago, Chile|Servicios Medicos Godoy Ltda., Santiago, Chile|Ccbr Cecim, Santiago, Chile|Centro Investigacion Clinica del Sur, Temuco, Chile|CECMI Ltda., Temuco, Chile|ICLE, Guadalajara, Jalisco, Mexico|Private Medical Practice, Guadalajara, Jalisco, Mexico|IMED Clin Trials, Monterrey, Nuevo Leon, Mexico|Cardiolink ClinTrials S.C., Monterrey, Nuevo Leon, Mexico|Centro de Estudios Clinicos y Especialidades Medicas S.C., Monterrey, Nuevo Leon, Mexico|Hospital de Angeles Xalapa, Xalapa, Veracruz, Mexico|Fundacion Cardiovascular de Aguascalientes, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Mentrials S.A.de C.V., Distrito Federal, Mexico|North Shore Hospital-Cardiology Research, Milford, Auckland, New Zealand|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital - Diabetes Clinic, Takapuna, Auckland, New Zealand|Christchurch Hospital, Lipids, Christchurch, Canterbury, New Zealand|Christchurch Hospital, Cardiology Research, Christchurch, Canterbury, New Zealand|Dunedin Hospital, Dunedin, Otago, New Zealand|Taranaki Base Hospital, New Plymouth, Taranaki, New Zealand|Hutt Hospital, Cardiology Dept, Lower Hutt, Wellington, New Zealand|Auckland City Hospital, Auckland, New Zealand|Hawkes Bay Regional Hospital, Hastings, New Zealand|Nelson Hospital, Cardiology Department, Nelson, New Zealand|Lakeland Clinical Trials, Rotorua, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Indywidualna Specjalistyczna Praktyka Lekarska, Bezrzecze, Poland|NZOZ ""Eskulap"", Biala Rawska, Poland|Podlaski Osrodek Kardiologii Janusz Korecki, Białystok, Poland|Centrum Medyczne KERmed, Bydgoszcz, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|Nzoz ""Mada-Med"", Chorzów, Poland|DIABET Centrum Medyczne s. c., Chrzanów, Poland|ISPL w Dziedzinie Kardiologii lek.med. Krzysztof Cymerman, Gdynia, Poland|NZOZ SCBK ProCordis, Gdynia, Poland|Gabinet Kardiologiczno-Internistyczny, Gdynia, Poland|Praktyka Lekarska dr n. med. Marek Bronisz, Inowroclaw, Poland|Piotr Mader Diabetic Clinic NZOZ PD-I, Kamieniec Ząbkowicki, Poland|NZOZ Eskulap SC, Koluszki, Poland|Ewa Mirek-Bryniarska Specjalistyczna Praktyka Lekarska, Kraków, Poland|LANDA' Specjalistyczne Gabinety Lekarskie, Kraków, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno, Kraków, Poland|Nzoz Cardiamed, Legnica, Poland|""CenterMed Lublin"" Sp. z o.o., Lublin, Poland|Indywidualna Praktyka Lekarska, Mrągowo, Poland|Zechowicz MEDEUSZ-PLUS, Olsztyn, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|NZOZ NEURO-KARD ""Ilkowski i Partnerzy"", Poznań, Poland|Specjalistyczna Przychodnia Lekarska MEDIKARD (SPL Medikard), Płock, Poland|Specjalistyczny Gabinet Lekarski, Tarnów, Poland|Lecznice Citomed Sp. z o.o., Toruń, Poland|Praktyka Lekarska Pawlowicz Lidia, Toruń, Poland|Centrum Medyczne AMED, Warszawa, Poland|Centrum Badawcze Wspolczesnej Terapii, Warszawa, Poland|SNZOZ Fundacji PROCLINICA, Warszawa, Poland|Centrum Zdrowia Wierzchoslawice, Wierzchosławice, Poland|Regionalna Poradnia Diabetologiczna, Wroclaw, Poland|Specjalistyczne Gabinety Lekarskie ""Medicor PLUS"", Włocławek, Poland|NZOZ ALL-MED Centrum Medyczne, Łódź, Poland|SP ZOZ w Lecznej, Łęczna, Poland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,77.0,30.0622189367338,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,195.69,12.03,1.0,1.0,2.0,21.51,56.65,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT02089438,TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Clinical Research Department, Lund, Sweden",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01686932,DIABETES MELLITUS TYPE 2,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Falkensee, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Sulzbach-Rosenberg, Germany|Novartis Investigative Site, Wallerfing, Germany",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT04237493,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jordan University Hospital, Amman, Amman Governorate, Jordan",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01812122,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Hospital, Seoul, Korea, Republic of",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Unknown status,NCT01565096,DIABETES MELLITUS TYPE II,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ikfe GmbH, Mainz, Germany",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT03693560,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"25 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Pharmacy - Damanhour University., Damanhūr, Egypt",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT02007278,TYPE 2 DIABETES|HYPOGLYCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Medellín, Antioquia, Colombia|Novartis Investigative Site, Manizales, Caldas, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Chía, Cundinamarca, Colombia|Novartis Investigative Site, Cali, Valle del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Monteria, Colombia",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Recruiting,NCT04485845,METABOLIC SYNDROME|DIABETE TYPE 2|KIDNEY INSUFFICIENCY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Diabetes & Endocrinology Institute, Cairo, Egypt",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Unknown status,NCT02999841,"DIABETES MELLITUS, TYPE 2|OBESITY",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Pinggu Hospital, Beijing, Beijing, China",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT03819127,MILD COGNITIVE IMPAIRMENT,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,A61K45/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01604213,TYPE 2 DIABETES MELLITUS|ISCHEMIC HEART DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Sheba Medical Center, Cardiac Rehabilitation Institute, Tel Hashomer, Israel",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT03253562,REDUCING THE ELEVATED BLOOD PRESSURE FOR DIABETIC HYPERTENSIVE PATIENTS,Female,40 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"National institute of diabetes and endocrinology, Cairo, Egypt",A61K45/06,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01679899,TYPE 2 DIABETES MELLITUS|MENOPAUSE|OSTEOPOROSIS|OSTEOPENIA,Female,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Diabetes Curitiba, Curitiba, Parana, Brazil",A61K45/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT03178591,"DIABETES MELLITUS, TYPE 2|ISCHEMIC HEART DISEASE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01099137,DIABETES,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT02176681,"HAEMODIALYZED, TYPE 2 DIABETES",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH d'Amiens, Amiens, France|CH de Besançon, Besancon, France|AURAL Colmar, Colmar, France|Hospices civils de Colmar, Colmar, France|CH de Dijon, Dijon, France|AURAL Mulhouse, Mulhouse, France|CH de Mulhouse, Mulhouse, France|CH de Nancy, Nancy, France|AURAL Clinique Sainte Anne, Strasbourg, France|Clinique Sainte Anne, Strasbourg, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|AURAL Strasbourg, Strasbourg, France|CH de Valenciennes, Valenciennes, France",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT02145611,TYPE 2 DIABETES MELLITUS|HYPERTENSION|ENDOTHELIAL DYSFUNCTION,All,"35 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01238978,TYPE 2 DIABETES MELLITUS|ELDERLY,All,65 Years to 80 Years   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Armentieres, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Creil, France|Novartis Investigative Site #2, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pau, France|Novartis Investigative Site, St Jean de la Ruelle, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours, France|Novartis Investigative Site, Venissieux, France|Novartis Investigative Site #2, Venissieux, France|Novartis Investigative Site, Versailles, France",A61K45/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT00894868,CONGESTIVE HEART FAILURE|TYPE II DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Praha 2, CZE, Czech Republic|Novartis Investigative Site, Benesov, Czech Republic|Novartis Investigative Site, Broumov, Czech Republic|Novartis Investigative Site, Havirov, Czech Republic|Novartis Investigative Site, Litomysl, Czech Republic|Novartis Investigative Site, Pardubice, Czech Republic|Novartis Investigative Site, Praha 4, Czech Republic|Novartis Investigative Site, Copenhagen NV, Denmark|Novartis Investigative Site, Copenhagen S, Denmark|Novartis Investigative Site, Frederiksberg, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Slagelse, Denmark|Novartis Investigative Site, Pärnu, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Alsdorf, Germany|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Kamp-Lintfort, Germany|Novartis Investigative Site, Saarlouis, Germany|Novartis Investigative Site, Senden, Germany|Novartis Investigative Site, Alexandroupolis, Greece|Novartis Investigative Site, Chios, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Secunderabad, Andhra Pradesh, India|Novartis Investigative Site, Visakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, Vishakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Vadodara, Gujrat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Mangalore, Karnataka, India|Novartis Investigative Site, Trivandrum, Kerala, India|Novartis Investigative Site, Indore, Madhya Pradesh, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Passirana di Rho, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Mercato San Severino, SA, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Preili, Latvia|Novartis Investigative Site, Alytus, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Klodzko, Poland|Novartis Investigative Site, Warsawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, District 2, Romania|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Baia-Mare, Maramures, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Moscow, Russia, Russian Federation|Novartis Investigative Site, Kaliningrad, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Dunajska Streda, Slovak Republic, Slovakia|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Komarno, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Modava nad Bodvou, Slovakia",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01147276,DIABETES|HYPOGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Department of Clinical Sciences Lund, Lund University, Lund, Sweden",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Unknown status,NCT01867502,"DIABETES MELLITUS, TYPE 2|HYPOGLYCEMIC AGENTS|DIABETIC BLOOD GLUCOSE MONITORING|EXERCISE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Clínicas de Porto Alegre Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01472432,CHRONIC FOOT ULCERS,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Second university of Naples, Naples, Italy",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01827280,1- MICROVASCULAR FUNCTION|2-OXIDATIVE STRESS|3-INFLAMMATION,Female,19 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Laboratory for Clinical and Experimental Research on Vascular Biology, Rio de Janeiro, Brazil",A61K45/06,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB04878,__VOGLIBOSE,4701559,Completed,NCT02049814,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hefei, Anhui, China|Maanshan, Anhui, China|Beijing, Beijing, China|Guangzhou, Guangdong, China|Shenzhen, Guangdong, China|Taishan, Guangdong, China|Zhuzhou, Hunan, China|Nanjing, Jiangsu, China|Xuzhou, Jiangsu, China|Changchun, Jilin, China|Jilin, Jilin, China|Shenyang, Liaoning, China|Qingdao, Shandong, China|Shanghai, Shanghai, China|Yan An, Shanxi, China|Yanan, Shanxi, China|Tianjin, Tianjin, China|Wenzhou, Zhejiang, China",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,69.7180640259553,8054.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,267.2762,153.64,8.0,8.0,1.0,26.02,59.55,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB04878,__VOGLIBOSE,4701559,Completed,NCT00970528,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wonju-si, Gang''weondo, Korea, Republic of|Busan, Korea, Korea, Republic of|Gyeonggi-do, Korea, Korea, Republic of|Gyeonggi-do, Korea, Korea, Republic of|Pusan, Korea, Korea, Republic of|Seoul, Korea, Korea, Republic of|Daegu, Korea, Republic of|Jeonju-si, Korea, Republic of|Seongbuk-gu Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,69.7180640259553,8054.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,267.2762,153.64,8.0,8.0,1.0,26.02,59.55,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB04878,__VOGLIBOSE,4701559,Unknown status,NCT02097342,TYPE 2 DIABETES MELLITUS|INSULIN SENSITIVITY/RESISTANCE,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Postgraduate Institute of Medical Education & Research, Chandigarh, India",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,69.7180640259553,8054.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,267.2762,153.64,8.0,8.0,1.0,26.02,59.55,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)[O-])c3O[C@H]2C[C@H]1O.[Na+],1,DB05229,__BERAPROST,6197328,Terminated,NCT02786979,TYPE 2 DIABETES,All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Site CN00001, Beijing, Beijing, China|Site CN00002, Beijing, Beijing, China|Site CN00004, Guangzhou, Guangdong, China|Site CN00003, Shanghai, Shanghai, China|Site CN00005, Chengdu, Sichuan, China|Site CN00006, Tianjin, Tianjin, China",A61K38/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,18.5301546232982,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,420.4738,89.82,5.0,2.0,3.0,44.85,123.56,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+],1,DB05245,__SILVER_SULFADIAZINE,3983209,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,765.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,357.13699999999994,95.17,6.0,1.0,2.0,24.1,63.4,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,1,DB05294,__VANDETANIB,RE42353,"Active, not recruiting",NCT01496313,THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Houston, Texas, United States|Research Site, Olomouc, Czechia|Research Site, Praha 5, Czechia|Research Site, Bangalore Karnataka, India|Research Site, Vellore, India|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Groningen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Gliwice, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Saint Petersburg, Russian Federation|Research Site, Cardiff, United Kingdom|Research Site, Greater London, United Kingdom|Research Site, London, United Kingdom|Research Site, Tyne & Wear, United Kingdom",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Withdrawn,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Terminated,NCT00569465,TYPE 2 DIABETES MELLITUS|HYPERTENSION,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","""San Giovanni Battista"" Hospital of Turin, Turin, Italy",1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,"Active, not recruiting",NCT04470310,TYPE 2 DIABETES,All,"19 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Recruiting,NCT03499704,"DIABETES MELLITUS, TYPE 2",All,"19 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Catholic University of Korea, Bucheon, St. Marys Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, ST. Vincents Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|YeungNam University Hospital, Daegu, Korea, Republic of|Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Recruiting,,NON-ALCOHOLIC STEATOHEPATITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,1,DB06204,__TAPENTADOL,6071970,Terminated,,PERIPHERAL NEUROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,185.0,59.9930183371321,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.47,221.3385,23.47,2.0,1.0,1.0,26.58,69.56,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,,LAPAROSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,1,DB06209,__PRASUGREL,5288726,Completed,NCT01684813,DIABETES MELLITUS TYPE II|ACUTE CORONARY SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Virgen del Rocío, Seville, Spain",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,56.0,17.478798332614602,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,373.441,46.61,3.0,0.0,4.0,37.7,96.81,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,1,DB06209,__PRASUGREL,5288726,Withdrawn,NCT03027934,DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,56.0,17.478798332614602,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,373.441,46.61,3.0,0.0,4.0,37.7,96.81,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,1,DB06209,__PRASUGREL,5288726,Completed,NCT03387826,MYOCARDIAL INFARCTION|DIABETES MELLITUS|CORONARY ARTERY DISEASE|RENAL DISEASE,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Attikon University Hospital, Chaidari, Greece",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,56.0,17.478798332614602,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,373.441,46.61,3.0,0.0,4.0,37.7,96.81,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Unknown status,NCT01716611,HYPONATREMIA|ASCITES,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Konkuk University Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Enrolling by invitation,NCT02476409,CONGESTIVE HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,NCT01346072,CARDIOVASCULAR DISEASES|HEART DISEASES|HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,DECOMPENSATED HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,NCT01019486,CORONARY ARTERY DISEASE|TYPE 1 DIABETES MELLITUS,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Unknown status,NCT02935855,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Policlinico San Matteo, Pavia, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1,1,DB06249,__ARZOXIFENE,6077852,Completed,NCT00190697,BREAST CANCER|ENDOMETRIAL CANCER|OVARIAN CANCER,Female,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician, Houston, Texas, United States",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,26.382471919341196,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.3,475.6,51.16,4.0,1.0,5.0,52.44,135.63,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03202563,TYPE 2 DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03660683,"DIABETES MELLITUS, TYPE 2|CARDIOVASCULAR DISEASES",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The GW Medical Faculty Associates, Washington, District of Columbia, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02765204,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept of Medical Sciences Uppsala University Hospital, Uppsala, Sweden",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02471404,TYPE 2 DIABETES MELLITUS|INADEQUATE GLYCAEMIC CONTROL,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Prelouc, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Neuenahr-Ahrweiler, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Bünde, Germany|Research Site, Daaden, Germany|Research Site, Darmstadt, Germany|Research Site, Datteln, Germany|Research Site, Deggingen, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Gelnhausen, Germany|Research Site, Giengen, Germany|Research Site, Goch, Germany|Research Site, Grevesmühlen, Germany|Research Site, Grossheirath, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hameln, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildesheim, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Höhenkirchen, Germany|Research Site, Jerichow, Germany|Research Site, Kallstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köln, Germany|Research Site, Köthen, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lichtenfels, Germany|Research Site, Lingen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Löhne, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marl, Germany|Research Site, Meine, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf A. Inn, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Neuwied Am Rhein, Germany|Research Site, Oldenburg, Germany|Research Site, Papenburg, Germany|Research Site, Pirna, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Rehlingen Siersburg, Germany|Research Site, Reinfeld, Germany|Research Site, Remagen, Germany|Research Site, Rhaunen, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Saarlouis, Germany|Research Site, Schwabenheim, Germany|Research Site, Speyer, Germany|Research Site, Stadtbergen, Germany|Research Site, Stolberg, Germany|Research Site, Straubing, Germany|Research Site, Stuttgart, Germany|Research Site, Sulzbach, Germany|Research Site, Trier, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wahlstedt, Germany|Research Site, Wangen, Germany|Research Site, Weinheim, Germany|Research Site, Westerkappeln, Germany|Research Site, Wetzlar, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hatvan, Hungary|Research Site, Kisvárda, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza-Szentetornya, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ács, Hungary|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chrzanow, Poland|Research Site, Gdańsk, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Legnica, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznan, Poland|Research Site, Sobótka, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Vrutky, Slovakia",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03959501,TYPE 2 DIABETES|KETONEMIA,All,"21 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"L2 Diabetes Centre, Queen Mary Hospital, Hong Kong, Hong Kong",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02973477,TYPE2 DIABETES|CARDIOVASCULAR DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Michigan, Ann Arbor, Michigan, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Withdrawn,NCT02719132,DIABETES MELLITUS TYPE 2,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02719756,DIABETES MELLITUS|HYPOGLYCEMIC EPISODES,All,"18 Years to 74 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Research Clinical Centre of the Russian Railways, JSC, Moscow, Russian Federation",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02501616,ENDOTHELIAL FUNCTION|TYPE 2 DIABETES,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boramae medical center, Seoul, Korea, Republic of",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03007329,"STEATOSIS, LIVER|TYPE2 DIABETES",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT03361098,TYPE 2 DIABETES MELLITUS|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VU Medical Center, Amsterdam, Noord-Holland, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02962492,EVALUATE KETOGENIC STRESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02682563,"DIABETES MELLITUS, TYPE 2|DIABETIC NEPHROPATHIES",All,"35 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02610088,DIABETES,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT04249778,HEART FAILURE|DIABETES,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Emory University Hospital, Atlanta, Georgia, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Terminated,NCT03152084,"DIABETES MELLITUS, TYPE 2|KIDNEY FUNCTION TESTS",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Almelo, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03338855,"DIABETES MELLITUS, TYPE 2|SKELETAL MUSCLE INSULIN SENSITIVITY",All,"40 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Research Site, Maastricht, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03269058,TYPE-2 DIABETES|ORAL ANTIDIABETICS,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU Dijon Bourgogne, Dijon, France|CHU de Nantes, Nantes, France",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02796170,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tulane University, New Orleans, Louisiana, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02914691,TYPE 2 DIABETES|DIABETIC NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Steno Diabetes Center, Gentofte, Denmark",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02956811,TYPE 2 DIABETES|LEFT VENTRICULAR HYPERTROPHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital, Dundee, United Kingdom",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03074630,"DIABETES MELLITUS, TYPE 2|HYPERCHOLESTEROLEMIA",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Academic Medical Center, Amsterdam, North Holland, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT04340908,"DIABETES MELLITUS, TYPE 2|CARDIAC SURGERY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Anzhen Hospital, Capital Mediacal University, Beijing, Beijing, China",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02211742,FASTING GLUCOSE|GLUCOSE EXCURSION|GLYCEMIC CONTROL,Male,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University Innsbruck, Department of Internal Medicine I, Innsbruck, Tirol, Austria",A61K47/12,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03782259,TYPE 2 DIABETES MELLITUS|MYOCARDIAL FIBROSIS|MYOCARDIAL INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","University of Washington, Seattle, Washington, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT03398577,CORONARY DISEASE WITH DIABETES MELLITUS,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Sheba Medical Center, Cardiac Rehabilitation Institute, Tel Hashomer, Israel",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03178591,"DIABETES MELLITUS, TYPE 2|ISCHEMIC HEART DISEASE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT04080518,DIABETES MELLITUS|HEART FAILURE,All,"22 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","National Heart Centre Singapore, Singapore, Singapore",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02919345,"DIABETES MELLITUS, TYPE 2|CORONARY ARTERY DISEASE|CAROTID ARTERY DISEASES",All,"40 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State University of Campinas, Campinas, Sao Paulo, Brazil",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT04200586,TYPE2 DIABETES|HEART FAILURE WITH REDUCED EJECTION FRACTION,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Queen Mary Hospital, Hong Kong, Hong Kong",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03592667,HYPERTENSION,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",A61K47/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03089333,"HYPERTENSION|DIABETES MELLITUS, TYPE 2|BLOOD PRESSURE|OBESITY|CARDIAC HYPERTROPHY|MICROALBUMINURIA|VASCULAR STIFFNESS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Campinas (UNICAMP), Campinas, São Paulo, Brazil",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,"Active, not recruiting",NCT04242758,RENAL FUNCTION DISORDER|GLUCOSE METABOLISM DISORDERS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Pisa, Pisa, Italy",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT03721874,PREDIABETIC STATE|SUBSTRATE OXIDATION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Maastricht University and Medical Centre, Maastricht, Limburg, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02700334,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",A61K47/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03006471,PREDIABETES|PREHYPERTENSION,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",A61K47/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Not yet recruiting,NCT04330079,CORONARY ARTERY DISEASE|PREDIABETIC STATE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Not yet recruiting,NCT04445714,TYPE 2 DIABETES,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT01206647,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetologische Schwerpunktpraxis Dr. Lorra / Dr. Bonnermann, Bochum, Germany|Zentrum für klinische Studien Dresden, GWT-TUD GmbH, Dresden, Germany|Gemeinschaftspraxis Partner der Gesundheit, Essen, Germany|IKFE Institute for Clinical Research and Development, Mainz, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Diabetes Zentrum Neuwied, Neuwied, Germany|ikfe Studiencenter Potsdam GmbH, Potsdam, Germany",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT01608724,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Benxi, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Dongguan, China|Research Site, Foshan, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hhht, China|Research Site, Hubei, China|Research Site, Jimo, China|Research Site, Jinan, China|Research Site, Kunming, China|Research Site, Linyi, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shantou, China|Research Site, Shenyang, China|Research Site, Shiyan, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xian, China|Research Site, Zhanjiang, China|Research Site, Zhengzhou, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Recruiting,NCT03660683,"DIABETES MELLITUS, TYPE 2|CARDIOVASCULAR DISEASES",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The GW Medical Faculty Associates, Washington, District of Columbia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT01267448,DIABETES MELLITUS TYPE 2|SEVERE HYPERGLYCEMIA - BLOOD GLUCOSE LEVEL >300MG/DL.,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Stroger Hospital of Cook County, Chicago, Illinois, United States|John Stroger Hospital of Cook County, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02307695,TYPE 1 DIABETES,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT02471404,TYPE 2 DIABETES MELLITUS|INADEQUATE GLYCAEMIC CONTROL,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Prelouc, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Neuenahr-Ahrweiler, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Bünde, Germany|Research Site, Daaden, Germany|Research Site, Darmstadt, Germany|Research Site, Datteln, Germany|Research Site, Deggingen, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Gelnhausen, Germany|Research Site, Giengen, Germany|Research Site, Goch, Germany|Research Site, Grevesmühlen, Germany|Research Site, Grossheirath, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hameln, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildesheim, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Höhenkirchen, Germany|Research Site, Jerichow, Germany|Research Site, Kallstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köln, Germany|Research Site, Köthen, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lichtenfels, Germany|Research Site, Lingen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Löhne, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marl, Germany|Research Site, Meine, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf A. Inn, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Neuwied Am Rhein, Germany|Research Site, Oldenburg, Germany|Research Site, Papenburg, Germany|Research Site, Pirna, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Rehlingen Siersburg, Germany|Research Site, Reinfeld, Germany|Research Site, Remagen, Germany|Research Site, Rhaunen, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Saarlouis, Germany|Research Site, Schwabenheim, Germany|Research Site, Speyer, Germany|Research Site, Stadtbergen, Germany|Research Site, Stolberg, Germany|Research Site, Straubing, Germany|Research Site, Stuttgart, Germany|Research Site, Sulzbach, Germany|Research Site, Trier, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wahlstedt, Germany|Research Site, Wangen, Germany|Research Site, Weinheim, Germany|Research Site, Westerkappeln, Germany|Research Site, Wetzlar, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hatvan, Hungary|Research Site, Kisvárda, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza-Szentetornya, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ács, Hungary|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chrzanow, Poland|Research Site, Gdańsk, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Legnica, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznan, Poland|Research Site, Sobótka, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Vrutky, Slovakia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT02917031,TYPE 2 DIABETES MELLITUS|HEART FAILURE,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site 1, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chicoutimi, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Viña del Mar, Chile|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kisvárda, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Rivne, Ukraine",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02583438,TYPE 2 DIABETES|OBESITY,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT02481479,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT|HEART FAILURE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Michael's Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Terminated,NCT01765270,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR DISEASE,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","Cardiology, PC, Birmingham, Alabama, United States|Cardio-Thoracic Surgeons PC, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Stanford University Medical Center, Palo Alto, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Duke University Medical Center (DUMC), Durham, North Carolina, United States|Chippenham Medical Center, Richmond, Virginia, United States|Charleston Area Medical Center (CAMC), Charleston, West Virginia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT01960205,PRE-DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shandong Provincial Hospital, Jinan, Shandong, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT01552018,CORONARY ARTERY DISEASE|DIABETES MELLITUS TYPE 2,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT02182895,DIABETES,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Hospital, Boston, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Enrolling by invitation,NCT01527747,TYPE 2 DIABETES|HYPERTRIGLYCERIDEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Oregon Health & Science University, Portland, Oregon, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02462369,MICROALBUMINURIA|MICROALBUMINURIA /CREATININE RATIOS ACR,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02742233,DIABETIC FOOT ULCER,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,NCT02104739,PREDIABETES|OBESITY,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The University of Texas Health Science Center at Houston, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Suspended,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1,DB06410,__DOXERCALCIFEROL,5707980,Completed,NCT00418600,SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hot Springs, Arkansas, United States|Downey, California, United States|Tarzana, California, United States|Atlanta, Georgia, United States|Cincinnati, Ohio, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Spokane, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,11.039241052177598,69.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.27,412.6478,40.46,2.0,2.0,3.0,51.58,130.36,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1,DB06410,__DOXERCALCIFEROL,5707980,Terminated,NCT00646282,"HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University, Atlanta, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,11.039241052177598,69.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.27,412.6478,40.46,2.0,2.0,3.0,51.58,130.36,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1,DB06410,__DOXERCALCIFEROL,5707980,Completed,NCT00528788,"HYPERPARATHYROIDISM, SECONDARY|KIDNEY FAILURE, CHRONIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center Dialysis Unit, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,11.039241052177598,69.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.27,412.6478,40.46,2.0,2.0,3.0,51.58,130.36,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1,DB06480,__PRUCALOPRIDE,6413988,Unknown Status,,GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,8.18086613688166,98.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,367.87,76.82,5.0,2.0,3.0,39.08,100.67,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Unknown status,NCT02935855,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Policlinico San Matteo, Pavia, Italy",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Completed,NCT03080181,CUSHING DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,"Active, not recruiting",NCT02775227,PANCREATIC FISTULA|PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Withdrawn,NCT02779257,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K51/083,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Unknown status,NCT02668172,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus Medical Center, Rotterdam, South Holland, Netherlands",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Completed,,OBSTRUCTIVE SLEEP APNEA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Recruiting,NCT03789695,ATRIAL FIBRILLATION|T2D|CHRONIC KIDNEY DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Suspended,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,CARDIOMYOPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
O=C([O-])CN(CCN(CC(=O)[O-])CC(COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+].[Na+].[Na+],1,DB06705,__GADOFOSVESET_TRISODIUM,6676929,Withdrawn,NCT02243059,OVARIAN NEOPLASMS,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University Hospital Maastricht, Maastricht, Netherlands",A61K49/085,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,957.87,268.96,15.0,0.0,3.0,69.28,241.55,23.0,1.0,0.0,0.0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0
O=C([O-])CN(CCN(CC(=O)[O-])CC(COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+].[Na+].[Na+],1,DB06705,__GADOFOSVESET_TRISODIUM,6676929,Withdrawn,,"NEOPLASMS, OVARIAN",,,,,"FISABIO, Elche, Alicante, Spain",A61K49/085,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,957.87,268.96,15.0,0.0,3.0,69.28,241.55,23.0,1.0,0.0,0.0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0
[I-].[K+],1,DB06715,__POTASSIUM_IODIDE,,Completed,NCT00946296,GRAVES DISEASE|HYPERTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"UMASS Memorial Health Care, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.2,166.0028,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB06717,__FOSAPREPITANT,5691336,Completed,NCT01432015,OVARIAN CANCER|UTERINE CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Gynecologic Oncology Associates, Newport Beach, California, United States",C07D413/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT03425747,CHRONIC HYPOPARATHYROIDISM,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Campus Bio-Medico University, Roma, Italy",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT04238208,DIABETIC NERVE PROBLEMS|DIABETIC NEUROPATHY|DIABETIC COMPLICATIONS NEUROLOGICAL,Male,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zainab Khan, Lahore, Punjab, Pakistan",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Recruiting,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Unknown status,NCT00417144,POLYCYSTIC OVARY SYNDROME|OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Eugonia, Athens, Greece",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Completed,NCT00417066,INFERTILITY|PREMATURE OVARIAN FAILURE,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eugonia, Athens, Greece",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Unknown status,NCT03477929,INFERTILITY/STERILITY,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale Bernabeo, Ortona, Chieti, Italy",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Completed,,FERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Completed,NCT00145405,ACROMEGALY,All,"22 Years to 72 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",A61M5/284,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Recruiting,,NEUROENDOCRINE TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Terminated,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C01F17/005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCc1ccc(S(N)(=O)=O)cc1,1,DB06795,__MAFENIDE,3983209,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.37,186.232,86.18,3.0,2.0,1.0,18.24,46.69,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,1,DB06803,__NICLOSAMIDE,4283400,Not yet recruiting,NCT04317430,DIABETIC NEPHROPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Pharmacy, Tanta University, Tanta, Egypt",A23K10/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,319.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.49,327.12,95.15,4.0,2.0,2.0,28.47,80.51,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,Unknown status,NCT01278290,CENTRAL PRECOCIOUS PUBERTY|SEXUAL PRECOCITY,Female,3 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Ciudad Autónoma de Buenos Aires, Argentina",A61K38/04,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,Completed,NCT01500863,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Instituto Valenciano de Infertilidad, Madrid, Spain",A61K38/04,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,Completed,NCT02102646,PROSTATE CANCER|METABOLIC SYNDROME|HYPOGONADISM|FATTY LIVER,Male,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Herlev Hospital, Herlev, Denmark",A61K38/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,"Active, not recruiting",NCT00840944,IDIOPATHIC SHORT STATURE,All,7 Years to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antwerp University Hospital, Edegem, Antwerpen, Belgium|Jessah Ziekenhuis, Hasselt, Limburg, Belgium|Kinderziekenhuis UGent, Gent, Oost Vlaanderen, Belgium|Hopital Universitaire Reine Fabiola (HUDERF), Brussels, Belgium|Kinderziekenhuis UZ Brussel, Brussel, Belgium|CHU ND-des Bruyères, Liege, Belgium",A61K38/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,Unknown status,NCT00438217,CENTRAL PRECOCIOUS PUBERTY,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Center of Pediatric endocrinology, Department of Pediatrics, University of Pisa, Pisa, Italy",A61K38/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,1,DB08689,__UBIQUINONE_Q1,,Recruiting,NCT04302532,COENZYME Q10,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Aziz medical center, Karachi, Sindh, Pakistan",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
O=C(O)C(Cl)Cl,1,DB08809,__DICHLOROACETIC_ACID,,Unknown Status,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.99,128.942,37.3,2.0,1.0,0.0,9.32,22.62,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Withdrawn,NCT03027934,DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT03387826,MYOCARDIAL INFARCTION|DIABETES MELLITUS|CORONARY ARTERY DISEASE|RENAL DISEASE,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Attikon University Hospital, Chaidari, Greece",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Unknown status,NCT02457130,CORONARY ARTERY DISEASE|DIABETES MELLITUS. TYPE 2,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Not yet recruiting,NCT04484259,"DIABETES MELLITUS, TYPE 2|CORONARY ARTERY DISEASE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Unknown status,NCT01643031,DIABETES MELLITUS|CORONARY DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rabin Medical Center, Petah-Tikva, Israel",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT02748330,"CORONARY ARTERY DISEASE|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT02742987,CORONARY ARTERY DISEASE|DIABETES MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT01823510,TYPE-2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT02663713,MYOCARDIAL INFARCTION|DIABETES MELLITUS|RENAL DISEASE|CORONARY ARTERY DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Cardiology Department Patras University Hospital, Rio, Achaia, Greece",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Recruiting,NCT04307511,ACUTE CORONARY SYNDROME PATIENTS WITH DIABETES AFTER PCI,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"shanghai Tongren hospital, Shanghai, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,1,DB08822,__AZILSARTAN_MEDOXOMIL,7157584,Completed,NCT02517866,ESSENTIAL HYPERTENSION|TYPE 2 DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hong Kong, Hong Kong, China|Changhua County, Taiwan|Kaohsiung City, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Pathumthani, Thailand",C07D413/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,23.8197909608,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.94,568.5336,139.57,7.0,1.0,6.0,57.73,149.52,10.0,1.0,0.0,0.0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1,DB08860,__PITAVASTATIN,5753675,Recruiting,NCT03532620,PREDIABETIC STATE|HYPERTENSION|DYSLIPIDEMIAS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fourth People's Hospital of Chongqing, Chongqing, Chongqing, China|First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|People's Hospital of Zhongshan City, Zhongshan, Guangdong, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Yichang Central Hospital, Yichang, Hubei, China|Taizhou Hospital of TCM, Taizhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China|Lanzhou University Second Hospital, Lanzhou, Qinghai, China|Yantaishan Hospital, Yantai, Yantai, Shandong, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,97.8746996858251,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,421.4608,90.65,5.0,3.0,4.0,43.76,115.74,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1,DB08860,__PITAVASTATIN,5753675,Completed,NCT00301392,DIABETES MELLITUS|GLUCOSE INTOLERANCE,All,"30 Years to 74 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The University of Tokyo, Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,97.8746996858251,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,421.4608,90.65,5.0,3.0,4.0,43.76,115.74,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1,DB08860,__PITAVASTATIN,5753675,Completed,NCT00889226,HYPERCHOLESTEROLEMIA WITH TYPE2DM,All,"25 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,97.8746996858251,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,421.4608,90.65,5.0,3.0,4.0,43.76,115.74,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,1,DB08869,__TESAMORELIN,5861379,Terminated,NCT01591902,DIABETIC RETINOPATHY|HIV,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Southwest Center for HIV/AIDS, Phoenix, Arizona, United States|Spectrum Medical Group, Phoenix, Arizona, United States|5P21 Rand Schrader Clinic, Los Angeles, California, United States|University of California CARE Clinic, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|VAMC, Infectious Disease Section 111W, San Francisco, California, United States|Capital Medical Associates, PC, Washington, District of Columbia, United States|Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States|Orange County Health Department, Orlando, Florida, United States|Triple O Research Institute, West Palm Beach, Florida, United States|Rowan Tree Medical , P.A., Wilton Manors, Florida, United States|Be Well Medical Center, P.C., Berkley, Michigan, United States|Southampton Clinical Research, Inc d.b.a. Central West Clinical Research, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Harold Hamm Diabetes Center at the University of Oklahoma, Oklahoma City, Oklahoma, United States|Fanno Creek Clinic, LLC, Portland, Oregon, United States|Central Texas Clinical Research, Austin, Texas, United States|St. Hope Foundation, Inc., Bellaire, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Atten: HIV Research Unit, Dallas, Texas, United States|Research Access Network, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States",C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,1,DB08875,__CABOZANTINIB,7579473,"Active, not recruiting",NCT01896479,MEDULLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Leonards, New South Wales, Australia|Herston, Queensland, Australia|Kurralta Park, South Australia, Australia|Heidelberg, Victoria, Australia|Parkville, Victoria, Australia|Québec, Quebec, Canada|Toronto, Canada|Osijek, Croatia|Zagreb, Croatia|Zagreb, Croatia|Bordeaux, Gironde, France|Angers, Maine-et-Loire, France|Lyon, Rhône, France|Villejuif, Val-de-Marne, France|Dijon, France|Paris, France|Strasbourg Cedex, France|Budapest, Hungary|Debrecen, Hungary|Jerusalem, Israel|Petach Tikva, Israel|Safed, Israel|Catania, CT, Italy|Roma, RM, Italy|Sienna, SI, Italy|Pisa, Toscana, Italy|Milano, Italy|Padua, Italy|Torino, Italy|Goyang, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Noord Holland, Netherlands|Leiden, Zuid-Holland, Netherlands|Groningen, Netherlands|Gliwice, Slaskie, Poland|Poznań, Wielkopolskie, Poland|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Timisoara, Romania|Novosibirsk, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Lund, Skane Ian, Sweden|Uppsala, Uppsala Ian, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT02180334,"DIABETES MELLITUS, TYPE 2",All,"20 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Seoul National University Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT01547104,DIABETES MELLITUS TYPE 2,All,"45 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"ikfe GmbH, Mainz, Rhineland-Palatinate, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT02106104,TYPE 2 DIABETES,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VU University Medical Center, Amsterdam, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT03004612,PREDIABETIC STATE|INSULIN RESISTANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT04088461,PREDIABETIC STATE|IMPAIRED GLUCOSE TOLERANCE|INSULIN RESISTANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Recruiting,NCT03642184,NEW ONSET DIABETES AFTER TRANSPLANT|KIDNEY TRANSPLANT; COMPLICATIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Withdrawn,NCT03504566,DIABETIC NEPHROPATHY TYPE 2,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Withdrawn,NCT02768220,SGLT-2 INHIBITORS|ADVANCED GLYCATION END PRODUCTS|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT02429232,OSTEOPOROSIS|DIABETES MELLITUS,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT02097342,TYPE 2 DIABETES MELLITUS|INSULIN SENSITIVITY/RESISTANCE,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Postgraduate Institute of Medical Education & Research, Chandigarh, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Not yet recruiting,NCT04341935,CORONAVIRUS INFECTION|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT03320031,TYPE 2 DIABETES MELLITUS|PERITONEAL DIALYSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT02061969,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Crestvew Nursing Home, Atlanta, Georgia, United States|Budd Terrace Nursing Home, Atlanta, Georgia, United States|Wesley Woods Nursing Home, Atlanta, Georgia, United States|VA Nursing Home, Decatur, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT02467478,TYPE 2 DIABETES|IMPAIRED RENAL FUNCTION,All,"30 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT01617824,TYPE 2 DIABETES|CHRONIC RENAL FAILURE,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"University Hospital Diabetes Outpatient Clinic, Padova, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Completed,NCT02350478,TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University of Graz, Department for Internal Medicine, Graz, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,NCT04562467,"CARDIOVASCULAR DISEASES|CARDIOVASCULAR RISK FACTOR|TRIGLYCERIDES HIGH|DIABETES MELLITUS, TYPE 2",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The Oshawa Clinic, Oshawa, Ontario, Canada|Langstaff Medical Clinic, Vaughan, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2,1,DB08890,__LINACLOTIDE,7304036,"Active, not recruiting",NCT03119584,CHRONIC CONSTIPATION|DIABETE MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Texas Tech University Health Sciences Center, El Paso, Texas, United States",C07K14/245,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,70.0,44.8469167744717,10.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,1526.736,573.91,22.0,19.0,6.0,145.88,368.0,13.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,1
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,1,DB08893,__MIRABEGRON,6346532,Unknown status,NCT03012113,OBESITY,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands",C07D233/26,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.2099016406907,16.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,396.506,100.27,5.0,4.0,3.0,44.2,113.23,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,,"RHINITIS, ALLERGIC, PERENNIAL",,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,NCT03267576,"DIABETES MELLITUS, TYPE 2",All,19 Years to 54 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Consultorio Privado, Guadalajara, Mexico|Investigación Clínica Especializada, Guadalajara, Mexico|Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico",A61K9/2031,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,"Active, not recruiting",NCT02653209,TYPE 2 DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Exeter Clinical Research Facility, Exeter, United Kingdom",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,NCT02920918,"HEART FAILURE, SYSTOLIC|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Not yet recruiting,NCT04288778,DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belgaum Diabetes Centre, Belgaum, India|Lifecare Hospital and Research Centre, Bengaluru, India|Kovai Diabetes Specialty Centre & Hospital, Coimbatore, India|Thumbay Hospital New life / Endocrinology, Hyderabad, India|Arthur Asirvatham Hospital, Madurai, India|Seth G. S. Medical College and KEM Hospital, Mumbai, India|Jehangir Clinical Development Center Pvt Ltd, Pune, India|Chellaram Diabetes Institute, Pune, India|Nirmal Hospital Pvt. Ltd., Surat, India|Jothydev's Diabetes Research Centre, Trivandrum, India",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,"Active, not recruiting",NCT02462421,DIABETES MELLITUS|GOUT|HYPERURICEMIA,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,NCT01989754,"DIABETES MELLITUS, TYPE 2|ALBUMINURIA",All,"30 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Little Rock, Arkansas, United States|Carmichael, California, United States|Concord, California, United States|Pismo Beach, California, United States|Roseville, California, United States|Thousand Oaks, California, United States|Denver, Colorado, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Opa-locka, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Tampa, Florida, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Valparaiso, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Mandeville, Louisiana, United States|Metairie, Louisiana, United States|Elkridge, Maryland, United States|Flint, Michigan, United States|Picayune, Mississippi, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Washington, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Cornelius, North Carolina, United States|Hickory, North Carolina, United States|Mooresville, North Carolina, United States|Canal Fulton, Ohio, United States|Franklin, Ohio, United States|Mason, Ohio, United States|Oklahoma City, Oklahoma, United States|Beaver, Pennsylvania, United States|Levittown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Tipton, Pennsylvania, United States|Greer, South Carolina, United States|Jefferson City, Tennessee, United States|Austin, Texas, United States|Pearland, Texas, United States|Bountiful, Utah, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Falls Church, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States|Wauwatosa, Wisconsin, United States|Buenos Aires, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Cordoba, Argentina|Mar Del Plata, Argentina|Moron, Argentina|Rosario, Argentina|Zarate, Buenos Aires, Argentina|Box Hill, Australia|Cairns, Australia|Daw Park, Australia|Freemantle, Australia|Liverpool, Australia|Melbourne, Australia|Newcastle, Australia|Sherwood, Australia|Sydney, Australia|Tasmania, Australia|Woden, Australia|Woolloongabba, Australia|Bonheiden, Belgium|Brugge, Belgium|Edegem, Belgium|Gent, Belgium|La Louvière, Belgium|Leuven, Belgium|Liege, Belgium|Liÿge, Belgium|Merksem, Belgium|Ransart, Belgium|Roeselare, Belgium|Tessenderlo, Belgium|Belem, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Mogi Das Cruzes, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Coquitlam, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Guelph, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Sarnia, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Lévis, Quebec, Canada|Quebec City, Quebec, Canada|Saint Marc Des Carriéres, Quebec, Canada|Sherbrooke, Quebec, Canada|Westmont, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Baotou, China|Beijing, China|Hangzhou, China|Jinan, China|Shenyang, China|Wuxi, China|Beroun, Czechia|Ostrava, Czechia|Plzen, Czechia|Praha 10, Czechia|Praha 1, Czechia|Praha 4, Czechia|Praha 8, Czechia|Znojmo, Czechia|Amiens, France|Bois Guillaume, France|Bordeaux, France|Dijon, France|Grenoble, France|La Rochelle Cedex 1, France|Le Creusot, France|Narbonne Cedex, France|Paris, France|Poitiers, France|Aschaffenburg, Germany|Aßlar, Germany|Bad Oeynhausen, Germany|Dortmund, Germany|Dresden, Germany|Freiburg, Germany|Hannover, Germany|Kassel, Germany|Mainz, Germany|Neuwied, Germany|Saarbrücken, Germany|Villingen-Schwenningen, Germany|Balatonfured, Hungary|Budapest, Hungary|Dunaújváros, Hungary|Eger, Hungary|Kecskemét, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Szekesfehervar, Hungary|Szikszó, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|*Osenza*, Italy|Arenzano, Italy|Bologna, Italy|Catanzaro, Italy|Chieri (Torino), Italy|Firenze, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Ravenna, Italy|Roma N/A, Italy|Roma, Italy|Sesto San Giovanni (Milano), Italy|Verona, Italy|Ansan, Korea, Republic of|Bucheon, Korea, Republic of|Busan, Korea, Republic of|Changwon, Korea, Republic of|Cheongju, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Iksan, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Seongnam-Si, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Ulsan, Korea, Republic of|Wonju-Si, Korea, Republic of|Batu Caves, Malaysia|Georgetown, Malaysia|Ipoh, Malaysia|Kelantan, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Aguascalientes, Mexico|Celaya, Mexico|Cuernavaca, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Mexico, Mexico|Pachuca De Soto, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Tampico, Mexico|Almelo, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Hoogeveen, Netherlands|Hoogezand, Netherlands|Kloosterhaar, Netherlands|Leiden, Netherlands|Meppel, Netherlands|Poortvliet, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Velp, Netherlands|Waalwijk, Netherlands|Wamel, Netherlands|Zoetermeer, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Newtown, New Zealand|Palmerston North, New Zealand|Rotorua, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Bialystok, Poland|Bydgoszcz, Poland|Chrzanow, Poland|Gdansk, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lublin, Poland|Oswiecim, Poland|Torun, Poland|Tychy, Poland|Warszawa, Poland|Wroclaw, Poland|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Kemerovo, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Rostov-On-Don, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tyumen, Russian Federation|Vsevolzhsk, Russian Federation|Yaroslavl, Russian Federation|A Coruna, Spain|Alcalá De Henares, Spain|Alicante, Spain|Almeria, Spain|Alzira, Spain|Barcelona, Spain|Ciudad Real, Spain|Cordoba, Spain|Ferrol, Spain|Figueres, Spain|Galdakao, Spain|Madrid, Spain|Malaga, Spain|Móstoles, Spain|Palma De Mallorca, Spain|Sabadell, Spain|San Sebastian De Los Reyes, Spain|Sant Joan D'Alacant, Spain|Santa Cruz De Tenerife, Spain|Santiago De Compostela, Spain|Segovia, Spain|Sevilla N/A, Spain|Sevilla, Spain|Valencia, Spain|Viladecans, Spain|Borås, Sweden|Goteborg, Sweden|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Lund, Sweden|Malmo, Sweden|Stockholm, Sweden|Uddevalla, Sweden|Uppsala, Sweden|Vallingby, Sweden|Västra Frölunda, Sweden|Kaohsiung County, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tiachung, Taiwan|Xindian, Taiwan|Cherkasy, Ukraine|Chernivtsy, Ukraine|Dnipropetrovsk, Ukraine|Ivan-Frankivsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Vinnytsya, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Addlestone, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bristol, United Kingdom|Bury St Edmunds, United Kingdom|Chesterfield, United Kingdom|Derby, United Kingdom|Doncaster, United Kingdom|Ipswich, United Kingdom|Leicester, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Salford, United Kingdom|Taunton, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Wellingborough, United Kingdom|Welwyn Garden City, United Kingdom",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,NCT01939496,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Gulf Shores, Alabama, United States|Avondale, Arizona, United States|Phoenix, Arizona, United States|Glendale, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Pismo Beach, California, United States|Rancho Cucamonga, California, United States|Roseville, California, United States|Sacramento, California, United States|Spring Valley, California, United States|Tustin, California, United States|Denver, Colorado, United States|Brandon, Florida, United States|Doral, Florida, United States|Fort Lauderdale, Florida, United States|Lake Worth, Florida, United States|Lauderdale Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|West Palm Beach, Florida, United States|Perry, Georgia, United States|Rincon, Georgia, United States|Indianapolis, Indiana, United States|Topeka, Kansas, United States|Lexington, Kentucky, United States|Mandeville, Louisiana, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Dearborn, Michigan, United States|Kalamazoo, Michigan, United States|Jackson, Mississippi, United States|St. Louis, Missouri, United States|Morganville, New Jersey, United States|Whiting, New Jersey, United States|Albuquerque, New Mexico, United States|Raleigh, North Carolina, United States|Oklahoma City, Oklahoma, United States|Altoona, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|Sugar Land, Texas, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Carolina, Puerto Rico|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Terminated,NCT02912455,"DIABETES MELLITUS, TYPE 2|OBESITY",All,"20 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cleveland Clinic, Cleveland, Ohio, United States",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Withdrawn,NCT02597309,"DIABETES, OBESITY",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Joslin Diabetes Center, Boston, Massachusetts, United States",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Withdrawn,NCT03190798,TYPE2 DIABETES MELLITUS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,NCT02360774,TYPE 2 DIABETES|OVERWEIGHT|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,TYPE II DIABETES IN SUBJECTS BMI 27 TO 32,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Completed,,ALBUMINURIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,1,DB08947,__IOPAMIDOL,5242683,Terminated,NCT00209417,RENAL INSUFFICIENCY|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","GE Healthcare, Princeton, New Jersey, United States|GE Healthcare, Amersham, United Kingdom",A61K49/0495,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,20.928561161420106,321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,777.0853,188.45,8.0,8.0,1.0,54.78,139.66,10.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0
C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,1,DB08947,__IOPAMIDOL,5242683,Terminated,NCT00782639,CHRONIC RENAL IMPAIRMENT|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","Bracco Diagnostics Inc., Princeton, New Jersey, United States",A61K49/0495,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,20.928561161420106,321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,777.0853,188.45,8.0,8.0,1.0,54.78,139.66,10.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0
C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,1,DB08947,__IOPAMIDOL,5242683,Completed,NCT00289614,KIDNEY DISEASES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Bracco Diagnostics, Inc., Princeton, New Jersey, United States",A61K49/0495,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,20.928561161420106,321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,777.0853,188.45,8.0,8.0,1.0,54.78,139.66,10.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT01461499,TYPE 2 DIABETES MELLITUS|HYPERTENSION,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shiga University of Medical Science, Otsu, Shiga, Japan",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT00660309,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Novartis Investigator Site, Boston, Massachusetts, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Unknown status,NCT01095822,DIABETES,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Dr. Pokov's Polyclinic. 6821 Reisterstown Road Suite 206, Baltimore, Maryland, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT00927394,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigative Site, Newark, Delaware, United States|Investigative Site, Kansas, Missouri, United States|Investigative Site, Camden, New Jersey, United States|Investigative Site, Philadelphia, Pennsylvania, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT00787605,HYPERTENSION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sites in USA, East Hanover, New Jersey, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT00818779,CORONARY ARTERY DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Texas Tech University Health Sciences Center, Lubbock, Texas, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Withdrawn,NCT00994253,HYPERTENSION|DIABETES TYPE 2,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"William Beaumont Hospital, Royal Oak, Michigan, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Unknown status,NCT00949351,TYPE 2 DIABETES WITH NEPHROPATHY,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lerdsin General Hospital, Bangkok, Thailand",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Terminated,NCT01349114,DIABETES|PRE-HYPERTENSION|HYPERTENSION,All,"19 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","UAB, Birmingham, Alabama, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Terminated,NCT00961207,MICROALBUMINURIA|MACROALBUMINURIC DIABETIC NEPHROPATHY|DIABETES|PROTEINURIA|ALBUMINURIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John H Stroger Hospital of Cook County, Chicago, Illinois, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1,1,DB09030,__VORAPAXAR,7304078,Completed,NCT02548650,MYOCARDIAL INFARCTION|DIABETES MELLITUS|PERIPHERAL ARTERIAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States",C07D417/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,67.0,55.68902852214622,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.9,492.5817,77.52,3.0,1.0,5.0,53.85,134.52,6.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,0,1
Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,1,DB09034,__SUVOREXANT,7951797,Recruiting,NCT03818581,TYPE 2 DIABETES MELLITUS|INSOMNIA|SLEEP DISORDER|INFLAMMATION,All,"25 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",C07D491/052,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,41.988541859175704,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.86,450.93,80.29,5.0,0.0,5.0,46.68,134.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT04243850,"DIABETES MELLITUS, TYPE 2|CHRONIC KIDNEY DISEASES",All,"45 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT03208465,DIABETES MELLITUS|CORONARY DISEASE,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Terminated,NCT02985242,"DIABETES MELLITUS, TYPE II",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Terminated,NCT02728453,DIABETES MELLITUS TYPE 2,All,"40 Years to 79 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hannover Medical School, Hannover, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04183868,TYPE 2 DIABETES|CARDIOVASCULAR RISK FACTOR,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Universital Hospital Mater Domini, Catanzaro, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT04238702,"DIABETES MELLITUS, TYPE 2|DIABETIC KIDNEY DISEASE",All,"35 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT01001962,HYPERTENSION|TYPE II DIABETES,All,"45 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hypertension 24h ABPM center Papageorgiou Hospital, Thessaloniki, Greece",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT03639545,"VASCULAR STIFFNESS|HYPOGLYCEMIC AGENTS|DIABETES COMPLICATIONS|DIABETES MELLITUS, TYPE 1",All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Centre Ljubljana, Ljubljana, Slovenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT03646292,NAFLD - NONALCOHOLIC FATTY LIVER DISEASE|TYPE2 DIABETES,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT02637973,TYPE 2 DIABETES|NON-ALCOHOLIC FATTY LIVER DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Charite Universitaetsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|German Diabetes Center, Dusseldorf, Germany|University Clinic Heidelberg, Heidelberg, Germany|University Clinic Tübingen, Tübingen, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT02964715,TYPE2 DIABETES|NAFLD,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04215445,DIABETIC RETINOPATHY|CHRONIC KIDNEY DISEASES|DIABETES MELLITUS,All,"35 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UKM Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT02589639,"DIABETES MELLITUS, TYPE 2",All,"20 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nakayama Clinic, Aichi, Japan|Kashiwa City Hospital, Chiba, Kashiwa, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka, Japan|Seiwakai Medical Corporation Nagata Hospital, Fukuoka, Yanagawa, Japan|Kunisaki Makoto Clinic, Fukuoka, Japan|Saiseikai Maebashi Hospital, Gunma, Maebashi, Japan|Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama, Japan|Jiyugaoka Yokoyama Naika Clinic, Hokkaido, Obihiro, Japan|Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan|Souen Diabetes Clinic, Hokkaido, Sapporo, Japan|Kotani Diabetes Clinic, Hyogo, Kobe, Japan|Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan|Noritake Clinic, Ibaraki, Ushiku, Japan|Yokoi Medical Clinic, Kagawa, I.M., Kagawa, Japan|Izuro Imamura Hospital, Kagoshima, Kagoshima, Japan|Wakamatsu Memorial Hospital, Kagoshima, Satsumasendai, Japan|Fukumoto clinic, Kagoshima, Japan|STOP DM SUZUKI DIABETES CLINIC, Kanagawa, I.M., Kanagawa, Atsugi, Japan|Takai Naika Clinic, Kanagawa, Kamakura, Japan|Kokan Clinic, Kanagawa, Kawasaki, Japan|Yoshimasa Diabetes & Endocrine Clinic, Kyoto, Kyoto, Japan|Medical Corporation KEISEIKAI Kajiyama clinic, Kyoto, kyoto, Japan|Saka General Clinic, Miyagi, Tagajo, Japan|North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan|Asama Nanroku Komoro Medical center, Nagano, Komoro, Japan|Abe Clinic, Oita, Oita, Japan|Tsuyama Chuo Hospital, Okayama, Tsuyama, Japan|Medical Corporation Kyojinkai Clinic Komatsu, Osaka, Neyagawa, Japan|Minamiosaka Hospital, Osaka, Osaka, Japan|OCROM Clinic, Osaka, Suita, Japan|AMC Nishi-umeda Clinic, Osaka, Japan|Shiraiwa Medical Clinic, Osaka, Japan|Ageo Central General Hospital, Saitama, Ageo, Japan|Medical Corporation Kaishinkai Masunaga Clinic, Saitama, Fujimi, Japan|Medical Corporation Fusa Shimizu Clinic Fusa, Saitama, Saitama, Japan|Seiwa Clinic, Tokyo, Adachi-ku, Japan|Juntendo University Hospital, Tokyo, Bunkyo-ku, Japan|Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan|HDC Atlas Clinic, Tokyo, Chiyoda-ku, Japan|Fukuwa Clinic, Tokyo, Chuo-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan|Tokyo Center Clinic, Tokyo, Chuo-ku, Japan|Shin Clinic, Tokyo, Ota-ku, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku, Japan|Sumida Chuou Hospital, Tokyo, Sumida-ku, Japan|Sagae City Hospital, Yamagata, Sagae, Japan|Clinic Sugiyama, Yamagata, Yamagata, Japan|Yamanashi Prefectural Central Hospital, Yamanashi, Kofu, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT04143321,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cardiac rehabilitation research center, Isfahan, Iran, Islamic Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04014192,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT03753087,"HEART FAILURE, DIASTOLIC|DIABETES MELLITUS, TYPE 2",All,"45 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Medical Research Center for Cardiology, Moscow, Russian Federation",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT02998970,DIABETES|CARDIOVASCULAR DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","St. Michael's Hospital, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT03485092,HEART FAILURE|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT02932436,"DIABETES MELLITUS, TYPE 2|DIASTOLIC DYSFUNCTION",All,"18 Years to 84 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention, Mainz, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT04061200,TYPE 2 DIABETES WITH RENAL MANIFESTATIONS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Steno Diabetes Center Copenhagen, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT04497792,CORONARY ARTERY DISEASE|DIABETES MELLITUS|PERCUTANEOUS CORONARY INTERVENTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT04523064,"DIABETES MELLITUS, TYPE 2|CORONARY ARTERY DISEASE|CORONARY ARTERY BYPASS SURGERY|ACUTE KIDNEY INJURY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Sao Paulo Medical School - The Heart Institute, Sao Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT03642184,NEW ONSET DIABETES AFTER TRANSPLANT|KIDNEY TRANSPLANT; COMPLICATIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT03560375,"DIABETES MELLITUS, TYPE 2|SARCOPENIA|WEIGHT LOSS|FRAILTY",All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The Institute of Endocrinology Metabolism and Hypertension, Tel Aviv, Israel",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT03157414,DIABETES MELLITUS|RENAL INSUFFICIENCY|SAFETY ISSUES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oslo University Hospital Rikshospitalet, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04117763,"DIABETES MELLITUS, TYPE 2|CORONARY HEART DISEASE|ARRYTHMIA, CARDIAC",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"InCor, São Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT03226457,HEART FAILURE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Dundee, Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT03877406,"DIABETES MELLITUS|FAT; INTOLERANCE, PANCREAS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT02833415,"OBESITY, VISCERAL",All,"30 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Texas Southwestern Medical Center, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Not yet recruiting,NCT04461041,CARDIOVASCULAR DISEASES|LEFT VENTRICULAR HYPERTROPHY,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Michael's Hospital, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT03271879,HEART FAILURE|DIABETES MELLITUS|ARRYTHMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Completed,NCT03050229,NOCTURNAL HYPERTENSION|T2DM (TYPE 2 DIABETES MELLITUS),All,"20 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Fukuoka University Chikushi Hospital, Fukuoka, Japan|Kotake Hospital, Fukuoka, Japan|Onga Hospital, Fukuoka, Japan|Ishiguro Clinic, Gifu, Japan|Higashiagatsuma-machi National Health Insurance Clinic, Gunma, Japan|Katsuya Iin, Hyogo, Japan|Minamisanriku Hospital, Miyagi, Japan|Shibuya Clinic, Saitama, Japan|International University of Health and Welfare Hospital, Tochigi, Japan|Jichi Medical University hospital, Tochigi, Japan|Utsunomiya higashi hospital, Tochigi, Japan|Kato Clinic, Tokyo, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT03912909,METABOLIC SYNDROME|TYPE 2 DIABETES MELLITUS|OBESITY,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Royal Perth Hospital, Perth, Western Australia, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Withdrawn,NCT03504566,DIABETIC NEPHROPATHY TYPE 2,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Withdrawn,NCT02768220,SGLT-2 INHIBITORS|ADVANCED GLYCATION END PRODUCTS|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,1,DB09068,__VORTIOXETINE,7144884,Completed,NCT03978286,DEPRESSION|TYPE 2 DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D295/033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,50.1036982278896,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,298.45,15.27,2.0,1.0,3.0,34.92,94.01,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,1,DB09068,__VORTIOXETINE,7144884,Not yet recruiting,NCT03580967,TYPE2 DIABETES|MAJOR DEPRESSIVE DISORDER,All,"40 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Loyola University Medical Center, Maywood, Illinois, United States",C07D295/033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,50.1036982278896,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,298.45,15.27,2.0,1.0,3.0,34.92,94.01,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0
COc1ccc(CN2CCNCC2)c(OC)c1OC,1,DB09069,__TRIMETAZIDINE,3959281,Completed,NCT00282360,CORONARY ARTERY DISEASE|TYPE II DIABETES MELLITUS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07D311/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,57.95601552393271,34.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.85,266.341,42.96,5.0,1.0,2.0,29.15,74.75,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,1,DB09074,__OLAPARIB,7151102,Recruiting,NCT04330040,OVARIAN CANCER|BREAST CANCER,Female,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Ahmedabad, India|Research Site, Bhubaneshwar, India|Research Site, Chandigarh, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,1,DB09074,__OLAPARIB,7151102,"Active, not recruiting",NCT02476968,BRCA OR HRR+ MUTATED OVARIAN CANCER PATIENTS,Female,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Bari, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Kielce, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Cristobal de La Laguna, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Wirral, United Kingdom",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,1,DB09075,__EDOXABAN,7365205,Unknown status,NCT02935855,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Policlinico San Matteo, Pavia, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,1,DB09078,__LENVATINIB,7253286,Recruiting,NCT03573960,THYROID NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City Cancer Centre, Vijayawada, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Shetty's Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Bhubaneshwar, Odisa, India|S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, India|BL Kapoor Hospital, New Delhi, New Delhi, India|Indrayani Hospital, Alandi, Pune, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I,1,DB09134,__IOVERSOL,4997983,Withdrawn,NCT00335101,CORONARY ARTERY DISEASE (CAD)|RENAL IMPAIRMENT|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,"GE Healthcare, Princeton, New Jersey, United States|GE Healthcare, Munich, Germany",C07C231/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,13.0762438653771,276.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,807.115,199.89,9.0,8.0,1.0,58.31,144.58,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I,1,DB09134,__IOVERSOL,4997983,Not yet recruiting,NCT03631771,HYPOTHYROIDISM,All,up to 3 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07C231/24,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,13.0762438653771,276.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,807.115,199.89,9.0,8.0,1.0,58.31,144.58,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Terminated,NCT03191201,"IRON-DEFICIENCY|IRON TOXICITY|GLUCOSE METABOLISM DISORDERS (INCLUDING DIABETES MELLITUS)|METABOLIC SIDE EFFECTS OF DRUGS|METABOLIC DISORDER, GLUCOSE|SAFETY ISSUES",Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Policlinique Médicale Universitaire, Lausanne, Vaud, Switzerland",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Unknown status,NCT02549768,PITUITARY NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Division de Anestesia - Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Unknown status,NCT02372149,PERIPHERAL NEUROPATHY|DIABETES MELLITUS|CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto General Hospital / Toronto Western Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB09156,__IOPROMIDE,5204005,Withdrawn,NCT00335101,CORONARY ARTERY DISEASE (CAD)|RENAL IMPAIRMENT|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,"GE Healthcare, Princeton, New Jersey, United States|GE Healthcare, Munich, Germany",C07C237/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,26.7110207601798,298.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,791.1119,168.66,8.0,6.0,1.0,57.56,144.82,11.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB09156,__IOPROMIDE,5204005,Not yet recruiting,NCT03631771,HYPOTHYROIDISM,All,up to 3 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07C237/46,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,34.0,26.7110207601798,298.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,791.1119,168.66,8.0,6.0,1.0,57.56,144.82,11.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,"Active, not recruiting",NCT02338921,TYPE 2 DIABETES,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Soo Lim, Seongnam, Gyeonggi, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Completed,NCT02285205,TYPE 2 DIABETES|NON-ALCOHOLIC FATTY LIVER DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Completed,,NON-ALCOHOLIC FATTY LIVER DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Active Not Recruiting,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NCCO[N+](=O)[O-])c1cccnc1,1,DB09220,__NICORANDIL,4769381,Unknown status,NCT02328521,"ANGINA, UNSTABLE|DIABETES MELLITUS",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Chinese PLA General Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.7786402184849,316.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,211.17700000000002,94.36,5.0,1.0,1.0,19.34,49.86,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,1,DB09230,__AZELNIDIPINE,4772596,Completed,NCT00454662,HYPERTENSION|CARDIOVASCULAR DISEASE|DIABETES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"COLM-Study Data Center, Kamiyacho MT Bld.14F, 4-3-20 Toranomon Minato-ku, Tokyo, Japan",C07D401/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,11.5320643134355,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.12,582.6569999999998,137.03,7.0,2.0,5.0,60.76,172.06,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,1
CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,1,DB09230,__AZELNIDIPINE,4772596,Completed,NCT00134160,HYPERTENSION|CARDIOVASCULAR DISEASES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University, 1-1-1 Honjyo, Kumamoto-City, Kumamoto, Japan|OSCAR-Study Data Center, ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan",C07D401/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,11.5320643134355,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.12,582.6569999999998,137.03,7.0,2.0,5.0,60.76,172.06,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,1
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,1,DB09236,__LACIDIPINE,4801599,Completed,NCT00328965,"DIABETES MELLITUS, TYPE 2|ESSENTIAL HYPERTENSION",All,"35 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D211/90,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,41.39715394566621,160.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,455.551,90.93,4.0,1.0,2.0,49.74,129.91,11.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0
COc1nc(C)nc(Cl)c1NC1=NCCN1,1,DB09242,__MOXONIDINE,4778678,Completed,NCT01504321,PCOS,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Heart Centre, Alfred Hospital, Prahran, Victoria, Australia",A61K9/7053,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.511653216698402,256.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.01,241.67700000000002,71.43,6.0,2.0,2.0,23.57,63.41,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
COc1nc(C)nc(Cl)c1NC1=NCCN1,1,DB09242,__MOXONIDINE,4778678,Unknown status,NCT01094769,DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alfred & Baker Medical Unit, Melbourne, Victoria, Australia",A61K9/7053,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.511653216698402,256.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.01,241.67700000000002,71.43,6.0,2.0,2.0,23.57,63.41,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,1,DB09265,__LIXISENATIDE,7918833,Completed,NCT02200991,TYPE 2 DIABETES,All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 392-107, Atsugi-shi, Japan|Investigational Site Number 392-125, Chiyoda-ku, Japan|Investigational Site Number 392-121, Chuoh-ku, Japan|Investigational Site Number 392-102, Ichihara-shi, Japan|Investigational Site Number 392-103, Kawaguchi-shi, Japan|Investigational Site Number 392-114, Kitamoto-shi, Japan|Investigational Site Number 392-122, Kobe-shi, Japan|Investigational Site Number 392-126, Kumamoto-shi, Japan|Investigational Site Number 392-127, Kumamoto-shi, Japan|Investigational Site Number 392-101, Kyoto-shi, Japan|Investigational Site Number 392-106, Matsudo-shi, Japan|Investigational Site Number 392-124, Mitaka-shi, Japan|Investigational Site Number 392-108, Mito-shi, Japan|Investigational Site Number 392-119, Nerima-ku, Japan|Investigational Site Number 392-117, Okayama-shi, Japan|Investigational Site Number 392-111, Sagamihara-shi, Japan|Investigational Site Number 392-110, Sapporo-shi, Japan|Investigational Site Number 392-116, Satsumasendai-shi, Japan|Investigational Site Number 392-105, Shizuoka-shi, Japan|Investigational Site Number 392-118, Suita-shi, Japan",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,1,DB09265,__LIXISENATIDE,7918833,Completed,NCT02941367,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 356005, Ahmedabad, India|Investigational Site Number 356002, Bangalore, India|Investigational Site Number 356015, Bangalore, India|Investigational Site Number 356008, Bangalore, India|Investigational Site Number 356009, Hyderabad, India|Investigational Site Number 356018, Hyderabad, India|Investigational Site Number 356010, Hyderabad, India|Investigational Site Number 356003, Hyderabad, India|Investigational Site Number 356007, Jaipur, India|Investigational Site Number 356019, Madurai, India|Investigational Site Number 356014, Mumbai, India|Investigational Site Number 356022, Nagpur, India|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376002, Safed, Israel|Investigational Site Number 414001, Kuwait, Kuwait|Investigational Site Number 792002, Zonguldak, Turkey",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,1,DB09265,__LIXISENATIDE,7918833,Terminated,NCT02767596,DIABETES MELLITUS TYPE 2,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bildirici Diabetes Center, Laniado Hospital, Netanya, Israel",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,1,DB09265,__LIXISENATIDE,7918833,Completed,NCT01973231,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Hradec Kralove, Czech Republic|Novo Nordisk Investigational Site, Mlada Boleslav, Czech Republic|Novo Nordisk Investigational Site, Olomouc, Czech Republic|Novo Nordisk Investigational Site, Plzen, Czech Republic|Novo Nordisk Investigational Site, Prostejov, Czech Republic|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, Rovaniemi, Finland|Novo Nordisk Investigational Site, Boulogne Billancourt, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, Hinx, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Lauterberg, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Lampertheim, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Baja, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Salgótarján, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Cittadella (PD), Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Terni, Italy|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Klaipeda, Lithuania|Novo Nordisk Investigational Site, Siauliai, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Chiswick, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Derby, United Kingdom|Novo Nordisk Investigational Site, Devon, United Kingdom|Novo Nordisk Investigational Site, Great Yarmouth, United Kingdom|Novo Nordisk Investigational Site, Lancaster, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sandbach, United Kingdom|Novo Nordisk Investigational Site, Taunton, United Kingdom",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,1,DB09265,__LIXISENATIDE,7918833,Completed,NCT02276196,DIABETIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|DIABETES MELLITUS|GLUCAGON-LIKE PEPTIDE 1,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU Universtiy Medical Center, Amsterdam, Netherlands",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2],1,DB09267,__STRONTIUM_RANELATE,,Completed,NCT01222026,PRIMARY HYPERPARATHYROIDISM|OSTEOPENIA|OSTEOPOROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Vienna, General Hospital Vienna (AKH Wien), Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.91,513.49,187.55,10.0,0.0,1.0,27.91,116.34,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O,1,DB09270,__UBIDECARENONE,4325942,Completed,,COENZYME Q10,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,21.158545350007106,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.94,863.3435,52.6,4.0,0.0,1.0,112.38,286.61,31.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1,1,DB09282,__MOLSIDOMINE,4731241,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,12.222016879196598,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,242.235,77.91,5.0,0.0,2.0,23.94,76.99,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Recruiting,NCT03938389,PREDIABETES|IMPAIRED GLUCOSE TOLERANCE|OBESITY|BLOOD PRESSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Recruiting,NCT04012476,HYPOCALCEMIA|TOTAL THYROIDECTOMY|HYPOPARATHYROIDISM POSTPROCEDURAL,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitari Son Espases, Palma De Mallorca, Illes Balears, Spain",A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC,1,DB09389,__NORGESTREL,4145416,Recruiting,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.25,312.453,37.3,2.0,1.0,4.0,36.83,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,1,DB09401,__ISOSORBIDE,4065488,Recruiting,NCT03514108,HEART FAILURE|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sygehus Sønderjylland, Aabenraa, Aabenraa, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Amager Hospital, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Copenhagen, Denmark|Glostrup Hospital, Copenhagen, Denmark|Herlev Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark|Herning Hospital, Herning, Denmark|Regionshospital Nordjylland, Hjørring, Hjørring, Denmark|Holbæk Hospital, Holbæk, Denmark|Horsens Hospital, Horsens, Denmark|Kolding Hospital, Kolding, Denmark|Nykøbing Falster Hospital, Nykøbing Falster, Denmark|Odense University Hospital, Odense, Denmark|Randers Hospital, Randers, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Vejle Hospital, Vejle, Denmark|Viborg Hospital, Viborg, Denmark",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,146.1412,58.92,4.0,2.0,2.0,13.54,31.38,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,1,DB09401,__ISOSORBIDE,4065488,Withdrawn,NCT02011620,ENDOTHELIAL DYSFUNCTION|BONE DISEASE,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Tameside General Hospital NHS Foundation Trust, Manchester, United Kingdom",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,146.1412,58.92,4.0,2.0,2.0,13.54,31.38,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,1,DB09401,__ISOSORBIDE,4065488,Completed,,MYOCARDIAL ISCHEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D493/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,146.1412,58.92,4.0,2.0,2.0,13.54,31.38,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
[Cl-].[Cl-].[Mg+2],1,DB09407,__MAGNESIUM_CHLORIDE,6248726,Completed,NCT00603499,DIABETES MELLITUS|HIGH BLOOD PRESSURE|HYPOMAGNESEMIA,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Biomedical Research Unit, Durango, Mexico",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.61,95.211,0.0,0.0,0.0,0.0,2.39,5.62,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])(O)O.[K+],1,DB09413,__MONOPOTASSIUM_PHOSPHATE,10632150,Recruiting,,POSTOPERATIVE COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,136.0855,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])(O)O.[Na+],1,DB09449,"__SODIUM_PHOSPHATE,_MONOBASIC",7084130,Completed,,OBSTRUCTIVE SLEEP APNEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,119.977,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB09477,__ENALAPRILAT,4374829,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",C07K5/0222,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,82.0,24.148339801638603,603.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.09,348.3936,106.94,6.0,3.0,2.0,35.82,90.06,8.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,NCT03425747,CHRONIC HYPOPARATHYROIDISM,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Campus Bio-Medico University, Roma, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
[I-].[Na+],1,DB11119,__SODIUM_IODIDE,,Completed,,TRANSIENT HYPOTHYROXINEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,149.8942,0.0,0.0,0.0,0.0,5.07,13.95,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,NCT00398853,TYPE 2 DIABETES,All,"25 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB11256,__LEVOMEFOLIC_ACID,5798338,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,459.4558,198.48,12.0,7.0,3.0,46.56,126.68,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Not Yet Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=[Fe]O[Fe]=O,1,DB11576,__FERRIC_OXIDE,,Completed,,MELASMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,159.687,43.37,2.0,0.0,0.0,7.03,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Cc1cc(CC(C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C)c(O)c(-n2nc3ccccc3n2)c1,1,DB11585,__DROMETRIZOLE_TRISILOXANE,,Completed,,MELASMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.5,501.849,69.4,5.0,1.0,3.0,54.24,137.97,9.0,1.0,0.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0
CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3,1,DB11629,__LAROPIPRANT,US-20030158246-A1,Completed,NCT02153879,TYPE 2 DIABETES MELLITUS|DYSLIPIDEMIA,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitari Sant Joan, Reus, Tarragona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.58,435.89,76.37,4.0,1.0,4.0,42.76,109.33,5.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1
CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3,1,DB11629,__LAROPIPRANT,US-20030158246-A1,Completed,NCT01118598,PCOS,Female,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hull & East Yorkshire Hospitals NHS Trust, Hull, United Kingdom",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.58,435.89,76.37,4.0,1.0,4.0,42.76,109.33,5.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not yet recruiting,NCT04528212,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tanta University Hospital, Tanta, El-Gharbia, Egypt",C09B61/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Unknown status,NCT01052597,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR ABNORMALITIES,All,"35 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"HRH Princess Maha Chakri Sirindhorn Medical Center, Ongkarak, Nakornnayok, Thailand",C09B61/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Unknown status,NCT01052025,TYPE 2 DIABETES|PRE-DIABETES|INSULIN RESISTANCE|CARDIOVASCULAR RISK,All,"35 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"HRH Princess Maha Chakri Sirindhorn Medical Center, Ongkarak, Nakornnayok, Thailand",C09B61/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Recruiting,NCT03917784,PRE-DIABETES,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital General de México Dr. Eduardo Liceaga, Mexico City, Cuauhtémoc, Mexico",C09B61/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,NCT02180334,"DIABETES MELLITUS, TYPE 2",All,"20 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Seoul National University Hospital, Seoul, Korea, Republic of",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Unknown status,NCT02606617,TYPE 2 DIABETES,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Unknown Status,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Terminated,NCT03118713,TYPE 2 DIABETES,All,"19 Years to 74 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site 13, Busan, Korea, Republic of|Site 02, Deagu, Korea, Republic of|Site 11, Guri-si, Korea, Republic of|Site 01, Seoul, Korea, Republic of|Site 05, Seoul, Korea, Republic of|Site 07, Seoul, Korea, Republic of|Site 09, Seoul, Korea, Republic of|Site 12, Suwon-si, Korea, Republic of",A61P3/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,NCT02875821,TYPE 2 DIABETES WITH NON-ALCOHOLIC FATTY LIVER (NAFLD),All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",A61P3/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
C/C(=C(\CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,DB11748,__BENFOTIAMINE,5229390,Unknown status,NCT00446810,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Herz- und Diabeteszentrum NRW, Georgstr. 11, Bad Oeynhausen, North Rhine-Westphalia, Germany",A23L29/045,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.751842953654,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,466.45,155.94,8.0,3.0,2.0,43.14,121.54,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
C/C(=C(\CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,DB11748,__BENFOTIAMINE,5229390,Completed,NCT00437008,ENDOTHELIAL DYSFUNCTION|TYPE 2 DIABETES MELLITUS,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Prevention,"Heart and Diabetes Center NRW, Bad Oeynhausen, Germany",A23L29/045,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.751842953654,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,466.45,155.94,8.0,3.0,2.0,43.14,121.54,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
C/C(=C(\CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,DB11748,__BENFOTIAMINE,5229390,Completed,NCT00565318,DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Isala Klinieken Hospital, Zwolle, Netherlands",A23L29/045,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.751842953654,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,466.45,155.94,8.0,3.0,2.0,43.14,121.54,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,1,DB11793,__NIRAPARIB,8859562,Recruiting,NCT03752216,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon, France|Centre Hospitalier de la Côte Basque, Bayonne, France|CHRU Jean Minjoz, Besançon, France|Clinique Tivoli, Bordeaux, France|Institut Bergonié, Bordeaux, France|Hôpital Fleyriat, Bourg-en-bresse, France|Centre François Baclesse, Caen, France|Centre Maurice Tubiana, Caen, France|Medipole de Savoie, Challes-les-Eaux, France|SASU Centre d'Oncologie et Radiothérapie 37, Chambray-lès-Tours, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard, Grenoble, France|Centre Léon Bérard, Lyon, France|Hôpital Privé Jean Mermoz, Lyon, France|CH Mont-de-Marsan, Mont-de-marsan, France|ICM Val d'Aurelle, Montpellier, France|ORACLE - Centre d'Oncologie de Gentilly, Nancy, France|Centre Antoine Lacassagne, Nice, France|Centre ONCOGARD - Institut de Cancérologie du Gard, Nimes, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Hôpital Cochin, Paris, France|Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France|Centre CARIO - HPCA, Plérin, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Polyclinique Francheville, Périgueux, France|Institut du Cancer Courlancy, Reims, France|Institut Jean Godinot, Reims, France|Centre Hospitalier Saint-Malo, Saint-Malo, France|Clinique Mutualiste de l'Estuaire, Saint-nazaire, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Clinique Pasteur - ONCOSUD, Toulouse, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,1,DB11817,__BARICITINIB,8158616,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,1,DB11824,__TOFOGLIFLOZIN,,Unknown status,NCT02649465,NON-ALCOHOLIC FATTY LIVER DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Disease Control and Homeostasis, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.5,386.444,99.38,6.0,4.0,4.0,41.48,103.33,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,1,DB11824,__TOFOGLIFLOZIN,,Completed,NCT02537834,TYPE 2 DIABETES,All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atsuta-ku, Aichi, Japan|Minato-ku, Aichi, Japan|Kisarazu, Chiba, Japan|Annaka, Gunma, Japan|Naka, Ibaraki, Japan|Sagamihara, Kanagawa, Japan|Kasaoka, Okayama, Japan|Shimono, Tochigi, Japan|Adachi-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.5,386.444,99.38,6.0,4.0,4.0,41.48,103.33,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,1,DB11827,__ERTUGLIFLOZIN,6890898,Not yet recruiting,NCT04167761,CARDIOVASCULAR DISEASES|ATHEROSCLEROSIS|TYPE 2 DIABETES|INSULIN RESISTANCE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Stanford University, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,88.0,34.2347892153842,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.21,436.89,108.61,7.0,4.0,4.0,44.95,109.07,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,1,DB11827,__ERTUGLIFLOZIN,6890898,Withdrawn,NCT03640221,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"35 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cedars-Sinai Medical Center, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,88.0,34.2347892153842,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.21,436.89,108.61,7.0,4.0,4.0,44.95,109.07,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,1,DB11827,__ERTUGLIFLOZIN,6890898,Not yet recruiting,NCT04071626,"HEART FAILURE, DIASTOLIC|DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,88.0,34.2347892153842,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.21,436.89,108.61,7.0,4.0,4.0,44.95,109.07,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,1,DB11827,__ERTUGLIFLOZIN,6890898,Not yet recruiting,NCT04027530,TYPE 2 DIABETES MELLITUS|DIABETIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|RENAL HYPOXIA|RENOPROTECTION|SGLT2 INHIBITOR|ERTUGLIFLOZIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VU University Medical Center, Amsterdam, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,88.0,34.2347892153842,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.21,436.89,108.61,7.0,4.0,4.0,44.95,109.07,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,1,DB11842,__ANGIOTENSIN_II,9572856,Unknown status,NCT00144144,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan",A61K38/085,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,86.2112158360541,2637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.87,1046.1786,408.84,17.0,13.0,4.0,107.02,269.81,29.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,0,1
CN1CC(=O)NC1=N,1,DB11846,__CREATININE,,Terminated,NCT02499185,ACUTE KIDNEY INJURY|ARTERIAL HYPERTENSION|OBESITY|CARDIO VASCULAR DISEASE|DIABETES MELLITUS|CHRONIC LIVER DISEASE|HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,113.1179,56.19,3.0,2.0,1.0,10.74,38.81,0.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
O=C1CSC(=O)N1,1,DB11898,"__2,4-THIAZOLIDINEDIONE",,Completed,NCT02730377,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Alhambra, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Elk Grove, California, United States|Novo Nordisk Investigational Site, Encinitas, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mirada, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Westminster, California, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Seminole, Florida, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Aurora, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Georgetown, Texas, United States|Novo Nordisk Investigational Site, Gonzales, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Missouri City, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Bellevue, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hubli, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Tukums, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adapazari, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.88,117.12,46.17,2.0,1.0,1.0,9.66,25.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C1CSC(=O)N1,1,DB11898,"__2,4-THIAZOLIDINEDIONE",,Completed,NCT02954692,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Turkey, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.88,117.12,46.17,2.0,1.0,1.0,9.66,25.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,1,DB11901,__APALUTAMIDE,8445507,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,73.82492453643809,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,477.44,89.33,4.0,1.0,4.0,43.44,113.6,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(CCOC(=O)OCCN5CCN(S(=O)(=O)c6ccc(OCC)c(-c7nc8c(CCC)nn(C)c8c(=O)[nH]7)c6)CC5)CC4)ccc3OCC)nc12,1,DB11927,__LODENAFIL_CARBONATE,7148350,Completed,NCT01180283,ERECTILE DYSFUNCTION,Male,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil|Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil|Hospital Ipiranga, São Paulo, Brazil",A61K47/56,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,64.16558861578261,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.65,1035.21,253.79,16.0,2.0,8.0,109.77,294.85,20.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1
Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,1,DB11950,__TENELIGLIPTIN,7074794,Unknown status,NCT02512523,TYPE 2 DIABETES,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HANDOK Inc., Seoul, Korea, Republic of",C07D401/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,59.0073718146163,36.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,426.57800000000003,56.64,5.0,1.0,5.0,46.91,121.78,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1
Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,1,DB11950,__TENELIGLIPTIN,7074794,Recruiting,NCT02449330,"DIABETES MELLITUS, TYPE 2",All,"20 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"National Cerebral and Cardiovascular Center, Suita, Japan",C07D401/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,59.0073718146163,36.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,426.57800000000003,56.64,5.0,1.0,5.0,46.91,121.78,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,1,DB11979,__ELAGOLIX,6872728,Not yet recruiting,NCT04060992,OVULATION; FAILURE OR LACK OF,Female,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,86.0,25.692519353580106,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.68,631.6,99.18,6.0,2.0,4.0,59.44,156.06,12.0,1.0,0.0,0.0,1,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,NCT02906709,TYPE 2 DIABETES,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,NCT00960973,DIABETES|PREDIABETIC STATE,Male,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Seoul National University Medical School, Seoul, Korea, Republic of",A23L3/44,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,1,DB12160,__BUCILLAMINE,4241086,Unknown Status,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,14.6204234173186,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.52,223.31,66.4,3.0,4.0,0.0,22.09,54.7,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Unknown Status,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Unknown Status,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB12407,__IOBITRIDOL,6437010,Completed,NCT01254552,TYPE 2 DIABETES MELLITUS|CORONARY ATHEROSCLEROSIS,All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Asan Medical Center, Seoul, Korea, Republic of",B01J49/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,21.8813527998521,81.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,835.169,191.1,9.0,7.0,1.0,61.59,156.01,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,NCT03202563,TYPE 2 DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Unknown status,NCT02500329,ENDOTHELIAL FUNCTION|TYPE 2 DIABETES|GEMIGLIPTIN|ACARBOSE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boramae medical center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,1,DB12417,__ANAGLIPTIN,EP-2275108-A1,Completed,NCT02330406,DIPEPTIDYL-PEPTIDASE 4 INHIBITORS|LDL CHOLESTEROL|GLYCOSYLATED HEMOGLOBIN|DIABETES MELLITUS|CORONARY DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Cardiovascular Medicine, Tomishiro Central Hospital, Tomishiro, Okinawa, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,61.89860161399611,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.7,383.45599999999996,115.42,6.0,2.0,3.0,40.91,114.17,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1
O=[O+][O-],1,DB12510,__OZONE,,Unknown Status,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
O=C(/C=C/C=C/c1ccc2c(c1)OCO2)N1CCCCC1,1,DB12582,__PIPERINE,4131687,Recruiting,,PRE-DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C41/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,10.940676399926,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,285.3377,38.77,3.0,0.0,3.0,32.32,82.9,3.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,1,DB12625,__EVOGLIPTIN,US-20100120790-A1,Enrolling by invitation,NCT03910361,TYPE2 DIABETES|NON-ALCOHOLIC FATTY LIVER DISEASE,All,"19 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,41.5285734820016,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.29,401.43,84.66,4.0,2.0,2.0,39.21,97.43,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,1,DB12625,__EVOGLIPTIN,US-20100120790-A1,Completed,NCT02974504,TYPE 2 DIABETES,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,41.5285734820016,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.29,401.43,84.66,4.0,2.0,2.0,39.21,97.43,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,1,DB12625,__EVOGLIPTIN,US-20100120790-A1,Unknown status,NCT02587975,"DIABETES MELLITUS, TYPE 2|OSTEOPOROSIS",Female,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dongguk University Ilsan Hospital, Goyang, Gyeonggi, Korea, Republic of",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,41.5285734820016,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.29,401.43,84.66,4.0,2.0,2.0,39.21,97.43,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,1,DB12625,__EVOGLIPTIN,US-20100120790-A1,Not yet recruiting,NCT04521452,CAVD,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Asan Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,41.5285734820016,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.29,401.43,84.66,4.0,2.0,2.0,39.21,97.43,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,1,DB13178,__INOSITOL,3959321,Unknown status,NCT01511835,GESTATIONAL DIABETES,Female,20 Years to 45 Years   (Adult),Other,,"AGUNCO, Rome, Italy",C07C53/126,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,24.411178874309503,5307.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,121.38,6.0,6.0,1.0,16.14,35.78,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,1,DB13178,__INOSITOL,3959321,Unknown status,NCT01246310,DEPRESSION|PCOS,Female,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Agunco, Rome, Italy",C07C53/126,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,24.411178874309503,5307.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,121.38,6.0,6.0,1.0,16.14,35.78,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C(=O)O)c1ccc2c(c1)Cc1cccnc1O2,1,DB13514,__PRANOPROFEN,3931205,Completed,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,255.2686,59.42,3.0,1.0,3.0,26.86,70.02,2.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,1,DB13679,__DEXCHLORPHENIRAMINE,4619934,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.6717797080022,310.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.74,274.79,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00546000,ATOPIC DERMATITIS,All,3 Months to 12 Months   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre for Health Care Medical Associates, Poway, California, United States|Rady Children's Hospital, San Diego, San Diego, California, United States|University of Miami, Dept. of Dermatology, Miami, Florida, United States|Adult & Pediatric Dermatology, Overland Park, Kansas, United States|Dermatology Center for Children and Young Adults, Eagan, Minnesota, United States|Central Dermatology, Saint Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Paddington Testing Company, Inc, Philadelphia, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB13919,__CANDESARTAN,5605919,Unknown status,NCT00328302,"DIABETES, TYPE I",All,"17 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Childrens Hospital, Karolinska University Hospital, Huddinge, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB13919,__CANDESARTAN,5605919,Unknown status,NCT00192803,NIDDM,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,"Internal Ward ""A"", Rambam Medical Center, Haifa, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Not yet recruiting,NCT04061200,TYPE 2 DIABETES WITH RENAL MANIFESTATIONS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Steno Diabetes Center Copenhagen, Gentofte, Denmark",A61M5/31593,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Not yet recruiting,NCT04538352,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",A61M5/31593,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Recruiting,NCT03596450,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Garden Grove, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Milpitas, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Napa, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Pomona, California, United States|Novo Nordisk Investigational Site, San Jose, California, United States|Novo Nordisk Investigational Site, Toluca Lake, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Tulare, California, United States|Novo Nordisk Investigational Site, Visalia, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Englewood, Colorado, United States|Novo Nordisk Investigational Site, Danbury, Connecticut, United States|Novo Nordisk Investigational Site, Hamden, Connecticut, United States|Novo Nordisk Investigational Site, Milford, Connecticut, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Blue Ridge, Georgia, United States|Novo Nordisk Investigational Site, Buford, Georgia, United States|Novo Nordisk Investigational Site, Columbus, Georgia, United States|Novo Nordisk Investigational Site, LaGrange, Georgia, United States|Novo Nordisk Investigational Site, Lilburn, Georgia, United States|Novo Nordisk Investigational Site, Locust Grove, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Sandersville, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Stockbridge, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Swainsboro, Georgia, United States|Novo Nordisk Investigational Site, Waycross, Georgia, United States|Novo Nordisk Investigational Site, Anderson, Indiana, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Berne, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Fort Wayne, Indiana, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Mishawaka, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, New Albany, Indiana, United States|Novo Nordisk Investigational Site, Richmond, Indiana, United States|Novo Nordisk Investigational Site, Ashland, Kentucky, United States|Novo Nordisk Investigational Site, Covington, Kentucky, United States|Novo Nordisk Investigational Site, Owensboro, Kentucky, United States|Novo Nordisk Investigational Site, Paris, Kentucky, United States|Novo Nordisk Investigational Site, Richmond, Kentucky, United States|Novo Nordisk Investigational Site, Belfast, Maine, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Columbia, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Springfield, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, Great Neck, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Yonkers, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Blanchester, Ohio, United States|Novo Nordisk Investigational Site, Canton, Ohio, United States|Novo Nordisk Investigational Site, Carlisle, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, McMinnville, Tennessee, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Arlington, Virginia, United States|Novo Nordisk Investigational Site, Chatham, Virginia, United States|Novo Nordisk Investigational Site, Colonial Heights, Virginia, United States|Novo Nordisk Investigational Site, Daleville, Virginia, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Falls Church, Virginia, United States|Novo Nordisk Investigational Site, Hampton, Virginia, United States|Novo Nordisk Investigational Site, Lynchburg, Virginia, United States|Novo Nordisk Investigational Site, Newport News, Virginia, United States|Novo Nordisk Investigational Site, Portsmouth, Virginia, United States|Novo Nordisk Investigational Site, Radford, Virginia, United States|Novo Nordisk Investigational Site, South Boston, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Warrenton, Virginia, United States|Novo Nordisk Investigational Site, Williamsburg, Virginia, United States|Novo Nordisk Investigational Site, Green Bay, Wisconsin, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States",A61M5/31593,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,NCT04189848,"HEALTHY VOLUNTEERS|DIABETES MELLITUS, TYPE 2|OVERWEIGHT|OBESITY",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Groningen, Netherlands",A61M5/31593,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Recruiting,NCT03985384,TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States",A61M5/31593,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Not Yet Recruiting,,NON-ALCOHOLIC FATTY LIVER DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,1,DB13943,__TESTOSTERONE_CYPIONATE,5340584,Recruiting,NCT03325647,KLINEFELTER SYNDROME,Male,31 Days to 90 Days   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Children's Hospital Colorado, Aurora, Colorado, United States",5,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,18.661574159633602,315.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,412.61400000000003,43.37,2.0,0.0,5.0,49.87,119.36,5.0,0.0,1.0,0.0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,1,DB13943,__TESTOSTERONE_CYPIONATE,5340584,Recruiting,NCT04439799,"HYPOGONADISM, MALE",Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Miller School of Medicine, Miami, Florida, United States",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,18.661574159633602,315.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,412.61400000000003,43.37,2.0,0.0,5.0,49.87,119.36,5.0,0.0,1.0,0.0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,1,DB13943,__TESTOSTERONE_CYPIONATE,5340584,Recruiting,,TESTICULAR HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,18.661574159633602,315.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,412.61400000000003,43.37,2.0,0.0,5.0,49.87,119.36,5.0,0.0,1.0,0.0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13944,__TESTOSTERONE_ENANTHATE,8021335,Completed,NCT01601327,IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM,Male,18 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gulhane School of Medicine Dep. of Endocrine and Metabolism, Ankara, Turkey|Gulhane School of Medicine Dep. of Endocrinology and Metabolism, Ankara, Turkey",A61M5/30,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13944,__TESTOSTERONE_ENANTHATE,8021335,Completed,,SARCOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,NCT00421460,HYPOGONADISM|ERECTILE DYSFUNCTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|Ramathibodi Hospital, Rajthevee, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Not yet recruiting,NCT03851627,"FATTY LIVER|OBESITY|TYPE2 DIABETES MELLITUS|HYPOGONADISM, MALE",Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,NCT03792321,"HYPOGONADISM, MALE|DIABETES MELLITUS, TYPE 2|OBESITY",Male,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Not yet recruiting,NCT03721497,BARIATRIC SURGERY CANDIDATE|MALE HYPOGONADISM|MUSCLE LOSS,Male,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,5,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,NCT03126656,HYPOGONADISM|CHRONIC HEART FAILURE,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Not Yet Recruiting,,BARIATRIC SURGERY CANDIDATE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Recruiting,,HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,NCT02352597,POLYCYSTIC OVARIES,Female,20 Years to 37 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Not yet recruiting,NCT04002635,"INFERTILITY, FEMALE|POLYCYSTIC OVARY SYNDROME|IVF|OVULATION DISORDER",Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,NCT01500863,OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Instituto Valenciano de Infertilidad, Madrid, Spain",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB13981,__NOMEGESTROL_ACETATE,4544555,Terminated,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",C07J7/0045,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,36.1403724922483,86.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.46,370.48900000000003,60.44,3.0,0.0,4.0,41.78,104.18,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,"Active, not recruiting",NCT01953107,OVARIAN CANCER|CERVICAL CANCER|UTERINE CANCER|ANEMIA,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Odette Cancer Centre, Toronto, Ontario, Canada",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT01278290,CENTRAL PRECOCIOUS PUBERTY|SEXUAL PRECOCITY,Female,3 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Ciudad Autónoma de Buenos Aires, Argentina",,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00240253,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Phoenix, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Salinas, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT02866786,PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Obstetrics & Gynecology, Cuttack, Odisha, India",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT01103518,AMENORRHEA|DYSMENORRHEA|MENSTRUATION DISTURBANCES|HYPERANDROGENISM,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital das Clínicas de Teresópolis, Teresópolis, Rio de Janeiro, Brazil",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00376064,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT02652884,TRANSIENT HYPOPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00211939,"CALCINOSIS|ARTERIOSCLEROSIS|HYPERPARATHYROIDISM, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Sciences Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT00677664,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of Sao Paulo, Sao Paulo, SP, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT02340013,INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"First Steps Fertility, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT03963752,IDIOPATHIC PRECOCIOUS PUBERTY,Female,5 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT03477929,INFERTILITY/STERILITY,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale Bernabeo, Ortona, Chieti, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00805935,POLYCYSTIC OVARIAN SYNDROME|INFERTILITY,Female,18 Years to 42 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States|Women's Medical Research Group LLC, Florida, Clearwater, Florida, United States|Fertility Center of Illinois, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Women & Infants' Hospital of RI, Providence, Rhode Island, United States|Center for Assisted Reproduction, Bedford, Texas, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00349258,OVARIAN HYPERSTIMULATION SYNDROME,Female,20 Years to 39 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Center for Advanced Reproductive Services, UCHC, Farmington, Connecticut, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01634321,CENTRAL PRECOCIOUS PUBERTY,All,4 Years to 9 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ajou University medical center, Soo-won, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB14681,__CORTISONE,3934580,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",A61F6/142,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,14.521858765067,2498.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,360.444,91.67,5.0,2.0,4.0,38.95,96.47,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,1,DB14726,__DABIGATRAN,6087380,Unknown status,NCT02935855,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Policlinico San Matteo, Pavia, Italy",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,1,DB14726,__DABIGATRAN,6087380,Recruiting,NCT03789695,ATRIAL FIBRILLATION|T2D|CHRONIC KIDNEY DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Recruiting,NCT03475589,STAGE IV CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Completed,NCT03384511,MALIGNANCIES|STOMACH CANCER|NON-SMALL CELL LUNG CANCER|ESOPHAGEAL CANCER|BREAST CANCER|OVARY CANCER|CERVICAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,DB14806,__AVEXITIDE,,Recruiting,,INSULIN SECRETION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,3369.8,1390.28,53.0,45.0,7.0,344.43,843.43,108.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB14936,__MENAQUINONE_6,6190695,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,24.37832399022561,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.01,580.8821,34.14,2.0,0.0,2.0,74.54,193.11,17.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@]1(C(=O)O)C[C@@H](F)C1,1,DB15237,__FLUCICLOVINE,,Recruiting,NCT03349463,CERVICAL CANCER|ENDOMETRIAL CANCER|OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Loyola University Medical Center, Maywood, Illinois, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,1,DB15323,__TRELAGLIPTIN,WO-2005095381-A1,Completed,NCT02771093,TYPE 2 DIABETES,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Naka-city, Ibaragi, Japan",A61P13/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,161.0,32.7488,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.83,357.389,93.67,5.0,1.0,3.0,35.56,104.48,3.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,1,DB15323,__TRELAGLIPTIN,WO-2005095381-A1,Recruiting,NCT04374864,DIABETES,All,25 Years to 39 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"The British University in Egypt, Cairo, El Sherouk, Egypt",A61P13/08 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,161.0,32.7488,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.83,357.389,93.67,5.0,1.0,3.0,35.56,104.48,3.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,1,DB15350,__D-CHIRO-INOSITOL,6153582,Completed,NCT01514942,PCOS,Female,20 Years to 40 Years   (Adult),Other,,"Istituto di Patologia Ostetrica e Ginecologica, Catania, Italy",A01N1/02,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,24.77258259923201,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,121.38,6.0,6.0,1.0,15.95,35.78,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,1,,_FLUCICLOVINE_F18,,Recruiting,NCT03349463,CERVICAL CANCER|ENDOMETRIAL CANCER|OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Loyola University Medical Center, Maywood, Illinois, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
C[C@]1(F)C[C@@](N)(C(=O)O)C1,1,,_FLUCICLOVINE,,Recruiting,NCT03349463,CERVICAL CANCER|ENDOMETRIAL CANCER|OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Loyola University Medical Center, Maywood, Illinois, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O,1,,_REGADENOSON,,Completed,NCT01019486,CORONARY ARTERY DISEASE|TYPE 1 DIABETES MELLITUS,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C([O-])[C@@H]1CCC(O)=N1.O=C([O-])[C@@H]1CCC(O)=N1.[Mg+2],1,,_MAGNESIUM_PIDOLATE,WO-1997038701-A1,Completed,NCT01181830,FAMILY HISTORY OF METABOLIC SYNDROME|FAMILY HISTORY OF DIABETES,All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Azienda Ospedaliera Universitaria Integrata - Division of Internal Medicine C, Verona, VR, Italy",A61K33/06,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1CNCCc2ccc(Cl)cc21.Cl,1,,_LORCASERIN_HYDROCHLORIDE,US-20090143576-A1,Completed,NCT02019264,CARDIOVASCULAR DISEASE|HIGH CARDIOVASCULAR RISK|OBESITY|OVERWEIGHT|TYPE 2 DIABETES,All,"40 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|UAB Medical Center, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Mobile Heart Specialists, PC, Mobile, Alabama, United States|Alaska Heart Institute, Anchorage, Alaska, United States|Connect Clinical Research Center, LCC, Chandler, Arizona, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Heart, PLLC, Glendale, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Clinical Research Alliance, Alhambra, California, United States|Central Cardiology, Bakersfield, California, United States|Cardiovascular Research Foundation of Southern Cal, Beverly Hills, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|San Diego Costal Endocrinology Group AMC, Chula Vista, California, United States|John Muir Physician Network Clinical Research Cent, Concord, California, United States|Medical Group of Encino, Encino, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|California Heart Specialists, Huntington Beach, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|La Mesa Cardiac Center, La Mesa, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Metabolic Clinic and Research Center, Los Angeles, California, United States|Beverly Hills Cardiology, Los Angeles, California, United States|VA Greater Los Angeles Health Care System, Los Angeles, California, United States|Clinical Interventions Research Institute, Mission Viejo, California, United States|Brigid Freyne MD Inc, Murrieta, California, United States|Valley Clinical Trials Inc, Northridge, California, United States|Carr Cardiology, Oceanside, California, United States|Northern California Clinical Research Center, Redding, California, United States|Sharp Rees-Stealy Medical Group, Inc., San Diego, California, United States|University of California San Diego, San Diego, California, United States|Ritchken and First MD's, San Diego, California, United States|West Coast Research LLC, San Ramon, California, United States|Coastal Multi-Specialty Research, Santa Ana, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Ronald Chochinov, MD, Ventura, California, United States|Ventura Cardiology Consultants, Ventura, California, United States|Infosphere Clinical Research, West Hills, California, United States|UCH-MHS Cardiac Research, Colorado Springs, Colorado, United States|Creekside Endocrine Associates PC, Denver, Colorado, United States|New West Physicians, PC, Golden, Colorado, United States|University of Colorado Health, Loveland, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Clinical Research Works, Bristol, Bristol, Connecticut, United States|Cardiology Associates of Fairfield County, Norwalk, Norwalk, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Trumbull, Connecticut, United States|Connecticut Heart and Vascular Center, Trumbull, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Red Clay Research, Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Aventura Heart Center, Aventura, Florida, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Meridien Research, Bradenton, Florida, United States|NOVA Southeastern University, Bradenton, Florida, United States|Bay Area Cardiology, Brandon, Florida, United States|Meridien Research, Brooksville, Brooksville, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Holy Cross Medical Group, Coral Springs, Florida, United States|Cardiology Research Associates, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Asclepius Medical Research, Doral, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Integrative Research Associates, Inc., Fort Lauderdale, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|George E. Platt, M.D., Green Cove Springs, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Larry K. Levinson, D.O., P.A., Hollywood, Florida, United States|Research Physicians Network Alliance, Hollywood, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Florida- Jacksonville, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Pharmax Research Clinic, Inc, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|United Clinical Research Corp., Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|South Florida Research Group LLC, Miami, Florida, United States|South Florida Research Solutions, Miramar, Florida, United States|Southwest Florida Research, Naples, Florida, United States|Ocala Research Institute, Inc, Ocala, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Cardiology Partners Clinical Research Institute, Palm Beach Gardens, Florida, United States|Palm Beach Gardens Research Center, Palm Beach Gardens, Florida, United States|Research Physicians Network Alliance, Pembrok, Pembroke Pines, Florida, United States|South Florida Research Solutions, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Columbia Primary Care, LLC d/b/a Heart and Health Institute, Plantation, Florida, United States|St Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Brevard Cardiovascular Research Associates Inc, Rockledge, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Safety Harbor, Florida, United States|Bayfront Health St. Petersburg, Research, Saint Petersburg, Florida, United States|Meridien Research - St. Petersburg, Saint Petersburg, Florida, United States|Professional Health Care of Pinellas, INC, Saint Petersburg, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Springfield Medical Center, Springfield, Florida, United States|Advanced Clinical Research Group, Stuart, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Healthpoint Medical Group, Inc, Tampa, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Lovelace Scientific Research, Venice, Florida, United States|Indian River Medical Center-Cardiology, Vero Beach, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cleveland Clinic Foundation, West Palm Beach, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Endocrinology, Atlanta, Georgia, United States|Rockdale Medical-Research Associates, Conyers, Georgia, United States|Atlanta Heart Specialists, Cumming, Georgia, United States|Urban Family Practice Associates/Clinical Research Advantage, Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Herman Clinical Research LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, Tucker, Georgia, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Consultants in Cardiovascular Medicine, Elmhurst, Illinois, United States|Clinical Investigation Specialists, Inc. in Gurnee, Gurnee, Illinois, United States|Advanced CardioVascular Consultants, SC, Rock Island, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of IN, LLC, Avon, Avon, Indiana, United States|Premier Healthcare, LLC, Bloomington, Indiana, United States|Deaconess Clinic, Inc., Evansville, Indiana, United States|American Health Network of IN, LLC, Franklin, Franklin, Indiana, United States|American Health Network of IN, LLC, Greenfield, Greenfield, Indiana, United States|American Health Network - Thomas Moretto, MD, Indianapolis, Indiana, United States|Medical Consultants PC, Muncie, Indiana, United States|American Health Network of IN, LLC, Muncie, Indiana, United States|Cardiology Associates of Northwest Indiana, P.C, Munster, Indiana, United States|The University of Iowa, College of Public Health, Iowa City, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Norton Heart Specialists, Louisville, Kentucky, United States|Norton Heart Specialists, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Central Maine Medical Center, Auburn, Maine, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Eastern Maine Medical Center Northeast Cardiology Associates, Bangor, Maine, United States|Southern Maine Health Care/Maine Medical Center Research Ins, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Medstar Cardiology Associates, Annapolis, Maryland, United States|Chesapeake Cardiovascular Associates, GBMC, Baltimore, Maryland, United States|Clinical Research, Inc, Baltimore, Maryland, United States|Medstar Union Memorial Heart Specialists, Baltimore, Maryland, United States|Medstar Union Memorial Hospital, Baltimore, Maryland, United States|Spectrum Clinical Research, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Shahid Saeed MD, PC, Baltimore, Maryland, United States|Maryland Heart Associates, LLC, Glen Burnie, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Lutherville Personal Physicians, Lutherville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Endocrine & Metabolic Consultants, Rockville, Maryland, United States|Lutherville Personal Physicians, Towson, Maryland, United States|Overlea Personal Physicians, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|MGH Weight Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New England Center for Clinical Research, IMCA, Fall River, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|ActivMed Practices, Methuen, Massachusetts, United States|Partners Community Physicians Organization, Natick, Massachusetts, United States|Partners Community Physicians Organization, Needham, Massachusetts, United States|Endeavor Medical Research PLC, Alpena, Michigan, United States|Cadillac Clinical Research, LLC, Cadillac, Michigan, United States|Westside Family Medical Center, PC, Kalamazoo, Michigan, United States|Cardiology Consultants of East Michigan, Lapeer, Michigan, United States|Marquette General Heart and Vascular Institute, Marquette, Michigan, United States|MidMichigan Medical Center, Midland, Michigan, United States|Nisus Research at McLaren Northern Michigan Hospital, Petoskey, Michigan, United States|Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States|Remedica LLC, Rochester, Michigan, United States|Michigan CardioVascular Institute, Saginaw, Michigan, United States|American Center for Clinical Trials, Southfield, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Minneapolis Heart Institute Foundation, Baxter, Minnesota, United States|Essentia Institute of Rural Health, Duluth, Minnesota, United States|MNCOME Clinic, Eagan, Minnesota, United States|Radiant Research, Inc., Edina, Minnesota, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Coast Cardiovascular Consultants PLLC, Gulfport, Mississippi, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|Diabetes & Endocrinology Specialists, Inc., Chesterfield, Missouri, United States|BodyAesthetic Research Center, Washington, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Montana Health Research Institute, Inc., Billings, Montana, United States|Glacier View Cardiology PC, Kalispell, Montana, United States|Internal Medical Associates of Grand Island, PC, Grand Island, Nebraska, United States|Clinical Research Advantage / Rita Chuang, M.D., Henderson, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Medicor Cardiology, PA, Bridgewater, New Jersey, United States|Advanced Heart Care, Bridgewater, New Jersey, United States|UmiMed Center LLC, East Brunswick, New Jersey, United States|Cardiovascular Associates of the Delaware Valley, Elmer, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Cardiovascular Associates of the Delaware Valley P, Haddon Heights, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|Rutgers New Jersey Medical School, Mine Hill, New Jersey, United States|Cardiovascular Associates Delaware Valley Sewell, Sewell, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|New Mexico Heart Institute, PA, Albuquerque, New Mexico, United States|Albany College of Medicine, Division of Endocrinology, Albany, New York, United States|Capital Cardiology Associates, Albany, New York, United States|United Medical Associates, PC, Binghamton, New York, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Long Island Heart Associates, Mineola, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Weill Cornell Medical College, New York, New York, United States|DiGiovanna Institute for Medical Education, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Northwell Health Physician Partners Cardiology, Southampton, New York, United States|Capital Cardiology Associates, Troy, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|Clinical Trials of America Inc., Cary, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Clinical Trials of America Inc. Hickory, Hickory, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Clinical Trials of America, Inc., Lenoir, North Carolina, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aultman Hospital, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research, Cincinnati, Ohio, United States|Delaware Research Group, LLC, Delaware, Ohio, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Community Health Care, Massillon, Ohio, United States|Apex Medical Research Inc., Springfield, Ohio, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Oklahoma Heart Institute, Tulsa, Oklahoma, United States|Vital Prospects Clinical Research Institute PC, Tulsa, Oklahoma, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Geisinger Health Clinic, Danville, Pennsylvania, United States|Geisinger Health System, Danville, Pennsylvania, United States|Doylestown Health Cardiology a Division of Doylestown Health, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Liberty Family Practice, Erie, Pennsylvania, United States|Endocrine Clinical Research LLC, Feasterville, Pennsylvania, United States|Joseph Lamantia, DO, Indiana, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Lycoming Internal Medicine, Inc., Jersey Shore, Pennsylvania, United States|Berkley Hills Clinicals, Johnstown, Pennsylvania, United States|Ilumina Clinical Associates, Johnstown, Johnstown, Pennsylvania, United States|Joseph Lamantia, DO, Johnstown, Pennsylvania, United States|Comprehensive Cardiology Consultants, Langhorne, Pennsylvania, United States|Detweiler Family Medicine and Associates PC, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Capital Area Research LLC, Newport, Pennsylvania, United States|Endocrine Metabolic Associates, Philadelphia, Pennsylvania, United States|Pottstown Medical Specialists, Inc. (PMSI), Pottstown, Pennsylvania, United States|Geisinger Clinic, Scranton, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Radiant Research, Inc., Greer, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Brown Clinic, PLLP, Watertown, South Dakota, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Research Associates of Jackson, Jackson, Tennessee, United States|Kore Cardiovascular Research, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Wellmont CVA Heart Institute, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Wellmont CVA Heart Institute, Kingsport, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Cardiology Wellness Center, Nashville, Tennessee, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Adriana Pop-Moody MD Clinic, PA, Corpus Christi, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Odilon Alvarado, M.D., Fort Worth, Texas, United States|Texas Health Physicians Group Fort Worth, Fort Worth, Texas, United States|Tand R Clinic, PA, Fort Worth, Texas, United States|San Gabriel Clinical Research, LLC, Georgetown, Texas, United States|Angiocardiac Care of Texas PA, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|West Houston Area Clinical Trial Consultants, LLC, Houston, Texas, United States|Endocrine and Psychiatry Center, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|Texas Cardiology Associates of Houston, Kingwood, Texas, United States|Jalil Aziz Khan M.D., P.A., Lewisville, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Medical Clinic of North Texas, Plano, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|Texas Diabetes, Round Rock, Texas, United States|Physician PrimeCare Research Institute, PLLC, San Antonio, Texas, United States|Cardiology Clinic of San Antonio, San Antonio, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Cardiovascular Associates of East Texas, Tyler, Texas, United States|Bay Area Total Health Medical Group, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Alexandria Clinical Research, LLC, Alexandria, Virginia, United States|Washington Center for Weight Management and Resear, Arlington, Virginia, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Cardiology Consultants of Danville, Inc., Danville, Virginia, United States|Danville Internal Medicine, Inc, Danville, Virginia, United States|Virginia Heart, Falls Church, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|INOVA Health Care Services, Manassas, Virginia, United States|Burke Internal Medicine and Research, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Health Research of Hampton Roads - Norfolk, Inc., Norfolk, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Clinical Research Partners, Richmond, Virginia, United States|Virginia Cardiovascular Specialists, Richmond, Virginia, United States|National Clinical Research-Richmond, Inc, Richmond, Virginia, United States|Selma Medical Associates, Winchester, Virginia, United States|Larry D. Stonesifer, MD, Inc PS, Federal Way, Washington, United States|Seattle Women's, Seattle, Washington, United States|Rowan Research Inc., Spokane, Washington, United States|MultiCare Research Institute, Tacoma, Washington, United States|Universal Research Group, Tacoma, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Prevea Clinic, Inc, Green Bay, Wisconsin, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Meriter hospital Inc., DBA: UnityPoint Health-Meriter Heart, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Gosford Hospital, Cardiology Clinical Trials, Gosford, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Illawarra Shoalhaven Local Health District, Clinical Trial and Research Unit, Wollongong, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Core Research Group, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Cardiology Research Department, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Endocrinology Department, Herston, Queensland, Australia|HeartCare Partners Clinical Research Unit, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Gold Coast Hospital, Cardiovascular Research Centre, Southport, Queensland, Australia|New Royal Adelaide Hospital, Cardiology Department, Adelaide, South Australia, Australia|Adelaide Medical Research, Ashford, South Australia, Australia|Lyell McEwin Hospital, Department of Cardiology, Elizabeth Vale, South Australia, Australia|Heart and Vascular Institute, Fullarton, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Geelong Cardiology Research Unit, Barwon Health, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Department of Medicine, Boronia Centre, Heidelberg Heights, Victoria, Australia|Avenue Cardiovascular Centre, Saint Kilda East, Victoria, Australia|Joondalup Cardiovascular Trials Foundation Inc, Joondalup, Western Australia, Australia|Fiona Stanley Hospital, Cardiology Research Department,CDO11, Murdoch, Western Australia, Australia|South Australian Medical Research Inst, Centre for Clinical Research, Adelaide, Australia|The Partners Clinical Research Centre, Nassau, Bahamas|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Nova Scotia Health Authority /QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|LMC Diabetes & Endocrinology - Brampton, Brampton, Ontario, Canada|McMaster University, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Aviva Clinical Trial Group In., Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Joanne F. Liutkus Medicine Professional Corp., Cambridge, Ontario, Canada|Saul Vizel Professional Medicine Corporation, Vizel Cardiac Research, Cambridge, Ontario, Canada|LMC Diabetes & Endocrinology (Etobicoke), Etobicoke, Ontario, Canada|Wharton Medical Clinic Clinical Trials Group Inc., Hamilton, Ontario, Canada|Saint Josephs Health Care London, London, Ontario, Canada|LMC Diabetes & Endocrinoly, Markham, Ontario, Canada|New Market Cardiology Research Group, Newmarket, Ontario, Canada|Dr. Michael Heffernan, Oakville, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|Dr. Cha, Oshawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Dr. Dinkar Shukla Professional Medicine Corporation, Sudbury, Ontario, Canada|Dr Roger Labonte Professional Medicine Corp, Sudbury, Ontario, Canada|LMC Diabetes & Endocrinology (Thornhill), Thornhill, Ontario, Canada|JJ DIG Research Ltd., Toronto, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St Michael's Hospital Health Centre, Toronto, Ontario, Canada|ViaCar Recherche Clinique, Brossard, Quebec, Canada|Q&T Research Outaouais Inc., Gatineau, Quebec, Canada|ViaCar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|Manna Research Inc, Levis, Quebec, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Centre hospitalier régional de Lanaudière, Saint-Charles-Borromee, Quebec, Canada|Recherche Clinique London, Sherbrooke, Quebec, Canada|CardioVasc HR, Inc., St Jean sur Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc., St-Lambert, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Ville Saint-Laurent, Quebec, Canada|Biomedica Research Group, Providencia, Santiago, Chile|Sociedad Medica Cardiologica El Llano, San Miguel, Santiago, Chile|Hospital Regional Concepcion, Concepcion, Chile|Cardiocob, Santiago, Chile|Servicios Medicos Godoy Ltda., Santiago, Chile|Ccbr Cecim, Santiago, Chile|Centro Investigacion Clinica del Sur, Temuco, Chile|CECMI Ltda., Temuco, Chile|ICLE, Guadalajara, Jalisco, Mexico|Private Medical Practice, Guadalajara, Jalisco, Mexico|IMED Clin Trials, Monterrey, Nuevo Leon, Mexico|Cardiolink ClinTrials S.C., Monterrey, Nuevo Leon, Mexico|Centro de Estudios Clinicos y Especialidades Medicas S.C., Monterrey, Nuevo Leon, Mexico|Hospital de Angeles Xalapa, Xalapa, Veracruz, Mexico|Fundacion Cardiovascular de Aguascalientes, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Mentrials S.A.de C.V., Distrito Federal, Mexico|North Shore Hospital-Cardiology Research, Milford, Auckland, New Zealand|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital - Diabetes Clinic, Takapuna, Auckland, New Zealand|Christchurch Hospital, Lipids, Christchurch, Canterbury, New Zealand|Christchurch Hospital, Cardiology Research, Christchurch, Canterbury, New Zealand|Dunedin Hospital, Dunedin, Otago, New Zealand|Taranaki Base Hospital, New Plymouth, Taranaki, New Zealand|Hutt Hospital, Cardiology Dept, Lower Hutt, Wellington, New Zealand|Auckland City Hospital, Auckland, New Zealand|Hawkes Bay Regional Hospital, Hastings, New Zealand|Nelson Hospital, Cardiology Department, Nelson, New Zealand|Lakeland Clinical Trials, Rotorua, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Indywidualna Specjalistyczna Praktyka Lekarska, Bezrzecze, Poland|NZOZ ""Eskulap"", Biala Rawska, Poland|Podlaski Osrodek Kardiologii Janusz Korecki, Białystok, Poland|Centrum Medyczne KERmed, Bydgoszcz, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|Nzoz ""Mada-Med"", Chorzów, Poland|DIABET Centrum Medyczne s. c., Chrzanów, Poland|ISPL w Dziedzinie Kardiologii lek.med. Krzysztof Cymerman, Gdynia, Poland|NZOZ SCBK ProCordis, Gdynia, Poland|Gabinet Kardiologiczno-Internistyczny, Gdynia, Poland|Praktyka Lekarska dr n. med. Marek Bronisz, Inowroclaw, Poland|Piotr Mader Diabetic Clinic NZOZ PD-I, Kamieniec Ząbkowicki, Poland|NZOZ Eskulap SC, Koluszki, Poland|Ewa Mirek-Bryniarska Specjalistyczna Praktyka Lekarska, Kraków, Poland|LANDA' Specjalistyczne Gabinety Lekarskie, Kraków, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno, Kraków, Poland|Nzoz Cardiamed, Legnica, Poland|""CenterMed Lublin"" Sp. z o.o., Lublin, Poland|Indywidualna Praktyka Lekarska, Mrągowo, Poland|Zechowicz MEDEUSZ-PLUS, Olsztyn, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|NZOZ NEURO-KARD ""Ilkowski i Partnerzy"", Poznań, Poland|Specjalistyczna Przychodnia Lekarska MEDIKARD (SPL Medikard), Płock, Poland|Specjalistyczny Gabinet Lekarski, Tarnów, Poland|Lecznice Citomed Sp. z o.o., Toruń, Poland|Praktyka Lekarska Pawlowicz Lidia, Toruń, Poland|Centrum Medyczne AMED, Warszawa, Poland|Centrum Badawcze Wspolczesnej Terapii, Warszawa, Poland|SNZOZ Fundacji PROCLINICA, Warszawa, Poland|Centrum Zdrowia Wierzchoslawice, Wierzchosławice, Poland|Regionalna Poradnia Diabetologiczna, Wroclaw, Poland|Specjalistyczne Gabinety Lekarskie ""Medicor PLUS"", Włocławek, Poland|NZOZ ALL-MED Centrum Medyczne, Łódź, Poland|SP ZOZ w Lecznej, Łęczna, Poland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,60.978664859648,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_MEGLUMINE,3937733,Completed,NCT01254552,TYPE 2 DIABETES MELLITUS|CORONARY ATHEROSCLEROSIS,All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Asan Medical Center, Seoul, Korea, Republic of",A61K49/0433,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,46.35824144232939,1671.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,1,,_DEXMEDETOMIDINE_HYDROCHLORIDE,US-20050101621-A1,Unknown status,NCT03312413,ANESTHESIA COMPLICATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","China,Chongqing The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,6.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Recruiting,NCT04306692,OVULATION INDUCTION|POLYCYSTIC OVARY SYNDROME|CLOMIPHENE|INOSITOL,Female,18 Years to 40 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Ghent, Belgium",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT02352597,POLYCYSTIC OVARIES,Female,20 Years to 37 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Recruiting,NCT03806036,PCOS,Female,20 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kasr Alainy medical school, Cairo, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT01219101,INFERTILITY,Female,25 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royan Institute, Tehran, Iran, Islamic Republic of",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Recruiting,NCT02436226,INFERTILITY|POLYCYSTIC OVARIAN SYNDROME,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Egypt|Private practice settings, Mansourah, Egypt|Obstetrics and Gynecology Department in Port Said University, Port Said, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT01004068,POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Withdrawn,NCT00502229,POLYCYSTIC OVARY SYNDROME|INFERTILITY,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pugliese Hospital, Catanzaro, Catanzaro, CZ, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT00558077,POLYCYSTIC OVARY SYNDROME|INFERTILITY|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Catanzaro/Italy, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT00471523,INFERTILITY|POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 41 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese Hospital"", Catanzaro, CZ, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Unknown status,NCT00461643,ANOVULATORY INFERTILITY RELATED TO POLYCYSTIC OVARY SYNDROME,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy|""Pugliese"" Hospital, Catanzaro, Italy|Pugliese-Ciaccio Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Recruiting,NCT04157725,PCO - POLYCYSTIC OVARIES|INFERTILITY,Female,18 Years to 40 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"American University of Beirut Medical Center, Beirut, Lebanon",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Recruiting,NCT04302532,COENZYME Q10,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Aziz medical center, Karachi, Sindh, Pakistan",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Unknown status,NCT02186782,INFERTILITY|ANOVULATION,Female,20 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansoura, Dakahlia, Egypt|Private practice settings, Mansoura, Dakahlia, Egypt|Private practice settings, Mit Ghamr, Dakahlia, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,,_GONADORELIN,3947569,Not yet recruiting,NCT03989024,POLYCYSTIC OVARY SYNDROME|INFERTILITY|OVULATION DISORDER,Female,24 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China",C07K7/23,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,24.5425984106449,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,,_GONADORELIN,3947569,Unknown status,NCT01278290,CENTRAL PRECOCIOUS PUBERTY|SEXUAL PRECOCITY,Female,3 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Ciudad Autónoma de Buenos Aires, Argentina",C07K7/23,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,24.5425984106449,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,1,,_TOFOGLIFLOZIN,,Unknown status,NCT02649465,NON-ALCOHOLIC FATTY LIVER DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Disease Control and Homeostasis, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,1,,_TOFOGLIFLOZIN,,Completed,NCT02537834,TYPE 2 DIABETES,All,"20 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atsuta-ku, Aichi, Japan|Minato-ku, Aichi, Japan|Kisarazu, Chiba, Japan|Annaka, Gunma, Japan|Naka, Ibaraki, Japan|Sagamihara, Kanagawa, Japan|Kasaoka, Okayama, Japan|Shimono, Tochigi, Japan|Adachi-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Withdrawn,NCT03315052,ACUTE CELLULAR GRAFT REJECTION|LIVER TRANSPLANT REJECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Terminated,NCT01002339,"DIABETES MELLITUS, ADULT-ONSET",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Antonio Osuna, Granada, Andalucía, Spain|Domingo Hernández, Málaga, Andalucía, Spain|Carmen Díaz Corte, Oviedo, Asturias, Spain|Carlos Gómez Alamillo, Santander, Cantabria, Spain|Juan Manuel Díaz, Barcelona, Cataluña, Spain|Francisco Moreso, Barcelona, Cataluña, Spain|Francisco Valdés, La Coruña, Galicia, Spain|Armando Torres Ramírez, La Laguna, S/C de Tenerife, Spain|Roberto Gallego, Las Palmas de Gran Canaria, Spain|Luis Pallardo, Valencia, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00296296,"KIDNEY TRANSPLANT|DIABETES MELLITUS, TYPE 2|DIABETIC NEPHROPATHY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford university Hospital and Clinics, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01092806,POST TRANSPLANT DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Oslo univeristy hospital, Rikshospitalet, Oslo, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00171496,KIDNEY TRANSPLANTATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Terminated,NCT00177138,DIABETES,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota-Fairview, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Unknown status,NCT01875224,NEW ONSET DIABETES AFTER TRANSPLANT|KIDNEY TRANSPLANTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"University of Arizona, Tucson, Arizona, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Unknown status,NCT02036554,"KIDNEY; COMPLICATIONS, ALLOGRAFT",All,"20 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"division of nephrology;Seoul St Mary's Hospital, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Not yet recruiting,NCT04496401,KIDNEY TRANSPLANTATION|PANCREAS TRANSPLANTATION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Nantes University Hospital, Nantes, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],1,,_INDOCYANINE_GREEN,3959455,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],1,,_INDOCYANINE_GREEN,3959455,Recruiting,NCT04012476,HYPOCALCEMIA|TOTAL THYROIDECTOMY|HYPOPARATHYROIDISM POSTPROCEDURAL,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitari Son Espases, Palma De Mallorca, Illes Balears, Spain",A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,1,,_DOXYCYCLINE_HYCLATE,,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01798225,PERIODONTAL DISEASE|TYPE 2 DIABETES MELLITUS,All,"13 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01375491,TYPE 2 DIABETES|OBESITY,All,18 Years to 60 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California San Diego Clinical trials Research Institute, La Jolla, California, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1.O,1,,_CEPHALEXIN,4486411,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,41.1343148729953,29.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1
C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_ENALAPRILAT,4656188,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.905911825704802,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT02639637,TYPE 2 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Recruiting,NCT03938389,PREDIABETES|IMPAIRED GLUCOSE TOLERANCE|OBESITY|BLOOD PRESSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00241124,HYPERTENSION,All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Investigative Centers, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Terminated,NCT00171600,HYPERTENSION|EARLY DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00171574,HYPERTENSION|DIABETIC NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Unknown status,NCT01095822,DIABETES,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Dr. Pokov's Polyclinic. 6821 Reisterstown Road Suite 206, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Unknown status,NCT00407680,TYPE 2 DIABETES MELLITUS|HYPERTENSION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kitasato University, 1-15-1 Kitasato Sagamihara, Kanagawa, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00241085,PROTEINURIA|HYPERTENSION|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT01375322,"HYPERTENSION|DIABETES MELLITUS, TYPE 2|ALBUMINURIA",All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00982358,HYPERTENSION|TYPE 2 DIABETES MELLITUS|CORONARY ARTERY DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Ulm, Department of Internal Medicine II, Ulm, Baden-Wuerttemberg, Germany|Charité University Medicine Berlin, Center for Cardiovascular Research, Outpatient Clinic, Berlin, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00239538,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"30 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Green Hospital, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States|Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|Memorial Research Medical Clinic, Long Beach, California, United States|1200, Los Angeles, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|8615, Nuena Park, California, United States|Boehringer Ingelheim Investigational Site, Orange, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|Boehringer Ingelheim Investigational Site, Sacramento, California, United States|595, San Francisco, California, United States|1805, Stockton, California, United States|Boehringer Ingelheim Investigational Site, Torrance, California, United States|2311, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|6448, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States|Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Pinellas Park, Florida, United States|Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States|Herron Medical Center, Ltd., Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Orland Park, Illinois, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|Boehringer Ingelheim Investigational Site, Shawnee, Kansas, United States|Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|200, Baltimore, Maryland, United States|Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|12401, St.Louis, Missouri, United States|Boehringer Ingelheim Investigational Site, Missoula, Montana, United States|Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|3, Buffalo, New York, United States|Comprehensive Clinical Research, Berlin, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston Salem, North Carolina, United States|Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|Boehringer Ingelheim Investigational Site, Marion, Ohio, United States|Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|Boehringer Ingelheim Investigational Site, Broomal, Pennsylvania, United States|6605, Bartlett, Tennessee, United States|108, Fayetteville, Tennessee, United States|Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|7777, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, El Paso, Texas, United States|Team Research of Texas, Harker Heights, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|420, Salt Lake City, Utah, United States|20901, Ettrick, Virginia, United States|Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|5000, Miwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, BsAs, Argentina|Boehringer Ingelheim Investigational Site, Coronel Suárez, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Sta. Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Emeritus Research, Malvern, Victoria, Australia|Boehringer Ingelheim Investigational Site, Prahran, Victoria, Australia|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Conquitlam, British Columbia, Canada|Dr. Hugh Tildesley, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, North York, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|Boehringer Ingelheim Investigational Site, Orleans, Ontario, Canada|Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Thunder Bay, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|91 Thomas-Chapais, Boucherville, Quebec, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|Pavillon St. Sacrement, Sainte-Foy, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|c/o Hemodynamics Offices, Saskatoon, Saskatchewan, Canada|Inje University Pusan Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Col. Del Valle, Mexico|Boehringer Ingelheim Investigational Site, Col. Magdalena de las Salinas, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección 16, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Zapopan, Jalisco, Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|National Taiwan University Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00550095,MICROALBUMINURIA|PROTEINURIA,All,"35 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site ,, Cairo, Egypt",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Unknown status,NCT00202618,HYPERTENSION|DIABETES MELLITUS|ALBUMINURIA,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shiga University of Medical Science, Otsu, Shiga, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00129233,HYPERTENSION|TYPE 2 DIABETES,All,"30 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00599885,HYPERTENSION|DIABETES|CORONARY ARTERY DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Korea University Anam Hospital, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00921570,DIABETES|HYPERTENSION|PROTEINURIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GATA Nephrology, Ankara, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00153023,DIABETIC NEPHROPATHIES|HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Hospital St. Anna, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|University Hospital Vihohrady, Prague 10, Czech Republic|General University Hospital, Prague 2, Czech Republic|District Hospital Tabor, Tabor, Czech Republic|Masaryk Hospital, Usti nad Labem, Czech Republic|Hospital Usti nad Orlici, Usti nad Orlici, Czech Republic|Medical Department, Copenhagen NV, Denmark|Medicinsk afdeling, Fredericia, Denmark|Medicinsk afdeling F, Endokrinologisk, Hiller?d, Denmark|Endokrinologisk afdeling, Hvidovre, Denmark|Medical Department, Roskilde, Denmark|Chu Sud, Amiens, France|Centre Hospitalier, Beauvais, France|Hopital Duchenne, Boulogne sur Mer cedex, France|Hopital Clemenceau, Caen cedex 5, France|Centre Hospitalier, Dunkerque, France|Hopital Albert Michalon, La Tronche, France|Hopital A.Mignot, Le Chesnay, France|Hopital Maison Blanche, Reims, France|Hopital Yves Le Foll, Saint Brieuc cedex 1, France|Hopital Saint Quentin, Saint Quentin, France|Centre Hospitalier, Valenciennes, France|Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|Diabetes Klinik Bad Mergentheim, Bad Mergentheim, Germany|Institut fur Klinische Forschung, Berlin, Germany|Charite Campus Buch, Berlin, Germany|KFH Dialysezentrum, Eberswalde, Germany|Universitatsklinik Heidelberg, Heidelberg, Germany|Boehringer Ingelheim Investigational Site, Karlsruhe, Germany|Institut fur Klinische Forschung, Mainz, Germany|Boehringer Ingelheim Investigational Site, Munster, Germany|Boehringer Ingelheim Investigational Site, Neuwied, Germany|Boehringer Ingelheim Investigational Site, Pirna, Germany|Boehringer Ingelheim Investigational Site, Riesa, Germany|Boehringer Ingelheim Investigational Site, Rosenheim, Germany|Boehringer Ingelheim Investigational Site, Saarbrucken, Germany|Boehringer Ingelheim Investigational Site, Saarlouis, Germany|Boehringer Ingelheim Investigational Site, Sinsheim, Germany|Boehringer Ingelheim Investigational Site, Speyer, Germany|Internist, Wurzburg, Germany|Azienda Ospedaliera Policlinico S. Orsola Malpighi, Bologna, Italy|Ospedali Riuniti di Livorno, Livorno, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Italy|Universita degli Studi ""Federico II"", Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IRCCS Policlinico S.Matteo, Pavia, Italy|Policlinico Monteluce, Perugia, Italy|Azienda Ospedaliera S. Maria degli Angeli, Pordenone, Italy|Ospedale ""S. Maria delle Croci"", Ravenna, Italy|Universita Tor Vergata, Roma, Italy|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Yonsei University Medical Center, Seoul, Korea, Republic of|Hospital Ipoh, Ipoh, Perak, Malaysia|University Sains Malaysia, Kelantan, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Penang General Hospital, Penang, Malaysia|Hospital Putrajaya, Selangor, Malaysia|Centro Hospitalar de Coimbra, Coimbra, Portugal|Hospital Distrital de Faro, Faro, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Hospital de Santa Marta, Lisboa, Portugal|Associac?o Protectora dos Diabeticos de Portugal, Lisboa, Portugal|Hospital Curry Cabral, Lisbon, Portugal|Hospital Pedro Hispano, Matosinhos, Portugal|Hospital de S. Jo?o, Porto, Portugal|Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Medical Academy named Sechenova I.M., Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|National Endocrinology Research Center of Russia, Moscow, Russian Federation|Russian State Medical University, Moscow, Russian Federation|President's Medical Center, Moscow, Russian Federation|Russian Cardiology Research Center, Moscow, Russian Federation|Russian Academy for Advanced Medical Studies, Moscow, Russian Federation|Moscow President's Medical Center, Moscow, Russian Federation|Regional Clinical Scientific Research Institute, Moscow, Russian Federation|City Hospital of Saint Elizaveta, St. Petersburg, Russian Federation|Military Medical Academy, St. Petersburg, Russian Federation|NovaMed, Banska Bystrica, Slovakia|Ministry Hospital of Internal Affairs, Bratislava, Slovakia|Faculty Hospital, Bratislava, Slovakia|Faculty Hospital of L. Derer, Bratislava, Slovakia|Diabetologic and Internal Clinic, Lucenec, Slovakia|Faculty Hospital, Nitra, Slovakia|Hospital Nove Mesto, Nove Mesto, Slovakia|Regional Hospital Nove Zamky, Nove Zamky, Slovakia|MSP-DIAGNOSTIK, Ltd., Trencin, Slovakia|Faculty Hospital Trnava, Trnava, Slovakia|Hospital Torrecardenas, Almeria, Spain|Hospital Ntra. Sra de Sonsoles, Avila, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital de Cabuenes, Gijon, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Buddhist Tzu Chi Hospital, Hualien City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chi Mei Medical Center, Taiwan, Taiwan|Dnyepropyetrovsk Medical Academy, Dnyepropetrovsk, Ukraine|Kharkiv Medical State University, Kharkov, Ukraine|Institute of Diabetic pathology problems, Kharkov, Ukraine|Institute of Cardiology, Kiev, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism, Kiev, Ukraine|Kyiv Clinical Hospital No. 1, Kyiv, Ukraine|Zaporozhye Regional Clinical Hospital, Zaporozhye, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
O.O.O.O.O.O.[Cl-].[Cl-].[Mg+2],1,,_MAGNESIUM_CHLORIDE,,Completed,NCT00603499,DIABETES MELLITUS|HIGH BLOOD PRESSURE|HYPOMAGNESEMIA,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Biomedical Research Unit, Durango, Mexico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)O.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,,_GONADORELIN_ACETATE,,Unknown status,NCT01278290,CENTRAL PRECOCIOUS PUBERTY|SEXUAL PRECOCITY,Female,3 Years to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Ciudad Autónoma de Buenos Aires, Argentina",,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+],1,,_LEVOTHYROXINE_SODIUM,WO-2006054120-A1,Completed,NCT03094416,HYPOTHYROIDISM;POSTABLATIVE,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Head and Neck Specialists, La Jolla, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|MedStar Union Memorial Hospital, Baltimore, Maryland, United States|NYC Health + Hospitals/ Queens, New York, New York, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Carolina Ear Nose and Throat Clinic, Orangeburg, South Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Stonesifer Endocrine Care & Clinical Research Inc., PS, Federal Way, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,32.7488,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00998335,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT01868542,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00607737,DIABETES,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Steno Diabetes Center, Gentofte, Denmark",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Unknown status,NCT01440439,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00564395,TYPE 1 DIABETES,All,"10 Years to 25 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Children's Hospital Endocrine and Diabetes Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Terminated,NCT00509925,"DIABETES|DIABETES MELLITUS, TYPE 1",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Guildford, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT02967211,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 076-001, Curitiba, Brazil|Investigational Site Number 076008, Fortaleza, Brazil|Investigational Site Number 076004, Fortaleza, Brazil|Investigational Site Number 076009, Rio de Janeiro, Brazil|Investigational Site Number 076-003, Sao Paulo, Brazil|Investigational Site Number 076011, São José dos Campos, Brazil|Investigational Site Number 076006, São paulo, Brazil|Investigational Site Number 076005, São Paulo, Brazil|Investigational Site Number 076010, Taguatinga, Brazil|Investigational Site Number 246008, Helsinki, Finland|Investigational Site Number 246007, Muurame, Finland|Investigational Site Number 246002, Oulu, Finland|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246009, Pori, Finland|Investigational Site Number 246004, Rauma, Finland|Investigational Site Number 250008, Amiens Cedex 1, France|Investigational Site Number 250011, Bordeaux, France|Investigational Site Number 250009, Caen, France|Investigational Site Number 250001, Corbeil Essonnes, France|Investigational Site Number 250005, Eaubonne, France|Investigational Site Number 250026, La Rochelle Cedex 1, France|Investigational Site Number 250020, Montpellier, France|Investigational Site Number 250015, Mulhouse, France|Investigational Site Number 250003, Paris, France|Investigational Site Number 250010, Pierre-Bénite, France|Investigational Site Number 250014, Pierre-Bénite, France|Investigational Site Number 250025, POITIERS Cedex, France|Investigational Site Number 250002, Valenciennes, France|Investigational Site Number 250013, Vandoeuvre Les Nancy Cedex, France|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300003, Kalamata, Greece|Investigational Site Number 300001, Lamia, Greece|Investigational Site Number 300004, Thessaloniki, Greece|Investigational Site Number 372003, Dublin 4, Ireland|Investigational Site Number 372002, Dublin 7, Ireland|Investigational Site Number 380033, Arzignano (VI), Italy|Investigational Site Number 380016, Catania, Italy|Investigational Site Number 380004, Catania, Italy|Investigational Site Number 380006, Catanzaro, Italy|Investigational Site Number 380031, Eboli, Italy|Investigational Site Number 380007, Forlì, Italy|Investigational Site Number 380018, Genova, Italy|Investigational Site Number 380020, Iglesias (CI), Italy|Investigational Site Number 380015, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380012, Milano, Italy|Investigational Site Number 380011, Orbassano (TO), Italy|Investigational Site Number 380026, Padova, Italy|Investigational Site Number 380021, Palermo, Italy|Investigational Site Number 380014, Partinico, Italy|Investigational Site Number 380032, Roma, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380023, Roma, Italy|Investigational Site Number 380036, San Benedetto del Tronto, Italy|Investigational Site Number 380024, Sarzana, Italy|Investigational Site Number 380013, Savigliano (CN), Italy|Investigational Site Number 380017, Sesto S. Giovanni, Italy|Investigational Site Number 380025, Torino, Italy|Investigational Site Number 642008, Arad, Romania|Investigational Site Number 642005, Baia MAre, Romania|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642006, Brasov, Romania|Investigational Site Number 642003, Cluj-Napoca, Romania|Investigational Site Number 642007, Cluj-Napoca, Romania|Investigational Site Number 642004, Targu-Mures, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724019, Barcelona, Spain|Investigational Site Number 724012, Barcelona, Spain|Investigational Site Number 724011, Barcelona, Spain|Investigational Site Number 724027, Castellón, Spain|Investigational Site Number 724028, Córdoba, Spain|Investigational Site Number 724008, Galdakao (Bilbao), Spain|Investigational Site Number 724010, León, Spain|Investigational Site Number 724001, LLeida, Spain|Investigational Site Number 724013, Madrid, Spain|Investigational Site Number 724018, Madrid, Spain|Investigational Site Number 724020, Málaga, Spain|Investigational Site Number 724025, Móstoles, Spain|Investigational Site Number 724006, Palma de Mallorca, Spain|Investigational Site Number 724007, Palma de Mallorca, Spain|Investigational Site Number 724024, Pontevedra, Spain|Investigational Site Number 724017, Sabadell, Spain|Investigational Site Number 724022, San Cristóbal de La Laguna - Sta. Cruz de Tenerife, Spain|Investigational Site Number 724003, San Juan de Alicante, Spain|Investigational Site Number 724030, Sant Joan Despí, Spain|Investigational Site Number 724023, Santa Cruz de Tenerife, Spain|Investigational Site Number 724014, Santiago de Compostela, Spain|Investigational Site Number 724005, Sevilla, Spain|Investigational Site Number 724016, Sevilla, Spain|Investigational Site Number 724004, Sevilla, Spain|Investigational Site Number 724021, Valencia, Spain|Investigational Site Number 724009, Valladolid, Spain|Investigational Site Number 724029, Vigo, Spain|Investigational Site Number 756003, Bern, Switzerland|Investigational Site Number 756002, St. Gallen, Switzerland|Investigational Site Number 826033, Atherstone, United Kingdom|Investigational Site Number 826016, Ayr, United Kingdom|Investigational Site Number 826039, Blackburn, United Kingdom|Investigational Site Number 826008, Bradford on Avon, United Kingdom|Investigational Site Number 826004, Chertsey, United Kingdom|Investigational Site Number 826038, Cornwall, United Kingdom|Investigational Site Number 826031, Coventry, United Kingdom|Investigational Site Number 826024, Darlington, United Kingdom|Investigational Site Number 826035, Dudley, United Kingdom|Investigational Site Number 826017, Glasgow, United Kingdom|Investigational Site Number 826025, Huntingdon, United Kingdom|Investigational Site Number 826002, Liverpool, United Kingdom|Investigational Site Number 826018, Manchester, United Kingdom|Investigational Site Number 826019, Manchester, United Kingdom|Investigational Site Number 826037, Manchester, United Kingdom|Investigational Site Number 826023, Norwich, United Kingdom|Investigational Site Number 826009, Nuneaton, United Kingdom|Investigational Site Number 826021, Plymouth, United Kingdom|Investigational Site Number 826006, Portsmouth, United Kingdom|Investigational Site Number 826020, Southampton, United Kingdom|Investigational Site Number 826013, Taunton, United Kingdom|Investigational Site Number 826007, Welwyn Garden City, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00742976,DIABETES TYPE 2|WEIGHT GAIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Dept of Endocrinology, Rigshospitalet, Copenhagen, København Ø, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00657943,TYPE 2 DIABETES|ATHEROSCLEROSIS|ARTERIOSCLEROSIS,All,"30 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rigshospitalet, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Gentofte Sygehus, Gentofte, Denmark|Steno Diabetes Center, Gentofte, Denmark|Herlev Hospital, Herlev, Denmark|Hillerod Sygehus, Hillerod, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Køge Sygehus, Koge, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(O)n2)cc1,1,,_AZILSARTAN,5243054,Completed,NCT02517866,ESSENTIAL HYPERTENSION|TYPE 2 DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hong Kong, Hong Kong, China|Changhua County, Taiwan|Kaohsiung City, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Pathumthani, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,14.423294112815402,112.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(O)n2)cc1,1,,_AZILSARTAN,5243054,Completed,NCT02079805,ESSENTIAL HYPERTENSION COMPLICATED BY TYPE 2 DIABETES MELLITUS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kyoto-Shi, Kyoto, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,14.423294112815402,112.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,1,,_SITAGLIPTIN_PHOSPHATE,,Completed,NCT00847080,REACTIVE HYPOGLYCEMIA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, Mexico",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,1,,_SITAGLIPTIN_PHOSPHATE,,Completed,NCT01131182,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,1,,_SITAGLIPTIN_PHOSPHATE,,Completed,NCT00833027,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,1,,_TRAMADOL_HYDROCHLORIDE,5414129,Completed,NCT00634543,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,19.975769522988106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00634543,DIABETIC NEUROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Withdrawn,NCT01116531,DIABETIC POLYNEUROPATHY|POSTHERPETIC NEURALGIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,"Active, not recruiting",NCT03469310,THYROID CANCER|THYROID NODULE|THYROID NEOPLASMS|THYROID GOITRE|THYROID DISEASES|PARATHYROID DISEASES|PARATHYROID ADENOMA|PARATHYROID HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"GME General Surgery Clinic, Edinburg, Texas, United States",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02246712,NEUROPATHIC PAIN|TYPE 1 DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Estadual Paulista Julio de Mesquita Filho, Araraquara, SP, Brazil",C07C213/10,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=S(=O)([O-])c1cc(O)ccc1O.O=S(=O)([O-])c1cc(O)ccc1O.[Ca+2],1,,_CALCIUM_DOBESILATE,4511557,Not yet recruiting,NCT04283162,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University, Nanjing, Jiangsu, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,31.869237561346196,68.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0
CCCCCCCCCCC(=O)O,1,,_UNDECANOATE,3932476,Completed,NCT00421460,HYPOGONADISM|ERECTILE DYSFUNCTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|Ramathibodi Hospital, Rajthevee, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand",C07C231/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCCCCC(=O)O,1,,_UNDECANOATE,3932476,Not yet recruiting,NCT03851627,"FATTY LIVER|OBESITY|TYPE2 DIABETES MELLITUS|HYPOGONADISM, MALE",Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",C07C231/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCCCCC(=O)O,1,,_UNDECANOATE,3932476,Completed,NCT03792321,"HYPOGONADISM, MALE|DIABETES MELLITUS, TYPE 2|OBESITY",Male,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07C231/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCCCCC(=O)O,1,,_UNDECANOATE,3932476,Not yet recruiting,NCT03721497,BARIATRIC SURGERY CANDIDATE|MALE HYPOGONADISM|MUSCLE LOSS,Male,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,C07C231/02,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCCCCC(=O)O,1,,_UNDECANOATE,3932476,Completed,NCT03126656,HYPOGONADISM|CHRONIC HEART FAILURE,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07C231/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE_ACETATE,,Completed,NCT00240253,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Phoenix, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Salinas, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00240253,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Phoenix, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Salinas, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00690235,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|DIABETES|WEIGHT GAIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00442767,TYPE 1 DIABETES,All,"12 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00502138,IDDM,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT02500329,ENDOTHELIAL FUNCTION|TYPE 2 DIABETES|GEMIGLIPTIN|ACARBOSE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boramae medical center, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT02605772,TYPE 2 DIABETES,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Terminated,NCT02072096,"DIABETES MELLITUS, TYPE 2",All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Florida Hospital, Orlando, Florida, United States|Athens Primary Care, Athens, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iderc, P.L.C., Des Moines, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Mercy Health Research, Saint Louis, Missouri, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Carolina Health Specialists, Myrtle Beach, South Carolina, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Stefan Ob Stainz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dortmund, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stuttgart, Germany|Manati Medical Center, Manati, Puerto Rico|American Telemedicine Center, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dundee, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ipswich, Suffolk, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Not yet recruiting,NCT03602638,ATHEROSCLEROSIS TYPE 2 DIABETES MELLITUS DIPEPTIDYL PEPTIDASE-4 INHIBITOR GLP-1,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Completed,NCT01863147,NEWLY DIAGNOSED TYPE 2 DIABETES|CORONARY ARTERY DISEASE,All,"55 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangda Xiang, Wuhan, Hubei, China|Wuhan General Hospital, Wuhan, Hubei, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Completed,NCT01279512,PCOS,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Royan Institute, Tehran, Iran, Islamic Republic of",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT03383068,PCOS|IMPAIRED GLUCOSE TOLERANCE,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT01175486,DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Completed,NCT01244971,DIABETES MELLITUS TYPE 2,All,45 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital, Stockholm, Sweden",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT02999841,"DIABETES MELLITUS, TYPE 2|OBESITY",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Pinggu Hospital, Beijing, Beijing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Completed,NCT00437918,DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea, Republic of|Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT00858676,DIABETES MELLITUS|IMPAIRED GLUCOSE TOLERANCE|CORONARY ARTERY DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University, Nagoya, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Completed,NCT00829660,CORONARY HEART DISEASE|ACUTE CORONARY SYNDROME|IMPAIRED GLUCOSE TOLERANCE|TYPE 2 DIABETES MELLITUS (T2DM),All,"50 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Chuiyangliu Hospital, Beijing, Beijing, China|China Meitan General Hospital, Beijing, Beijing, China|Beijing Anzhen Hospital of The Capital University of Medical Sciences, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Beijing Ji Shui Tan Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Fu Xing Hospital, Beijing, Beijing, China|Beijing Shijingshan Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Aerospace Central Hospital, Beijing, Beijing, China|Affiliated to The Capital University of Medical Sciences Beijing Friendship Hospital, Beijing, Beijing, China|Wangjing Hospital of CACMS, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|Beijing Healthy Palace Hospital, Beijing, Beijing, China|Aerospace 731 Hospital, Beijing, Beijing, China|General Hospital of Second Artillery PLA, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|PLA General Hospital, Beijing, Beijing, China|Anzhen Hospital of The Capital University of Medical Sciences 2nd., Beijing, Beijing, China|Beijing Pinggu Hospital, Beijing, Beijing, China|Beijing Yanhua Hospital, Beijing, Beijing, China|Chongqing Medical University Second Afflicated Hospital, Chongqing, Chongqing, China|Chongqing Zhongshan Hospital, Chongqing, Chongqing, China|Chongqing Third People's Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Da Ping Hospital, Chongqing, Chongqing, China|The Second People's Hospital of Chongqing, Chongqing, Chongqing, China|Fujian Provincial Hospital, Fuzhou, Fujian, China|Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China|The People's Hospital of Fujian Province, Fuzhou, Fujian, China|The First Hospital of Xiamen, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China|Wu Jing Zhong Dui Hospital of Guangdong Province, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Zhong Shan City People's Hospital, Zhongshan, Guangdong, China|The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China|Liuzhou Worker's Hospital, Liuzhou, Guangxi, China|Liuzhou People's Hospital, Liuzhou, Guangxi, China|Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|303 Hospital of People's Liberation Army, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Bethune International Peace Hospital, Shijiazhuang, Hebei, China|Tangshan Workers Hospital, Tangshan, Hebei, China|The Affiliated Hospital of North China Coal Medical University, Tangshan, Hebei, China|Yu Tian County Hospital, Tangshan, Hebei, China|The Third Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China|Da Qing Oilfield General Hospital, Da Qing, Heilongjiang, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan Science & Technology University, Luoyang, Henan, China|Luo Yang Central Hospital, Affiliated to Zhengzhou University, Luoyang, Henan, China|The First Affiliated Hospital of Henan College of TCM, Zhengzhou, Henan, China|The People's Hospital of Zhengzhou, Zhengzhou, Henan, China|The Second Affiliated Hospital of Zhengzhou University, ZhengZhou, Henan, China|Union Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Tongji Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Pu'ai Hospital of Wuhan City, Wuhan, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Fourth Hospital of Changsha, Changsha, Hunan, China|Xiangya Hospital Central-South University, Changsha, Hunan, China|The Third Hospital of Changsha, Changsha, Hunan, China|The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Baotou Central Hospital, Baotou, Inner Mongolia, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China|Inner Mongolia Hospital, Hohhot, Inner Mongolia, China|81st Hospital of Chinese PLA, NanJing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Nanjing Zhongda Hospital, Nanjing, Jiangsu, China|BENQ Hospital, Nanjing, Jiangsu, China|Jiangsu Province Official Hospital, NanJing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jiangsu Provincial Hospital of TCM, NanJing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Wuxi No.3 People's Hospital, Wuxi, Jiangsu, China|Hospital Affiliated Xuzhou Medical University, Xuzhou, Jiangsu, China|The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China|Jiujiang University Hospital, Jiujiang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|The Central Hospital of Anshan, Anshan, Liaoning, China|Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|The First Hospital of Dalian Medical University, Dalian, Liaoning, China|Dalian Central Hospital, Dalian, Liaoning, China|Xianyang Central Hospital, Shengyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The People's Hospital of Liaoning Province, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The Fourth Hospital of China Medical University, Shenyang, Liaoning, China|The First Hospital of Yinchuan, Yinchuan, Ningxia, China|Affiliated Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China|Xi'an Central Hospital, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Affiliated Hospital of Xi'an Medical college, Xi'an, Shaanxi, China|Affiliated Hospital of Yan'an University, Yan'an, Shaanxi, China|Yan'an People's Hospital, Yanan, Shaanxi, China|The First Hospital of Yulin, Yulin, Shaanxi, China|The Central Hospital of Jinan, Jinan, Shandong, China|The First People's Hospital of Jinan, Jinan, Shandong, China|The General Hospital of Jinan Military Region, Jinan, Shandong, China|Linyi People's Hospital, Linyi, Shandong, China|Hospital Affiliated of Medical School, Qingdao University, Qingdao, Shandong, China|The Qingdao Municiple Hospital, Qingdao, Shandong, China|Qingdao Fuwai Hospital, Shibei, Shandong, China|Taian City Central Hospital, Taian, Shandong, China|Shanghai Ninth People's Hospital, Shanghai, Shanghai, China|Ruijin Hospital Affiliated to the Shanghai Jiaotong University Medical School, Shanghai, Shanghai, China|Shanghai Central Hospital of Xuhui District, Shanghai, Shanghai, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China|Shanghai Huadong Hospital, Shanghai, Shanghai, China|Shanghai Putuo District People's Hospital, Shanghai, Shanghai, China|Putuo District Center Hospital, Shanghai, Shanghai, China|Tongji Hospital of Tongji University, Shanghai, Shanghai, China|Shanghai Tenth People's Hospital, Shanghai, Shanghai, China|Number 411 Hospital of PLA, Shanghai, Shanghai, China|Shanghai Central Hospital of Yangpu District, Shanghai, Shanghai, China|Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai East Hospital, Shanghai, Shanghai, China|Renji Hospital Affilicated to Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Pudong New Area Gongli Hospital, Shanghai, Shanghai, China|Changhai Hospital, Shanghai, Shanghai, China|Shanghai Zhabei District Shibei Hospital, Shanghai, Shanghai, China|Shanghai Jinshan Hospital, Shanghai, Shanghai, China|Shanghai Pudong New District People's Hospital, Shanghai, Shanghai, China|General Hospital of Tisco, Taiyuan, Shanxi, China|The Third Engineering Bureau Hospital of Ministry of Railway, Taiyuan, Shanxi, China|Taiyuan City Central Hospital, Taiyuan, Shanxi, China|Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China|PLA No.323 Hospital, Xi'an, Shanxi, China|Chengdu First People's Hospital, Chengdu, Sichuan, China|Chengdu Second People's Hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|The West China Hospital, Chengdu, Sichuan, China|Sichuan Mianyang 404 Hospital, Sichuan, Sichuan, China|Tianjin Union Hospital, Tianjin, Tianjin, China|Tianjin Chest Hospital, Tianjin, Tianjin, China|Tianjin Union Medicine Centre, Tianjin, Tianjin, China|Army Police's Medical College Affiliated Hospital, Tianjin, Tianjin, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|Tianjin First Center Hospital, Tianjin, Tianjin, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Dagang Oil-Field General Hospital, Tianjin, Tianjin, China|The Fifth Central Hospital of Tianjin, Tianjin, Tianjin, China|First Affiliated Hospital of the Medical College, Shihezi, Xinjiang, China|Xin Jiang Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China|General Hospital of Xinjiang Production and Construction Corps, Urumqi, Xinjiang, China|The 474th Hospital of PLA, Urumqi, Xinjiang, China|The First Teaching Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|The First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|People's Hospital of Yuxi City, Yuxi, Yunnan, China|Zhe Jiang Hospital, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital Affiliated With School of Medicine, Zhe Jiang University, Hangzhou, Zhejiang, China|Prince of Wales Hospital, Hong Kong, Hong Kong",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC.O,1,,_CISAPRIDE,6224905,Terminated,NCT01286090,GASTROPARESIS|DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/2072,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,28.9122979937986,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O,1,,_PERINDOPRIL_ARGININE,US-20110301357-A1,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",A61P9/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,57.2989178422554,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[n-]n2)cc1.[K+],1,,_LOSARTAN_POTASSIUM,5859258,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",C07D403/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.4890038809831,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT04222686,TYPE 2 DIABETES,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00155064,HYPERALDOSTERONISM,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Taiwan University Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Terminated,NCT00456963,DIABETES MELLITUS|HYPERTENSION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Istituto Auxologico Italiano., Milan, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Not yet recruiting,NCT04238702,"DIABETES MELLITUS, TYPE 2|DIABETIC KIDNEY DISEASE",All,"35 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT01603940,HYPERTENSION|DIABETES,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00419835,MACROALBUMINURIC DIABETIC NEPHROPATHY,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT03006952,DIABETIC NEPHROPATHY,All,"38 Years to 76 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00168857,HYPERTENSION|DIABETIC NEPHROPATHY,All,"21 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Montgomery, Alabama, United States|Boehringer Ingelheim Investigational Site, Little Rock, Arkansas, United States|Boehringer Ingelheim Investigational Site, Lancaster, California, United States|Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|VA of Greater Los Angeles, Los Angeles, California, United States|UCI Medical Center, Orange, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Boehringer Ingelheim Investigational Site, Santa Ana, California, United States|UCLA Medical Center, Sylmar, California, United States|Torrance Clinical Research, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Boehringer Ingelheim Investigational Site, Wheatridge, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|Boehringer Ingelheim Investigational Site, Largo, Florida, United States|Boehringer Ingelheim Investigational Site, Ocala, Florida, United States|Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Rush Presbyterian - St. Lukes Medical Center, Chicago, Illinois, United States|Boehringer Ingelheim Investigational Site, Demoine, Iowa, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States|Boehringer Ingelheim Investigational Site, Towson, Maryland, United States|Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Springfield, Massachusetts, United States|Boehringer Ingelheim Investigational Site, Eatontown, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Boehringer Ingelheim Investigational Site, Flushing, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Harlem Hospital, New York, New York, United States|Northport VAMC - Medical Service (111), Northport, New York, United States|Wake Nephrology Associates, PA, Raleigh, North Carolina, United States|The Cleveland Foundation, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|University of Texas Health and Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Burlington, Vermont, United States|University of Virginia Health Science Center, Charlottesville, Virginia, United States|Boehringer Ingelheim Investigational Site, Gig Harbor, Washington, United States|Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Boehringer Ingelheim Investigational Site, Buenos aIRES, Argentina|Clinica Coronel Suarez, Coronel Suarez, Argentina|Boehringer Ingelheim Investigational Site, Córdoba, Argentina|Boehringer Ingelheim Investigational Site, Paraná, Argentina|Boehringer Ingelheim Investigational Site, Provincia de Buenos Aires, Argentina|Boehringer Ingelheim Investigational Site, Rosario, Santa Fé, Argentina|Hospital San Bernardo, Salta, Argentina|Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|Boehringer Ingelheim Investigational Site, Kippa-Ring, Queensland, Australia|Lyell McEwin Hospital Department of medicine, Elizabeth, South Australia, Australia|Geelong Clinical Research Centre, Geelong, Victoria, Australia|Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia|Universidade Federal do Pará, Belém, Brazil|Boehringer Ingelheim Investigational Site, Botucatu, Brazil|Faculdade de Medicina Universidade Federal de Juiz de Fora, Juiz de Fora ¿ MG, Brazil|Boehringer Ingelheim Investigational Site, Vila Clementino, São Paulo, Brazil|Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada|BC Endocrine Research Foundation, Vancouver, British Columbia, Canada|Endocrine Research Society, Vancouver, British Columbia, Canada|University of Manitoba, Diabetes Research Group, Winnipeg, Manitoba, Canada|Division of Respirology, Halifax, Nova Scotia, Canada|Boehringer Ingelheim Investigational Site, Kitchener, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Credit Valley Hospital, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|The Ottawa Hospital - Riverside Campus, Ottawa, Ontario, Canada|LIfestyle Metabolism Centre - Thornhill, Thornhill, Ontario, Canada|Boehringer Ingelheim Investigational Site, Timmins, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook & Woman's College Health Science Centre, Toronto, Ontario, Canada|Humber River Regional Hospital, Dialysis Unit, Weston, Ontario, Canada|Boehringer Ingelheim Investigational Site, Laval, Quebec, Canada|CHUM - Hote-Dieu, Montreal, Quebec, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada|Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|Dongsan Medical Center, Daegu, Korea, Republic of|National Health Insurance Corporation, Ilsan Hospital, Gyunggido, Korea, Republic of|Yongdong Severance Hospital, Seoul, Korea, Republic of|Fracc. Magallanes, Acapulco Guerrero, Mexico|Boehringer Ingelheim Investigational Site, Col. Sección XVI, Deleg. Tlalpan, Mexico|Boehringer Ingelheim Investigational Site, Guadalajara, Jalisco, Mexico|Cardiology, Guadalajara, Mexico|Hospital Civil Nuevo de Guadalajara, Guadalajara, Mexico|Dep of Neurology, Metepec, Mexico|Cardiologia, México, D.F., Mexico|Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1st Floor Hagely Hostel, Christchurch, New Zealand|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Hualien, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|Cathay General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Bumrungrad Hospital, Bangkok, Thailand|Pramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Division of Hypertension, Bangkok, Thailand|Thummasart University Hospital, Bangkok, Thailand|Maharaj Nakom Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00237588,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,"Cardiovascular and Renal Research Center/ Department of Cardiology, Ullevaal University Hospital, Oslo, Norway",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Completed,NCT03080181,CUSHING DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,"Active, not recruiting",NCT02775227,PANCREATIC FISTULA|PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Withdrawn,NCT02779257,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Unknown status,NCT02668172,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus Medical Center, Rotterdam, South Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Not yet recruiting,NCT04445714,TYPE 2 DIABETES,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT01206647,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetologische Schwerpunktpraxis Dr. Lorra / Dr. Bonnermann, Bochum, Germany|Zentrum für klinische Studien Dresden, GWT-TUD GmbH, Dresden, Germany|Gemeinschaftspraxis Partner der Gesundheit, Essen, Germany|IKFE Institute for Clinical Research and Development, Mainz, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Diabetes Zentrum Neuwied, Neuwied, Germany|ikfe Studiencenter Potsdam GmbH, Potsdam, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT01608724,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Benxi, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Dongguan, China|Research Site, Foshan, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hhht, China|Research Site, Hubei, China|Research Site, Jimo, China|Research Site, Jinan, China|Research Site, Kunming, China|Research Site, Linyi, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shantou, China|Research Site, Shenyang, China|Research Site, Shiyan, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xian, China|Research Site, Zhanjiang, China|Research Site, Zhengzhou, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Recruiting,NCT03660683,"DIABETES MELLITUS, TYPE 2|CARDIOVASCULAR DISEASES",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The GW Medical Faculty Associates, Washington, District of Columbia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT01267448,DIABETES MELLITUS TYPE 2|SEVERE HYPERGLYCEMIA - BLOOD GLUCOSE LEVEL >300MG/DL.,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Stroger Hospital of Cook County, Chicago, Illinois, United States|John Stroger Hospital of Cook County, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02307695,TYPE 1 DIABETES,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT02471404,TYPE 2 DIABETES MELLITUS|INADEQUATE GLYCAEMIC CONTROL,All,"18 Years to 74 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Prelouc, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Neuenahr-Ahrweiler, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Bünde, Germany|Research Site, Daaden, Germany|Research Site, Darmstadt, Germany|Research Site, Datteln, Germany|Research Site, Deggingen, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Gelnhausen, Germany|Research Site, Giengen, Germany|Research Site, Goch, Germany|Research Site, Grevesmühlen, Germany|Research Site, Grossheirath, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hameln, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildesheim, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Höhenkirchen, Germany|Research Site, Jerichow, Germany|Research Site, Kallstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köln, Germany|Research Site, Köthen, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lichtenfels, Germany|Research Site, Lingen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Löhne, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marl, Germany|Research Site, Meine, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf A. Inn, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Neuwied Am Rhein, Germany|Research Site, Oldenburg, Germany|Research Site, Papenburg, Germany|Research Site, Pirna, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Rehlingen Siersburg, Germany|Research Site, Reinfeld, Germany|Research Site, Remagen, Germany|Research Site, Rhaunen, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Saarlouis, Germany|Research Site, Schwabenheim, Germany|Research Site, Speyer, Germany|Research Site, Stadtbergen, Germany|Research Site, Stolberg, Germany|Research Site, Straubing, Germany|Research Site, Stuttgart, Germany|Research Site, Sulzbach, Germany|Research Site, Trier, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wahlstedt, Germany|Research Site, Wangen, Germany|Research Site, Weinheim, Germany|Research Site, Westerkappeln, Germany|Research Site, Wetzlar, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hatvan, Hungary|Research Site, Kisvárda, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza-Szentetornya, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ács, Hungary|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chrzanow, Poland|Research Site, Gdańsk, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Legnica, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznan, Poland|Research Site, Sobótka, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Vrutky, Slovakia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT02917031,TYPE 2 DIABETES MELLITUS|HEART FAILURE,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site 1, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chicoutimi, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Viña del Mar, Chile|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kisvárda, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Rivne, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02583438,TYPE 2 DIABETES|OBESITY,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT02481479,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT|HEART FAILURE",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Michael's Hospital, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Terminated,NCT01765270,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR DISEASE,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","Cardiology, PC, Birmingham, Alabama, United States|Cardio-Thoracic Surgeons PC, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Stanford University Medical Center, Palo Alto, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Duke University Medical Center (DUMC), Durham, North Carolina, United States|Chippenham Medical Center, Richmond, Virginia, United States|Charleston Area Medical Center (CAMC), Charleston, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT01960205,PRE-DIABETES,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shandong Provincial Hospital, Jinan, Shandong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT01552018,CORONARY ARTERY DISEASE|DIABETES MELLITUS TYPE 2,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT02182895,DIABETES,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Enrolling by invitation,NCT01527747,TYPE 2 DIABETES|HYPERTRIGLYCERIDEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Oregon Health & Science University, Portland, Oregon, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02462369,MICROALBUMINURIA|MICROALBUMINURIA /CREATININE RATIOS ACR,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02742233,DIABETIC FOOT ULCER,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Completed,NCT02104739,PREDIABETES|OBESITY,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
C/N=C(\N)N(C)C(=N)N.Cl,1,,_METFORMIN_XR,,Unknown status,NCT01267448,DIABETES MELLITUS TYPE 2|SEVERE HYPERGLYCEMIA - BLOOD GLUCOSE LEVEL >300MG/DL.,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Stroger Hospital of Cook County, Chicago, Illinois, United States|John Stroger Hospital of Cook County, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0
C/N=C(\N)N(C)C(=N)N.Cl,1,,_METFORMIN_XR,,Completed,NCT02252965,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Please contact the Merck KGaA Communication Center, Darmstadt, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0
C/N=C(\N)N(C)C(=N)N.Cl,1,,_METFORMIN_XR,,Completed,NCT01864174,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Central Alabama Research, Birmingham, Alabama, United States|Terence T. Hart, Md, Muscle Shoals, Alabama, United States|Clini Res Advantage Desert Clin Res, Llc, Mesa, Arizona, United States|Clinical Res Advantage Central, Phoenix, Arkansas, United States|Marin Endocrine Care And Research, Inc., Greenbrae, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Actca, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|R. Srinivasan, M.D., Inc., Monterey Park, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Valley Clinical Trials, Northridge, California, United States|Center For Clinical Trials Of Sacramento, Inc., Sacramento, California, United States|Clinical Research Advantage, Colorado Springs, Colorado, United States|Clinical Research Advantage, Colorado Springs, Colorado, United States|Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Clinical Research Advantage, Inc/Co Springs Health Partners, Briar, Colorado Springs, Colorado, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Family Care Partners, Jacksonville, Florida, United States|Omega Research Consultants, Llc, Orlando, Florida, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Gulfcoast Medical Research Center, Llc, Tampa, Florida, United States|Cedar-Crosse Research Ctr, Chicago, Illinois, United States|Clinical Research Advantage, Inc./Family Medicine Associates, Evansville, Indiana, United States|American Health Network Of In Llc, Muncie, Indiana, United States|Columbia Medical Practice, Columbia, Maryland, United States|Centennial Medical Group, Elkridge, Maryland, United States|Drs. Rodbard And Dempsey, Rockville, Maryland, United States|Ny Clinical Trials, New York, New York, United States|White Oak Family Physicians, Pa, Asheboro, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Medical Research Unlimited, Inc., Cincinnati, Ohio, United States|Lion Research, Norman, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Integrated Medical Group Pc / Fleetwood Medical Assoc., Fleetwood, Pennsylvania, United States|Palmetto Clinical Trial Services Llc, Fountain Inn, South Carolina, United States|Holston Medical Group, Bristol, Tennessee, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Independence Family Medicine, Virginia Beach, Virginia, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Burlington, Ontario, Canada|Local Institution, Collingwood, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Newmarket, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, London, Canada|Local Institution, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Ceske Budejovice, Czechia|Local Institution, Krnov, Czechia|Local Institution, Liberec, Czechia|Local Institution, Litomysl, Czechia|Local Institution, Novy Jicin, Czechia|Local Institution, Ostrava - Kuncice, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 1, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Aschaffenburg, Bayern, Germany|Local Institution, Munster, Nordrhein-Westfalen, Germany|Local Institution, Leipzig, Saxony, Germany|Local Institution, Berlin, Germany|Local Institution, Heidelberg, Germany|Local Institution, Leipzig, Germany|Local Institution, Lohne, Germany|Local Institution, Myen, Germany|Local Institution, Papenburg, Germany|Local Institution, Pirna, Germany|Local Institution, Pecs, Baranya, Hungary|Local Institution, Szigetvar, Baranya, Hungary|Local Institution, Satoraljaujhely, Borsod-Abauj-Zemplen, Hungary|Local Institution, Hodmezvasarhely, Csongrad, Hungary|Local Institution, Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Local Institution, Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Csorna, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Mosonmagyarovar, Hungary|Local Institution, Nagykanizsa, Hungary|Local Institution, Oroshaza, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szentes, Hungary|Local Institution, Szobathely, Hungary|Local Institution, Gdansk, Pomorskie, Poland|Local Institution, Katowice, Slaskie, Poland|Local Institution, Bialystok, Poland|Local Institution, Bialystok, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lublin, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Zamosc, Poland|Fb Med Research, Psc, Caguas, Puerto Rico|Local Institution, Caguas, Puerto Rico|Local Institution, Carolina, Puerto Rico|Policlinica Dr. Luis Rodriguez, Carolina, Puerto Rico|Local Institution, Las Lomas, Puerto Rico|Luis Rivera-Colon, Md, Las Lomas, Puerto Rico|Local Institution, Ponce, Puerto Rico|Ponce School Of Medicine, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Research & Cardiovascular Corp, Ponce, Puerto Rico|Caparra Internal Med Res Ctr, Rio Grande, Puerto Rico|Local Institution, Rio Grande, Puerto Rico|Altamira Family Medicine And Research Institute, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|The Office Of Miguel Sosa-Padilla, Md, San Juan, Puerto Rico|Local Institution, Alba Iulia, Romania|Local Institution, Bacau, Romania|Local Institution, Bacau, Romania|Local Institution, Baia Mare, Romania|Local Institution, Brasov, Romania|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Constanta, Romania|Local Institution, Ploiesti, Romania|Local Institution, Satu Mare, Romania|Local Institution, Tg Mures, Romania|Local Institution, Mthatha, Eastern CAPE, South Africa|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Welkom, FREE State, South Africa|Local Institution, Lyttelton, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwazulu-Natal, South Africa|Local Institution, Phoenix, Durban, Kwazulu-Natal, South Africa|Local Institution, Brits, North-West, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Worcester, Western CAPE, South Africa|Local Institution, Potchefstroom, South Africa|Local Institution, Monifieth, AFO, United Kingdom|Local Institution, Carmarthen, CAT, United Kingdom|Local Institution, Fife, FIF, United Kingdom|Local Institution, Chippenham, Wiltshire, United Kingdom|Local Institution, Chippenham, WLT, United Kingdom|Local Institution, Addlestone, United Kingdom|Local Institution, Bath, United Kingdom|Local Institution, Cardenden Fife, United Kingdom|Local Institution, Dundee, United Kingdom|Local Institution, Dundee, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Nuneaton, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0
C/N=C(\N)N(C)C(=N)N.Cl,1,,_METFORMIN_XR,,"Active, not recruiting",NCT02915198,PREDIABETIC STATE|ATHEROSCLEROSIS|METFORMIN,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT02104739,PREDIABETES|OBESITY,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01951651,TYPE 2 DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT02072096,"DIABETES MELLITUS, TYPE 2",All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Florida Hospital, Orlando, Florida, United States|Athens Primary Care, Athens, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iderc, P.L.C., Des Moines, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Mercy Health Research, Saint Louis, Missouri, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Carolina Health Specialists, Myrtle Beach, South Carolina, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Stefan Ob Stainz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dortmund, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stuttgart, Germany|Manati Medical Center, Manati, Puerto Rico|American Telemedicine Center, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dundee, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ipswich, Suffolk, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01235819,TYPE 1 DIABETES,All,"12 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Command Hospital, Lucknow, UP, India",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Unknown status,NCT03383068,PCOS|IMPAIRED GLUCOSE TOLERANCE,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT03352869,POLYCYSTIC OVARY SYNDROME|OVERWEIGHT AND OBESITY|DISORDER OF GLUCOSE REGULATION,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital Department of Endocrinology and Metabolism, Shanghai, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Recruiting,NCT04029272,PCOS,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00546728,IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Diabetes Center at Park Nicollet, St. Louis Park, Minnesota, United States|St. Paul Heart Clinic, St. Paul, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Not yet recruiting,NCT04307797,TYPE2 DIABETES|OBESITY,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT01791465,HUMAN IMMUNODEFICIENCY VIRUS INFECTION|DIABETES MELLITUS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT02303730,"DIABETES MELLITUS, TYPE 2|NON-ALCOHOLIC FATTY LIVER DISEASE",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism, Shanghai Minhang Central Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Huadong Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Shanghai Changzheng Hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01006889,NONALCOHOLIC FATTY LIVER DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT03007329,"STEATOSIS, LIVER|TYPE2 DIABETES",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01076842,DIABETES TYPE 2,All,"18 Years to 90 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MedStar Research Institute, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Withdrawn,NCT00572689,GESTATIONAL DIABETES,Female,18 Years to 50 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Georgetown University Medical Center, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT00799435,"DIABETES MELLITUS, TYPE 2|HEART FAILURE, DIASTOLIC",All,"30 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Unknown status,NCT03361098,TYPE 2 DIABETES MELLITUS|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VU Medical Center, Amsterdam, Noord-Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Unknown status,NCT03029351,TYPE2 DIABETES|KIDNEY DISEASES,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT01381926,TYPE 2 DIABETES MELLITUS|BONE REMODELING,Female,"45 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Unknown status,NCT02962492,EVALUATE KETOGENIC STRESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00766857,TYPE 2 DIABETES MELLITUS|CONGESTIVE HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU University Medical Center, Amsterdam, Noord-Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT02802514,DIABETES,All,18 Years to 50 Years   (Adult),Industry|Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00845182,TYPE 2 DIABETES|HEALTHY|IMPAIRED GLUCOSE TOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Barter Research Center, ALM VA Hospital, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00974272,TYPE 2 DIABETES MELLITUS|IMPAIRED GLUCOSE TOLERANCE,All,"35 Years to 70 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phoenix VA Medical Center, Phoenix, Arizona, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00456885,OBESITY|IMPAIRED GLUCOSE TOLERANCE,Female,25 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Not yet recruiting,NCT03292315,SPINAL CORD INJURIES|INSULIN RESISTANCE|PRE DIABETES|OBESITY,All,"18 Years to 69 Years   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kessler Institute for Rehabilitation, West Orange, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01590433,OBESITY,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT02690883,DIABETIC NEPHROPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Withdrawn,NCT00845559,OBESITY|INSULIN RESISTANCE|IMPAIRED GLUCOSE TOLERANCE|CARDIOVASCULAR DISEASE,All,"13 Years to 25 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Unknown status,NCT02595606,DRY EYE SYNDROMES|DIABETES MELLITUS,All,"17 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clinical Research Center, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Completed,NCT00311870,DIABETIC NEPHROPATHY,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Steno Diabetes Center, Gentofte, Denmark",A61K9/2009,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Unknown status,NCT00430040,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetes - Endocrinology Center of Western New York, Buffalo, New York, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Completed,NCT00241124,HYPERTENSION,All,65 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Investigative Centers, Germany",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Terminated,NCT00171600,HYPERTENSION|EARLY DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Completed,NCT00171574,HYPERTENSION|DIABETIC NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis Pharmaceuticals, Basel, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O.O,1,,_CALCIFEDIOL,,Completed,NCT01939977,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O.O,1,,_CALCIFEDIOL,,Completed,NCT03588884,SECONDARY HYPERPARATHYROIDISM DUE TO RENAL CAUSES|VITAMIN D DEFICIENCY|CKD STAGE 3|CKD STAGE 4,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institute of Clinical Research, Inc., Garden Grove, California, United States|Research by Design, LLC, Chicago, Illinois, United States|Spaulding Clinical Research, West Bend, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Completed,NCT00245206,SCHIZOPHRENIA|ALZHEIMER'S DISEASE|DEMENTIA,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, San Diego, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Unknown status,NCT01742390,SEXUAL DYSFUNCTION|HYPERPROLACTINEMIA,All,"12 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of mental health, Peking University, Beijing, Beijing, China|The first hospital of Hebei Province University, Shijiazhuang, Hebei, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Completed,NCT00236379,SCHIZOPHRENIA|DIABETES MELLITUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Completed,NCT00287820,SCHIZOPHRENIA|DIABETES|METABOLIC SYNDROME|HYPERGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Psychaitric Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
CN1CC(=O)N=C1N,1,,_CREATININE,,Terminated,NCT02499185,ACUTE KIDNEY INJURY|ARTERIAL HYPERTENSION|OBESITY|CARDIO VASCULAR DISEASE|DIABETES MELLITUS|CHRONIC LIVER DISEASE|HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,1,,_CALCITONIN,,Completed,NCT03342001,HYPOTHYROIDISM,All,"18 Years to 88 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Center for Diabetes and Endocrinology, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,1,,_CALCITONIN,,Recruiting,NCT03935984,PRIMARY HYPERPARATHYROIDISM|HYPERCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"ProMedica Toledo Hospital, Toledo, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,1,,_DULOXETINE_HYDROCHLORIDE,EP-1273301-A2,Completed,NCT00266643,"DIABETIC NEUROPATHY, PAINFUL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ft. Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tallahassee, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Peters, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,58.7116778578615,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,,_CURCUMIN,WO-2002069910-A2,Not yet recruiting,NCT04528212,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tanta University Hospital, Tanta, El-Gharbia, Egypt",A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,,_CURCUMIN,WO-2002069910-A2,Unknown status,NCT01052597,TYPE 2 DIABETES MELLITUS|CARDIOVASCULAR ABNORMALITIES,All,"35 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"HRH Princess Maha Chakri Sirindhorn Medical Center, Ongkarak, Nakornnayok, Thailand",A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,,_CURCUMIN,WO-2002069910-A2,Unknown status,NCT01052025,TYPE 2 DIABETES|PRE-DIABETES|INSULIN RESISTANCE|CARDIOVASCULAR RISK,All,"35 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"HRH Princess Maha Chakri Sirindhorn Medical Center, Ongkarak, Nakornnayok, Thailand",A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,,_CURCUMIN,WO-2002069910-A2,Recruiting,NCT03917784,PRE-DIABETES,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital General de México Dr. Eduardo Liceaga, Mexico City, Cuauhtémoc, Mexico",A61K8/315,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,,_DAPTOMYCIN,4874843,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,,_DAPTOMYCIN,4874843,Terminated,NCT00463801,STAPHYLOCOCCAL SKIN INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Italy, Novartis Italy, Italy|Novartis Italy, Saronno, Italy",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT00454662,HYPERTENSION|CARDIOVASCULAR DISEASE|DIABETES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"COLM-Study Data Center, Kamiyacho MT Bld.14F, 4-3-20 Toranomon Minato-ku, Tokyo, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT00134160,HYPERTENSION|CARDIOVASCULAR DISEASES,All,65 Years to 84 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University, 1-1-1 Honjyo, Kumamoto-City, Kumamoto, Japan|OSCAR-Study Data Center, ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT00654745,TYPE 2 DIABETES|HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Sylmar, California, United States|Tustin, California, United States|Aventura, Florida, United States|DeLand, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Las Vegas, Nevada, United States|New Windsor, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Taylors, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT00403481,HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Mesa, Arizona, United States|Searcy, Arkansas, United States|Los Angeles, California, United States|Roseville, California, United States|Tustin, California, United States|Deland, Florida, United States|Pembroke Pines, Florida, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Jackson, Mississippi, United States|Florissant, Missouri, United States|Williamsville, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|New Talenwell, Tennessee, United States|New Tazewell, Tennessee, United States|Colleyville, Texas, United States|Corpus Christi, Texas, United States|Richardson, Texas, United States|Murray, Utah, United States|Norfolk, Virginia, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT01684748,OVERWEIGHT|OBESE|PREHYPERTENSION|HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Recruiting,NCT03514108,HEART FAILURE|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sygehus Sønderjylland, Aabenraa, Aabenraa, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Amager Hospital, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Copenhagen, Denmark|Glostrup Hospital, Copenhagen, Denmark|Herlev Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark|Herning Hospital, Herning, Denmark|Regionshospital Nordjylland, Hjørring, Hjørring, Denmark|Holbæk Hospital, Holbæk, Denmark|Horsens Hospital, Horsens, Denmark|Kolding Hospital, Kolding, Denmark|Nykøbing Falster Hospital, Nykøbing Falster, Denmark|Odense University Hospital, Odense, Denmark|Randers Hospital, Randers, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Vejle Hospital, Vejle, Denmark|Viborg Hospital, Viborg, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT03236740,PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SCB Medical College, Cuttack, Orissa, India",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,"Active, not recruiting",NCT03774108,PREDIABETES|HIV-1-INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT03796975,TYPE 2 DIABETES MELLITUS|NON-ALCOHOLIC FATTY LIVER DISEASE|EFFICACY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Not yet recruiting,NCT04288778,DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belgaum Diabetes Centre, Belgaum, India|Lifecare Hospital and Research Centre, Bengaluru, India|Kovai Diabetes Specialty Centre & Hospital, Coimbatore, India|Thumbay Hospital New life / Endocrinology, Hyderabad, India|Arthur Asirvatham Hospital, Madurai, India|Seth G. S. Medical College and KEM Hospital, Mumbai, India|Jehangir Clinical Development Center Pvt Ltd, Pune, India|Chellaram Diabetes Institute, Pune, India|Nirmal Hospital Pvt. Ltd., Surat, India|Jothydev's Diabetes Research Centre, Trivandrum, India",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Not yet recruiting,NCT04284722,HYPERGLYCEMIA|METFORMIN|TYPE 2 DIABETES|HYPERLACTATEMIA,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Withdrawn,NCT02881528,PREDIABETIC STATE,All,5 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NHS Ayrshire & Arran, Kilmarnock, Ayrshire, United Kingdom|NHS Grampian, Aberdeen, Grampian, United Kingdom|NHS Lanarkshire, Wishaw, Lanarkshire, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT03361878,"DIABETES MELLITUS, TYPE 2|METFORMIN ADVERSE REACTION",All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT04549415,CHRONIC HEART FAILURE|CORONARY ARTERY DISEASE|PREDIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Centre of Cardiology and Internal Medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyzstan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1,1,,_ORGANON,,Unknown status,NCT00417144,POLYCYSTIC OVARY SYNDROME|OVARIAN HYPERSTIMULATION SYNDROME,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Eugonia, Athens, Greece",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1
COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1,1,,_ORGANON,,Completed,NCT00417066,INFERTILITY|PREMATURE OVARIAN FAILURE,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eugonia, Athens, Greece",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1
CC(=O)O.C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,,_METHYLPREDNISOLONE_ACETATE,4012508,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,25.331115628657603,217.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Unknown status,NCT00144144,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Unknown status,NCT01500590,DIABETES|HYPERTENSIVE DISEASE,All,"35 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Authority, HKEC, FM&PHC, Hong Kong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Completed,NCT01461499,TYPE 2 DIABETES MELLITUS|HYPERTENSION,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shiga University of Medical Science, Otsu, Shiga, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Completed,NCT01588795,DIABETIC NEPHROPATHY|PERSISTENT PROTEINURIA WITH TYPE II DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CIC Hopital europeen george pompidou, Paris, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,1,,_ANGIOTENSIN_II,,Unknown status,NCT00144144,"HYPERTENSION|DIABETES MELLITUS, TYPE 2",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
CCCCCCOC(=O)/N=C(\N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,,_DABIGATRAN_ETEXILATE,,Recruiting,NCT03789695,ATRIAL FIBRILLATION|T2D|CHRONIC KIDNEY DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT00204373,ZOLLINGER-ELLISON SYNDROME|MULTIPLE ENDOCRINE NEOPLASIA,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,,_CORTISONE,,Recruiting,NCT03760835,CONGENITAL ADRENAL HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O,1,,_FRUCTOSE,3931402,Completed,NCT03003507,CRITICAL ILLNESS,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,30.0293640526499,16396.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,1,,_DOXORUBICIN_HYDROCHLORIDE,4003996,Completed,NCT00727961,OVARIAN NEOPLASMS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,1,,_CYPROTERONE,4725439,Completed,NCT02866786,PCOS,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Obstetrics & Gynecology, Cuttack, Odisha, India",A61K9/0034,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.1011314400706,180.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,1,,_CYPROTERONE,4725439,Unknown status,NCT01103518,AMENORRHEA|DYSMENORRHEA|MENSTRUATION DISTURBANCES|HYPERANDROGENISM,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital das Clínicas de Teresópolis, Teresópolis, Rio de Janeiro, Brazil",A61K9/0034,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.1011314400706,180.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,1,,_CYPROTERONE,4725439,Unknown status,NCT02027337,POLYCYSTIC OVARIAN SYNDROME|HYPERANDROGENISM|MENSTRUAL IRREGULARITIES,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Tyumen State Medical Academy, Tyumen, Russian Federation",A61K9/0034,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,25.1011314400706,180.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Completed,NCT02097615,SOFT TISSUE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Leon, Leon, Guanajuato, Mexico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Recruiting,NCT03209466,DIABETIC FOOT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universidad de Guanajuato, Leon, Guanajuato, Mexico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,1,,_TOLVAPTAN,5753677,Unknown status,NCT01716611,HYPONATREMIA|ASCITES,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Konkuk University Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,1,,_TOLVAPTAN,5753677,Enrolling by invitation,NCT02476409,CONGESTIVE HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,35.3847101583194,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,1,,_TOLVAPTAN,5753677,Completed,NCT01346072,CARDIOVASCULAR DISEASES|HEART DISEASES|HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,35.3847101583194,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,,_OCTREOTIDE_ACETATE,,Completed,NCT00376064,ACROMEGALY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Completed,NCT03267576,"DIABETES MELLITUS, TYPE 2",All,19 Years to 54 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Consultorio Privado, Guadalajara, Mexico|Investigación Clínica Especializada, Guadalajara, Mexico|Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,"Active, not recruiting",NCT02653209,TYPE 2 DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Exeter Clinical Research Facility, Exeter, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Completed,NCT02920918,"HEART FAILURE, SYSTOLIC|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Not yet recruiting,NCT04288778,DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belgaum Diabetes Centre, Belgaum, India|Lifecare Hospital and Research Centre, Bengaluru, India|Kovai Diabetes Specialty Centre & Hospital, Coimbatore, India|Thumbay Hospital New life / Endocrinology, Hyderabad, India|Arthur Asirvatham Hospital, Madurai, India|Seth G. S. Medical College and KEM Hospital, Mumbai, India|Jehangir Clinical Development Center Pvt Ltd, Pune, India|Chellaram Diabetes Institute, Pune, India|Nirmal Hospital Pvt. Ltd., Surat, India|Jothydev's Diabetes Research Centre, Trivandrum, India",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,"Active, not recruiting",NCT02462421,DIABETES MELLITUS|GOUT|HYPERURICEMIA,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Completed,NCT01989754,"DIABETES MELLITUS, TYPE 2|ALBUMINURIA",All,"30 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Little Rock, Arkansas, United States|Carmichael, California, United States|Concord, California, United States|Pismo Beach, California, United States|Roseville, California, United States|Thousand Oaks, California, United States|Denver, Colorado, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Opa-locka, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Tampa, Florida, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Valparaiso, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Mandeville, Louisiana, United States|Metairie, Louisiana, United States|Elkridge, Maryland, United States|Flint, Michigan, United States|Picayune, Mississippi, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Washington, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Cornelius, North Carolina, United States|Hickory, North Carolina, United States|Mooresville, North Carolina, United States|Canal Fulton, Ohio, United States|Franklin, Ohio, United States|Mason, Ohio, United States|Oklahoma City, Oklahoma, United States|Beaver, Pennsylvania, United States|Levittown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Tipton, Pennsylvania, United States|Greer, South Carolina, United States|Jefferson City, Tennessee, United States|Austin, Texas, United States|Pearland, Texas, United States|Bountiful, Utah, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Falls Church, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States|Wauwatosa, Wisconsin, United States|Buenos Aires, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Cordoba, Argentina|Mar Del Plata, Argentina|Moron, Argentina|Rosario, Argentina|Zarate, Buenos Aires, Argentina|Box Hill, Australia|Cairns, Australia|Daw Park, Australia|Freemantle, Australia|Liverpool, Australia|Melbourne, Australia|Newcastle, Australia|Sherwood, Australia|Sydney, Australia|Tasmania, Australia|Woden, Australia|Woolloongabba, Australia|Bonheiden, Belgium|Brugge, Belgium|Edegem, Belgium|Gent, Belgium|La Louvière, Belgium|Leuven, Belgium|Liege, Belgium|Liÿge, Belgium|Merksem, Belgium|Ransart, Belgium|Roeselare, Belgium|Tessenderlo, Belgium|Belem, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Mogi Das Cruzes, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Coquitlam, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Guelph, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Sarnia, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Lévis, Quebec, Canada|Quebec City, Quebec, Canada|Saint Marc Des Carriéres, Quebec, Canada|Sherbrooke, Quebec, Canada|Westmont, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Baotou, China|Beijing, China|Hangzhou, China|Jinan, China|Shenyang, China|Wuxi, China|Beroun, Czechia|Ostrava, Czechia|Plzen, Czechia|Praha 10, Czechia|Praha 1, Czechia|Praha 4, Czechia|Praha 8, Czechia|Znojmo, Czechia|Amiens, France|Bois Guillaume, France|Bordeaux, France|Dijon, France|Grenoble, France|La Rochelle Cedex 1, France|Le Creusot, France|Narbonne Cedex, France|Paris, France|Poitiers, France|Aschaffenburg, Germany|Aßlar, Germany|Bad Oeynhausen, Germany|Dortmund, Germany|Dresden, Germany|Freiburg, Germany|Hannover, Germany|Kassel, Germany|Mainz, Germany|Neuwied, Germany|Saarbrücken, Germany|Villingen-Schwenningen, Germany|Balatonfured, Hungary|Budapest, Hungary|Dunaújváros, Hungary|Eger, Hungary|Kecskemét, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Szekesfehervar, Hungary|Szikszó, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|*Osenza*, Italy|Arenzano, Italy|Bologna, Italy|Catanzaro, Italy|Chieri (Torino), Italy|Firenze, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Ravenna, Italy|Roma N/A, Italy|Roma, Italy|Sesto San Giovanni (Milano), Italy|Verona, Italy|Ansan, Korea, Republic of|Bucheon, Korea, Republic of|Busan, Korea, Republic of|Changwon, Korea, Republic of|Cheongju, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Iksan, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Seongnam-Si, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Ulsan, Korea, Republic of|Wonju-Si, Korea, Republic of|Batu Caves, Malaysia|Georgetown, Malaysia|Ipoh, Malaysia|Kelantan, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Aguascalientes, Mexico|Celaya, Mexico|Cuernavaca, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Mexico, Mexico|Pachuca De Soto, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Tampico, Mexico|Almelo, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Hoogeveen, Netherlands|Hoogezand, Netherlands|Kloosterhaar, Netherlands|Leiden, Netherlands|Meppel, Netherlands|Poortvliet, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Velp, Netherlands|Waalwijk, Netherlands|Wamel, Netherlands|Zoetermeer, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Newtown, New Zealand|Palmerston North, New Zealand|Rotorua, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Bialystok, Poland|Bydgoszcz, Poland|Chrzanow, Poland|Gdansk, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lublin, Poland|Oswiecim, Poland|Torun, Poland|Tychy, Poland|Warszawa, Poland|Wroclaw, Poland|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Kemerovo, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Rostov-On-Don, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tyumen, Russian Federation|Vsevolzhsk, Russian Federation|Yaroslavl, Russian Federation|A Coruna, Spain|Alcalá De Henares, Spain|Alicante, Spain|Almeria, Spain|Alzira, Spain|Barcelona, Spain|Ciudad Real, Spain|Cordoba, Spain|Ferrol, Spain|Figueres, Spain|Galdakao, Spain|Madrid, Spain|Malaga, Spain|Móstoles, Spain|Palma De Mallorca, Spain|Sabadell, Spain|San Sebastian De Los Reyes, Spain|Sant Joan D'Alacant, Spain|Santa Cruz De Tenerife, Spain|Santiago De Compostela, Spain|Segovia, Spain|Sevilla N/A, Spain|Sevilla, Spain|Valencia, Spain|Viladecans, Spain|Borås, Sweden|Goteborg, Sweden|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Lund, Sweden|Malmo, Sweden|Stockholm, Sweden|Uddevalla, Sweden|Uppsala, Sweden|Vallingby, Sweden|Västra Frölunda, Sweden|Kaohsiung County, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tiachung, Taiwan|Xindian, Taiwan|Cherkasy, Ukraine|Chernivtsy, Ukraine|Dnipropetrovsk, Ukraine|Ivan-Frankivsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Vinnytsya, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Addlestone, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bristol, United Kingdom|Bury St Edmunds, United Kingdom|Chesterfield, United Kingdom|Derby, United Kingdom|Doncaster, United Kingdom|Ipswich, United Kingdom|Leicester, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Salford, United Kingdom|Taunton, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Wellingborough, United Kingdom|Welwyn Garden City, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Completed,NCT01939496,"DIABETES MELLITUS, TYPE 2|HYPERTENSION",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Gulf Shores, Alabama, United States|Avondale, Arizona, United States|Phoenix, Arizona, United States|Glendale, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Pismo Beach, California, United States|Rancho Cucamonga, California, United States|Roseville, California, United States|Sacramento, California, United States|Spring Valley, California, United States|Tustin, California, United States|Denver, Colorado, United States|Brandon, Florida, United States|Doral, Florida, United States|Fort Lauderdale, Florida, United States|Lake Worth, Florida, United States|Lauderdale Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|West Palm Beach, Florida, United States|Perry, Georgia, United States|Rincon, Georgia, United States|Indianapolis, Indiana, United States|Topeka, Kansas, United States|Lexington, Kentucky, United States|Mandeville, Louisiana, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Dearborn, Michigan, United States|Kalamazoo, Michigan, United States|Jackson, Mississippi, United States|St. Louis, Missouri, United States|Morganville, New Jersey, United States|Whiting, New Jersey, United States|Albuquerque, New Mexico, United States|Raleigh, North Carolina, United States|Oklahoma City, Oklahoma, United States|Altoona, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|Sugar Land, Texas, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Carolina, Puerto Rico|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Terminated,NCT02912455,"DIABETES MELLITUS, TYPE 2|OBESITY",All,"20 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cleveland Clinic, Cleveland, Ohio, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Withdrawn,NCT02597309,"DIABETES, OBESITY",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Joslin Diabetes Center, Boston, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Withdrawn,NCT03190798,TYPE2 DIABETES MELLITUS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Completed,NCT02360774,TYPE 2 DIABETES|OVERWEIGHT|OBESITY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Recruiting,NCT03475589,STAGE IV CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Completed,NCT03384511,MALIGNANCIES|STOMACH CANCER|NON-SMALL CELL LUNG CANCER|ESOPHAGEAL CANCER|BREAST CANCER|OVARY CANCER|CERVICAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jinan, Shandong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,1,,_LANREOTIDE,,Completed,NCT00145405,ACROMEGALY,All,"22 Years to 72 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,,_BETAMETHASONE_ACETATE,3962430,Unknown status,NCT02652884,TRANSIENT HYPOPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,152.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1
C1CSCN1,1,,_THIAZOLIDINE,,Completed,NCT02730377,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Alhambra, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Elk Grove, California, United States|Novo Nordisk Investigational Site, Encinitas, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mirada, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Westminster, California, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Seminole, Florida, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Aurora, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Georgetown, Texas, United States|Novo Nordisk Investigational Site, Gonzales, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Missouri City, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Bellevue, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hubli, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Tukums, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adapazari, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C1CSCN1,1,,_THIAZOLIDINE,,Completed,NCT02954692,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Turkey, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(C(=O)O)cc1,1,,_MEGLITINIDE,4221815,Completed,NCT02730377,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Alhambra, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Elk Grove, California, United States|Novo Nordisk Investigational Site, Encinitas, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mirada, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Westminster, California, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Seminole, Florida, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Aurora, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Georgetown, Texas, United States|Novo Nordisk Investigational Site, Gonzales, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Missouri City, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Bellevue, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hubli, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Tukums, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adapazari, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",C07D333/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,56.2475615515718,1088.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(C(=O)O)cc1,1,,_MEGLITINIDE,4221815,Completed,NCT02954692,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Turkey, Turkey",C07D333/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,56.2475615515718,1088.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_CETIRIZINE_HYDROCHLORIDE,5993833,Completed,NCT03047278,"NEUROPATHIC PAIN|TYPE 2 DIABETES MELLITUS|DIABETIC NEUROPATHY, PAINFUL",All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.NC12CC3CC(CC(C3)C1)C2,1,,_AMANTADINE_HYDROCHLORIDE,4148896,Terminated,NCT00975611,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Freedom Trail Clinic, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,13.5362122425511,292.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,,_THYROXINE,3938953,Unknown status,NCT00111735,HYPOTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia",G01N33/78,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.698576972833106,803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,,_DESMOPRESSIN,4613500,Completed,NCT00337766,"HEMORRHAGE|BLOOD LOSS, SURGICAL|POSTOPERATIVE HEMORRHAGE",All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy|Istituto Policlinico S.Donato, Milano, Italy|Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia, Milan, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy",A61K9/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,30.489332429824,674.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],1,,_ATORVASTATIN_CALCIUM,5316765,Recruiting,NCT03532620,PREDIABETIC STATE|HYPERTENSION|DYSLIPIDEMIAS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fourth People's Hospital of Chongqing, Chongqing, Chongqing, China|First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|People's Hospital of Zhongshan City, Zhongshan, Guangdong, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Yichang Central Hospital, Yichang, Hubei, China|Taizhou Hospital of TCM, Taizhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China|Lanzhou University Second Hospital, Lanzhou, Qinghai, China|Yantaishan Hospital, Yantai, Yantai, Shandong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,32.3620608226041,4059.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2],1,,_PITAVASTATIN_CALCIUM,EP-1325745-B1,Recruiting,NCT03532620,PREDIABETIC STATE|HYPERTENSION|DYSLIPIDEMIAS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fourth People's Hospital of Chongqing, Chongqing, Chongqing, China|First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|People's Hospital of Zhongshan City, Zhongshan, Guangdong, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Yichang Central Hospital, Yichang, Hubei, China|Taizhou Hospital of TCM, Taizhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China|Lanzhou University Second Hospital, Lanzhou, Qinghai, China|Yantaishan Hospital, Yantai, Yantai, Shandong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,81.3815478757264,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-],1,,_THIAMINE,3946115,Unknown status,NCT01725412,DIABETIC NEPHROPATHY,All,30 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Royal University Hospital, Saskatoon, Saskatchewan, Canada",A23K20/158,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,2969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,1,,_BUPROPION_HYDROCHLORIDE,RE33994,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,1,,_COSYNTROPIN,4127537,Withdrawn,NCT03752190,ADRENAL INSUFFICIENCY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,C07K14/6755,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.4130885644469,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,1,0
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,,_FOSAPREPITANT,,Completed,NCT01432015,OVARIAN CANCER|UTERINE CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Gynecologic Oncology Associates, Newport Beach, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
C/C(=C(/CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,,_BENFOTIAMINE,,Unknown status,NCT00446810,"DIABETES MELLITUS, TYPE 2",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Herz- und Diabeteszentrum NRW, Georgstr. 11, Bad Oeynhausen, North Rhine-Westphalia, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
C/C(=C(/CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,,_BENFOTIAMINE,,Completed,NCT00437008,ENDOTHELIAL DYSFUNCTION|TYPE 2 DIABETES MELLITUS,All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Prevention,"Heart and Diabetes Center NRW, Bad Oeynhausen, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
C/C(=C(/CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,1,,_BENFOTIAMINE,,Completed,NCT00565318,DIABETIC NEPHROPATHY,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Isala Klinieken Hospital, Zwolle, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
O=C(O)O,1,,_BICARBONATE,,Completed,NCT02502071,TYPE 1 DIABETES|DIABETIC NEPHROPATHY|DIABETIC KIDNEY DISEASE,All,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)O,1,,_BICARBONATE,,Unknown status,NCT00950079,CONTRAST INDUCED NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|Busan Saint Mary Hospital, Busan, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Cheonan, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gangneung Asan Hospital, Gangneung, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1CC2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,,_ZOTAROLIMUS,,Recruiting,NCT03321032,CORONARY ARTERY DISEASE|DIABETES MELLITUS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Completed,NCT00512707,ERECTILE DYSFUNCTION|TESTOSTERONE DEFICIENCY|DIABETES,Male,"40 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Boston University Medical Center, Boston, Massachusetts, United States",A61K9/19,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,1,,_PIOGLITAZONE_HYDROCHLORIDE,5356913,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,17.8730569416209,190.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,1,,_PIOGLITAZONE_HYDROCHLORIDE,5356913,Not yet recruiting,NCT03950505,NON-ALCOHOLIC STEATOHEPATITIS|TYPE2 DIABETES,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,17.8730569416209,190.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Not yet recruiting,NCT04522622,ADYNAMIC BONE DISEASE|CHRONIC KIDNEY DISEASES|CARDIAC DISEASE|CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Herlev and Gentofte Hospital, Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,"Active, not recruiting",NCT03472846,POSTMENOPAUSAL OSTEOPOROSIS|DIABETES TYPE 2,Female,"60 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Medical University Vienna; St. Vincent Hospital, Vienna, Austria",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,,_ESTROGEN,,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Unknown status,NCT02232971,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Hvidovre University Hospital, Hvidovre, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Recruiting,NCT04053712,TYPE 1 DIABETES|HYPOGLYCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Not yet recruiting,NCT04307797,TYPE2 DIABETES|OBESITY,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Completed,NCT02516150,TYPE 1 DIABETES,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Completed,NCT01155206,DIABETES,All,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"University Health Network, Toronto General Hospital, Toronto,, Ontario, Canada",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,,_LEUPROLIDE_ACETATE,4851211,Recruiting,NCT04094467,PCOS,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ahmed Abbas, Assiut, Cairo, Egypt",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,,_LEUPROLIDE_ACETATE,4851211,Completed,NCT00805935,POLYCYSTIC OVARIAN SYNDROME|INFERTILITY,Female,18 Years to 42 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States|Women's Medical Research Group LLC, Florida, Clearwater, Florida, United States|Fertility Center of Illinois, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Women & Infants' Hospital of RI, Providence, Rhode Island, United States|Center for Assisted Reproduction, Bedford, Texas, United States",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,,_LEUPROLIDE_ACETATE,4851211,Completed,NCT00349258,OVARIAN HYPERSTIMULATION SYNDROME,Female,20 Years to 39 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Center for Advanced Reproductive Services, UCHC, Farmington, Connecticut, United States",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O,1,,_CETRORELIX_ACETATE,5635161,Enrolling by invitation,NCT03763786,INFERTILITY,Female,18 Years to 42 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oxford Fertility, Oxford, United Kingdom",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,23.8855007289677,530.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,1,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O,1,,_CETRORELIX_ACETATE,5635161,Unknown status,NCT03477929,INFERTILITY/STERILITY,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale Bernabeo, Ortona, Chieti, Italy",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,23.8855007289677,530.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,1,1,1,1
CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,,_GANIRELIX_ACETATE,,Unknown status,NCT03477929,INFERTILITY/STERILITY,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale Bernabeo, Ortona, Chieti, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Not yet recruiting,NCT03700645,DIABETES MELLITUS|ISCHEMIC HEART DISEASE|MULTI VESSEL CORONARY ARTERY DISEASE,All,"40 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02829177,TYPE 1 DIABETES|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Steno Diabetes Center, Gentofte, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Unknown status,NCT03195153,DIABETES MELLITUS TYPE 2 PLATELETS REACTIVITY STATIN,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Policlinico Umberto I, Rome, Roma, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_FENTANYL_CITRATE,4486423,Completed,NCT01308320,THYROID NEOPLASMS,Female,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Severance Hospital, Seoul, Korea, Republic of",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
O.OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,,_LACTULOSE,WO-2005016898-A2,Completed,NCT03666546,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Clinical Research Center (CRC), Graz, Austria",A61P25/00 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O,1,,_BERAPROST,5403867,Terminated,NCT02786979,TYPE 2 DIABETES,All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Site CN00001, Beijing, Beijing, China|Site CN00002, Beijing, Beijing, China|Site CN00004, Guangzhou, Guangdong, China|Site CN00003, Shanghai, Shanghai, China|Site CN00005, Chengdu, Sichuan, China|Site CN00006, Tianjin, Tianjin, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,16.0988932010924,256.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
NC(CS)C(=O)O,1,,_CYSTEINE,,Completed,NCT02239107,PCOS,Female,18 Years to 39 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,,_BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,1,,_RETINAL,3953524,Completed,NCT00802269,PROLIFERATIVE DIABETIC RETINOPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asociacion para Evitar la Ceguera en Mexico, Mexico City, DF, Mexico",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
O=C([O-])CCCc1ccccc1.[Na+],1,,_SODIUM_PHENYLBUTYRATE,5605930,Completed,NCT00533559,DIABETES|INSULIN RESISTANCE,Male,35 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,"Toronto General Hospital, Toronto, Ontario, Canada",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,35.680404115074204,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Withdrawn,NCT00227773,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL CARCINOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
NC(=O)NCCC[C@H](N)C(=O)O,0,DB00155,__CITRULLINE,3950513,Terminated,NCT02772887,TYPE 2 DIABETES,Female,"14 Years to 40 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,78.7860120331013,1323.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,175.1857,118.44,4.0,4.0,0.0,17.35,41.33,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1
C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,0,DB00179,__MASOPROCOL,3995632,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",B01J4/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,26.2510523830058,271.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,302.3649,80.92,4.0,4.0,2.0,33.63,86.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00923247,MEDULLARY THYROID CARCINOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT01056601,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00416793,ACINAR CELL ADENOCARCINOMA OF THE PANCREAS|DUCT CELL ADENOCARCINOMA OF THE PANCREAS|STAGE IV PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MD Anderson Cancer Network, Houston, Texas, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Withdrawn,NCT00610792,OVARIAN CANCER,Female,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Gynecologic Oncology, Università Catholica Sacre Cuore, Campbasso, Italy|Istituto Europeo di Oncologia (IEO), Milan, Italy|Istituto Nazionale dei Tumori, Milan, Italy|Dept. Procreational Medicine, Università di Pisa, Pisa, Italy|Kantonsspital St. Gallen, St. Gallen, CH, Switzerland|Gynecologic Oncology Unit, Ospedale Sant' Anna, Turin, Switzerland|Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland",C07K5/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,0,DB00207,__AZITHROMYCIN,5192535,Withdrawn,NCT01379196,GRAVES OPHTHALMOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,0,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00324324,BREAST CANCER|CHRONIC MYELOPROLIFERATIVE DISORDERS|GESTATIONAL TROPHOBLASTIC TUMOR|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUROBLASTOMA|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT01086332,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00227,__LOVASTATIN,6080428,Terminated,NCT00585052,OVARIAN CANCER,Female,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,0,DB00279,__LIOTHYRONINE,3961894,Terminated,NCT00488644,HYPOTHYROIDISM|BRAIN TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",G01N33/78,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,25.561099817244703,766.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,650.9735,92.78,4.0,3.0,2.0,43.92,113.43,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT03225781,PANCREATIC CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Verona Hospital, Verona, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,0,DB00295,__MORPHINE,5378474,Terminated,NCT00660348,PAIN|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,0,DB00303,__ERTAPENEM,5478820,Withdrawn,NCT00392028,AMPUTATION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ha'Emek Medical Center, Afula, Israel|Haemek Medical Center INFECTIOUS DISEASES UNIT, Afula, Israel|Haemek Medical Center INFECTIOUS DISEASES UNIT, Afula, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,0,DB00305,__MITOMYCIN,7806265,Terminated,NCT00276744,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CCCC(CCC)C(=O)O,0,DB00313,__VALPROIC_ACID,6419953,Terminated,NCT00525135,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Comprehensive Cancer Center, San Francisco, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CN(C)CCC=C1c2ccccc2CCc2ccccc21,0,DB00321,__AMITRIPTYLINE,3965255,Terminated,NCT03591458,TYPE1 DIABETES MELLITUS|HYPOGLYCEMIA UNAWARENESS,All,21 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States",A61K9/282,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB00324,__FLUOROMETHOLONE,3962414,Withdrawn,NCT00824811,EPIPHORA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT02331251,ADVANCED CANCER|BREAST CANCER|SARCOMA|PANCREATIC CANCER|SMALL CELL LUNG CANCER|OVARIAN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States|Western Regional Medical Center, Goodyear, Arizona, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,DB00377,__PALONOSETRON,5202333,Terminated,NCT00903396,ANAL CANCER|CARCINOMA OF THE APPENDIX|COLORECTAL CANCER|EXTRAHEPATIC BILE DUCT CANCER|GALLBLADDER CANCER|GASTRIC CANCER|GASTROINTESTINAL CARCINOID TUMOR|LIVER CANCER|NAUSEA AND VOMITING|PANCREATIC CANCER|PRIMARY PERITONEAL CAVITY CANCER|SMALL INTESTINE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Bettendorf, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Wesley Medical Center, Wichita, Kansas, United States|Michiana Hematology Oncology PC - Niles, Niles, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fergus Falls Medical Group, PA, Fergus Falls, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare - La Crosse Campus, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Door County Cancer Center at Door County Memorial Hospital, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00095693,ANAPLASTIC THYROID CANCER|INSULAR THYROID CANCER|RECURRENT THYROID CANCER|STAGE III FOLLICULAR THYROID CANCER|STAGE III PAPILLARY THYROID CANCER|STAGE IV FOLLICULAR THYROID CANCER|STAGE IV PAPILLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00526799,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|St. Vincent Hospital Cynecologic Oncology, Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States",C07D209/46,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00522301,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan - Kettering Cancer Center, New York, New York, United States",C07D209/46,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00126568,ANAPLASTIC THYROID CANCER|RECURRENT THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Withdrawn,NCT01736878,MEDULLARY THYROID CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital Ulm, Clinic for Nuclear Medicine, Ulm, Baden-Wuerttemberg, Germany",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB00428,__STREPTOZOCIN,4978332,Terminated,NCT00609765,PANCREATIC CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,38.6701985667056,1048.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.7,265.2206,151.92,7.0,5.0,1.0,23.74,55.96,3.0,0.0,1.0,0.0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,0,DB00434,__CYPROHEPTADINE,3968115,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.719645167251905,797.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,287.3981,3.24,1.0,0.0,4.0,34.17,105.17,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,0,DB00445,__EPIRUBICIN,4950738,Terminated,NCT01167738,PANCREATIC CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Scientifico H. San Raffaele, Milan, Italy",A61K41/0042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,0,DB00445,__EPIRUBICIN,4950738,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",A61K41/0042,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT01202890,OVARIAN CANCER|EPITHELIAL OVARIAN CANCER|FALLOPIAN TUBE CARCINOMA|PRIMARY PERITONEAL CARCINOMA,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of New Mexico Cancer Center, Albuquerque, New Mexico, United States",C07D401/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT00903630,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States",C07D401/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,0,DB00497,__OXYCODONE,5508042,Terminated,NCT01063868,"DIABETIC NEUROPATHY, PAINFUL|DIABETIC POLYNEUROPATHY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mesa, Arizona, United States|Tucson, Arizona, United States|Fruitland Park, Florida, United States|New Port Richey, Florida, United States|Oviedo, Florida, United States|Tampa, Florida, United States|Libertyville, Illinois, United States|Franklin, Indiana, United States|Paducah, Kentucky, United States|Wellesley Hills, Massachusetts, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Greenville, North Carolina, United States|Hickory, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Kettering, Ohio, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Dallas, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Virginia Beach, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,0,DB00499,__FLUTAMIDE,3995060,Terminated,NCT01428193,POLYCYSTIC OVARY SYNDROME|HYPERANDROGENISM,Female,13 Years to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States",1,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,26.6453109920121,2145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.55,276.2118,74.92,3.0,1.0,1.0,23.2,63.42,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,0,DB00499,__FLUTAMIDE,3995060,Terminated,NCT00729560,PCOS,Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","Virginia Commonwealth University General Clinical Research Center, Richmond, Virginia, United States",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,26.6453109920121,2145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.55,276.2118,74.92,3.0,1.0,1.0,23.2,63.42,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00002819,OVARIAN CANCER,Female,"up to 65 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Primary Purpose: Treatment,"Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Togus, Togus, Maine, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Vermont Cancer Center, Burlington, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Veterans Affairs Medical Center - Richmond, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States",7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00004221,MALIGNANT OVARIAN MIXED EPITHELIAL TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|PRIMARY PERITONEAL CARCINOMA|STAGE III OVARIAN CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT02650635,COLORECTAL ADENOCARCINOMA|METASTATIC PANCREATIC ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT COLORECTAL CARCINOMA|RECURRENT MELANOMA OF THE SKIN|RECURRENT NON-SMALL CELL LUNG CARCINOMA|RECURRENT PANCREATIC CARCINOMA|RECURRENT RENAL CELL CARCINOMA|SOLID NEOPLASM|STAGE IV BREAST CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV RENAL CELL CANCER|STAGE IV SKIN MELANOMA|STAGE IVA COLORECTAL CANCER|STAGE IVA PANCREATIC CANCER|STAGE IVB COLORECTAL CANCER|STAGE IVB PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01312376,OVARIAN CARCINOMA|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00652899,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01583686,CERVICAL CANCER|PANCREATIC CANCER|OVARIAN CANCER|MESOTHELIOMA|LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT02465983,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT00551265,FALLOPIAN TUBE CARCINOMA|PRIMARY PERITONEAL CARCINOMA|RECURRENT OVARIAN CARCINOMA|STAGE III OVARIAN CANCER|STAGE IV OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT02948101,RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT02390739,METASTATIC THYROID CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Suspended,NCT03127124,PANCREATIC ADENOCARCINOMA METASTATIC,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institutes for Medicine, El Segundo, California, United States",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Terminated,NCT00262951,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Withdrawn,NCT02575508,COLON ADENOCARCINOMA|METASTATIC PANCREATIC ADENOCARCINOMA|PANCREATIC ADENOCARCINOMA|PANCREATIC DUCTAL ADENOCARCINOMA|RECTAL ADENOCARCINOMA|STAGE III PANCREATIC CANCER|STAGE IIIA COLON CANCER|STAGE IIIA RECTAL CANCER|STAGE IIIB COLON CANCER|STAGE IIIB RECTAL CANCER|STAGE IIIC COLON CANCER|STAGE IIIC RECTAL CANCER|STAGE IV PANCREATIC CANCER|STAGE IVA COLON CANCER|STAGE IVA RECTAL CANCER|STAGE IVB COLON CANCER|STAGE IVB RECTAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,0,DB00549,__ZAFIRLUKAST,4859692,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,0,DB00569,__FONDAPARINUX,,Withdrawn,NCT00659399,OVARIAN CARCINOMA,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute Clinical Cancer Center, New York, New York, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,1508.263,805.48,44.0,19.0,5.0,122.56,255.85,27.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,DB00570,__VINBLASTINE,3932417,Terminated,NCT00072215,EXTRAGONADAL GERM CELL TUMOR|TESTICULAR GERM CELL TUMOR,Male,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northeast Alabama Regional Medical Center, Anniston, Alabama, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Naval Medical Center - San Diego, San Diego, California, United States|Veterans Affairs Medical Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|West Suburban Center for Cancer Care, River Forest, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Baptist Hospital East - Louisville, Louisville, Kentucky, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, United States|New Hampshire Oncology-Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|NorthEast Oncology Associates - Concord, Concord, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, United States|Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, United States|Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Miriam Hospital at Lifespan, Providence, Rhode Island, United States|Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Virginia Oncology Associates - Norfolk, Norfolk, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke, Roanoke, Virginia, United States|St. Mary's Medical Center, Huntington, West Virginia, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|McGill Cancer Centre at McGill University, Montreal, Quebec, Canada",C07D519/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,15409.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,810.9741,154.1,9.0,3.0,9.0,87.46,222.42,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,0,DB00607,__NAFCILLIN,4217274,Withdrawn,,OSTEOMYELITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,19.450091377646306,817.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,414.475,95.94,5.0,2.0,4.0,42.22,108.14,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00617929,CANCER,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00310050,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00864513,PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1,0,DB00648,__MITOTANE,4133893,Terminated,NCT00778817,RECURRENT ADRENOCORTICAL CARCINOMA|STAGE III ADRENOCORTICAL CARCINOMA|STAGE IV ADRENOCORTICAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,19.4829462617302,1707.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.08,320.041,0.0,0.0,0.0,2.0,29.93,79.97,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Suspended,NCT03127124,PANCREATIC ADENOCARCINOMA METASTATIC,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institutes for Medicine, El Segundo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT02782182,PANCREATIC DUCTAL ADENOCARCINOMA (PDAC),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT01359007,ADENOCARCINOMA OF PANCREAS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT00227617,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL TUMOR|LUNG CANCER|NEOPLASTIC SYNDROME|NEUROENDOCRINE TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Univeristy of California, San Francisco, San Francisco, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT01050426,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kent Oncology Centre, Tunbridge Wells, Maidstone, United Kingdom|Royal Surrey County Hospital NHS Trust, Guildford, Surrey, United Kingdom|The Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Royal Bournemouth Hospital, Bournemouth, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Poole Hospital NHS Trust, Poole, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Withdrawn,NCT03197584,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
CNC[C@H](O)c1ccc(O)c(O)c1,0,DB00668,__EPINEPHRINE,5665071,Withdrawn,NCT00605774,TYPE 1 DIABETES,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61M5/31511,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,0,DB00749,__ETODOLAC,3939178,Terminated,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,41.0686051048276,2463.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,287.3535,62.32,3.0,2.0,3.0,31.94,81.16,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT00100828,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT00276744,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT02331251,ADVANCED CANCER|BREAST CANCER|SARCOMA|PANCREATIC CANCER|SMALL CELL LUNG CANCER|OVARIAN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States|Western Regional Medical Center, Goodyear, Arizona, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT02782182,PANCREATIC DUCTAL ADENOCARCINOMA (PDAC),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT01359007,ADENOCARCINOMA OF PANCREAS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT02423954,ADVANCED CANCER|PANCREATIC CANCER|RENAL CELL CANCER|NON SMALL CELL LUNG CANCER|COLORECTAL CARCINOMA|ENDOMETRIAL|UTERINE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT01760252,METASTATIC PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mount Sinai Beth Israel, New York, New York, United States|St-Lukes Roosevelt Hospital Medical Center, New York, New York, United States|Beth Israel Comprehensive Care Center, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT00180960,COLON TUMORS|RECTUM TUMORS|APPENDIX TUMORS|PERITONEUM TUMORS|ENDOCRINE TUMORS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Gustave-Roussy, Villejuif, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT00053833,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States|Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|California Cancer Center, Fresno, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|MBCCOP - Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Veterans Affairs Medical Center - New Orleans, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States|Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|Providence Hospital - Southfield, Southfield, Michigan, United States|Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States|MBCCOP - University of New Mexico HSC, Albuquerque, New Mexico, United States|Veterans Affairs Medical Center - Albany, Albany, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|James P. Wilmot Cancer Center at the University of Rochester Medical Center, Rochester, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States|Oregon Cancer Institute, Portland, Oregon, United States|Veterans Affairs Medical Center - Portland, Portland, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|Veterans Affairs Medical Center - Temple, Temple, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Withdrawn,NCT02575508,COLON ADENOCARCINOMA|METASTATIC PANCREATIC ADENOCARCINOMA|PANCREATIC ADENOCARCINOMA|PANCREATIC DUCTAL ADENOCARCINOMA|RECTAL ADENOCARCINOMA|STAGE III PANCREATIC CANCER|STAGE IIIA COLON CANCER|STAGE IIIA RECTAL CANCER|STAGE IIIB COLON CANCER|STAGE IIIB RECTAL CANCER|STAGE IIIC COLON CANCER|STAGE IIIC RECTAL CANCER|STAGE IV PANCREATIC CANCER|STAGE IVA COLON CANCER|STAGE IVA RECTAL CANCER|STAGE IVB COLON CANCER|STAGE IVB RECTAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
C[C@](N)(Cc1ccc(O)cc1)C(=O)O,0,DB00765,__METYROSINE,4117161,Terminated,NCT01127503,VELO-CARDIO-FACIAL SYNDROME|PSYCHOSIS,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCFS International Center, Syracuse, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,16.3617322737633,105.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.9,195.2151,83.55,4.0,3.0,1.0,19.9,51.81,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT00003380,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT00005612,OVARIAN CANCER,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT00002478,CERVICAL CANCER|OVARIAN CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States",7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,0,DB00798,__GENTAMICIN,,Terminated,NCT02036528,DIABETIC FOOT ULCERS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital Center, Washington, District of Columbia, United States|GF Professional Research, Corp., Miami Lakes, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Advanced Foot and Ankle Institute of Georgia LLC, Smyrna, Georgia, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|Utah Valley Medical Center, Provo, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,0,DB00798,__GENTAMICIN,,Terminated,NCT00658957,DIABETIC FOOT ULCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Chesapeake Foot and Ankle Center, Pasadena, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT02831179,FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|MALIGNANT SOMATOSTATINOMA|MERKEL CELL CARCINOMA|METASTATIC ADRENAL GLAND PHEOCHROMOCYTOMA|METASTATIC CARCINOID TUMOR|MULTIPLE ENDOCRINE NEOPLASIA TYPE 1|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B|NEUROENDOCRINE NEOPLASM|NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|PANCREATIC GLUCAGONOMA|PANCREATIC INSULINOMA|RECURRENT ADRENAL CORTEX CARCINOMA|RECURRENT ADRENAL GLAND PHEOCHROMOCYTOMA|RECURRENT MERKEL CELL CARCINOMA|SOMATOSTATIN-PRODUCING NEUROENDOCRINE TUMOR|STAGE III ADRENAL CORTEX CARCINOMA|STAGE III THYROID GLAND MEDULLARY CARCINOMA|STAGE IIIA MERKEL CELL CARCINOMA|STAGE IIIB MERKEL CELL CARCINOMA|STAGE IV ADRENAL CORTEX CARCINOMA|STAGE IV MERKEL CELL CARCINOMA|STAGE IVA THYROID GLAND MEDULLARY CARCINOMA|STAGE IVB THYROID GLAND MEDULLARY CARCINOMA|STAGE IVC THYROID GLAND MEDULLARY CARCINOMA|THYMIC CARCINOID TUMOR|VIP-PRODUCING NEUROENDOCRINE TUMOR|WELL DIFFERENTIATED ADRENAL CORTEX CARCINOMA|ZOLLINGER ELLISON SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT02836028,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT00601289,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,0,DB00889,__GRANISETRON,5952340,Terminated,NCT01275664,NAUSEA AND VOMITING|OVARIAN BRENNER TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROMUCINOUS CARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|STAGE II OVARIAN CANCER|STAGE IIA FALLOPIAN TUBE CANCER|STAGE IIA OVARIAN CANCER|STAGE IIB FALLOPIAN TUBE CANCER|STAGE IIB OVARIAN CANCER|STAGE IIC FALLOPIAN TUBE CANCER|STAGE IIC OVARIAN CANCER|STAGE IIIA FALLOPIAN TUBE CANCER|STAGE IIIA OVARIAN CANCER|STAGE IIIA PRIMARY PERITONEAL CANCER|STAGE IIIB FALLOPIAN TUBE CANCER|STAGE IIIB OVARIAN CANCER|STAGE IIIB PRIMARY PERITONEAL CANCER|STAGE IIIC FALLOPIAN TUBE CANCER|STAGE IIIC OVARIAN CANCER|STAGE IIIC PRIMARY PERITONEAL CANCER|STAGE IV FALLOPIAN TUBE CANCER|STAGE IV OVARIAN CANCER|STAGE IV PRIMARY PERITONEAL CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States|Women and Infants Hospital, Providence, Rhode Island, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,39.7215548573892,477.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.64,312.4170000000001,50.16,3.0,1.0,4.0,35.57,101.83,2.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,0,DB00904,__ONDANSETRON,5344658,Terminated,NCT00609765,PANCREATIC CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Withdrawn,NCT00842582,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Central Dupage Hospital, Winfield, Illinois, United States",C07H19/12,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,DB00947,__FULVESTRANT,6774122,Withdrawn,NCT03197584,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,0,DB00968,__METHYLDOPA,3988341,Withdrawn,NCT03396484,TYPE 1 DIABETES,All,"8 Years and older   (Child, Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,C07D209/20,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,28.0580710076182,717.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,211.2145,103.78,5.0,4.0,1.0,20.73,53.79,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Withdrawn,NCT00378781,CANCER,All,"Child, Adult, Older Adult",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,0,DB01026,__KETOCONAZOLE,5456851,Terminated,NCT01535157,OVARIAN CANCER|CANCER OF OVARY|CANCER OF THE OVARY|OVARY NEOPLASMS|PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States",A61K8/49,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,0,DB01026,__KETOCONAZOLE,5456851,Terminated,NCT01584297,GRANULOSA CELL TUMOUR OF THE OVARY,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital del Mar, Barcelona, Spain|Hospital Reina Sofía, Cordoba, Spain|Hospital La Paz, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Complejo Hospitalario de Navarra, Navarra, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",A61K8/49,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,0,DB01026,__KETOCONAZOLE,5456851,Withdrawn,NCT02147964,GONADOTROPIN DEFICIENCY,Male,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Medical Center (Health Sciences), Seattle, Washington, United States",A61K8/49,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00253461,"LUNG CANCER|METASTATIC CANCER|OVARIAN CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01003938,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bellevue Hospital Center, New York, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Tisch Hospital, New York, New York, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00003382,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Community Hospital of Los Gatos, Los Gatos, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01177501,OVARIAN CANCER|RELAPSES,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Frédéric Selle, Paris, France",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00287859,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT02107378,EPITHELIAL OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brno, Czech Republic|Nový Jičín, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Prague, Czech Republic|Cologne, Germany|Dresden, Germany|Erlangen, Germany|Bialystok, Poland|Krakow, Poland|Lublin, Poland|Poznan, Poland",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT02569957,MALIGNANT OVARIAN ENDOMETRIOID TUMOR|MALIGNANT OVARIAN SEROUS TUMOR|RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00004221,MALIGNANT OVARIAN MIXED EPITHELIAL TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|PRIMARY PERITONEAL CARCINOMA|STAGE III OVARIAN CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00313612,RECURRENT OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States|NYU Cancer Institute, New York, New York, United States",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01840943,EPITHELIAL OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing, China|Chang Sha, China|Guangzhou, China|Jinan, China|Nanjing, China|Nanning, China|Wuhan, China",C07D491/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00005029,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler Air Force Base, Mississippi, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",C07D491/22,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT02100007,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of WA Seattle Cancer Care Alliance, Seattle, Washington, United States|The Bays St Mary's Hospital, London, England, United Kingdom|Sarah Cannon Research Instititute UK, London, England, United Kingdom",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,0,DB01041,__THALIDOMIDE,6235756,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00583622,OVARIAN CANCER,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00523809,BREAST CANCER|OVARIAN CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00523809,BREAST CANCER|OVARIAN CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT01312376,OVARIAN CARCINOMA|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",C07H19/16,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00652899,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT01583686,CERVICAL CANCER|PANCREATIC CANCER|OVARIAN CANCER|MESOTHELIOMA|LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Withdrawn,NCT02390739,METASTATIC THYROID CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,0,DB01085,__PILOCARPINE,3947573,Terminated,NCT03460964,DIABETES,All,18 Years to 60 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"UCSD Altman Clinical and Translational Research Institute, San Diego, California, United States|UCSD, San Diego, California, United States",C08L71/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Suspended,NCT01918644,STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT02352831,PANCREATIC CANCER|CANCER OF PANCREAS|CANCER OF THE PANCREAS|PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00276744,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT02243007,RESECTABLE PANCREATIC CANCER|PANCREATIC DUCTAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT01836432,PANCREATIC CANCER|PANCREATIC CARCINOMA NON-RESECTABLE|LOCALLY ADVANCED MALIGNANT NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Cancer Center, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Stamford Hospital, Stamford, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|USF Tampa General, Tampa, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Beaumont CCOP, Royal Oak, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Renown Regional Medical Center, Reno, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|University of Washington - Seattle Cancer Center Alliance, Seattle, Washington, United States|Vince Lombardi Cancer Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT01921751,PANCREATIC ADENOCARCINOMA|STAGE III PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Saint Joseph Hospital, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|University of Rochester, Rochester, New York, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Mary's Hospital, Green Bay, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Door County Cancer Center, Sturgeon Bay, Wisconsin, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00881621,PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Medical Center, Washington, District of Columbia, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00959946,ADVANCED BREAST CANCER (PARTS 1 AND 2)|ADVANCED PANCREATIC CANCER (PART 1)|ADVANCED COLORECTAL CANCER (PART 1)|ADVANCED CHOLANGIOCARCINOMA (PART 1)|ADVANCED GLIOBLASTOMA MULTIFORME (PART 1),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Saint Herblain, France|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Madrid, Spain",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT01233505,"ADENOCARCINOMA OF THE PANCREAS|ADENOCARCINOMA OF THE STOMACH|BRCA1 MUTATION CARRIER|BRCA2 MUTATION CARRIER|OVARIAN MUCINOUS CYSTADENOCARCINOMA|RECURRENT BREAST CANCER|RECURRENT COLON CANCER|RECURRENT GASTRIC CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|STAGE IA BREAST CANCER|STAGE IB BREAST CANCER|STAGE II BREAST CANCER|STAGE IIIA BREAST CANCER|STAGE IIIB BREAST CANCER|STAGE IIIC BREAST CANCER|STAGE IV BREAST CANCER|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00354523,SOLID TUMOR|THYROID CANCER,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT02423954,ADVANCED CANCER|PANCREATIC CANCER|RENAL CELL CANCER|NON SMALL CELL LUNG CANCER|COLORECTAL CARCINOMA|ENDOMETRIAL|UTERINE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00354601,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07H19/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT01760252,METASTATIC PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mount Sinai Beth Israel, New York, New York, United States|St-Lukes Roosevelt Hospital Medical Center, New York, New York, United States|Beth Israel Comprehensive Care Center, New York, New York, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00006812,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Treatment,"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada",C07H19/06,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00833859,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT02915172,ADVANCED CANCER|MALIGNANT NEOPLASM OF BREAST|MALIGNANT NEOPLASMS OF BONE AND ARTICULAR CARTILAGE|MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF EYE BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF ILL-DEFINED SECONDARY AND UNSPECIFIED SITES|MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES|MALIGNANT NEOPLASMS OF LIP ORAL CAVITY AND PHARYNX|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MESOTHELIAL AND SOFT TISSUE|MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS|MALIGNANT NEOPLASMS OF THYROID AND OTHER ENDOCRINE GLANDS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT03197584,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT02831179,FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|MALIGNANT SOMATOSTATINOMA|MERKEL CELL CARCINOMA|METASTATIC ADRENAL GLAND PHEOCHROMOCYTOMA|METASTATIC CARCINOID TUMOR|MULTIPLE ENDOCRINE NEOPLASIA TYPE 1|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B|NEUROENDOCRINE NEOPLASM|NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|PANCREATIC GLUCAGONOMA|PANCREATIC INSULINOMA|RECURRENT ADRENAL CORTEX CARCINOMA|RECURRENT ADRENAL GLAND PHEOCHROMOCYTOMA|RECURRENT MERKEL CELL CARCINOMA|SOMATOSTATIN-PRODUCING NEUROENDOCRINE TUMOR|STAGE III ADRENAL CORTEX CARCINOMA|STAGE III THYROID GLAND MEDULLARY CARCINOMA|STAGE IIIA MERKEL CELL CARCINOMA|STAGE IIIB MERKEL CELL CARCINOMA|STAGE IV ADRENAL CORTEX CARCINOMA|STAGE IV MERKEL CELL CARCINOMA|STAGE IVA THYROID GLAND MEDULLARY CARCINOMA|STAGE IVB THYROID GLAND MEDULLARY CARCINOMA|STAGE IVC THYROID GLAND MEDULLARY CARCINOMA|THYMIC CARCINOID TUMOR|VIP-PRODUCING NEUROENDOCRINE TUMOR|WELL DIFFERENTIATED ADRENAL CORTEX CARCINOMA|ZOLLINGER ELLISON SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT00118300,CERVICAL CANCER|ENDOMETRIAL CANCER|OVARIAN CANCER|VAGINAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07H19/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CN(C)CCC=C1c2ccccc2COc2ccccc21,0,DB01142,__DOXEPIN,6211229,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
NCCCNCCSP(=O)(O)O,0,DB01143,__AMIFOSTINE,5424471,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
NCCCNCCSP(=O)(O)O,0,DB01143,__AMIFOSTINE,5424471,Terminated,NCT00003624,CERVICAL CANCER|ENDOMETRIAL CANCER|FALLOPIAN TUBE CANCER|NEUROTOXICITY|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER|SARCOMA,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Supportive Care,"Chao Family Comprehensive Cancer Center, Orange, California, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States",6,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,0,DB01167,__ITRACONAZOLE,6407079,Terminated,NCT03119077,PCOS,Female,"45 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00072215,EXTRAGONADAL GERM CELL TUMOR|TESTICULAR GERM CELL TUMOR,Male,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northeast Alabama Regional Medical Center, Anniston, Alabama, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Naval Medical Center - San Diego, San Diego, California, United States|Veterans Affairs Medical Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|West Suburban Center for Cancer Care, River Forest, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Baptist Hospital East - Louisville, Louisville, Kentucky, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, United States|New Hampshire Oncology-Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|NorthEast Oncology Associates - Concord, Concord, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, United States|Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, United States|Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Miriam Hospital at Lifespan, Providence, Rhode Island, United States|Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Virginia Oncology Associates - Norfolk, Norfolk, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke, Roanoke, Virginia, United States|St. Mary's Medical Center, Huntington, West Virginia, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|McGill Cancer Centre at McGill University, Montreal, Quebec, Canada",1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00967291,PANCREATIC CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Scientifico H. San Raffaele, Milan, Italy",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,DB01204,__MITOXANTRONE,3977953,Terminated,NCT00002819,OVARIAN CANCER,Female,"up to 65 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Primary Purpose: Treatment,"Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Togus, Togus, Maine, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Vermont Cancer Center, Burlington, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Veterans Affairs Medical Center - Richmond, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States",C12C3/00,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00276744,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT02331251,ADVANCED CANCER|BREAST CANCER|SARCOMA|PANCREATIC CANCER|SMALL CELL LUNG CANCER|OVARIAN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States|Western Regional Medical Center, Goodyear, Arizona, United States",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00583622,OVARIAN CANCER,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00303888,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00354601,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00833859,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00539968,PROSTATE CANCER|BREAST CANCER|OVARIAN CANCER|LUNG CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00004037,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Withdrawn,NCT02083536,OVARIAN CANCER|OVARIAN CARCINOMA|RECURRENT OVARIAN CANCER|RECURRENT OVARIAN CARCINOMA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT00598091,REFRACTORY SOLID TUMORS|PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Lineberger, Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT00544908,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,0,DB01259,__LAPATINIB,6391874,Terminated,NCT00447122,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lifespan Hospitals, Providence, Rhode Island, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,0,DB01259,__LAPATINIB,6391874,Terminated,NCT00317434,OVARIAN CANCER,Female,"19 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States",C07D401/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,0,DB01259,__LAPATINIB,6391874,Terminated,NCT00881621,PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Medical Center, Washington, District of Columbia, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,0,DB01259,__LAPATINIB,6391874,Terminated,NCT00447226,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bedford, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Webster, Texas, United States|GSK Investigational Site, Leesburg, Virginia, United States|GSK Investigational Site, Newport News, Virginia, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,0,DB01262,__DECITABINE,5654333,Terminated,NCT00748527,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,"Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Saint Bartholomew's Hospital, London, England, United Kingdom|Royal Marsden - London, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Weston General Hospital, Weston-super-Mare, England, United Kingdom|Belfast City Hospital Trust Incorporating Belvoir Park Hospital, Belfast, Northern Ireland, United Kingdom|Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCc2ccccc2)CC1,0,DB01535,__CARFENTANIL,3998834,Suspended,,NEURALGIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/333,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,11.269225240764598,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,394.5066,49.85,3.0,0.0,3.0,44.6,114.38,8.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,0,DB01607,__TICARCILLIN,4127649,Withdrawn,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,934.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.99,384.42699999999996,124.01,6.0,3.0,3.0,36.14,87.93,5.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,0,DB01609,__DEFERASIROX,6465504,Terminated,NCT01159067,"IRON OVERLOAD|ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA|ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL NEGATIVE|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC EOSINOPHILIC LEUKEMIA|CHRONIC MYELOMONOCYTIC LEUKEMIA|CHRONIC NEUTROPHILIC LEUKEMIA|CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|DE NOVO MYELODYSPLASTIC SYNDROMES|DISSEMINATED NEUROBLASTOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE MIXED CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT LYMPHOBLASTIC LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 3 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|NONCONTIGUOUS STAGE II MARGINAL ZONE LYMPHOMA|NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA|POOR PROGNOSIS METASTATIC GESTATIONAL TROPHOBLASTIC TUMOR|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES|PRIMARY MYELOFIBROSIS|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MALIGNANT TESTICULAR GERM CELL TUMOR|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT NEUROBLASTOMA|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|SECONDARY MYELODYSPLASTIC SYNDROMES|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE II OVARIAN EPITHELIAL CANCER|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MALIGNANT TESTICULAR GERM CELL TUMOR|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MULTIPLE MYELOMA|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IIIA BREAST CANCER|STAGE IIIB BREAST CANCER|STAGE IIIC BREAST CANCER|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV BREAST CANCER|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"City of Hope, Duarte, California, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,0,DB01609,__DEFERASIROX,6465504,Terminated,NCT00602446,BREAST CANCER|IRON OVERLOAD|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|NEUROBLASTOMA|OVARIAN CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,0,DB01645,__GENISTEIN,5213971,Withdrawn,NCT00882765,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"UCLA, Los Angeles, California, United States",C12N15/76,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB02379,__BETA-D-GLUCOSE,3964974,Withdrawn,NCT00753740,CANCER|OVARIAN CANCER|SOLID TUMOR,Female,"18 Years to 78 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois, Decatur, Illinois, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Schwartz Gynecologic Onclology, PLLC, Brightwaters, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Chattanooga GYN Oncology, Chattanooga, Tennessee, United States|The Methodist Hospital, Houston, Texas, United States|Riverside Gynecology & Oncology, Newport News, Virginia, United States",C12Q1/54,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB02379,__BETA-D-GLUCOSE,3964974,Withdrawn,NCT02103998,TRANSIENT HYPOTHYROXINEMIA OF PREMATURITY (THOP),All,up to 24 Hours   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Maria Fareri Childrens Hospital, Valhalla, New York, United States",C12Q1/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCCCCCCCCCCCC(=O)O,0,DB02448,__N-TRIDECANOIC_ACID,3932476,Withdrawn,NCT03255889,PCOS,Male,21 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Medicine Unit, National University Health System, Singapore, Singapore",C07C231/02,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,400.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.57,214.3443,37.3,2.0,1.0,0.0,27.95,63.28,11.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00910000,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01249443,"HIV INFECTION|RECURRENT ANAL CANCER|RECURRENT BREAST CANCER|RECURRENT ESOPHAGEAL CANCER|RECURRENT GASTRIC CANCER|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE IV ANAL CANCER|STAGE IV BREAST CANCER|STAGE IV ESOPHAGEAL CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00976183,OVARIAN NEOPLASMS,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Associates, Newport Beach, California, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00948688,PANCREATIC CANCER|ADENOCARCINOMA OF THE PANCREAS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00831493,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,0,DB02659,__CHOLIC_ACID,3937815,Terminated,NCT00004442,INFANTILE REFSUM'S DISEASE|ZELLWEGER SYNDROME|BIFUNCTIONAL ENZYME DEFICIENCY|ADRENOLEUKODYSTROPHY,All,up to 5 Years   (Child),Other,Primary Purpose: Treatment,,C07J9/005,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,2.20127723361875,405.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,408.5714,97.99,5.0,4.0,4.0,46.93,110.79,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,0,DB02659,__CHOLIC_ACID,3937815,Terminated,,ADRENOLEUKODYSTROPHY,,,,,"FISABIO, Elche, Alicante, Spain",C07J9/005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,2.20127723361875,405.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,408.5714,97.99,5.0,4.0,4.0,46.93,110.79,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,0,DB02901,__STANOLONE,4071623,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,20.5014476683299,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,290.4403,37.3,2.0,1.0,4.0,34.69,83.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0
Oc1ccccc1,0,DB03255,__PHENOL,,Terminated,NCT02532101,UNCONTROLLED INSULIN-TREATED TYPE 2 DIABETES MELLITUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Seberang Jaya Hospital, Seberang Jaya, Penang, Malaysia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.39,94.1112,20.23,1.0,1.0,1.0,9.81,28.04,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT01494012,RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|MALIGNANT TUMOR OF PERITONEUM|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT00095693,ANAPLASTIC THYROID CANCER|INSULAR THYROID CANCER|RECURRENT THYROID CANCER|STAGE III FOLLICULAR THYROID CANCER|STAGE III PAPILLARY THYROID CANCER|STAGE IV FOLLICULAR THYROID CANCER|STAGE IV PAPILLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT00253461,"LUNG CANCER|METASTATIC CANCER|OVARIAN CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,0,DB04572,__THIOTEPA,4766149,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,0,DB04572,__THIOTEPA,4766149,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,0,DB04573,__ESTRIOL,3939186,Terminated,NCT00302731,MENOPAUSE,Female,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",C07J1/0096,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,14.390439228731502,1136.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,288.3814,60.69,3.0,3.0,4.0,33.07,81.27,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0
Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,0,DB04786,__SURAMIN,4218535,Terminated,NCT00002921,ADRENOCORTICAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MBCCOP - University of South Alabama, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Beckman Research Institute, City of Hope, Duarte, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Medical Center, Sacramento, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Loyola University Medical Center, Maywood, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Louisiana State University Hospital - Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|CCOP - Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Providence Hospital - Southfield, Southfield, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|University of New Mexico Cancer Research & Treatment Center, Albuquerque, New Mexico, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|CCOP - Dayton, Kettering, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Oregon Cancer Center at Oregon Health Sciences University, Portland, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Tech University Health Science Center, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States",C12Q1/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,20.4028830160783,297.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,1297.28,483.75,23.0,12.0,8.0,120.22,314.9,16.0,1.0,0.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,0,DB04845,__IXABEPILONE,6605599,Terminated,NCT01012362,BREAST CANCER|LUNG CANCER|COLON CANCER|PANCREATIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|SARCOMA|HEPATOCELLULAR CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,62.5556992956734,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,506.7,112.05,6.0,3.0,3.0,56.86,136.71,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,0,DB04849,__CEDIRANIB,WO-2001074360-A1,Suspended,NCT03660826,ENDOMETRIAL UNDIFFERENTIATED CARCINOMA|ENDOMETRIOID ADENOCARCINOMA|RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA|RECURRENT UTERINE CORPUS CANCER|STAGE IV UTERINE CORPUS CANCER AJCC V7|STAGE IVA UTERINE CORPUS CANCER AJCC V7|STAGE IVB UTERINE CORPUS CANCER AJCC V7,Female,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Mercy Cancer Center - Rocklin, Rocklin, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Woodland Memorial Hospital, Woodland, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Medical Center of the Rockies, Loveland, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Baptist Health Richmond, Richmond, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Women's Cancer Care Associates LLC, Albany, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mount Sinai Chelsea, New York, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Hope Women's Cancer Centers-Asheville, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Carolina Surgical Clinic of Charlotte PA, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Novant Health Presbyterian Medical Center Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Novant Health Oncology Specialists-Kernersville, Kernersville, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Lake Norman Radiation Oncology Center-Mooresville, Mooresville, North Carolina, United States|Novant Health Oncology Specialists-Mount Airy, Mount Airy, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Carolina Oncology Associates PA, Salisbury, North Carolina, United States|Rowan Regional Medical Center, Salisbury, North Carolina, United States|Novant Health Oncology Specialists-Statesville, Statesville, North Carolina, United States|Novant Health Oncology Specialists-Davidson County, Thomasville, North Carolina, United States|Novant Health Oncology Specialists-Wilkesboro, Wilkesboro, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Sanford Medical Center Fargo, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Methodist Willowbrook Hospital, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",A61K45/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2,0,DB04864,__HUPERZINE_A,5106979,Terminated,,TRAUMATIC BRAIN INJURY (TBI),,,,,"FISABIO, Elche, Alicante, Spain",C07D215/48,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,24.969711903735103,196.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,242.3162,55.12,2.0,2.0,3.0,26.87,75.8,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1
Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,0,DB04879,__VATALANIB,6258812,Withdrawn,NCT00227773,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL CARCINOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,30.0,20.6657220887492,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.5,346.81300000000016,50.7,4.0,1.0,4.0,36.52,100.98,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,0,DB04896,__MILNACIPRAN,6602911,Terminated,NCT01288937,IDIOPATHIC PERIPHERAL NEUROPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Columbia University Medical Center, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
Oc1ccc(C2=Cc3ccc(O)cc3OC2)cc1,0,DB04915,__IDRONOXIL,WO-2000049009-A1,Terminated,NCT00303888,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",C07D311/36,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,44.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,240.25400000000002,49.69,3.0,2.0,3.0,25.76,69.73,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
N[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(=O)O)c1ccccc1)C(=O)O,0,DB04972,__CANFOSFAMIDE,,Terminated,,"NEOPLASMS, OVARIAN",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,787.46,225.74,10.0,5.0,1.0,74.17,175.76,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Terminated,,RETINAL DETACHMENT,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CC(C)c1cc(Oc2c(Br)cc(NC(=O)CC(=O)O)cc2Br)ccc1O,0,DB05035,__EPROTIROME,WO-2003039456-A2,Terminated,NCT01410383,HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07C45/00 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,32.7488,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.36,487.144,95.86,4.0,3.0,2.0,40.47,104.92,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,0,DB05076,__FENRETINIDE,4190594,Terminated,NCT00017134,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Primary Purpose: Prevention,"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Colorado Gynecologic Oncology Group P.C., Aurora, Colorado, United States|Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|George Bray Cancer Center at New Britain General Hospital, New Britain, Connecticut, United States|Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States|Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|University of Minnesota Medical Center & Children's Hospital - Fairview, Minneapolis, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University Cancer Institute, Portland, Oregon, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States",C07D213/87,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,0,DB05076,__FENRETINIDE,4190594,Terminated,NCT01535157,OVARIAN CANCER|CANCER OF OVARY|CANCER OF THE OVARY|OVARY NEOPLASMS|PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States",C07D213/87,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT02367352,ADVANCED SOLID TUMORS|OVARIAN CANCER|SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chiba, Japan|Shizuoka, Japan|Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,0,DB05239,__COBIMETINIB,7803839,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,0,DB05255,__RONACALERET,7514473,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C217/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,64.3955728043697,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,447.523,78.79,5.0,3.0,3.0,47.78,118.36,11.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0
COc1ccc(C[C@H](O)c2cc(OC)c(OC)c(OC)c2)cc1O,0,DB05284,__CA4P,,Terminated,NCT00507429,ANAPLASTIC THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins, Baltimore, Maryland, United States|University of Minnesota Otolaryngology Department, Minneapolis, Minnesota, United States|Ireland Cancer Center/Division od Hematology, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Belarus National Medical University, Minsk, Belarus|Regional Oncology Dispensary with Inpatient Sector, Plodiv, Bulgaria|Specialized Hospital for Active Treatment of Oncology, Sofia, Bulgaria|Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy, Sofia, Bulgaria|University Hospital, Cairo, Cairo, Egypt|Mediciti Hospital, Hyderabaad, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Apollo Cancer Institute, New Delhi, Delhi, India|Kidwai Memorial Hospital, Bangalore, Karnataka, India|Shirdi Sai Baba Cancer Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Christian Medial College, Vellore, Tamil Nadu, India|Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology, Tel-Aviv, Israel|Lo Studio E la Cura, Milano, Italy|INT Napoli Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy|Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy|Zaklad Medyczny Nuklearnej i Endykrynologii, Gliwice, Poland|Klinika Nowotworow Glowy i Szyji, Warszawa, Poland|Institutul Oncologic, Cluj-Napoca, Romania|SC Meditech SRL, Craiova, Romania|Centr of Medical Oncology, Iasi, Romania|Clinical County Hospital Sibiu, Sibiu, Romania|Emergency Clinical County Hospital ""Sf. loan cel Nou"", Suceava, Romania|City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|Ukrainian Academy of Medical Science, Lomonosova 33/43, Kiev, Ukraine|Regional Clinical Oncology Dispensary, Lvov, Ukraine|Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom|Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom|Southampton Hospital Oncology Centre, Southampton, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,334.3637,77.38,6.0,2.0,2.0,34.48,89.75,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00211471,SEVERE DIABETIC RETINOPATHY|CENTRAL RETINAL VEIN OCCLUSION|CHRONIC INFLAMMATION|INFECTIOUS DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00211406,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,,MACULAR DEGENERATION,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Lu+3],0,DB05296,__MOTEXAFIN_LUTETIUM,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,1166.136,178.75,15.0,2.0,5.0,106.08,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
CCC(C)SSc1ncc[nH]1,0,DB05448,__PX-12,US-20040116496-A1,Terminated,NCT00417287,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry|NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,32.7488,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.78,188.31400000000002,28.68,1.0,1.0,1.0,19.94,50.87,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0
CS(=O)(=O)O.O=c1[nH]c2c(c3ccccc13)Cc1cc(S(=O)(=O)NCCCN3CCOCC3)ccc1-2,0,DB05549,__INO-1001,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.22,535.63,87.74,5.0,2.0,5.0,47.65,121.05,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,NCT00574951,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Lake/University Ireland Cancer Center, Mentor, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Harrington Cancer Center, Amarillo, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
O=P(O)(NCCCl)NCCCl,0,DB05668,__PALIFOSFAMIDE,,Terminated,NCT01808534,ADULT CENTRAL NERVOUS SYSTEM GERM CELL TUMOR|ADULT TERATOMA|MALIGNANT EXTRAGONADAL GERM CELL TUMOR|MALIGNANT EXTRAGONADAL NON-SEMINOMATOUS GERM CELL TUMOR|EXTRAGONADAL SEMINOMA|RECURRENT MALIGNANT TESTICULAR GERM CELL TUMOR|RECURRENT OVARIAN GERM CELL TUMOR|STAGE IV EXTRAGONADAL NON-SEMINOMATOUS GERM CELL TUMOR|STAGE IV EXTRAGONADAL SEMINOMA|STAGE IV OVARIAN GERM CELL TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University Cancer Center, Indianapolis, Indiana, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.37,221.02200000000002,61.36,3.0,3.0,0.0,19.0,46.2,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Terminated,NCT01888965,COLORECTAL CANCER|PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University- Lombardi Cancer Center, Washington, District of Columbia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Withdrawn,NCT02108782,GASTRINOMA|GLUCAGONOMA|INSULINOMA|PANCREATIC POLYPEPTIDE TUMOR|RECURRENT ISLET CELL CARCINOMA|SOMATOSTATINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Withdrawn,NCT02048943,"DUCT CELL ADENOCARCINOMA OF THE PANCREAS|RECURRENT PANCREATIC CANCER|STAGE III PANCREATIC CANCER|STAGE IV PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,0,DB05943,__RESATORVID,US-20110184034-A1,Terminated,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,361.81,72.47,3.0,1.0,2.0,33.37,85.5,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,0,DB05983,__BARDOXOLONE_METHYL,US-20130303797-A1,Terminated,NCT00529113,PANCREATIC NEOPLASMS|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rocky Mountain Cancer Center (US Oncology), Denver, Colorado, United States|Cancer Centers of Florida (US Oncology), Ocoee, Florida, United States|Central Indiana Cancer Centers (US Oncology), Indianapolis, Indiana, United States|Sammons Cancer Center (US Oncology), Dallas, Texas, United States|Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology), Vancouver, Washington, United States",C07J75/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.2676440994681,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.29,505.699,84.23,4.0,0.0,5.0,58.23,144.36,2.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,0,DB05983,__BARDOXOLONE_METHYL,US-20130303797-A1,Terminated,NCT01549769,"RENAL INSUFFICIENCY, CHRONIC|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07J75/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.2676440994681,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.29,505.699,84.23,4.0,0.0,5.0,58.23,144.36,2.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,0,DB05983,__BARDOXOLONE_METHYL,US-20130303797-A1,Terminated,NCT01500798,CHRONIC KIDNEY DISEASE|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07J75/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.2676440994681,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.29,505.699,84.23,4.0,0.0,5.0,58.23,144.36,2.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,0,DB05983,__BARDOXOLONE_METHYL,US-20130303797-A1,Withdrawn,NCT01576887,END-STAGE RENAL DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07J75/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.2676440994681,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.29,505.699,84.23,4.0,0.0,5.0,58.23,144.36,2.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,0,DB06013,__ALDOXORUBICIN,,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,750.758,267.84,15.0,7.0,6.0,75.89,189.86,12.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,0,DB06155,__RIMONABANT,5624941,Terminated,NCT00449605,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-aventis adminsitrative office, Santiago, Chile|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,28.9780077619663,443.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.47,463.787,50.16,3.0,1.0,4.0,47.96,122.83,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,0,DB06155,__RIMONABANT,5624941,Terminated,NCT00577148,FATTY LIVER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Cove, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Shangai, China|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,28.9780077619663,443.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.47,463.787,50.16,3.0,1.0,4.0,47.96,122.83,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,0,DB06155,__RIMONABANT,5624941,Terminated,NCT00478972,OBESITY|DIABETES MELLITUS TYPE 2,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Tokyo, Japan",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,28.9780077619663,443.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.47,463.787,50.16,3.0,1.0,4.0,47.96,122.83,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,0,DB06155,__RIMONABANT,5624941,Terminated,NCT00458081,"OBESITY|MICROALBUMINURIA|DIABETES MELLITUS, TYPE 2|DYSLIPIDEMIA",All,"30 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Barcelona, Spain",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,28.9780077619663,443.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.47,463.787,50.16,3.0,1.0,4.0,47.96,122.83,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,0,DB06155,__RIMONABANT,5624941,Terminated,NCT00325650,PREDIABETIC STATE,All,"35 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sanofi-Aventis, Bridgewater, New Jersey, United States",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,28.9780077619663,443.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.47,463.787,50.16,3.0,1.0,4.0,47.96,122.83,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,0,DB06159,__RUBITECAN,5552156,Terminated,NCT00113256,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Compassionate Cancer Care Medical Group, Corona, California, United States|11100 Warner Avenue, Ste. 200, Fountain Valley, California, United States|The Cancer Research & Prevention Center, Soquel, California, United States|Mile High Oncology, Denver, Colorado, United States|Norton Healthcare, Inc., Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Medical Oncology, Baton Rouge, Louisiana, United States|N. Mississippi Hematology & Oncology Associates, Tupelo, Mississippi, United States|Kansas City Cancer Center, Kansas City, Missouri, United States|Cancer Research of Long Island, Great Neck, New York, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,17.4459434485307,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.88,393.355,122.87,6.0,1.0,5.0,38.87,100.81,2.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,0,DB06159,__RUBITECAN,5552156,Withdrawn,NCT00006267,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,17.4459434485307,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.88,393.355,122.87,6.0,1.0,5.0,38.87,100.81,2.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00091195,PRIMARY PERITONEAL CAVITY CANCER|RECURRENT OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"High Point Regional Hospital, High Point, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",C12P21/02,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00084461,GASTRINOMA|GLUCAGONOMA|INSULINOMA|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|PANCREATIC POLYPEPTIDE TUMOR|PULMONARY CARCINOID TUMOR|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT ISLET CELL CARCINOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SOMATOSTATINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,NCT00442598,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Premiere Oncology of Arizona, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|California Cancer Center, Greenbrae, California, United States|UCI Chao Family Comprehensive Cancer Center, Orange, California, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Louisville Oncology Clinical Research Program, Louisville, Kentucky, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Gabrail Cancer Center, Canton, Ohio, United States|Gynecologic Oncology Research & Development, LLC, Greenville, South Carolina, United States|Harrington Cancer Center, Amarillo, Texas, United States",C07C291/02,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,DB06182,__TALABOSTAT,,Terminated,NCT00116389,PANCREATIC CANCER|NEOPLASM METASTASIS|ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwest Alabama Cancer Center, PC, Florence, Alabama, United States|Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States|Oncology Associates, PC, Hartford, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Central Brevard, Rockledge, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Yagnesh V. Oza, MD, Mt. Vernon, Illinois, United States|Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States|Cancer Care Center, Inc., New Albany, Indiana, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Huron Medical Center, Port Huron, Michigan, United States|Billings Clinic, Billings, Montana, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|New York Oncology Hematology/Albany Regional Cancer Center, Albany, New York, United States|Hematology-Oncology Associates of Rockland, New City, New York, United States|Dayton Oncology and Hematology, Kettering, Ohio, United States|Lawrence M. Stallings, MD, Wooster, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Clinic, The, Portland, Oregon, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Oncology, PA, Presbyterian, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Elkins Pancreas Center, Houston, Texas, United States|Saint Luke's Episcopal Hospital, Houston, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,214.07,86.79,4.0,3.0,1.0,23.37,52.34,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,0,DB06199,__ATRASENTAN,5767144,Terminated,NCT00653328,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Georgia Hematology Oncology Associates, P.C., Macon, Georgia, United States|Kentuckiana Cancer Institute, Louisville, Kentucky, United States|The Jones Clinic, Germantown, Tennessee, United States|Jackson-Madison County Hospital, Jackson, Tennessee, United States|St. Thomas Health Services, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",C07D403/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,30.0,36.5674859853385,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.09,510.6218,88.54,7.0,1.0,4.0,55.33,140.14,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,0,DB06199,__ATRASENTAN,5767144,Terminated,NCT01858532,DIABETIC NEPHROPATHY,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D403/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,36.5674859853385,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.09,510.6218,88.54,7.0,1.0,4.0,55.33,140.14,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06233,__RIDAFOROLIMUS,,Terminated,NCT01243762,NEOPLASMS MALIGNANT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,990.222,201.5,12.0,2.0,4.0,107.25,267.98,8.0,1.0,0.0,0.0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,0,DB06281,__TORCETRAPIB,6197786,Terminated,NCT00134264,CORONARY DISEASE|DIABETES MELLITUS,All,"45 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Alabaster, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Gilbert, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Modesto, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Longmont, Colorado, United States|Pfizer Investigational Site, Guilford, Connecticut, United States|Pfizer Investigational Site, Hartford, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Coral Gables, Florida, United States|Pfizer Investigational Site, Fort Meyers, Florida, United States|Pfizer Investigational Site, Jacksonville Beach, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Lakeland, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Aurora, Illinois, United States|Pfizer Investigational Site, Blue Island, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Davenport, Iowa, United States|Pfizer Investigational Site, des Moines, Iowa, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Witchita, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Marrero, Louisiana, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Bel Air, Maryland, United States|Pfizer Investigational Site, Columbia, Maryland, United States|Pfizer Investigational Site, Towson, Maryland, United States|Pfizer Investigational Site, Westminster, Maryland, United States|Pfizer Investigational Site, Abington, Massachusetts, United States|Pfizer Investigational Site, Haverhill, Massachusetts, United States|Pfizer Investigational Site, Natick, Massachusetts, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, St. Paul, Minnesota, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Papillon, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Concord, New Hampshire, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Manchester, New Hampshire, United States|Pfizer Investigational Site, Elmer, New Jersey, United States|Pfizer Investigational Site, Haddon Heights, New Jersey, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, Garden City, New York, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Winston-salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Mansfield, Ohio, United States|Pfizer Investigational Site, Sandusky, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Burien, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Concord, New South Wales, Australia|Pfizer Investigational Site, East Gosford, New South Wales, Australia|Pfizer Investigational Site, St. Leonards, New South Wales, Australia|Pfizer Investigational Site, Wollongong, New South Wales, Australia|Pfizer Investigational Site, Chermside, Queensland, Australia|Pfizer Investigational Site, Herston, Queensland, Australia|Pfizer Investigational Site, Woolloongabba, Queensland, Australia|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Bedford Park, South Australia, Australia|Pfizer Investigational Site, Woodville, South Australia, Australia|Pfizer Investigational Site, Clayton, Victoria, Australia|Pfizer Investigational Site, Fitzroy, Victoria, Australia|Pfizer Investigational Site, Footscray, Victoria, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, Prahran, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, Joondalup, Western Australia, Australia|Pfizer Investigational Site, Camperdown, Australia|Pfizer Investigational Site, Darlinghurst, Australia|Pfizer Investigational Site, Geelong, Australia|Pfizer Investigational Site, Launceston, Tas, Australia|Pfizer Investigational Site, Melbourne, Australia|Pfizer Investigational Site, Nedlands, Australia|Pfizer Investigational Site, Perth, Australia|Pfizer Investigational Site, Southport, Australia|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Cornwall, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Scarborough, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sainte-foy, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste-foy, Quebec, Canada|Pfizer Investigational Site, Saint John's, Canada|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, AN Rotterdam, Netherlands|Pfizer Investigational Site, Apeldoorn, Netherlands|Pfizer Investigational Site, Arnhem, Netherlands|Pfizer Investigational Site, Breda, Netherlands|Pfizer Investigational Site, Cappelle aan den IJssel, Netherlands|Pfizer Investigational Site, Delft, Netherlands|Pfizer Investigational Site, Eindhoven, Netherlands|Pfizer Investigational Site, Goes, Netherlands|Pfizer Investigational Site, Gouda, Netherlands|Pfizer Investigational Site, Groningen, Netherlands|Pfizer Investigational Site, Heerlen, Netherlands|Pfizer Investigational Site, Hertogenbosch, Netherlands|Pfizer Investigational Site, Hoorn, Netherlands|Pfizer Investigational Site, Leiden, Netherlands|Pfizer Investigational Site, Maastricht, Netherlands|Pfizer Investigational Site, Nijmegen, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Sittard, Netherlands|Pfizer Investigational Site, Utrecht, Netherlands|Pfizer Investigational Site, Velp, Netherlands|Pfizer Investigational Site, Venlo, Netherlands|Pfizer Investigational Site, Zoetermeer, Netherlands|Pfizer Investigational Site, Sant Coloma de Gramenet, Barcelona, Spain|Pfizer Investigational Site, Terrasa, Barcelona, Spain|Pfizer Investigational Site, Jerez de La Frontera, Cadiz, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, San Sebastian, Guipuzcoa, Spain|Pfizer Investigational Site, Ferrol, La Coruna, Spain|Pfizer Investigational Site, Santiago De Compostela, La Coruña, Spain|Pfizer Investigational Site, Almeria, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Ciudad Real, Spain|Pfizer Investigational Site, Granada, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malaga, Spain|Pfizer Investigational Site, Salamanca, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Borås, Sweden|Pfizer Investigational Site, Eskilstuna, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Helsingborg, Sweden|Pfizer Investigational Site, Hässleholm, Sweden|Pfizer Investigational Site, Karlshamn, Sweden|Pfizer Investigational Site, Koping, Sweden|Pfizer Investigational Site, Linköping, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Molndal, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Ostersund, Sweden|Pfizer Investigational Site, Skelleftea, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uddevalla, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Vaxjo, Sweden|Pfizer Investigational Site, Västervik, Sweden|Pfizer Investigational Site, Wrexham, Clwyd, United Kingdom|Pfizer Investigational Site, Woolwich, London, United Kingdom|Pfizer Investigational Site, Glasgow, Scotland, United Kingdom|Pfizer Investigational Site, Aberdeen, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Bournemouth, United Kingdom|Pfizer Investigational Site, Brighton, East Sussex, United Kingdom|Pfizer Investigational Site, Bristol, United Kingdom|Pfizer Investigational Site, Cardiff, United Kingdom|Pfizer Investigational Site, Chichester, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Exeter, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Harrow, United Kingdom|Pfizer Investigational Site, Leicester, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Newcastle-upon-Tyne, United Kingdom|Pfizer Investigational Site, Romford, United Kingdom|Pfizer Investigational Site, Shrewsbury, United Kingdom|Pfizer Investigational Site, Warwick, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,45.0,17.9387667097887,97.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.29,600.4733,59.08,3.0,0.0,3.0,50.67,128.89,10.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06287,__TEMSIROLIMUS,5362718,Terminated,NCT00593008,PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06287,__TEMSIROLIMUS,5362718,Terminated,NCT02423954,ADVANCED CANCER|PANCREATIC CANCER|RENAL CELL CANCER|NON SMALL CELL LUNG CANCER|COLORECTAL CARCINOMA|ENDOMETRIAL|UTERINE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06287,__TEMSIROLIMUS,5362718,Terminated,NCT00926107,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Alexandra"" Hospital, Dept. of Clinical Therapeutics, Oncology, Athens, Greece|""Attikon"" University Hospital, 2nd Dept. of Internal Medicine-Propaedeutic, Oncology Section, Athens, Greece|Hygeia Hospital, 1st Dept. of Medical Oncology, Athens, Greece|Hygeia Hospital, 2nd Dept. of Medical Oncology, Athens, Greece|Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology, Athens, Greece|Chania General Hospital, Oncology Dept., Chania, Greece|Ioannina University Hospital, Dept. of Medical Oncology, Ioannina, Greece|Larissa University Hospital, Oncology Dept., Larissa, Greece|University Hospital of Patras, Oncology Dept, Patras, Greece|Metropolitan Hospital, 1st Dept. of Medical Oncology, Pireaus, Greece|Metropolitan Hospital, 2nd Dept. of Medical Oncology, Pireaus, Greece|""Papageorgiou"" General Hospital, Dept. of Medical Oncology, Thessaloniki, Greece",C07D498/18,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,0,DB06309,__REFAMETINIB,US-20090082457-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,19.7786402184849,30.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.11,572.337,107.89,6.0,4.0,3.0,46.34,116.29,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,0,DB06313,__BNC105,,Withdrawn,NCT01624493,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Christchurch Hospital, Christchurch, Canterbury, New Zealand",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.13,452.352,133.89,8.0,2.0,3.0,43.41,109.33,8.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,0,DB06350,__ELINOGREL,WO-2012072824-A1,Terminated,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,38.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,523.94,136.71,6.0,4.0,4.0,49.7,125.95,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,NCT00006262,OVARIAN CANCER,Female,"21 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,0,DB06448,__LONAFARNIB,WO-2004022559-A1,Terminated,NCT00539968,PROSTATE CANCER|BREAST CANCER|OVARIAN CANCER|LUNG CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61P19/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.34,638.822,79.53,3.0,1.0,5.0,60.09,149.31,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06461,__SQUALAMINE,5607691,Withdrawn,NCT02349516,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NJ Retina, New Brunswick, New Jersey, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,21.3556746545103,338.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.48,627.97,133.91,7.0,5.0,4.0,77.15,174.42,16.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,NCT00261352,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Fortaleza, CE, Brazil|Research Site, Goiânia, GO, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Curitiba, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bolton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Hastings, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Napanee, Ontario, Canada|Research Site, Newboro, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Porvoo, Finland|Research Site, Savonlinna, Finland|Research Site, Seinäjoki, Finland|Research Site, Suonenjoki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vaasa, Finland|Research Site, Aix En Provence, France|Research Site, Ambriere Les Vallees, France|Research Site, Beziers, France|Research Site, Briey Cedex, France|Research Site, Broglie, France|Research Site, Chateau Gontier, France|Research Site, Cremeaux, France|Research Site, Falaise, France|Research Site, Fontaine Saint Martin, France|Research Site, Freyming Merlebach, France|Research Site, GAN, France|Research Site, Hyeres, France|Research Site, Jarny, France|Research Site, Jort, France|Research Site, L'aigle, France|Research Site, Lambersart, France|Research Site, Le Lavandou, France|Research Site, Lille, France|Research Site, Lomme Cedex, France|Research Site, Marange Silvange, France|Research Site, Marignane, France|Research Site, Mars La Tour, France|Research Site, Martigues, France|Research Site, Mayenne, France|Research Site, Metz, France|Research Site, Mondelange, France|Research Site, Montbrison, France|Research Site, Montpellier, France|Research Site, Moutiers, France|Research Site, Nantes Cedex 01, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Roanne, France|Research Site, Roquevaire, France|Research Site, Rugles, France|Research Site, Saint Chamond, France|Research Site, Saint Jean de Luz, France|Research Site, Tantonville, France|Research Site, Heidelberg, Baden-Württemberg, Germany|Research Site, Stuttgart, Baden-Württemberg, Germany|Research Site, München, Bayern, Germany|Research Site, Frankfurt, Hessen, Germany|Research Site, Hannover, Niedersachsen, Germany|Research Site, Düsseldorf, Nordrhein-Westfalen, Germany|Research Site, Münster, Nordrhein-Westfalen, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Aschaffenburg, Germany|Research Site, Beckum, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Essen, Germany|Research Site, Gelnhausen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Heilbronn, Germany|Research Site, Künzing, Germany|Research Site, Nürnberg, Germany|Research Site, Pirna, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Gy¿r, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Siófok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Mumbai, Mashatra, India|Research Site, Bangalore, India|Research Site, Delhi, India|Research Site, India, India|Research Site, Jakarta, DKI Jakarta, Indonesia|Research Site, Malang, East Java, Indonesia|Research Site, Kuala Lumpur, Malaysia|Research Site, Penang, Malaysia|Research Site, Petaling Jaya, Malaysia|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Elverum, Norway|Research Site, Fredrikstad, Norway|Research Site, Hamar, Norway|Research Site, Oslo, Norway|Research Site, Paradis, Norway|Research Site, Trondheim, Norway|Research Site, Tvedestrand, Norway|Research Site, Cebu City, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Almada, Portugal|Research Site, Amadora, Portugal|Research Site, Caldas da Rainha, Portugal|Research Site, Elvas, Portugal|Research Site, Lisboa, Portugal|Research Site, Portalegre, Portugal|Research Site, Moscow, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Singapore, Singapore|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Ilanz, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Monthey, Switzerland|Research Site, Sion, Switzerland|Research Site, Zürich, Switzerland|Research Site, Yong-Kang City, Tainan County, Taiwan|Research Site, Changhua, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan",C07C309/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,NCT00229684,"DIABETES MELLITUS, TYPE 2",All,"45 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Research Site, Pasadena, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Reno, Nevada, United States|Research Site, Flushing, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Cheswick, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Midland, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Gig Harbor, Washington, United States|Research Site, Seattle, Washington, United States",C07C309/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01080248,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01012362,BREAST CANCER|LUNG CANCER|COLON CANCER|PANCREATIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|SARCOMA|HEPATOCELLULAR CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01392352,RENAL CELL CARCINOMA|SOFT TISSUE SARCOMA|GLIOBLASTOMA|OVARIAN CANCER|CERVICAL CANCER|BREAST CANCER|NON-SMALL CELL LUNG CANCER|SMALL CELL LUNG CANCER|PANCREATIC CANCER|MELANOMA|GASTROINTESTINAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01035658,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Hospital Cancer Insitute, Orlando, Florida, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",C07D231/56,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT02055690,"OVARIAN NEOPLASMS|NEOPLASMS, OVARIAN|OVARIAN CANCER",Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal United Hospital Bath NHS Trust, Bath, United Kingdom|City Hospital, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|University Collage London Hospitals NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Merseyside, United Kingdom|Mount Vernon Cancer Centre (East and North Herts NHS Trust), Middlesex, United Kingdom|Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle-upon-Tyne And Wear, United Kingdom|Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom",C07D231/56,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,0,DB06603,__PANOBINOSTAT,6552065,Terminated,NCT01056601,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,0,DB06616,__BOSUTINIB,6002008,Terminated,NCT01025570,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,0,DB06616,__BOSUTINIB,6002008,Terminated,NCT00959946,ADVANCED BREAST CANCER (PARTS 1 AND 2)|ADVANCED PANCREATIC CANCER (PART 1)|ADVANCED COLORECTAL CANCER (PART 1)|ADVANCED CHOLANGIOCARCINOMA (PART 1)|ADVANCED GLIOBLASTOMA MULTIFORME (PART 1),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Saint Herblain, France|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Madrid, Spain",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,0,DB06624,__TARANABANT,US-20060270650-A1,Terminated,NCT00430742,OBESITY TYPE 2 DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,515.96,75.01,4.0,1.0,3.0,50.13,132.14,9.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1
COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,0,DB06629,__ZIBOTENTAN,6060475,Terminated,NCT00929162,PATIENTS WITH ADVANCED OVARIAN CANCER SENSITIVE TO PLATINUM-BASED CHEMOTHERAPY,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dusseldorf, Germany|Research Site, Essen, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Lich, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Rostock, Germany|Research Site, Wiesbaden, Germany|Research Site, Milano, MI, Italy|Research Site, Perugia, PG, Italy|Research Site, Aviano, PN, Italy|Research Site, Campobasso, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy",C07D401/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,16.8217006509373,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,424.44,132.99,8.0,1.0,4.0,42.05,118.89,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1
CNCCc1ccccn1,0,DB06698,__BETAHISTINE,4159332,Terminated,,WEIGHT GAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,19.220107189059306,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.59,136.1943,24.92,2.0,1.0,1.0,15.85,41.33,3.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,0,DB06702,__FESOTERODINE,6858650,Terminated,NCT02262936,NOCTURIA,Female,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mount Sinai Hospital, Toronto, Ontario, Canada",C07C229/38,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,51.253619170824784,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.45,411.5769,49.77,3.0,1.0,2.0,48.29,124.08,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,0,DB06702,__FESOTERODINE,6858650,Withdrawn,NCT00713921,URINARY INCONTINENCE|BLADDER DYSFUNCTION,Female,"21 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Vanderbilt Univiersity, Nashville, Tennessee, United States",C07C229/38,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,51.253619170824784,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.45,411.5769,49.77,3.0,1.0,2.0,48.29,124.08,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1,0,DB06735,__ENCLOMIPHENE,4061733,Withdrawn,NCT02160704,INFERTILITY,Male,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Baylor College of Medicine, Houston, Texas, United States",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,654.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.08,405.97,12.47,2.0,0.0,3.0,46.93,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,0,DB06777,__CHENODEOXYCHOLIC_ACID,3965131,Terminated,NCT00004442,INFANTILE REFSUM'S DISEASE|ZELLWEGER SYNDROME|BIFUNCTIONAL ENZYME DEFICIENCY|ADRENOLEUKODYSTROPHY,All,up to 5 Years   (Child),Other,Primary Purpose: Treatment,,C07J9/005,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.953120187272805,910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,392.57199999999995,77.76,4.0,3.0,4.0,46.28,109.27,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
CC(=O)O.CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,DB06788,__HISTRELIN,8062652,Terminated,,GENDER DYSPHORIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,77.176122712992,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,1443.632,446.86,17.0,16.0,8.0,138.34,360.07,34.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,0,DB06809,__PLERIXAFOR,RE42152,Terminated,NCT03277209,PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",C07D401/14 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,0,DB06809,__PLERIXAFOR,RE42152,Terminated,NCT02790957,DIABETES|WOUNDS|CRITICAL LIMB ISCHEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital of Padova, Padova, Italy",C07D401/14 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
NCCNCCNCCN,0,DB06824,__TRIETHYLENETETRAMINE,3931122,Terminated,NCT01213888,DIABETIC RETINOPATHY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","Eye Care Centre - Vancouver Coastal Health, Vancouver, British Columbia, Canada",C02F1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,23.3926774677098,4248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,146.2339,76.1,4.0,4.0,0.0,18.04,43.32,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
NCCNCCNCCN,0,DB06824,__TRIETHYLENETETRAMINE,3931122,Withdrawn,NCT01295073,MACULAR EDEMA FOLLOWING CATARACT SURGERY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center, Vancouver, British Columbia, Canada",C02F1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,23.3926774677098,4248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,146.2339,76.1,4.0,4.0,0.0,18.04,43.32,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Terminated,NCT01282333,ADVANCED ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|REGIONAL TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|STAGE III BLADDER CANCER|STAGE III PANCREATIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV BLADDER CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV PANCREATIC CANCER|TRANSITIONAL CELL CARCINOMA OF THE BLADDER|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Terminated,NCT01233505,"ADENOCARCINOMA OF THE PANCREAS|ADENOCARCINOMA OF THE STOMACH|BRCA1 MUTATION CARRIER|BRCA2 MUTATION CARRIER|OVARIAN MUCINOUS CYSTADENOCARCINOMA|RECURRENT BREAST CANCER|RECURRENT COLON CANCER|RECURRENT GASTRIC CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|STAGE IA BREAST CANCER|STAGE IB BREAST CANCER|STAGE II BREAST CANCER|STAGE IIIA BREAST CANCER|STAGE IIIB BREAST CANCER|STAGE IIIC BREAST CANCER|STAGE IV BREAST CANCER|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Withdrawn,NCT02831179,FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|MALIGNANT SOMATOSTATINOMA|MERKEL CELL CARCINOMA|METASTATIC ADRENAL GLAND PHEOCHROMOCYTOMA|METASTATIC CARCINOID TUMOR|MULTIPLE ENDOCRINE NEOPLASIA TYPE 1|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A|MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B|NEUROENDOCRINE NEOPLASM|NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR|PANCREATIC GLUCAGONOMA|PANCREATIC INSULINOMA|RECURRENT ADRENAL CORTEX CARCINOMA|RECURRENT ADRENAL GLAND PHEOCHROMOCYTOMA|RECURRENT MERKEL CELL CARCINOMA|SOMATOSTATIN-PRODUCING NEUROENDOCRINE TUMOR|STAGE III ADRENAL CORTEX CARCINOMA|STAGE III THYROID GLAND MEDULLARY CARCINOMA|STAGE IIIA MERKEL CELL CARCINOMA|STAGE IIIB MERKEL CELL CARCINOMA|STAGE IV ADRENAL CORTEX CARCINOMA|STAGE IV MERKEL CELL CARCINOMA|STAGE IVA THYROID GLAND MEDULLARY CARCINOMA|STAGE IVB THYROID GLAND MEDULLARY CARCINOMA|STAGE IVC THYROID GLAND MEDULLARY CARCINOMA|THYMIC CARCINOID TUMOR|VIP-PRODUCING NEUROENDOCRINE TUMOR|WELL DIFFERENTIATED ADRENAL CORTEX CARCINOMA|ZOLLINGER ELLISON SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Withdrawn,NCT03032614,BREAST CANCER STAGE IV|OVARIAN CANCER|BRCA1 MUTATION|BRCA2 MUTATION,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1,0,DB07425,__SOBETIROME,5883294,Withdrawn,NCT03196765,X-LINKED ADRENOLEUKODYSTROPHY,Male,"4 Years to 18 Years   (Child, Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Austral, Buenos Aires, Argentina|Hospital General de ninos Pedro de Elizalde, Buenos Aires, Argentina|Monash Health, Clayton, Victoria, Australia|Hospital Clínico San Borja Arriarán, Santiago, Chile|Hospital Dr. Luis Calvo Mackenna, Santiago, Chile|Fundacion Cardioinfantil, Bogotá, Colombia|Hôpital Bicêtre - Paris Sud, Paris, France|Endocrinology Research Center, Moscow, Russian Federation|Moscow Morozov's Children Clinical Hospital, Moscow, Russian Federation|Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation|National Children's Specialized Hospital 'OKHMATDET', Kiev, Ukraine|Great Ormond Street Hospital for Children, London, United Kingdom|Manchester Children's Hospital, Manchester, United Kingdom",C07C59/70,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.8957062773362,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,328.4022,66.76,4.0,2.0,2.0,36.6,94.6,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0
Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1,0,DB07425,__SOBETIROME,5883294,Withdrawn,NCT01787578,X-LINKED ADRENOLEUKODYSTROPHY|ADRENOMYELONEUROPATHY,Male,18 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health & Science University, Portland, Oregon, United States",C07C59/70,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.8957062773362,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,328.4022,66.76,4.0,2.0,2.0,36.6,94.6,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,0,DB08079,__AMG-208,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,383.4027,74.43,6.0,0.0,5.0,40.72,119.54,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)NC(=O)CCl)CO2,0,DB08633,__TNP-470,,Terminated,NCT00038701,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,401.88199999999995,89.69,5.0,1.0,3.0,41.47,98.45,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)NC(=O)CCl)CO2,0,DB08633,__TNP-470,,Terminated,,"NEOPLASMS, PANCREATIC",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,401.88199999999995,89.69,5.0,1.0,3.0,41.47,98.45,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
NCCc1c[nH]c2ccccc12,0,DB08653,__TRYPTAMINE,3930948,Terminated,,QUALITY OF LIFE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.21,160.2157,41.81,1.0,2.0,2.0,18.34,50.37,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,0,DB08834,__TAUROURSODEOXYCHOLIC_ACID,5260074,Suspended,NCT03462940,"DIABETES MELLITUS, TYPE 2|INSULIN RESPONSE|ENDOTHELIAL DYSFUNCTION",All,"21 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Boston Medical Center, Boston, Massachusetts, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,16.591716462350302,243.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.38,499.71,123.93,6.0,4.0,4.0,56.75,130.68,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
C=C1C[C@@H]2CC[C@@]34C[C@@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,DB08871,__ERIBULIN,6214865,Withdrawn,NCT03032614,BREAST CANCER STAGE IV|OVARIAN CANCER|BRCA1 MUTATION|BRCA2 MUTATION,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D493/22,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.8156430316844,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,729.908,146.39,12.0,2.0,9.0,82.15,186.0,4.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,0,DB08877,__RUXOLITINIB,7598257,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,0,DB08877,__RUXOLITINIB,7598257,Terminated,NCT01822756,SOLID TUMORS|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Gainesville, Florida, United States|Sarasota, Florida, United States|Durham, North Carolina, United States|Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,0,DB08877,__RUXOLITINIB,7598257,Terminated,NCT02119663,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Huntsville, Alabama, United States|Fayetteville, Arkansas, United States|Beverly Hills, California, United States|La Jolla, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Thomasville, Georgia, United States|Harvey, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Minneapolis, Minnesota, United States|Saint Louis Park, Minnesota, United States|Bolivar, Missouri, United States|Basking Ridge, New Jersey, United States|Cherry Hill, New Jersey, United States|Voorhees, New Jersey, United States|Commack, New York, United States|Fresh Meadows, New York, United States|Harrison, New York, United States|New York, New York, United States|Rochester, New York, United States|Rockville Centre, New York, United States|Sleepy Hollow, New York, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Hershey, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Greenville, South Carolina, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Lubbock, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Falls Church, Virginia, United States|Newport News, Virginia, United States|Seattle, Washington, United States|Green Bay, Wisconsin, United States|Graz, Austria|Linz, Austria|Salzburg, Austria|Vienna, Austria|Wein, Austria|Santiago, Chile|Vitacura, Chile|Bogota, Colombia|Medellin, Colombia|Naestved, Denmark|Odense C, Denmark|Bordeaux, France|Brest Cedex, France|Dijon, France|Lyon, France|Nancy, France|Cork, Ireland|Dubin, Ireland|Galway, Ireland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Monterrey, Mexico|Oaxaca, Mexico|Toluca, Mexico|Amsterdam, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Braga, Portugal|Lisboa, Portugal|Porto, Portugal|San Juan, Puerto Rico|Linköping, Sweden|Uppsala, Sweden|Bellinzona, Switzerland|Geneve, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,0,DB08896,__REGORAFENIB,7351834,Terminated,NCT02383433,METASTATIC PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,0,DB08896,__REGORAFENIB,7351834,Terminated,NCT02278783,OVARIAN CANCER|PRIMARY PERITONEAL CANCER|FALLOPIAN TUBE CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",C07D209/46,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Terminated,NCT01838642,THYROID NEOPLASMS,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,0,DB08911,__TRAMETINIB,7378423,Suspended,NCT01902173,ADULT SOLID NEOPLASM|RECURRENT COLON CARCINOMA|RECURRENT MELANOMA|RECURRENT OVARIAN CARCINOMA|STAGE IIIC COLON CANCER|STAGE IIIC OVARIAN CANCER|STAGE IIIC SKIN MELANOMA|STAGE IV SKIN MELANOMA,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States",C07C275/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,0,DB08911,__TRAMETINIB,7378423,Terminated,NCT02703571,SOLID TUMORS FOR PHASE IB|PANCREATIC CANCER FOR PHASE II|COLORECTAL CANCER FOR PHASE II,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Sylvester Comp Cancer Ctr, Miami, Florida, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain",C07C275/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,0,DB08912,__DABRAFENIB,7994185,Suspended,NCT01902173,ADULT SOLID NEOPLASM|RECURRENT COLON CARCINOMA|RECURRENT MELANOMA|RECURRENT OVARIAN CARCINOMA|STAGE IIIC COLON CANCER|STAGE IIIC OVARIAN CANCER|STAGE IIIC SKIN MELANOMA|STAGE IV SKIN MELANOMA,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0
CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,0,DB08915,__ALEGLITAZAR,WO-2002092084-A1,Withdrawn,NCT01893242,"DIABETES MELLITUS TYPE 2, KIDNEY DISEASE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61P3/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.7,437.50800000000004,81.79,5.0,1.0,4.0,46.4,127.76,9.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Withdrawn,NCT02289144,"METASTATIC ANAPLASTIC THYROID CANCER|LOCALLY ADVANCED ANAPLASTIC, UNDIFFERENTIATED THYROID CANCER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center, Dallas, Texas, United States",C07D239/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,0,DB09119,__ESLICARBAZEPINE_ACETATE,5753646,Terminated,NCT01129960,PAINFUL DIABETIC NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIAL - Portela & Cª, S.A., S. Mamede do Coronado, Portugal",C07D223/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,22.7027249019487,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,296.32599999999996,72.63,2.0,1.0,3.0,30.19,81.44,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,0,DB09119,__ESLICARBAZEPINE_ACETATE,5753646,Terminated,,PAINFUL DIABETIC NEUROPATHY (PDN),,,,,"FISABIO, Elche, Alicante, Spain",C07D223/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,22.7027249019487,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,296.32599999999996,72.63,2.0,1.0,3.0,30.19,81.44,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1,0,DB09200,__RIVOGLITAZONE,6150371,Terminated,NCT00571519,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Huntsville, Alabama, United States|Huntsville, Alabama, United States|San Diego, California, United States|San Francisco, California, United States|Ridgefield, Connecticut, United States|Fort Lauderdale, Florida, United States|Pembroke Pines, Florida, United States|Port Gibson, Mississippi, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Kettering, Ohio, United States|Fleetwood, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Simpsonville, South Carolina, United States|Daingerfield, Texas, United States|Dallas, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,64.0,23.7212263085484,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,397.45,82.45,5.0,1.0,4.0,41.96,105.33,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
Cc1c(Cl)cccc1Nc1ccccc1C(=O)O,0,DB09216,__TOLFENAMIC_ACID,4594357,Withdrawn,NCT02159248,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Cancer Center at Orlando Health, Orlando, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,23.6555165403807,795.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.64,261.704,49.33,3.0,2.0,2.0,26.46,71.65,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0
O=c1[nH]c(=O)n(C2CCCO2)cc1F,0,DB09256,__TEGAFUR,3948897,Terminated,NCT03002831,ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China",C07D405/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,29.897944516314503,918.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.09,200.169,58.64,3.0,1.0,2.0,17.52,44.5,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,0,DB09280,__LUMACAFTOR,7495103,Terminated,NCT02858843,CYSTIC FIBROSIS|DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.37,452.414,97.75,6.0,2.0,5.0,44.12,111.97,5.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,0,DB09280,__LUMACAFTOR,7495103,Withdrawn,NCT02653027,DIABETES|CYSTIC FIBROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.37,452.414,97.75,6.0,2.0,5.0,44.12,111.97,5.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
[123I-],0,DB09420,__IODIDE_I-123,,Withdrawn,,THYROID CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,122.9061,0.0,0.0,0.0,0.0,5.07,13.95,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,0,DB11089,__DOCUSATE,4156715,Terminated,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/466,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.9716215938725,95.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,422.577,106.97,5.0,1.0,0.0,46.82,107.35,18.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
OC[C@H](O)[C@@H](O)[C@H](O)CO,0,DB11195,__XYLITOL,,Withdrawn,NCT01561508,DIABETES,All,"8 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,152.1458,101.15,5.0,5.0,0.0,14.42,32.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB11217,__ARBUTIN,4620850,Suspended,,MELASMA,,,,,"FISABIO, Elche, Alicante, Spain",A61Q5/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,26.875295180599107,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,272.2512,119.61,7.0,5.0,2.0,25.88,62.16,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C,0,DB11231,__LYCOPENE,,Withdrawn,NCT01377961,"METABOLIC SYNDROME|DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Internal Medicine, Galveston, Texas, United States|Stark Diabetes Center Clinic, Galveston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,9.16,536.888,0.0,0.0,0.0,0.0,73.69,197.81,16.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],0,DB11246,__COPPER_GLUCONATE,4112066,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61Q11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,0,DB11363,__ALECTINIB,9126931,Terminated,NCT03131206,ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)|RET-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)|RET-POSITIVE THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Irvine, Irvine, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1
O=C(O)c1cc(O)c2c(c1)C(C1c3cc(C(=O)O)cc(O)c3C(=O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc31)c1cccc(OC3OC(CO)C(O)C(O)C3O)c1C2=O,0,DB11365,__SENNOSIDES,,Terminated,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.94,862.7460000000003,347.96,20.0,12.0,8.0,81.49,205.44,9.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0
Clc1ccc(CCCOCCCN2CCCCC2)cc1,0,DB11642,__PITOLISANT,7169928,Terminated,NCT04026750,TYPE 1 DIABETES|HYPOGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","High Point Clinical Trials Center, High Point, North Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,31.967802213597803,39.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.47,295.85,12.47,2.0,0.0,2.0,35.5,86.81,8.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,DB11682,__DAPRODUSTAT,,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.48,393.44,124.09,6.0,2.0,3.0,40.18,96.89,5.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Terminated,NCT01843062,DIFFERENTIATED THYROID CANCER,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Torrance, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Barretos, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Odense C, Denmark|Research Site, Angers Cedex 01, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex 5, France|Research Site, Lyon, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif Cedex, France|Research Site, Augsburg, Germany|Research Site, Essen, Germany|Research Site, Leipzig, Germany|Research Site, Catania, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Gliwice, Poland|Research Site, Kielce, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Terminated,,DIFFERENTIATED THYROID CANCER (DTC),,,,,"FISABIO, Elche, Alicante, Spain",C07D401/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,0,DB11692,__PAVINETANT,,Terminated,,POLYCYSTIC OVARY SYNDROME (PCOS),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.52,459.56,88.16,4.0,2.0,4.0,49.06,128.96,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,NCT00003514,MERKEL CELL CARCINOMA|ISLET CELL CARCINOMA|NEUROENDOCRINE CARCINOMA|PITUITARY TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Burzynski Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Suspended,NCT03602586,MALIGNANT OVARIAN CLEAR CELL TUMOR|RECURRENT OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Advance Oncology Center, Aguadilla, Puerto Rico|Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|Hematologia Oncologia San Pablo, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Primary Care Physician Group, San Juan, Puerto Rico|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico|Centro de Hematologia y Oncologia del Sur, Santa Isabel, Puerto Rico",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Terminated,NCT01685255,OVARIAN CANCER|GENITOURINARY (GU) TUMORS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Evanston, Illinois, United States|Joliet, Illinois, United States|Iowa City, Iowa, United States|Covington, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Bridgewater, New York, United States|Buffalo, New York, United States|Mineola, New York, United States|Durham, North Carolina, United States|Abington, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Greenville, South Carolina, United States|Bendigo, Australia|Heidelberg, Australia|Herston, Australia|Milton, Australia|Randwick, Australia|Calgary, Alberta, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Ekaterinburg, Russian Federation|Izhevsk, Russian Federation|Krasnodar, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Orenburg, Russian Federation|St. Petersburg, Russian Federation|Ufa, Russian Federation|Chernivtsi, Ukraine|Dnepropetrovsk, Ukraine|Kharkiv, Ukraine|Lutsk, Ukraine|Bebington, United Kingdom|Cardiff, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Keighley, United Kingdom|Leeds, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|West Midlands, United Kingdom",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Terminated,NCT02575807,PLATINUM-RESISTANT OVARIAN CANCER|PLATINUM-RESISTANT FALLOPIAN CANCER|PLATINUM-RESISTANT PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States|Stanford Cancer Center, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM - Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Withdrawn,NCT03432676,ATM GENE MUTATION|DELETERIOUS BRCA1 GENE MUTATION|DELETERIOUS BRCA2 GENE MUTATION|HOMOLOGOUS RECOMBINATION DEFICIENCY|PANCREATIC DUCTAL ADENOCARCINOMA|STAGE II PANCREATIC CANCER AJCC V8|STAGE IIA PANCREATIC CANCER AJCC V8|STAGE IIB PANCREATIC CANCER AJCC V8|STAGE III PANCREATIC CANCER AJCC V8|STAGE IV PANCREATIC CANCER AJCC V8,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,NCT00998686,TYPE 2 DIABETES,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phenomix Investigational Site 105, Montgomery, Alabama, United States|Phenomix Investigational Site 121, Tempe, Arizona, United States|Phenomix Investigational Site 137, Tempe, Arizona, United States|Phenomix Investigational Site 105, Anaheim, California, United States|Phenomix Investigational Site 103, Long Beach, California, United States|Phenomix Investigational Site 106, Los Angeles, California, United States|Phenomix Investigational Site 143, Coral Gables, Florida, United States|Phenomix Investigational Site 142, Hialeah, Florida, United States|Phenomix Investigational Site 133, Kissimmee, Florida, United States|Phenomix Investigational Site 101, Honolulu, Hawaii, United States|Phenomix Investigational Site 135, Chicago, Illinois, United States|Phenomix Investigational Site 124, Indianapolis, Indiana, United States|Phenomix Investigational Site 136, Brockton, Massachusetts, United States|Phenomix Investigational Site 138, Biloxi, Mississippi, United States|Phenomix Investigational Site 122, Las Vegas, Nevada, United States|Phenomix Investigational Site 140, Las Vegas, Nevada, United States|Phenomix Investigational Site 110, Trenton, New Jersey, United States|Phenomix Investigational Site 116, Albuquerque, New Mexico, United States|Phenomix Investigational Site 107, Winston-Salem, North Carolina, United States|Phenomix Investigational Site 112, Greenville, South Carolina, United States|Phenomix Investigational Site 102, Dallas, Texas, United States|Phenomix Investigational Site 104, San Antonio, Texas, United States|Phenomix Investigational Site 100, Kenosha, Wisconsin, United States|Phenomix Investigational Site 402, Buenos Aires, Argentina|Phenomix Investigational Site 408, Buenos Aires, Argentina|Phenomix Investigational Site 410, Mendoza, Argentina|Phenomix Investigational Site 208, Praha 10, Czech Republic|Phenomix Investigational Site 209, Praha 4 Chodov, Czech Republic|Phenomix Investigational Site 207, Unicov, Czech Republic|Phenomix Investigational Site 707, Shastrinagar, Jaipur, India|Phenomix Investigational Site 701, Bangalore, Karnataka, India|Phenomix Investigational Site 705, Trivandrum, Kerala, India|Phenomix Investigational Site 706, Indore, Madhya Pradesh, India|Phenomix Investigational Site 711, Mumbai, Maharashtra, India|Phenomix Investigational Site 607, Arequipa, Peru|Phenomix Investigational Site 601, Ica, Peru|Phenomix Investigational Site 604, Lima, Peru|Phenomix Investigational Site 610, Lima, Peru|Phenomix Investigational Site 300, Gdansk, Poland|Phenomix Investigational Site 309, Karkow, Poland|Phenomix Investigational Site 303, Katowice, Poland|Phenomix Investigational Site 306, Pulawy, Poland|Phenomix Investigational Site 305, Warszawa, Poland|Phenomix Investigational Site 302, Wroclaw, Poland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,NCT01089790,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 86 Years   (Adult, Older Adult)",Industry,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Forest Investigative Site 064, Birmingham, Alabama, United States|Forest Investigative Site 020, Birmingham, Alabama, United States|Forest Investigative Site 025, Muscle Shoals, Alabama, United States|Forest Investigative Site 059, Chandler, Arizona, United States|Forest Investigative Site 113, Gilbert, Arizona, United States|Forest Investigative Site 096, Goodyear, Arizona, United States|Forest Investigative Site 080, Peoria, Arizona, United States|Forest Investigative Site 098, Phoenix, Arizona, United States|Forest Investigative Site 133, Phoenix, Arizona, United States|Forest Investigative Site 044, Scottsdale, Arizona, United States|Forest Investigative Site 087, Tucson, Arizona, United States|Forest Investigative Site 061, Anaheim, California, United States|Forest Investigative Site 152, Anaheim, California, United States|Forest Investigative Site 041, Chula Vista, California, United States|Forest Investigative Site 049, Encinitas, California, United States|Forest Investigative Site 022, Greenbrae, California, United States|Forest Investigative Site 047, Harbor City, California, United States|Forest Investigative Site 010, Huntington Park, California, United States|Forest Investigative Site 070, Los Angeles, California, United States|Forest Investigative Site 111, Northridge, California, United States|Forest Investigative Site 031, Riverside, California, United States|Forest Investigative Site 091, Roseville, California, United States|Forest Investigative Site 140, Sacramento, California, United States|Forest Investigative Site 067, Sacramento, California, United States|Forest Investigative Site 145, San Mateo, California, United States|Forest Investigative Site 112, Santa Ana, California, United States|Forest Investigative Site 128, Tustin, California, United States|Forest Investigative Site 011, Walnut Creek, California, United States|Forest Investigative Site 063, West Hills, California, United States|Forest Investigative Site 115, Colorado Springs, Colorado, United States|Forest Investigative Site 088, Denver, Colorado, United States|Forest Investigative Site 156, Boca Raton, Florida, United States|Forest Investigative Site 148, Brandenton, Florida, United States|Forest Investigative Site 073, Clearwater, Florida, United States|Forest Investigative Site 004, Daytona Beach, Florida, United States|Forest Investigative Site 052, DeLand, Florida, United States|Forest Investigative Site 144, Hialeah, Florida, United States|Forest Investigative Site 129, Hollywood, Florida, United States|Forest Investigative Site 062, Jacksonville, Florida, United States|Forest Investigative Site 125, Miami Lakes, Florida, United States|Forest Investigative Site 161, Miami, Florida, United States|Forest Investigative Site 157, Miami, Florida, United States|Forest Investigative Site 154, Miami, Florida, United States|Forest Investigative Site 050, Miami, Florida, United States|Forest Investigative Site 122, Miami, Florida, United States|Forest Investigative Site 069, New Port Richey, Florida, United States|Forest Investigative Site 012, Ocala, Florida, United States|Forest Investigative Site 015, Orlando, Florida, United States|Forest Investigative Site 131, Ormond Beach, Florida, United States|Forest Investigative Site 127, Pembroke Pines, Florida, United States|Forest Investigative Site 018, Sarasota, Florida, United States|Forest Investigative Site 075, St Petersburg, Florida, United States|Forest Investigative Site 138, Tamarac, Florida, United States|Forest Investigative Site 026, West Palm Beach, Florida, United States|Forest Investigative Site 045, Atlanta, Georgia, United States|Forest Investigative Site 079, Augusta, Georgia, United States|Forest Investigative Site 077, Decatur, Georgia, United States|Forest Investigative Site 042, Dunwoody, Georgia, United States|Forest Investigative Site 084, Roswell, Georgia, United States|Forest Investigative Site 132, Roswell, Georgia, United States|Forest Investigative Site 009, Meridian, Idaho, United States|Forest Investigative Site 030, Peoria, Illinois, United States|Forest Investigative Site 123, Springfield, Illinois, United States|Forest Investigative Site 100, Evansville, Indiana, United States|Forest Investigative Site 097, Evansville, Indiana, United States|Forest Investigative Site 053, Kansas City, Kansas, United States|Forest Investigative Site 008, Wichita, Kansas, United States|Forest Investigative Site 078, Erlanger, Kentucky, United States|Forest Investigative Site 107, Lexington, Kentucky, United States|Forest Investigative Site 024, Madisonville, Kentucky, United States|Forest Investigative Site 034, Covington, Louisiana, United States|Forest Investigative Site 035, Baltimore, Maryland, United States|Forest Investigative Site 046, Oxon Hill, Maryland, United States|Forest Investigative Site 165, Rockville, Maryland, United States|Forest Investigative Site 003, Brockton, Massachusetts, United States|Forest Investigative Site 055, Brockton, Massachusetts, United States|Forest Investigative Site 118, New Bedford, Massachusetts, United States|Forest Investigative Site 007, Waltham, Massachusetts, United States|Forest Investigative Site 163, Cadillac, Michigan, United States|Forest Investigative Site 002, Dearborn, Michigan, United States|Forest Investigative Site 029, St. Clair Shores, Michigan, United States|Forest Investigative Site 054, Edina, Minnesota, United States|Forest Investigative Site 142, St. Louis, Missouri, United States|Forest Investigative Site 143, St. Louis, Missouri, United States|Forest Investigative Site 013, Grand Island, Nebraska, United States|Forest Investigative Site 150, Omaha, Nebraska, United States|Forest Investigative Site 072, Las Vegas, Nevada, United States|Forest Investigative Site 065, Las Vegas, Nevada, United States|Forest Investigative Site 147, Berkeley Heights, New Jersey, United States|Forest Investigative Site 137, Albuquerque, New Mexico, United States|Forest Investigative Site 101, Albuquerque, New Mexico, United States|Forest Investigative Site 006, Albany, New York, United States|Forest Investigative Site 081, New Hyde Park, New York, United States|Forest Investigative Site 016, New York, New York, United States|Forest Investigative Site 151, New York, New York, United States|Forest Investigative Site 155, Asheboro, North Carolina, United States|Forest Investigative Site 094, Charlotte, North Carolina, United States|Forest Investigative Site 051, Charlotte, North Carolina, United States|Forest Investigative Site 117, Charlotte, North Carolina, United States|Forest Investigative Site 135, Durham, North Carolina, United States|Forest Investigative Site 058, Lenoir, North Carolina, United States|Forest Investigative Site 038, Morehead City, North Carolina, United States|Forest Investigative Site 040, Salisbury, North Carolina, United States|Forest Investigative Site 082, Winston-Salem, North Carolina, United States|Forest Investigative Site 039, Akron, Ohio, United States|Forest Investigative Site 023, Cincinnati, Ohio, United States|Forest Investigative Site 043, Columbus, Ohio, United States|Forest Investigative Site 057, Dayton, Ohio, United States|Forest Investigative Site 032, Kettering, Ohio, United States|Forest Investigative Site 141, Marion, Ohio, United States|Forest Investigative Site 159, Marion, Ohio, United States|Forest Investigative Site 153, Zanesville, Ohio, United States|Forest Investigative Site 083, Bethany, Oklahoma, United States|Forest Investigative Site 149, Norman, Oklahoma, United States|Forest Investigative Site 102, Ashland, Oregon, United States|Forest Investigative Site 005, Eugene, Oregon, United States|Forest Investigative Site 001, Medford, Oregon, United States|Forest Investigative Site 130, Bensalem, Pennsylvania, United States|Forest Investigative Site 037, Harleysville, Pennsylvania, United States|Forest Investigative Site 126, Jenkintown, Pennsylvania, United States|Forest Investigative Site 158, Morrisville, Pennsylvania, United States|Forest Investigative Site 066, Philadelphia, Pennsylvania, United States|Forest Investigative Site 036, Tipton, Pennsylvania, United States|Forest Investigative Site 103, Greer, South Carolina, United States|Forest Investigative Site 090, Manning, South Carolina, United States|Forest Investigative Site 033, Pelzer, South Carolina, United States|Forest Investigative Site 048, Bristol, Tennessee, United States|Forest Investigative Site 114, Chattanooga, Tennessee, United States|Forest Investigative Site 104, Chattanooga, Tennessee, United States|Forest Investigative Site 099, Arlington, Texas, United States|Forest Investigative Site 056, Corpus Christi, Texas, United States|Forest Investigative Site 071, Dallas, Texas, United States|Forest Investigative Site 017, Dallas, Texas, United States|Forest Investigative Site 124, Dallas, Texas, United States|Forest Investigative Site 162, Desoto, Texas, United States|Forest Investigative Site 136, Houston, Texas, United States|Forest Investigative Site 106, Houston, Texas, United States|Forest Investigative Site 014, Irving, Texas, United States|Forest Investigative Site 139, Irving, Texas, United States|Forest Investigative Site 160, New Braunfels, Texas, United States|Forest Investigative Site 146, San Antonio, Texas, United States|Forest Investigative Site 109, San Antonio, Texas, United States|Forest Investigative Site 119, San Antonio, Texas, United States|Forest Investigative Site 076, Salt Lake City, Utah, United States|Forest Investigative Site 121, Arlington, Virginia, United States|Forest Investigative Site 028, Virginia Beach, Virginia, United States|Forest Investigative Site 068, Renton, Washington, United States|Forest Investigative Site 092, Spokane, Washington, United States|Forest Investigative Site 027, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,NCT00958269,TYPE 2 DIABETES MELLITUS|RENAL IMPAIRMENT,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phenomix Investigational Site 115, Tempe, Arizona, United States|Phenomix Investigational Site 121, Long Beach, California, United States|Phenomix Investigational Site 110, Lynwood, California, United States|Phenomix Investigational Site 118, Lynwood, California, United States|Phenomix Investigational Site 119, Orange, California, United States|Phenomix Investigational Site 109, Palm Springs, California, United States|Phenomix Investigational Site 122, Whittier, California, United States|Phenomix Investigational Site 112, Lauderdale Lakes, Florida, United States|Phenomix Investigational Site 104, Ocala, Florida, United States|Phenomix Investigational Site 116, Pembroke Pines, Florida, United States|Phenomix Investigational Site 101, Augusta, Georgia, United States|Phenomix Investigational Site 117, Honolulu, Hawaii, United States|Phenomix Investigational Site 102, Baton Rouge, Louisiana, United States|Phenomix Investigational Site 100, Rockville, Maryland, United States|Phenomix Investigational Site 125, Rockville, Maryland, United States|Phenomix Investigational Site 114, Springfield Gardens, New York, United States|Phenomix Investigational Site 120, Winston-Salem, North Carolina, United States|Phenomix Investigational Site 107, Columbia, South Carolina, United States|Phenomix Investigational Site 111, Nashville, Tennessee, United States|Phenomix Investigational Site 103, Fort Worth, Texas, United States|Phenomix Investigational Site 106, Houston, Texas, United States|Phenomix Investigational Site 108, San Antonio, Texas, United States|Phenomix Investigational Site 113, Alexandria, Virginia, United States|Phenomix Investigational Site 208, Kemerovo, Russian Federation|Phenomix Investigational Site 203, Moscow, Russian Federation|Phenomix Investigational Site 204, Moscow, Russian Federation|Phenomix Investigational Site 209, Moscow, Russian Federation|Phenomix Investigational Site 211, Moscow, Russian Federation|Phenomix Investigational Site 205, Novosibirsk, Russian Federation|Phenomix Investigational Site 207, Perm., Russian Federation|Phenomix Investigational Site 206, Petrozavodsk, Russian Federation|Phenomix Investigational Site 200, St. Petersburg, Russian Federation|Phenomix Investigational Site 201, St. Petersburg, Russian Federation|Phenomix Investigational Site 210, St. Petersburg, Russian Federation|Phenomix Investigational Site 212, St. Petersburg, Russian Federation|Phenomix Investigational Site 213, St. Petersburg, Russian Federation|Phenomix Investigational Site 304, Chernivtsi, Ukraine|Phenomix Investigational Site 300, Kyiv, Ukraine|Phenomix Investigational Site 301, Kyiv, Ukraine|Phenomix Investigational Site 306, Kyiv, Ukraine|Phenomix Investigational Site 302, Odesa, Ukraine|Phenomix Investigational Site 303, Vinnytsa, Ukraine|Phenomix Investigational Site 307, Zaporizhzhya, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,NCT00865592,TYPE 2 DIABETES MELLITUS|TYPE 2 DIABETES,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norwalk, California, United States|Orange, California, United States|Santa Ana, California, United States|Daytona Beach, Florida, United States|Kissimmee, Florida, United States|Atlanta, Georgia, United States|Phenomix Investigational Site 663, Honolulu, Hawaii, United States|Brockton, Massachusetts, United States|St. Louis, Missouri, United States|Cincinnati, Ohio, United States|El Paso, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Phenomix Investigational Site 103, Buenos Aires, Argentina|Phenomix Investigational Site 110, Buenos Aires, Argentina|Phenomix Investigational Site 111, Buenos Aires, Argentina|Phenomix Investigational Site 106, Caba, Argentina|Phenomix Investigational Site 112, Corrientes, Argentina|Phenomix Investigational Site 102, Paraná, Argentina|Bangalore, Karnataka, India|Chennai, Tamil Nadu, India|Gulbarga, Karnataka, India|Hyderabad, Andhara Pradesh, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Navi Mumbai, Maharashtra, India|Pune, Maharashtra, India|Phenomix Investigational Site 403, Kuching, Sarawak, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Perak, Malaysia|Phenomix Investigational Site 404, Putrajaya, Malaysia|Sarawak, Malaysia|Phenomix Investigational Site 604, Arequipa, Peru|Phenomix Investigational Site 606, Lambayeque, Peru|Phenomix Investigational Site 600, Lima, Peru|Phenomix Investigational Site 601, Lima, Peru|Phenomix Investigational Site 602, Lima, Peru|Phenomix Investigational Site 609, Lima, Peru|Phenomix Investigational Site 703, Cebu City, Philippines|Manila, NCR, Philippines|Quezon City, NCR, Philippines|San Juan, NCR, Philippines|Phenomix Investigational Site 802, Brasov, Romania|Phenomix Investigational Site 806, Brasov, Romania|Phenomix Investigational Site 800, Bucharest, Romania|Phenomix Investigational Site 803, Bucharest, Romania|Phenomix Investigational Site 805, Bucharest, Romania|Phenomix Investigational Site 807, Bucharest, Romania|Phenomix Investigational Site 804, Galati, Romania|Phenomix Investigational Site 801, Ploieşti, Romania|Phenomix Investigational Site 808, Sibiu, Romania|Phenomix Investigational Site 551, Ivano-Frankivsk, Ukraine|Phenomix Investigational Site 557, Kharkiv, Ukraine|Phenomix Investigational Site 564, Kharkiv, Ukraine|Phenomix Investigational Site 550, Kharkov, Ukraine|Phenomix Investigational Site 555, Kiev, Ukraine|Phenomix Investigational Site 556, Kiev, Ukraine|Phenomix Investigational Site 562, Kiev, Ukraine|Phenomix Investigational Site 563, Kiev, Ukraine|Phenomix Investigational Site 554, Kylv, Ukraine|Phenomix Investigational Site 565, Lutsk, Ukraine|Phenomix Investigational Site 553, Lviv, Ukraine|Phenomix Investigational Site 561, Poltava, Ukraine|Phenomix Investigational Site 560, Simferopol, Ukraine|Phenomix Investigational Site 559, Vinnitsa, Ukraine|Phenomix Investigational Site 552, Zaporzhzhia, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,NCT00970424,"DIABETES MELLITUS, TYPE II",All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Forest Investigative Site 064, Birmingham, Alabama, United States|Forest Investigative Site 020, Birmingham, Alabama, United States|Forest Investigative Site 059, Chandler, Arizona, United States|Forest Investigative Site 096, Litchfield, Arizona, United States|Forest Investigative Site 098, Phoenix, Arizona, United States|Forest Investigative Site 044, Scottsdale, Arizona, United States|Forest Investigative Site 087, Tucson, Arizona, United States|Forest Investigative Site 061, Anaheim, California, United States|Forest Investigative Site 041, Chula Vista, California, United States|Forest Investigative Site 049, Encinitas, California, United States|Forest Investigative Site 022, Greenbrae, California, United States|Forest Investigative Site 047, Harbor City, California, United States|Forest Investigative Site 010, Huntington Park, California, United States|Forest Investigative Site 111, Northridge, California, United States|Forest Investigative Site 031, Riverside, California, United States|Forest Investigative Site 091, Roseville, California, United States|Forest Investigative Site 067, Sacramento, California, United States|Forest Investigative Site 112, Santa Ana, California, United States|Forest Investigative Site 011, Walnut Creek, California, United States|Forest Investigative Site 063, West Hills, California, United States|Forest Investigative Site 115, Colorado Springs, Colorado, United States|Forest Investigative Site 073, Clearwater, Florida, United States|Forest Investigative Site 004, Daytona Beach, Florida, United States|Forest Investigative Site 052, DeLand, Florida, United States|Forest Investigative Site 062, Jacksonville, Florida, United States|Forest Investigative Site 021, Miami, Florida, United States|Forest Investigative Site 050, Miami, Florida, United States|Forest Investigative Site 122, Miami, Florida, United States|Forest Investigative Site 015, Orlando, Florida, United States|Forest Investigative Site 018, Sarasota, Florida, United States|Forest Investigative Site 075, St. Petersburg, Florida, United States|Forest Investigative Site 026, West Palm Beach, Florida, United States|Forest Investigative Site 045, Atlanta, Georgia, United States|Forest Investigative Site 079, Augusta, Georgia, United States|Forest Investigative Site 009, Meridian, Idaho, United States|Forest Investigative Site 60, Melrose Park, Illinois, United States|Forest Investigative Site 030, Peoria, Illinois, United States|Forest Investigative Site 100, Evansville, Indiana, United States|Forest Investigative Site 097, Evansville, Indiana, United States|Forest Investigative Site 053, Kansas City, Kansas, United States|Forest Investigative Site 008, Wichita, Kansas, United States|Forest Investigative Site 078, Erlanger, Kentucky, United States|Forest Investigative Site 024, Madisonville, Kentucky, United States|Forest Investigative Site 034, Covington, Louisiana, United States|Forest Investigative Site 035, Baltimore, Maryland, United States|Forest Investigative Site 046, Oxon Hill, Maryland, United States|Forest Investigative Site 118, New Bedford, Massachusetts, United States|Forest Investigative Site 007, Waltham, Massachusetts, United States|Forest Investigative Site 002, Dearborn, Michigan, United States|Forest Investigative Site 029, St. Clair Shores, Michigan, United States|Forest Investigative Site 054, Edina, Minnesota, United States|Forest Investigative Site 013, Grand Island, Nebraska, United States|Forest Investigative Site 072, Las Vegas, Nevada, United States|Forest Investigative Site 065, Las Vegas, Nevada, United States|Forest Investigative Site 081, New Hyde Park, New York, United States|Forest Investigative Site 016, New York, New York, United States|Forest Investigative Site 094, Charlotte, North Carolina, United States|Forest Investigative Site 051, Charlotte, North Carolina, United States|Forest Investigative Site 117, Charlotte, North Carolina, United States|Forest Investigative Site 058, Lenoir, North Carolina, United States|Forest Investigative Site 038, Morehead City, North Carolina, United States|Forest Investigative Site 040, Salisbury, North Carolina, United States|Forest Investigative Site 039, Akron, Ohio, United States|Forest Investigative Site 023, Cincinnati, Ohio, United States|Forest Investigative Site 043, Columbus, Ohio, United States|Forest Investigative Site 057, Dayton, Ohio, United States|Forest Investigative Site 032, Kettering, Ohio, United States|Forest Investigative Site 149, Norman, Oklahoma, United States|Forest Investigative Site 102, Ashland, Oregon, United States|Forest Investigative Site 005, Eugene, Oregon, United States|Forest Investigative Site 037, Harleysville, Pennsylvania, United States|Forest Investigative Site 066, Philadelphia, Pennsylvania, United States|Forest Investigative Site 036, Tipton, Pennsylvania, United States|Forest Investigative Site 103, Greer, South Carolina, United States|Forest Investigative Site 090, Manning, South Carolina, United States|Forest Investigative Site 033, Pelzer, South Carolina, United States|Forest Investigative Site 114, Chattanooga, Tennessee, United States|Forest Investigative Site 104, Chattanooga, Tennessee, United States|Forest Investigative Site 099, Arlington, Texas, United States|Forest Investigative Site 056, Corpus Christi, Texas, United States|Forest Investigative Site 017, Dallas, Texas, United States|Forest Investigative Site 124, Dallas, Texas, United States|Forest Investigative Site 106, Houston, Texas, United States|Forest Investigative Site 014, Irving, Texas, United States|Forest Investigative Site 109, San Antonio, Texas, United States|Forest Investigative Site 076, Salt Lake City, Utah, United States|Forest Investigative Site 028, Virginia Beach, Virginia, United States|Forest Investigative Site 092, Spokane, Washington, United States|Forest Investigative Site 027, Milwaukee, Wisconsin, United States|Forest Investigative Site 209, Mogilev, Belarus|Forest Investigative Site 401, Dresden, Germany|Forest Investigative Site 402, Dresden, Germany|Forest Investigative Site 403, Mainz, Germany|Forest Investigative Site 614, Vijayawada, Andhra Pradesh, India|Forest Investigative Site 618, Ahmedabad, Gujarat, India|Forest Investigative Site 620, Haryana, Karnal, India|Forest Investigative Site 607, Bangalore, Karnataka, India|Forest Investigative Site 606, Bangalore, Karnataka, India|Forest Investigative Site 602, Bangalore, Karnataka, India|Forest Investigative Site 604, Bangalore, Karnataka, India|Forest Investigative Site 601, Mangalore, Karnataka, India|Forest Investigative Site 616, Nagpur, Maharashtra, India|Forest Investigative Site 617, Nasik, Maharashtra, India|Forest Investigative Site 612, Pune, Maharashtra, India|Forest Investigative Site 603, Channi, Tamil Nadu, India|Forest Investigative Site 613, Chennai, Tamil Nadu, India|Forest Investigative Site 615, Vellore, Tamil Nadu, India|Forest Investigative Site 702, Kaunas, Lithunia, Lithuania|Forest Investigative Site 703, Kaunas, Lithunia, Lithuania|Forest Investigative Site 704, Klaipeda, Lithunia, Lithuania|Forest Investigative Site 705, Vilnius, Lithunia, Lithuania|Forest Investigative Site 909, Bacau, Romania|Forest Investigative Site 906, Bucuresti, Romania|Forest Investigative Site 908, Bucuresti, Romania|Forest Investigative Site 903, Satu Mare, Romania|Forest Investigative Site 901, Sibiu, Romania|Forest Investigative Site 905 Romania, Tg Mures, Romania|Forest Investigative Site 902, Timisoara, Romania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)C(C)C)C(N)=O,0,DB11724,__BOMBESIN,,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,1619.87,686.13,22.0,23.0,4.0,166.6,418.43,51.0,1.0,0.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,0,DB11730,__RIBOCICLIB,8324225,Terminated,NCT02703571,SOLID TUMORS FOR PHASE IB|PANCREATIC CANCER FOR PHASE II|COLORECTAL CANCER FOR PHASE II,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Sylvester Comp Cancer Ctr, Miami, Florida, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,1,1
O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,0,DB11735,__GALACTOSE,3933788,Terminated,NCT00427986,DIABETIC MACULAR OEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57,, Glostrup, Denmark",C12P21/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,30.817881270662603,12963.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.13,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,0,DB11741,__FAMITINIB,WO-2007085188-A1,Terminated,NCT01994213,GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,410.49300000000005,68.44,3.0,2.0,4.0,46.14,119.31,6.0,0.0,1.0,0.0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,0,DB11760,__TALAZOPARIB,8012976,Withdrawn,NCT02627430,ADULT SOLID NEOPLASM|ESTROGEN RECEPTOR NEGATIVE|FALLOPIAN TUBE SEROUS NEOPLASM|HER2/NEU NEGATIVE|OVARIAN SEROUS ADENOCARCINOMA|OVARIAN SEROUS TUMOR|PRIMARY PERITONEAL SEROUS ADENOCARCINOMA|PROGESTERONE RECEPTOR NEGATIVE|RECURRENT BREAST CARCINOMA|RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA|TRIPLE-NEGATIVE BREAST CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,0,DB11760,__TALAZOPARIB,8012976,Withdrawn,NCT02567396,ESTROGEN RECEPTOR NEGATIVE|HEAD AND NECK SQUAMOUS CELL CARCINOMA|HER2/NEU NEGATIVE|HORMONE-RESISTANT PROSTATE CANCER|METASTATIC PANCREATIC ADENOCARCINOMA|PROGESTERONE RECEPTOR NEGATIVE|SOLID NEOPLASM|STAGE III MESOTHELIOMA|STAGE IIIA GASTRIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIA OVARIAN CANCER|STAGE IIIA SMALL CELL LUNG CARCINOMA|STAGE IIIB GASTRIC CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IIIB OVARIAN CANCER|STAGE IIIB SMALL CELL LUNG CARCINOMA|STAGE IIIC GASTRIC CANCER|STAGE IIIC OVARIAN CANCER|STAGE IV MESOTHELIOMA|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN CANCER|STAGE IV SMALL CELL LUNG CARCINOMA|TRIPLE-NEGATIVE BREAST CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,0,DB11760,__TALAZOPARIB,8012976,Withdrawn,NCT02836028,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1
CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,0,DB11781,__TOSEDOSTAT,,Terminated,NCT02352831,PANCREATIC CANCER|CANCER OF PANCREAS|CANCER OF THE PANCREAS|PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.9,406.47900000000004,124.96,5.0,4.0,2.0,42.88,105.13,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,0,DB11782,__BIRINAPANT,,Terminated,NCT01681368,EPITHELIAL OVARIAN CANCER|PERITONEAL NEOPLASMS|FALLOPIAN TUBE NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.21,806.957,194.92,8.0,8.0,6.0,86.23,214.65,15.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,0,DB11782,__BIRINAPANT,,Withdrawn,NCT02756130,HIGH GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA|HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA|PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA|RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.21,806.957,194.92,8.0,8.0,6.0,86.23,214.65,15.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0
CCCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1,0,DB11792,__MIRODENAFIL,US-20030171361-A1,Terminated,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,56.7403848128298,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.85,531.67,116.47,7.0,2.0,4.0,57.75,146.61,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,0,DB11800,__TIVOZANIB,US-20040229876-A1,Terminated,NCT01972516,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D335/02,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,84.0,34.760467360726,23.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.25,454.86300000000006,107.74,5.0,2.0,4.0,44.26,120.85,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,0,DB11812,__TALAPORFIN,,Terminated,,MACULAR DEGENERATION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,711.7719999999997,235.66,11.0,7.0,5.0,76.96,189.23,12.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0
C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C[C@](C)(OC(C)=O)[C@H]2[C@@H]1OC(=O)CCCCCCC,0,DB11813,__MIPSAGARGIN,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,1409.5410000000006,529.98,23.0,13.0,3.0,148.12,339.89,50.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1
N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl,0,DB11814,__PF-03882845,7781428,Terminated,NCT01488877,TYPE 2 DIABETIC NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, DeLand, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, New York, New York, United States",C07D231/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,34.0048050267972,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,419.91,76.69,5.0,1.0,5.0,45.39,126.55,3.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,DB11816,__OMECAMTIV_MECARBIL,US-20060014761-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,NCT01484860,ADENOCARCINOMA OF THE PANCREAS|METASTATIC DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Princess Margaret Hospital, Toronto, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,,ADENOCARCINOMA OF THE PANCREAS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,,ADVANCED GASTRIC CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,0,DB11891,__CUDC-907,,Terminated,NCT03002623,THYROID NEOPLASMS|POORLY DIFFERENTIATED AND UNDIFFERENTIATED THYROID CANCER|DIFFERENTIATED THYROID CANCER,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,508.56,138.72,11.0,2.0,5.0,53.01,145.82,7.0,1.0,0.0,0.0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1
COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,0,DB11891,__CUDC-907,,Terminated,,DIFFERENTIATED THYROID CANCER (DTC),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,508.56,138.72,11.0,2.0,5.0,53.01,145.82,7.0,1.0,0.0,0.0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1
CC(=O)Nc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(C)=O)C(=O)N[C@H](Cc2ccc(NC(C)=O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)cc1,0,DB11906,__ACYLINE,,Withdrawn,NCT02147964,GONADOTROPIN DEFICIENCY,Male,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Medical Center (Health Sciences), Seattle, Washington, United States",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.34,1533.24,428.65,16.0,14.0,7.0,161.67,413.52,40.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02367690,DIABETIC FOOT ULCERS,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"South Pacific Clinical Trials, Auckland, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1,0,DB11965,__SJG-136,,Terminated,NCT01200797,RECURRENT FALLOPIAN TUBE CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hartford Hospital, Hartford, Connecticut, United States|Oncology Associates PC, Hartford, Connecticut, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,556.619,102.26,8.0,0.0,6.0,61.87,157.22,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0
Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,0,DB11968,__MK-7145,US-20100286123-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,46.686790283168,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.33,466.534,99.54,6.0,2.0,5.0,49.95,128.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1,0,DB11970,__BURIXAFOR,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,566.732,151.9,11.0,6.0,4.0,65.83,161.18,14.0,1.0,0.0,0.0,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,NCT02369796,HYPOGONADOTROPIC HYPOGONADISM,Male,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oxford, Oxfordshire, United Kingdom",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
O=c1c(-c2ccccc2)coc2ccccc12,0,DB12007,__ISOFLAVONE,4234577,Withdrawn,NCT01377961,"METABOLIC SYNDROME|DIABETES MELLITUS, NON-INSULIN-DEPENDENT",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Internal Medicine, Galveston, Texas, United States|Stark Diabetes Center Clinic, Galveston, Texas, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.041479291155802,192.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.51,222.243,26.3,2.0,0.0,3.0,23.64,65.74,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT01962948,RECURRENT FALLOPIAN TUBE CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT02012192,EPITHELIAL OVARIAN CANCER|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University Innsbruck, Department for Gynaecology and Obstetrics, Innsbruck, Austria|Katholieke Universiteit Leuven, Dept. of Gynaecologic Oncology, Leuven, Belgium|Centre de lutte contre le cancer Francois Baclesse, Caen, France|Centre Anticancereux Léon Bérard, Lyon, France|Assistance Publique - Hôpitaux de Paris Medical Oncology Department, Paris, France|Universitätsmedizin Berlin Charité, Dept. for Gynecology, Berlin, Germany|University Hospital Carl Gustav Carus Dresden, Department of Gynaecology and Obstetrics, Dresden, Germany|Kliniken Essen Mitte, Evang. Huyssens-Stiftung / Knappschaft GmbH Department of Gynaecologic Oncology, Essen, Germany|Universitätsklinikum Hamburg-Eppendorf Dept. of Gynecology and Gynecologic Oncology, Hamburg, Germany|Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,0,DB12064,__BMS-777607,,Withdrawn,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,512.893,106.78,5.0,2.0,4.0,49.23,132.8,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,NCT02101684,METASTATIC OR ADVANCED NON-RESECTABLE GRANULOSA CELL OVARIAN TUMORS,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Del Mar, Barcelona, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@]12CCC(=O)C=C1CC[C@@H]1C2=CC[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,0,DB12081,__ANECORTAVE,4876250,Terminated,NCT00211471,SEVERE DIABETIC RETINOPATHY|CENTRAL RETINAL VEIN OCCLUSION|CHRONIC INFLAMMATION|INFECTIOUS DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,11.7620485020226,46.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,344.45099999999996,74.6,4.0,2.0,4.0,38.24,96.66,2.0,0.0,1.0,0.0,1,0,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CCC(=O)C=C1CC[C@@H]1C2=CC[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,0,DB12081,__ANECORTAVE,4876250,Terminated,NCT00211406,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,11.7620485020226,46.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,344.45099999999996,74.6,4.0,2.0,4.0,38.24,96.66,2.0,0.0,1.0,0.0,1,0,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1,0,DB12096,__PF-05175157,US-20110111046-A1,Terminated,NCT01792635,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Profil Institute for Clinical Research, Inc., Chula Vista, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,23.261257931374306,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.24,405.50199999999995,83.88,4.0,1.0,5.0,45.27,126.12,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,1,1,1
Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1,0,DB12096,__PF-05175157,US-20110111046-A1,Terminated,NCT02053103,TYPE 2 DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Pfizer Investigational Site, Orlando, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,23.261257931374306,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.24,405.50199999999995,83.88,4.0,1.0,5.0,45.27,126.12,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,1,1,1
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,DB12109,__CPI-613,US-20100190858-A1,Terminated,NCT00907166,CANCER|PANCREATIC CANCER|PANCREATIC CARCINOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eastchester Center for Cancer Care, Bronx, New York, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,34.629047824390604,2.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.59,388.58,37.3,2.0,1.0,2.0,45.88,114.56,13.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,DB12109,__CPI-613,US-20100190858-A1,Withdrawn,NCT01830322,METASTATIC PANCREATIC ADENOCARCINOMA,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eastchester Center for Cancer Care, Bronx, New York, United States|Temple Vasicek Cancer Treatment Center, Temple, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,34.629047824390604,2.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.59,388.58,37.3,2.0,1.0,2.0,45.88,114.56,13.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,DB12109,__CPI-613,US-20100190858-A1,Withdrawn,NCT03374852,PANCREATIC DUCTAL ADENOCARCINOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,52.0,34.629047824390604,2.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.59,388.58,37.3,2.0,1.0,2.0,45.88,114.56,13.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB12144,__BMS-275183,,Terminated,,TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,845.936,239.75,11.0,4.0,5.0,86.51,208.21,16.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,0,DB12228,__TELCAGEPANT,EP-2007764-B1,Terminated,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,28.68231380521161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,566.523,97.88,4.0,2.0,5.0,52.43,134.6,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,NCT03417076,TYPE 2 DIABETES,Male,18 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Site, Madison, Wisconsin, United States",A61P3/00 ,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,0,DB12242,__AZD-7762,EP-1732920-B1,Terminated,,ADVANCED SOLID MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,74.4491673340315,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.7,362.42199999999997,96.25,3.0,4.0,3.0,37.31,95.54,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,0,DB12255,__VADADUSTAT,US-20070299086-A1,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,39.5572804369699,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.53,306.7,99.52,5.0,3.0,2.0,29.63,75.51,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CC(C)OP(=O)(OC(C)C)C(Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OC(C)C)OC(C)C,0,DB12276,__APOMINE,6048995,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/404,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,19.7129304503172,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.53,562.665,91.29,3.0,1.0,1.0,61.56,151.23,14.0,1.0,0.0,0.0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,0,DB12332,__RUCAPARIB,6495541,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO,0,DB12376,__RICOLINOSTAT,WO-2011091213-A2,Terminated,NCT02661815,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massacusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,56.0,32.7488,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.04,433.51199999999994,107.45,6.0,3.0,3.0,48.16,122.73,11.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1
Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,0,DB12405,__TRICIRIBINE,5633235,Terminated,NCT01690468,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,34.7276124766422,177.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,320.309,144.47,8.0,4.0,4.0,31.22,90.56,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB12406,__LISOFYLLINE,5281731,Terminated,NCT01603121,TYPE 1 DIABETES,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Eastern Virginia Medical School Strelitz Diabetes Center, Norfolk, Virginia, United States",C07F7/1804,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.1604550401445,245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.78,280.328,78.67,4.0,1.0,2.0,30.03,74.65,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,0,DB12415,__GALETERONE,WO-2008154382-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0
O=C1NS(=O)(=O)c2ccccc21,0,DB12418,__SACCHARIN,3933748,Withdrawn,NCT01488383,HYPERGLYCEMIA|HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Basque Public Health Service-Osakidetza (Lakuabizkarra primary care center and Txagorritxu hospital), Vitoria-Gasteiz, Alava, Spain",C09J4/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,17.150249491775998,3698.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.09,183.185,63.24,3.0,1.0,2.0,16.02,42.39,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+](=O)[O-])c1,0,DB12445,__NITROASPIRIN,WO-2002030866-A1,Terminated,NCT00157508,TYPE 2 DIABETES|EARLY NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,"Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,331.28,104.97,5.0,0.0,2.0,31.6,81.5,8.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,0,DB12491,__FASIGLIFAM,US-20100004312-A1,Terminated,NCT01834274,"DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Huntsville, Alabama, United States|Chandler, Arizona, United States|Glendale, Arizona, United States|Little Rock, Arkansas, United States|Fresno, California, United States|Garden Grove, California, United States|Modesto, California, United States|San Diego, California, United States|Thousand Oaks, California, United States|Lakewood, Colorado, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|North Miami, Florida, United States|Pembroke Pines, Florida, United States|Sanford, Florida, United States|Atlanta, Georgia, United States|Conyers, Georgia, United States|Evans, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Council Bluffs, Iowa, United States|Augusta, Kansas, United States|Omaha, Nebraska, United States|New York, New York, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Carlisle, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Fort Mill, South Carolina, United States|Laurens, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Victoria, Texas, United States|Salt Lake City, Utah, United States|Coronel Suarez, Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Calgary, Alberta, Canada|Red Deer, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Karlovac, Croatia|Krapinske Toplice, Croatia|Slavonski Brod, Croatia|Virovitica, Croatia|Zagreb, Croatia|Budapest, Hungary|Godollo, Hungary|Kistarcsa, Hungary|Satoraljaujhely, Hungary|Szeged, Hungary|Seri Manjung, Perak, Malaysia|Taiping, Perak, Perak, Malaysia|Taiping, Perak, Malaysia|Putrajaya, Selangor, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Ica, Peru|Lima, Peru|Cebu City, Philippines|Iloilo City, Philippines|Marikina City, Philippines|Pasig, Philippines|Quezon City, Philippines|West Fairview, Quezon City, Philippines|Gdansk, Poland|Lodz, Poland|Oswiecim, Poland|Rzeszow, Poland|Sobotka, Poland|Wroclaw, Poland|Zgierz, Poland|Barnaul, Russian Federation|Kemerovo, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bloemfontein, Free State, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Bangkoknoi, Bangkok, Thailand|Rajathevee, Bangkok, Thailand|Muang, Khon Kaen, Thailand|Klongluang, Pathum Thani, Thailand|Hat Yai, Songkhla, Thailand|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Vinnytsia, Ukraine",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,35.4175650424033,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.43,524.63,99.13,7.0,1.0,4.0,58.35,142.67,11.0,1.0,0.0,0.0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,0,DB12491,__FASIGLIFAM,US-20100004312-A1,Terminated,NCT01549964,GLYCEMIC CONTROL,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Muscle Shoals, Alabama, United States|Mesa, Arizona, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Chula Vista, California, United States|El Cajon, California, United States|La Mesa, California, United States|Laguna Hills, California, United States|National City, California, United States|Paramount, California, United States|San Diego, California, United States|Stockton, California, United States|Tustin, California, United States|West Hills, California, United States|Trumbull, Connecticut, United States|Coral Gables, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|West Palm Beach, Florida, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Greenfield, Indiana, United States|Muncie, Indiana, United States|Lexington, Kentucky, United States|Owensboro, Kentucky, United States|Hyattsville, Maryland, United States|Troy, Michigan, United States|Picayune, Mississippi, United States|St. Louis, Missouri, United States|Haddon Heights, New Jersey, United States|Rosedale, New York, United States|Calabash, North Carolina, United States|Charlotte, North Carolina, United States|Monroe, North Carolina, United States|Morehead City, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Norman, Oklahoma, United States|Lancaster, Pennsylvania, United States|Levittown, Pennsylvania, United States|Spartanburg, South Carolina, United States|Crossville, Tennessee, United States|Memphis, Tennessee, United States|Carrollton, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|Katy, Texas, United States|McKinney, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Camperdown, New South Wales, Australia|Maroubra, New South Wales, Australia|Redcliffe, Queensland, Australia|Adelaide, South Australia, Australia|Daw Park, South Australia, Australia|Box Hill, Victoria, Australia|Fitzroy, Victoria, Australia|Melbourne, Victoria, Australia|Byala, Bulgaria|Kazanlak, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Cakovec, Croatia|Karlovac, Croatia|Krapinske Toplice, Croatia|Rijeka, Croatia|Slavonski Brod, Croatia|Split, Croatia|Zadar, Croatia|Zagreb, Croatia|Beroun, Czech Republic|Brno, Czech Republic|Havlickuv Brod, Czech Republic|Kladno, Czech Republic|Kromeriz, Czech Republic|Mlada Boleslav, Czech Republic|Ostrava - Moravska Ostrava, Czech Republic|Ostrava, Czech Republic|Pardubice, Czech Republic|Pisek, Czech Republic|Plzen, Czech Republic|Praha 11, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Praha 6, Czech Republic|Praha 8, Czech Republic|Usti nad Labem, Czech Republic|Baja, Hungary|Balatonfured, Hungary|Budaors, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Godollo, Hungary|Gyongyos, Hungary|Gyula, Hungary|Hodmezovasarhely, Hungary|Kecskemet, Hungary|Kistelek, Hungary|Kisvarda, Hungary|Komarom, Hungary|Mohacs, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szeged, Hungary|Szekszard, Hungary|Szikszo, Hungary|Szolnok, Hungary|Szombathely, Hungary|Urhida, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Sesto San Giovanni, Milano, Italy|Firenze, Italy|Milano, Italy|Pavia, Italy|Goyang-si, Gyeonggi-do, Korea, Republic of|Seongnam-Si, Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Johor Bahru, Johor, Malaysia|Alor Setar, Kedah, Malaysia|Kota Bharu, Kelantan, Malaysia|Cheras, Kuala Lumpur, Malaysia|Lembah Pantai, Kuala Lumpur, Malaysia|Petaling Jaya, Selangor, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Banska Bystrica, Slovakia|Bardejov, Slovakia|Bratislava, Slovakia|Kosice - Saca, Slovakia|Kosice, Slovakia|Levice, Slovakia|Lucenec, Slovakia|Moldava nad Bodvou, Slovakia|Nitra, Slovakia|Pezinok, Slovakia|Presov, Slovakia|Prievidza, Slovakia|Sahy, Slovakia|Stropkov, Slovakia|Sturovo, Slovakia|Svidnik, Slovakia|Trebisov, Slovakia|Trencin, Slovakia|Zilina, Slovakia|Patumwan, Bangkok, Thailand|Rachathevi, Bangkok, Thailand|Rajtevi, Bangkok, Thailand|Ratchathewi, Bangkok, Thailand|Muang, Chiang Mai, Thailand|Muang, Nakhon Ratchasima, Thailand|Hatyai, Songkhla, Thailand|Bangkok, Thailand|Khon Kaen, Thailand",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,35.4175650424033,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.43,524.63,99.13,7.0,1.0,4.0,58.35,142.67,11.0,1.0,0.0,0.0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,0,DB12491,__FASIGLIFAM,US-20100004312-A1,Terminated,NCT01982253,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Goodyear, Arizona, United States|Long Beach, California, United States|Los Angeles, California, United States|North Hollywood, California, United States|Norwalk, California, United States|Tustin, California, United States|Boynton Beach, Florida, United States|Coral Gables, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Franklin, Indiana, United States|Greenfield, Indiana, United States|Muncie, Indiana, United States|Council Bluffs, Iowa, United States|Topeka, Kansas, United States|Lexington, Kentucky, United States|Metairie, Louisiana, United States|Flint, Michigan, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Mooresville, North Carolina, United States|Morganton, North Carolina, United States|Salisbury, North Carolina, United States|Maumee, Ohio, United States|Norman, Oklahoma, United States|Corvallis, Oregon, United States|Portland, Oregon, United States|Harleysville, Pennsylvania, United States|Levittown, Pennsylvania, United States|Uniontown, Pennsylvania, United States|Greer, South Carolina, United States|Carrollton, Texas, United States|Dallas, Texas, United States|Edinburg, Texas, United States|Houstan, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Salt Lake City, Utah, United States|Burke, Virginia, United States|Manassas, Virginia, United States|Byala, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sevlievo, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Lodz, Poland|Oswiecim, Poland|Poznan, Poland|Rzeszow, Poland|Sobotka, Poland|Torun, Poland|Zgierz, Poland|Baia Mare, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Oradea, Romania|Ploiesti, Romania|Bardejov, Slovakia|Bratislava, Slovakia|Dolny Kubin, Slovakia|Komarno, Slovakia|Levice, Slovakia|Lucenec, Slovakia|Nitra, Slovakia|Pezinok, Slovakia|Sabinov, Slovakia|Stropkov, Slovakia|Sturovo, Slovakia|Svidnik, Slovakia|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Kharkiv, Ukraine|Kyiv, Ukraine|Simferopol, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,35.4175650424033,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.43,524.63,99.13,7.0,1.0,4.0,58.35,142.67,11.0,1.0,0.0,0.0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,0,DB12491,__FASIGLIFAM,US-20100004312-A1,Withdrawn,NCT02015780,TYPE 2 DIABETES MELLITUS|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Whittier, California, United States|Westminster, Colorado, United States|Tampa, Florida, United States|Rosedale, New York, United States|Cincinnati, Ohio, United States|Charleston, South Carolina, United States|San Antonio, Texas, United States|Pazardzhik, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Baja, Hungary|Gyula, Hungary|Kaposvar, Hungary|Szigetvar, Hungary|Zalaegerszeg, Hungary|Zamosc, Poland|Banska Bystrica, Slovakia|Bardejov, Slovakia|Myjava, Slovakia|Puchov, Slovakia|Senica, Slovakia|Svidnik, Slovakia|Trstena, Slovakia|Bloemfontein, Free State, South Africa|Cape Town, Western Cape, South Africa|Worcester, Western Cape, South Africa|Donetsk, Ukraine|Kyiv, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,35.4175650424033,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.43,524.63,99.13,7.0,1.0,4.0,58.35,142.67,11.0,1.0,0.0,0.0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O,0,DB12495,__SELEPRESSIN,,Terminated,,"SHOCK, SEPTIC",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.61,1048.29,391.33,13.0,12.0,3.0,108.02,267.71,21.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,NCT00557518,"DIABETES MELLITUS, TYPE 1|DIABETIC NEPHROPATHY",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|International Diabetes Institute, Caulfield, Victoria, Australia|Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia|Austin Health, Heidelburg, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Steno Diabetes Center, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,0,DB12511,__IMIGLITAZAR,6251926,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,19.3515267253947,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.16,470.525,94.15,6.0,1.0,4.0,52.47,141.78,11.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0
CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1,0,DB12512,__VERUCERFONT,WO-2006044958-A1,Withdrawn,,CONGENITAL ADRENAL HYPERPLASIA (CAH),,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.05,406.49,90.37,6.0,1.0,4.0,45.29,127.24,5.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNCc1ccc([123I])cc1)C(=O)O)C(=O)O,0,DB12514,__IOFOLASTAT_I-123,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,531.337,165.06,8.0,6.0,1.0,46.59,114.95,14.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,0,DB12522,__TOREFORANT,WO-2007117399-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,392.551,69.73,5.0,2.0,4.0,48.0,131.1,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1
CCCCCCCC/C=C\CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC,0,DB12528,__GLYCERYL_TRIERUCATE,,Suspended,NCT00004418,ADRENOLEUKODYSTROPHY,Male,18 Months to 6 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kennedy Krieger Institute, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,10.74,1053.751,78.9,3.0,0.0,0.0,142.96,327.46,65.0,1.0,0.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0
NC(=O)CC[C@@H](C(=O)O)N(CCNC(=S)Nc1ccc2c(c1)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21)C(=O)c1ccc(NCc2cnc3nc(N)[nH]c(=O)c3n2)cc1,0,DB12559,__EC-17,,Terminated,NCT01511055,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic, Rochester, Minnesota, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,872.87,306.04,13.0,9.0,8.0,88.11,233.84,13.0,1.0,0.0,0.0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,0,DB12577,__FOSBRETABULIN,WO-1992016486-A1,Terminated,NCT02641639,PLATINUM RESISTANT OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mitchell Cancer Institute - USA Health System, Mobile, Alabama, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Oncology Institute of Hope and Innovation, Lynwood, California, United States|University of California Irvine, Orange, California, United States|California Pacific Medical Center, Research Institute, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States|Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering, Hartford, Connecticut, United States|Stamford Hospital - Bennett Cancer Center, Stamford, Connecticut, United States|Sylvester Comprehensive Cancer Center University of Miami, Miami, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Maine Medical Center, Scarborough, Maine, United States|Mercy Medical Center; The Institute for Cancer Care, Baltimore, Maryland, United States|HCA Midwest Division - Sarah Cannon Cancer Institute, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oklahoma Heath Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|OHSU Center for Women's Health & Knight Cancer Institute, Portland, Oregon, United States|Willamette Valley Cancer Institute, Springfield, Oregon, United States|Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering, Allentown, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Gibbs Cancer Center & Research Institute Spartanburg Medical Center, Spartanburg, South Carolina, United States|Texas Oncology, P.A., Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|Dallas County Hospital District d/b/a Parkland Health and Hospital System, Dallas, Texas, United States|Simmons Comprehensive Cancer Center; UT Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Texas Oncology, P.A., The Woodlands, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|UZ Leuven, Leuven, Belgium|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen (AöR) Klinik für Frauenheilkunde und Geburtshilfe, Essen, Germany|Universitäts-Frauenklinik Dept. für Frauengesundheit, Tubingen, Germany",C07F9/12,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,32.7488,51.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,396.332,103.68,7.0,2.0,2.0,38.29,100.22,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,0,DB12577,__FOSBRETABULIN,WO-1992016486-A1,Terminated,NCT00077103,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",C07F9/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,32.7488,51.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,396.332,103.68,7.0,2.0,2.0,38.29,100.22,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,0,DB12577,__FOSBRETABULIN,WO-1992016486-A1,Terminated,NCT02055690,"OVARIAN NEOPLASMS|NEOPLASMS, OVARIAN|OVARIAN CANCER",Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal United Hospital Bath NHS Trust, Bath, United Kingdom|City Hospital, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|University Collage London Hospitals NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Merseyside, United Kingdom|Mount Vernon Cancer Centre (East and North Herts NHS Trust), Middlesex, United Kingdom|Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle-upon-Tyne And Wear, United Kingdom|Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom",C07F9/12,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,32.7488,51.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,396.332,103.68,7.0,2.0,2.0,38.29,100.22,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,0,DB12577,__FOSBRETABULIN,WO-1992016486-A1,Withdrawn,NCT01701349,ANAPLASTIC THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07F9/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,32.7488,51.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,396.332,103.68,7.0,2.0,2.0,38.29,100.22,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)n[nH]1,0,DB12588,__AZD-1480,EP-1945631-B1,Terminated,,ADVANCED SOLID MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,74.2520380295283,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.75,348.76599999999996,104.3,7.0,3.0,3.0,33.8,91.12,5.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,0,DB12594,__AZD-9056,WO-2001044170-A1,Withdrawn,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61P1/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.33,419.01,61.36,3.0,3.0,4.0,47.83,118.78,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
COc1ccc(C[C@@H](O)c2cc(OC)c(OC)c(OC)c2)cc1O,0,DB12596,__COMBRETASTATIN,6011042,Terminated,,PLATINUM RESISTANT OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D519/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.809585412431396,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,334.36800000000005,77.38,6.0,2.0,2.0,34.18,89.75,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,DB12602,__PENTETREOTIDE,6180082,Terminated,NCT00002947,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD LANGERHANS CELL HISTIOCYTOSIS|GASTROINTESTINAL CARCINOID TUMOR|HEAD AND NECK CANCER|INTRAOCULAR MELANOMA|ISLET CELL TUMOR|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|NEOPLASTIC SYNDROME|NEUROENDOCRINE CARCINOMA OF THE SKIN|PHEOCHROMOCYTOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Yale Comprehensive Cancer Center, New Haven, Connecticut, United States",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,57.0,26.2510523830058,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1394.58,494.22,23.0,17.0,5.0,140.9,353.02,34.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0
O=C(O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1,0,DB12629,"__3,5-DIIODOTHYROPROPIONIC_ACID",6534676,Terminated,NCT00311987,HYPERCHOLESTEROLEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,25.4953900490769,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.09,510.066,66.76,3.0,2.0,2.0,37.6,96.91,5.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1,0,DB12649,__IBIPINABANT,WO-2006045799-A2,Withdrawn,NCT00541567,OBESITY AND TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,53.0,32.7488,38.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,487.4,74.13,6.0,1.0,4.0,49.54,127.45,3.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,0,DB12651,__BARDOXOLONE,,Terminated,NCT00529113,PANCREATIC NEOPLASMS|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rocky Mountain Cancer Center (US Oncology), Denver, Colorado, United States|Cancer Centers of Florida (US Oncology), Ocoee, Florida, United States|Central Indiana Cancer Centers (US Oncology), Indianapolis, Indiana, United States|Sammons Cancer Center (US Oncology), Dallas, Texas, United States|Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology), Vancouver, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.39,491.67199999999997,95.23,5.0,1.0,5.0,56.02,139.59,1.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,0,DB12651,__BARDOXOLONE,,Terminated,NCT01549769,"RENAL INSUFFICIENCY, CHRONIC|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.39,491.67199999999997,95.23,5.0,1.0,5.0,56.02,139.59,1.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,0,DB12651,__BARDOXOLONE,,Terminated,NCT01500798,CHRONIC KIDNEY DISEASE|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.39,491.67199999999997,95.23,5.0,1.0,5.0,56.02,139.59,1.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,0,DB12651,__BARDOXOLONE,,Withdrawn,NCT01576887,END-STAGE RENAL DISEASE|TYPE 2 DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.39,491.67199999999997,95.23,5.0,1.0,5.0,56.02,139.59,1.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,0,DB12668,__METENKEFALIN,EP-0415470-A2,Terminated,,TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",C12Y304/11011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.126347563605,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.28,573.67,199.95,8.0,7.0,2.0,58.85,149.01,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,0,DB12678,__RELAMORELIN,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0
CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,0,DB12686,__PHA-793887,US-20070004705-A1,Terminated,,ADVANCED/METASTATIC SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,56.0504322470687,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.01,361.4817,81.33,4.0,2.0,3.0,41.3,104.73,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0,DB12713,__SOTAGLIFLOZIN,US-20100016422-A1,Terminated,NCT03761134,TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 1560039, Baotou, China|Investigational Site Number 1560040, Baotou, China|Investigational Site Number 1560001, Beijing, China|Investigational Site Number 1560038, Beijing, China|Investigational Site Number 1560035, Cangzhou, China|Investigational Site Number 1560020, Changchun, China|Investigational Site Number 1560012, Changchun, China|Investigational Site Number 1560011, Changsha, China|Investigational Site Number 1560021, Changzhou, China|Investigational Site Number 1560024, Chongqing, China|Investigational Site Number 1560028, Dalian, China|Investigational Site Number 1560010, Dalian, China|Investigational Site Number 1560036, Dalian, China|Investigational Site Number 1560030, Fuzhou, China|Investigational Site Number 1560032, Guangzhou, China|Investigational Site Number 1560027, Guangzhou, China|Investigational Site Number 1560041, Hangzhou, China|Investigational Site Number 1560046, Harbin, China|Investigational Site Number 1560009, Hefei, China|Investigational Site Number 1560025, Hohhot, China|Investigational Site Number 1560026, Huai'An, China|Investigational Site Number 1560006, Jinan, China|Investigational Site Number 1560033, Kunming, China|Investigational Site Number 1560034, Luoyang, China|Investigational Site Number 1560014, Nanjing, China|Investigational Site Number 1560018, Pingxiang, China|Investigational Site Number 1560003, Shanghai, China|Investigational Site Number 1560004, Shanghai, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560005, Shenyang, China|Investigational Site Number 1560019, Shijiazhuang, China|Investigational Site Number 1560017, Suzhou, China|Investigational Site Number 1560022, Wuhan, China|Investigational Site Number 1560023, Wuxi, China|Investigational Site Number 1560015, Xiangtan, China|Investigational Site Number 1560043, Yuncheng, China|Investigational Site Number 1560042, Zhengzhou, China|Investigational Site Number 1560007, Zhenjiang, China|Investigational Site Number 1560037, Zhongshan, China|Investigational Site Number 1560016, Zhuzhou, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,35.8446785354935,16.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,424.94,79.15,5.0,3.0,3.0,44.93,110.87,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,0,DB12744,__CGI-1842,WO-2006076593-A1,Terminated,NCT01149434,CANCER|NEUROENDOCRINE|OVARIAN CANCER|COLON CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,82.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.85,466.339,94.2,4.0,3.0,4.0,44.0,123.59,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1
O=C(O)CC[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1,0,DB12852,__MK-0752,WO-2004013090-A1,Terminated,NCT01243762,NEOPLASMS MALIGNANT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C315/04 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,442.9,71.44,4.0,1.0,3.0,42.38,105.98,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0
O[C@H]([C@@H]1CO1)[C@@H](O)[C@H]1CO1,0,DB12873,__DIANHYDROGALACTITOL,US-20020037328-A1,Withdrawn,NCT03281681,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,11.663483849771,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,146.142,62.22,4.0,2.0,2.0,13.67,31.38,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT03348631,FIGO GRADE 1 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA|FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA|RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA|RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA|RECURRENT UTERINE CORPUS CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CTCA at Western Regional Medical Center, Goodyear, Arizona, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Memorial Hospital North, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|Medical Center of the Rockies, Loveland, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic PLLC, Baton Rouge, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Aultman Alliance Community Hospital, Alliance, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Bon Secours Maryview Medical Center, Portsmouth, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Health Center at Harbour View, Suffolk, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,DB12978,__PEXIDARTINIB,7893075,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,39.064457175712,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.64,417.82,66.49,4.0,2.0,4.0,39.33,105.89,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC,0,DB13038,__GLYCERYL_TRIOLEATE,3953179,Suspended,NCT00004418,ADRENOLEUKODYSTROPHY,Male,18 Months to 6 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kennedy Krieger Institute, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",C10M107/10,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.57163391445409,1494.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.82,885.4321,78.9,3.0,0.0,0.0,116.96,272.25,53.0,1.0,0.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0
O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,0,DB13053,__CP-195543,WO-2001034134-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.41,428.407,66.76,4.0,2.0,4.0,41.92,109.38,5.0,0.0,1.0,0.0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,NCT00249301,BREAST NEOPLASM|COLON NEOPLASM|PANCREATIC NEOPLASM|BLADDER NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Sarah Cannon Research Institute, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,,ADVANCED MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,0,DB13062,__ME-344,,Terminated,NCT02100007,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of WA Seattle Cancer Care Alliance, Seattle, Washington, United States|The Bays St Mary's Hospital, London, England, United Kingdom|Sarah Cannon Research Instititute UK, London, England, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,348.398,69.92,4.0,3.0,4.0,36.89,100.63,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21,0,DB13872,__LORMETAZEPAM,4065451,Terminated,,SLEEP INITIATION AND MAINTENANCE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,70.736565432555,105.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.92,335.185,52.9,3.0,1.0,3.0,32.21,85.82,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
CCCC[C@]1(CC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2cccc(NC(=O)N[C@@H]3O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](OCc4ccccc4)[C@H]3O)c2)[C@H]1O,0,DB13914,__VOLIXIBAT,,Terminated,,NON-ALCOHOLIC STEATOHEPATITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,805.96,221.26,12.0,6.0,5.0,83.77,205.73,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,0,1
CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,0,DB13930,__ULIXERTINIB,,Terminated,,CANCER OF PANCREAS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.09,433.33,90.04,4.0,4.0,3.0,44.39,117.51,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1
CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2cc(O)c(S(=O)(=O)O)cc2S(=O)(=O)O)cc1,0,DB13967,__PATENT_BLUE,4243693,Terminated,NCT02540551,OVARIAN NEOPLASMS|SENTINEL NODE,Female,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Maastricht UMC, Dept. Obst&Gyn, Maastricht, Netherlands",A01N3/00,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,19.285816957227002,103.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,561.69,135.22,8.0,3.0,3.0,59.14,173.8,9.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[177Lu+3],0,DB13985,__LUTETIUM_LU_177_DOTATATE,10596276,Withdrawn,NCT04106843,LOCALLY ADVANCED ADRENAL GLAND PHEOCHROMOCYTOMA|LOCALLY ADVANCED PARAGANGLIOMA|METASTATIC ADRENAL GLAND PHEOCHROMOCYTOMA|METASTATIC PARAGANGLIOMA|METASTATIC PARATHYROID GLAND CARCINOMA|PITUITARY GLAND CARCINOMA|SOMATOSTATIN RECEPTOR POSITIVE|STAGE III THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IV THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVA THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVB THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVC THYROID GLAND MEDULLARY CARCINOMA AJCC V8|UNRESECTABLE ADRENAL GLAND PHEOCHROMOCYTOMA|UNRESECTABLE PARAGANGLIOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",A61K33/24 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,17.0,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.78,1609.55,505.95,24.0,14.0,6.0,144.31,397.34,26.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,0,DB13994,__AZD-7325,US-20070142328-A1,Suspended,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C,0,DB14027,__TASPOGLUTIDE,,Terminated,NCT01051011,DIABETES MELLITUS TYPE 2,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing, China|Beijing, China|Beijing, China|Beijng, China|Chengdu, China|Chongqing, China|Guangzhou, China|Hangzhou, China|Hefei, China|Nanjing, China|Nanjing, China|Nanning, China|Shanghai, China|Shi Jiazhuang, China|Tianjin (天津), China|Tianjin, China|Hong Kong, Hong Kong|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Kangwon-do, Korea, Republic of|Kyounggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Johor Bahru, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Penang, Malaysia|Putrajaya, Malaysia|Selangor, Malaysia|Cebu, Philippines|Iloilo, Philippines|Manila, Philippines|Manila, Philippines|Manila, Philippines|Pasig, Philippines|Chia-Yi City, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Nakhonratchasima, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,3339.763,1385.09,52.0,49.0,6.0,342.22,847.48,108.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,0
F[B-](F)(F)F.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Cu+],0,DB14106,__TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I)_TETRAFLUOROBORATE,,Terminated,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.94,602.99,13.59,1.0,0.0,0.0,12.7,41.61,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])[O-].[Li+].[Li+],0,DB14509,__LITHIUM_CARBONATE,,Terminated,NCT00582712,MEDULLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uniersity of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.28,73.89,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,0,DB14554,__DOTATATE,9375498,Withdrawn,NCT04106843,LOCALLY ADVANCED ADRENAL GLAND PHEOCHROMOCYTOMA|LOCALLY ADVANCED PARAGANGLIOMA|METASTATIC ADRENAL GLAND PHEOCHROMOCYTOMA|METASTATIC PARAGANGLIOMA|METASTATIC PARATHYROID GLAND CARCINOMA|PITUITARY GLAND CARCINOMA|SOMATOSTATIN RECEPTOR POSITIVE|STAGE III THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IV THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVA THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVB THYROID GLAND MEDULLARY CARCINOMA AJCC V8|STAGE IVC THYROID GLAND MEDULLARY CARCINOMA AJCC V8|UNRESECTABLE ADRENAL GLAND PHEOCHROMOCYTOMA|UNRESECTABLE PARAGANGLIOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07B59/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,46.5882256309164,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.85,1435.63,497.46,24.0,17.0,6.0,144.3,364.83,26.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,0,DB14575,__ESLICARBAZEPINE,WO-2004031155-A1,Terminated,NCT01129960,PAINFUL DIABETIC NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIAL - Portela & Cª, S.A., S. Mamede do Coronado, Portugal",A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,32.7488,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,254.2839,66.56,2.0,2.0,3.0,26.45,72.29,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
O=[N+]([O-])c1nccn1CC(O)C[18F],0,DB14830,__FLUOROMISONIDAZOLE_F-18,,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,188.149,81.19,4.0,1.0,1.0,15.65,40.27,4.0,0.0,1.0,0.0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
CCOc1ccc2c(c1)[C@]1(CC[C@H](OCCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC,0,DB14923,__SATAVAPTAN,,Terminated,NCT00728091,HYPONATREMIA|INAPPROPRIATE ADH SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.6,643.8,123.71,9.0,1.0,5.0,70.85,171.17,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21,0,DB14945,__FLORBENAZINE_F-18,,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,364.49199999999996,41.93,4.0,1.0,3.0,42.07,101.86,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0
CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,0,DB14955,__PF-04634817,US-20110144129-A1,Terminated,NCT01994291,"MACULAR EDEMA, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Retina Research Institute, LLC, Phoenix, Arizona, United States|Retinal Consultants of Arizona, Phoenix, Arizona, United States|Sunny View Medical Center, Phoenix, Arizona, United States|Premier Research Group Limited, Phoenix, Arizona, United States|Retina Centers, P.C., Tucson, Arizona, United States|Retina Institute of California, Arcadia, California, United States|Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Retinal Diagnostic Center, Campbell, California, United States|Retina Associates of Orange County, Laguna Hills, California, United States|Southern California Desert Retina Consultants, Palm Desert, California, United States|American Institute of Research (Administrative Only), Whittier, California, United States|New England Retina Associates, New London, Connecticut, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Southeast Retina Center, PC, Augusta, Georgia, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|TLC Eyecare & Laser Center, Jackson, Michigan, United States|Wm Beaumont Medical Office Building, Royal Oak, Michigan, United States|Charlotte Eye Ear Nose and Throat Associates PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Cleveland, Ohio, United States|Retina Associates of Cleveland, Youngstown, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|University of Oklahoma -OU Physicians, Oklahoma City, Oklahoma, United States|Retina Vitreous Consultants, Pittsburgh, Pennsylvania, United States|Associates in Ophthalmology Ltd, West Mifflin, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Brain B.Berger,MD,PA, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Rocky Mountain Retina Consultants, Salt Lake City, Utah, United States|MC Comac Medical, Sofia, Bulgaria|Fakultní nemocnice Hradec Králové, Ocni klinika, Hradec Kralove, Czech Republic|Fakultní nemocnice Hradec Králové, Nemocnicni lekarna, Hradec Kralove, Czech Republic|Fakultni nemocnice Ostrava, lekarna, Ostrava - Poruba, Czech Republic|Fakultni nemocnice Ostrava, Ocni klinika, Ostrava - Poruba, Czech Republic|Fakultni nemocnice Kralovske Vinohrady, Oftalmologicka klinika, Praha 10, Czech Republic|Fakultni nemocnice Kralovske Vinohrady, Ustavni lekarna, Praha 10, Czech Republic|Universitätsklinikum Regensburg, Regensburg, Bavaria, Germany|Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Universitatsmedizin Mainz, Mainz, Germany|Augenärzte am St. Franziskus-Hospital, Muenster, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Knappschaftsklinikum GmbH, Sulzbach, Saar, Germany|Universitatsklinikum Tubingen, Tubingen, Germany|Semmelweis Egyetem, Szemészeti Klinika, Budapest, Hungary|Bajcsy-Zsilinszky Korhaz, Szemeszet, Budapest, Hungary|Budapest Retina Associates Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Szemklinika, Debrecen, Hungary|Ganglion Orvosi Kozpont, Pecs, Hungary|Csolnoky Ferenc Korhaz, Szemeszeti Osztaly, Veszprem, Hungary|Hadassah Medical Organization, Hadassah Medical Center, Ein Karem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Spitalul Clinic Republican, Chisinau, Moldova, Republic of|Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza Radeckiego We Wrocławiu, Klinika Okulistyki, Wroclaw, Poland|Med Life SA, Sectia Oftalmologie, Bucuresti, Romania|Institutul National de Diabet, Nutritie si Boli Metabolice ""N.C.Paulescu"", Bucuresti, Romania",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,511.59,79.82,7.0,1.0,5.0,51.84,128.3,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,NCT00868790,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,0,DB14969,__GTX-758,US-20070265296-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,181.0,60.0587281052999,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.09,341.314,60.77,3.0,2.0,3.0,32.11,88.88,3.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,0,DB14982,__MIRANSERTIB,,Terminated,,ENDOMETRIAL CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.66,432.531,95.64,5.0,2.0,6.0,48.66,150.66,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H]1[C@H]2N(C(=O)CN(C)N2C(=O)NCc2ccccc2)[C@@H](Cc2ccc(OP(=O)(O)O)cc2)C(=O)N1Cc1cccc2cccnc12,0,DB15034,__PRI-724,WO-2014061828-A1,Terminated,NCT01302405,ADVANCED SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Scottsdale, Arizona, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States|Mayo Clinic, Department of Oncology, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.09,658.6519999999998,155.85,8.0,3.0,6.0,65.6,171.76,8.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Terminated,,DIABETES MELLITUS AND HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,0,DB15057,__NUC-1031,,Terminated,NCT03146663,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of California, Orange, California, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|SCRI, Saint Petersburg, Florida, United States|SCRI - Florida, West Palm Beach, Florida, United States|The University of Chicago, Chicago, Illinois, United States|Minnesota Oncology Hematology, PA, Edina, Minnesota, United States|SCRI - HCA Health Midwest, Kansas City, Missouri, United States|Nashville Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology - Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Swedish Cancer Institue, Seattle, Washington, United States|Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom|Cancer Research UK Clinical Trial Unit, Glasgow, United Kingdom|ICR Royal Marsden Hospital, London, United Kingdom|Imperial College Healthcare Trust, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Oxford University Hospitals, Oxford, United Kingdom",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.43,580.482,162.01,7.0,3.0,4.0,53.24,134.78,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,0,DB15057,__NUC-1031,,Suspended,,"NEOPLASMS, PANCREATIC",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.43,580.482,162.01,7.0,3.0,4.0,53.24,134.78,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1
CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2,0,DB15195,__MIBENRATIDE,,Withdrawn,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,2097.27,940.67,37.0,32.0,5.0,203.7,528.21,32.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,1,1
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,0,DB15205,__CAPROMORELIN,6107306,Terminated,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0202,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,17.7416374052855,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,505.619,117.33,6.0,2.0,4.0,54.59,140.17,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1
CCS(=O)(=O)CCCC12CCC(c3nnc(-c4ccccc4C(F)(F)F)n3C)(CC1)CC2,0,DB15209,__MK-0736,WO-2010068580-A1,Terminated,NCT00806585,TYPE 2 DIABETES MELLITUS|HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.29,469.57,64.85,4.0,0.0,4.0,48.86,130.55,8.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0
CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,0,DB15212,__PEMAFIBRATE,,Terminated,NCT03345901,DIABETIC RETINOPATHY|DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|Retinal Diagnostic Center, Campbell, California, United States|Macula & Retina Institute, Glendale, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|South Coast Retina Center, Long Beach, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Glenview, Illinois, United States|Illinois Retina Associates, S.C., Oak Park, Illinois, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Mid-America Retina Consultants, P.A., Overland Park, Kansas, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Retina Center, PA, Minneapolis, Minnesota, United States|The Retina Institute, Saint Louis, Missouri, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Retina Research Center, Austin, Texas, United States|Robert E. Torti, MD, PA dba Retina Specialists, DeSoto, Texas, United States|Valley Retina Institute, DeSoto, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|University Health Network - Toronto Western Hospital, Toronto, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.22,490.556,94.26,7.0,1.0,4.0,53.86,134.68,13.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,0,DB15250,__VERCIRNON,US-20130059893-A1,Withdrawn,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,37.848826464609104,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.15,444.93,90.18,4.0,1.0,3.0,45.01,118.09,5.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,0,DB15266,__TAK-580,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,506.29,135.78,7.0,3.0,3.0,43.95,114.04,6.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,0,DB15273,__VS-4718,,Terminated,NCT02651727,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.55,501.51,87.75,7.0,3.0,4.0,50.39,131.1,8.0,1.0,0.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1
O=C(O)CN1C(=O)[C@@H](NC(=O)C2(C[C@@H](CCc3cccc4ccccc34)C(=O)O)CCCC2)CCc2ccccc21,0,DB15356,__SLV-334,US-20050153936-A1,Terminated,,TRAUMATIC BRAIN INJURY (TBI),,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,29.3394114868888,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.23,556.659,124.01,6.0,3.0,5.0,60.13,152.87,10.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1(C(=O)O[11CH3])CCN(CCc2ccccc2)CC1,0,DB15360,"__CARFENTANIL,_C-11",,Suspended,,NEURALGIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,393.515,49.85,3.0,0.0,3.0,43.78,114.38,8.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(=O)C3CCCC3)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)C)c4cccs4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB15384,__SIMOTAXEL,,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,896.01,230.52,10.0,4.0,7.0,91.58,221.91,16.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,0,DB15418,__AZD-9977,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,399.37800000000004,96.97,5.0,2.0,4.0,38.12,101.36,3.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,0,DB15440,__GSK-3117391,,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,403.523,100.55,5.0,3.0,3.0,45.52,108.98,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1.O=C(O)/C=C\C(=O)O,0,,_CEDIRANIB_MALEATE,EP-1699782-B1,Suspended,NCT03660826,ENDOMETRIAL UNDIFFERENTIATED CARCINOMA|ENDOMETRIOID ADENOCARCINOMA|RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA|RECURRENT UTERINE CORPUS CANCER|STAGE IV UTERINE CORPUS CANCER AJCC V7|STAGE IVA UTERINE CORPUS CANCER AJCC V7|STAGE IVB UTERINE CORPUS CANCER AJCC V7,Female,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Mercy Cancer Center - Rocklin, Rocklin, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Woodland Memorial Hospital, Woodland, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Medical Center of the Rockies, Loveland, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Baptist Health Richmond, Richmond, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Women's Cancer Care Associates LLC, Albany, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mount Sinai Chelsea, New York, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Hope Women's Cancer Centers-Asheville, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Carolina Surgical Clinic of Charlotte PA, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Novant Health Presbyterian Medical Center Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Novant Health Oncology Specialists-Kernersville, Kernersville, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Lake Norman Radiation Oncology Center-Mooresville, Mooresville, North Carolina, United States|Novant Health Oncology Specialists-Mount Airy, Mount Airy, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Carolina Oncology Associates PA, Salisbury, North Carolina, United States|Rowan Regional Medical Center, Salisbury, North Carolina, United States|Novant Health Oncology Specialists-Statesville, Statesville, North Carolina, United States|Novant Health Oncology Specialists-Davidson County, Thomasville, North Carolina, United States|Novant Health Oncology Specialists-Wilkesboro, Wilkesboro, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Sanford Medical Center Fargo, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Methodist Willowbrook Hospital, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,66.1368816608144,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Suspended,NCT03127124,PANCREATIC ADENOCARCINOMA METASTATIC,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institutes for Medicine, El Segundo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT02782182,PANCREATIC DUCTAL ADENOCARCINOMA (PDAC),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT01359007,ADENOCARCINOMA OF PANCREAS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT00227617,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL TUMOR|LUNG CANCER|NEOPLASTIC SYNDROME|NEUROENDOCRINE TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Univeristy of California, San Francisco, San Francisco, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT01050426,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kent Oncology Centre, Tunbridge Wells, Maidstone, United Kingdom|Royal Surrey County Hospital NHS Trust, Guildford, Surrey, United Kingdom|The Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Royal Bournemouth Hospital, Bournemouth, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Poole Hospital NHS Trust, Poole, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Withdrawn,NCT03197584,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Suspended,NCT03127124,PANCREATIC ADENOCARCINOMA METASTATIC,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institutes for Medicine, El Segundo, California, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Withdrawn,NCT01473303,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,0,,_DEXTRAN,4201772,Suspended,NCT00990444,DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Karolinska Trial Alliance, Phase I Unit, Stockholm, Solna, Stockholm, Sweden",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,0,,_DEXTRAN,4201772,Withdrawn,NCT00790439,"DIABETES MELLITUS, TYPE I",All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,0,,_FOSBRETABULIN_TROMETHAMINE,,Terminated,NCT02641639,PLATINUM RESISTANT OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mitchell Cancer Institute - USA Health System, Mobile, Alabama, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Oncology Institute of Hope and Innovation, Lynwood, California, United States|University of California Irvine, Orange, California, United States|California Pacific Medical Center, Research Institute, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States|Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering, Hartford, Connecticut, United States|Stamford Hospital - Bennett Cancer Center, Stamford, Connecticut, United States|Sylvester Comprehensive Cancer Center University of Miami, Miami, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Maine Medical Center, Scarborough, Maine, United States|Mercy Medical Center; The Institute for Cancer Care, Baltimore, Maryland, United States|HCA Midwest Division - Sarah Cannon Cancer Institute, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oklahoma Heath Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|OHSU Center for Women's Health & Knight Cancer Institute, Portland, Oregon, United States|Willamette Valley Cancer Institute, Springfield, Oregon, United States|Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering, Allentown, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Gibbs Cancer Center & Research Institute Spartanburg Medical Center, Spartanburg, South Carolina, United States|Texas Oncology, P.A., Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|Dallas County Hospital District d/b/a Parkland Health and Hospital System, Dallas, Texas, United States|Simmons Comprehensive Cancer Center; UT Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Texas Oncology, P.A., The Woodlands, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|UZ Leuven, Leuven, Belgium|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen (AöR) Klinik für Frauenheilkunde und Geburtshilfe, Essen, Germany|Universitäts-Frauenklinik Dept. für Frauengesundheit, Tubingen, Germany",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,0,,_VEDOTIN,,Terminated,NCT02689219,GERM CELL TUMORS|TESTIS CANCER|TESTICULAR CANCER|EMBRYONAL CARCINOMA|NONSEMINOMATOUS GERM CELL TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O.CS(=O)(=O)O,0,,_TALABOSTAT_MESYLATE,,Terminated,NCT00116389,PANCREATIC CANCER|NEOPLASM METASTASIS|ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwest Alabama Cancer Center, PC, Florence, Alabama, United States|Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States|Oncology Associates, PC, Hartford, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Central Brevard, Rockledge, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Yagnesh V. Oza, MD, Mt. Vernon, Illinois, United States|Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States|Cancer Care Center, Inc., New Albany, Indiana, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Huron Medical Center, Port Huron, Michigan, United States|Billings Clinic, Billings, Montana, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|New York Oncology Hematology/Albany Regional Cancer Center, Albany, New York, United States|Hematology-Oncology Associates of Rockland, New City, New York, United States|Dayton Oncology and Hematology, Kettering, Ohio, United States|Lawrence M. Stallings, MD, Wooster, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Clinic, The, Portland, Oregon, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Oncology, PA, Presbyterian, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Elkins Pancreas Center, Houston, Texas, United States|Saint Luke's Episcopal Hospital, Houston, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,,_TALABOSTAT,,Terminated,NCT00116389,PANCREATIC CANCER|NEOPLASM METASTASIS|ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwest Alabama Cancer Center, PC, Florence, Alabama, United States|Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States|Oncology Associates, PC, Hartford, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Central Brevard, Rockledge, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Yagnesh V. Oza, MD, Mt. Vernon, Illinois, United States|Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States|Cancer Care Center, Inc., New Albany, Indiana, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Huron Medical Center, Port Huron, Michigan, United States|Billings Clinic, Billings, Montana, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|New York Oncology Hematology/Albany Regional Cancer Center, Albany, New York, United States|Hematology-Oncology Associates of Rockland, New City, New York, United States|Dayton Oncology and Hematology, Kettering, Ohio, United States|Lawrence M. Stallings, MD, Wooster, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Clinic, The, Portland, Oregon, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Oncology, PA, Presbyterian, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Elkins Pancreas Center, Houston, Texas, United States|Saint Luke's Episcopal Hospital, Houston, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,0,,_RALOXIFEN,,Terminated,NCT01607320,PCOS,Female,18 Years to 36 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Greenville Hospital System, Greenville, South Carolina, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE,,Terminated,NCT01494012,RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|MALIGNANT TUMOR OF PERITONEUM|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE,,Terminated,NCT00095693,ANAPLASTIC THYROID CANCER|INSULAR THYROID CANCER|RECURRENT THYROID CANCER|STAGE III FOLLICULAR THYROID CANCER|STAGE III PAPILLARY THYROID CANCER|STAGE IV FOLLICULAR THYROID CANCER|STAGE IV PAPILLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE,,Terminated,NCT00253461,"LUNG CANCER|METASTATIC CANCER|OVARIAN CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT01494012,RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|MALIGNANT TUMOR OF PERITONEUM|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT00095693,ANAPLASTIC THYROID CANCER|INSULAR THYROID CANCER|RECURRENT THYROID CANCER|STAGE III FOLLICULAR THYROID CANCER|STAGE III PAPILLARY THYROID CANCER|STAGE IV FOLLICULAR THYROID CANCER|STAGE IV PAPILLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT00253461,"LUNG CANCER|METASTATIC CANCER|OVARIAN CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00095693,ANAPLASTIC THYROID CANCER|INSULAR THYROID CANCER|RECURRENT THYROID CANCER|STAGE III FOLLICULAR THYROID CANCER|STAGE III PAPILLARY THYROID CANCER|STAGE IV FOLLICULAR THYROID CANCER|STAGE IV PAPILLARY THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00522301,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan - Kettering Cancer Center, New York, New York, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00126568,ANAPLASTIC THYROID CANCER|RECURRENT THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,0,,_IRINOTECAN_HYDROCHLORIDE,,Terminated,NCT02345460,PANCREATIC ADENOCARCINOMA|POORLY DIFFERENTIATED MALIGNANT NEOPLASM|RESECTABLE PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER|UNDIFFERENTIATED PANCREATIC CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,0,,_IRINOTECAN_HYDROCHLORIDE,,Terminated,NCT00100828,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,0,,_IRINOTECAN_HYDROCHLORIDE,,Withdrawn,NCT02575508,COLON ADENOCARCINOMA|METASTATIC PANCREATIC ADENOCARCINOMA|PANCREATIC ADENOCARCINOMA|PANCREATIC DUCTAL ADENOCARCINOMA|RECTAL ADENOCARCINOMA|STAGE III PANCREATIC CANCER|STAGE IIIA COLON CANCER|STAGE IIIA RECTAL CANCER|STAGE IIIB COLON CANCER|STAGE IIIB RECTAL CANCER|STAGE IIIC COLON CANCER|STAGE IIIC RECTAL CANCER|STAGE IV PANCREATIC CANCER|STAGE IVA COLON CANCER|STAGE IVA RECTAL CANCER|STAGE IVB COLON CANCER|STAGE IVB RECTAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,0,,_IRINOTECAN_HYDROCHLORIDE,,Withdrawn,NCT01473303,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
Cl.Cl.NCCNCCNCCN,0,,_TRIENTINE_HYDROCHLORIDE,5688516,Terminated,NCT01213888,DIABETIC RETINOPATHY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","Eye Care Centre - Vancouver Coastal Health, Vancouver, British Columbia, Canada",A61L29/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,37.5202776237705,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Cl.Cl.NCCNCCNCCN,0,,_TRIENTINE_HYDROCHLORIDE,5688516,Withdrawn,NCT01295073,MACULAR EDEMA FOLLOWING CATARACT SURGERY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center, Vancouver, British Columbia, Canada",A61L29/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,37.5202776237705,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O,0,,_DESVENLAFAXINE_SUCCINATE,US-20060223791-A1,Terminated,NCT01050218,"DIABETIC NEUROPATHY, PAINFUL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,32.7488,13.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC,0,,_SATAVAPTAN,,Terminated,NCT00728091,HYPONATREMIA|INAPPROPRIATE ADH SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21.O=P(O)(O)O.O=P(O)(O)O,0,,_MOTESANIB_DIPHOSPHATE,,Terminated,NCT00574951,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Lake/University Ireland Cancer Center, Mentor, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Harrington Cancer Center, Amarillo, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,0,,_GENTAMICIN,,Terminated,NCT02036528,DIABETIC FOOT ULCERS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital Center, Washington, District of Columbia, United States|GF Professional Research, Corp., Miami Lakes, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Advanced Foot and Ankle Institute of Georgia LLC, Smyrna, Georgia, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|Utah Valley Medical Center, Provo, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,0,,_GENTAMICIN,,Terminated,NCT00658957,DIABETIC FOOT ULCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Chesapeake Foot and Ankle Center, Pasadena, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl,0,,_ATRASENTAN_HYDROCHLORIDE,,Terminated,NCT00653328,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Georgia Hematology Oncology Associates, P.C., Macon, Georgia, United States|Kentuckiana Cancer Institute, Louisville, Kentucky, United States|The Jones Clinic, Germantown, Tennessee, United States|Jackson-Madison County Hospital, Jackson, Tennessee, United States|St. Thomas Health Services, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00482625,INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS|RECURRENT PANCREATIC CANCER|STAGE IA PANCREATIC CANCER|STAGE IB PANCREATIC CANCER|STAGE IIA PANCREATIC CANCER|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California Medical Center At Irvine-Orange Campus, Orange, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00470535,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00276744,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT02331251,ADVANCED CANCER|BREAST CANCER|SARCOMA|PANCREATIC CANCER|SMALL CELL LUNG CANCER|OVARIAN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States|Western Regional Medical Center, Goodyear, Arizona, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00583622,OVARIAN CANCER,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00303888,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00354601,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00833859,PANCREATIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00539968,PROSTATE CANCER|BREAST CANCER|OVARIAN CANCER|LUNG CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00004037,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Withdrawn,NCT02083536,OVARIAN CANCER|OVARIAN CARCINOMA|RECURRENT OVARIAN CANCER|RECURRENT OVARIAN CARCINOMA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT00002819,OVARIAN CANCER,Female,"up to 65 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Primary Purpose: Treatment,"Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Togus, Togus, Maine, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Vermont Cancer Center, Burlington, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Veterans Affairs Medical Center - Richmond, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States",7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00002819,OVARIAN CANCER,Female,"up to 65 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Primary Purpose: Treatment,"Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Togus, Togus, Maine, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Vermont Cancer Center, Burlington, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Veterans Affairs Medical Center - Richmond, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States",6,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00004221,MALIGNANT OVARIAN MIXED EPITHELIAL TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|PRIMARY PERITONEAL CARCINOMA|STAGE III OVARIAN CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01548573,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT02650635,COLORECTAL ADENOCARCINOMA|METASTATIC PANCREATIC ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT COLORECTAL CARCINOMA|RECURRENT MELANOMA OF THE SKIN|RECURRENT NON-SMALL CELL LUNG CARCINOMA|RECURRENT PANCREATIC CARCINOMA|RECURRENT RENAL CELL CARCINOMA|SOLID NEOPLASM|STAGE IV BREAST CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV RENAL CELL CANCER|STAGE IV SKIN MELANOMA|STAGE IVA COLORECTAL CANCER|STAGE IVA PANCREATIC CANCER|STAGE IVB COLORECTAL CANCER|STAGE IVB PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01312376,OVARIAN CARCINOMA|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00652899,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01583686,CERVICAL CANCER|PANCREATIC CANCER|OVARIAN CANCER|MESOTHELIOMA|LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT02465983,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT03563144,METASTATIC PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT00551265,FALLOPIAN TUBE CARCINOMA|PRIMARY PERITONEAL CARCINOMA|RECURRENT OVARIAN CARCINOMA|STAGE III OVARIAN CANCER|STAGE IV OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT02948101,RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT02390739,METASTATIC THYROID CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00091195,PRIMARY PERITONEAL CAVITY CANCER|RECURRENT OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"High Point Regional Hospital, High Point, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00084461,GASTRINOMA|GLUCAGONOMA|INSULINOMA|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|PANCREATIC POLYPEPTIDE TUMOR|PULMONARY CARCINOID TUMOR|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT ISLET CELL CARCINOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SOMATOSTATINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,0,,_STREPTOZOCIN,5691307,Terminated,NCT00609765,PANCREATIC CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,76.0,41.6271381342532,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00031837,PANCREATIC CANCER|THROMBOEMBOLISM,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|CCOP - Kansas City, Kansas City, Missouri, United States|CCOP - Hematology-Oncology Associates of Central New York, East Syracuse, New York, United States|University of Rochester Cancer Center CCOP Research Base, Rochester, New York, United States|CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, United States|CCOP - Columbus, Columbus, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Northwest, Tacoma, Washington, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00049608,BREAST CANCER|COLORECTAL CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00003378,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",C07D307/33,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT01282333,ADVANCED ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|REGIONAL TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|STAGE III BLADDER CANCER|STAGE III PANCREATIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV BLADDER CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV PANCREATIC CANCER|TRANSITIONAL CELL CARCINOMA OF THE BLADDER|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT01739439,ACINAR CELL ADENOCARCINOMA OF THE PANCREAS|DUCT CELL ADENOCARCINOMA OF THE PANCREAS|STAGE IIB PANCREATIC CANCER|STAGE III PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00003382,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Community Hospital of Los Gatos, Los Gatos, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States",C07D307/33,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00003851,MALNUTRITION|PANCREATIC CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT01025882,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT02383433,METASTATIC PANCREATIC ADENOCARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT02048943,"DUCT CELL ADENOCARCINOMA OF THE PANCREAS|RECURRENT PANCREATIC CANCER|STAGE III PANCREATIC CANCER|STAGE IV PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT00369954,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,C07D307/33,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT00253526,ADENOCARCINOMA OF THE PANCREAS|RECURRENT PANCREATIC CANCER|STAGE I PANCREATIC CANCER|STAGE II PANCREATIC CANCER|STAGE III PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Primary Purpose: Treatment,,C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00003382,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Community Hospital of Los Gatos, Los Gatos, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States",A61K49/0021,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00005612,OVARIAN CANCER,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",A61K49/0021,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00287859,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",A61K49/0021,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT02569957,MALIGNANT OVARIAN ENDOMETRIOID TUMOR|MALIGNANT OVARIAN SEROUS TUMOR|RECURRENT FALLOPIAN TUBE CARCINOMA|RECURRENT OVARIAN CARCINOMA|RECURRENT PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",A61K49/0021,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00004221,MALIGNANT OVARIAN MIXED EPITHELIAL TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|PRIMARY PERITONEAL CARCINOMA|STAGE III OVARIAN CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",A61K49/0021,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00005029,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler Air Force Base, Mississippi, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",A61K49/0021,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0,,_IMATINIB_MESYLATE,WO-2002018368-A1,Terminated,NCT00281996,PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0,,_IMATINIB_MESYLATE,WO-2002018368-A1,Terminated,NCT00042952,OVARIAN DYSGERMINOMA|RECURRENT MALIGNANT TESTICULAR GERM CELL TUMOR|RECURRENT OVARIAN GERM CELL TUMOR|STAGE II MALIGNANT TESTICULAR GERM CELL TUMOR|STAGE II OVARIAN GERM CELL TUMOR|STAGE III MALIGNANT TESTICULAR GERM CELL TUMOR|STAGE III OVARIAN GERM CELL TUMOR|TESTICULAR SEMINOMA,All,"15 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer and Leukemia Group B, Chicago, Illinois, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,,_PALONOSETRON_HYDROCHLORIDE,5202333,Terminated,NCT00903396,ANAL CANCER|CARCINOMA OF THE APPENDIX|COLORECTAL CANCER|EXTRAHEPATIC BILE DUCT CANCER|GALLBLADDER CANCER|GASTRIC CANCER|GASTROINTESTINAL CARCINOID TUMOR|LIVER CANCER|NAUSEA AND VOMITING|PANCREATIC CANCER|PRIMARY PERITONEAL CAVITY CANCER|SMALL INTESTINE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Bettendorf, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Wesley Medical Center, Wichita, Kansas, United States|Michiana Hematology Oncology PC - Niles, Niles, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fergus Falls Medical Group, PA, Fergus Falls, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare - La Crosse Campus, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Door County Cancer Center at Door County Memorial Hospital, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl,0,,_CINACALCET_HYDROCHLORIDE,WO-2006127933-A1,Terminated,NCT01439867,"CHRONIC KIDNEY DISEASE|HYPERPARATHYROIDISM, SECONDARY",All,up to 2189 Days   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Praha 5, Czechia|Research Site, Bron cedex, France|Research Site, Lille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Heidelberg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Genova, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Chihuahua, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Grafton, Auckland, New Zealand|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Kosice, Slovakia",A61P3/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,103.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_ROSIGLITAZONE_MALEATE,EP-0658161-B1,Terminated,NCT00612066,CUSHING'S DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,48.7566479804513,85.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_ROSIGLITAZONE_MALEATE,EP-0658161-B1,Terminated,NCT00616642,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,48.7566479804513,85.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0
CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl,0,,_DOXEPIN_HYDROCHLORIDE,4370324,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,28.2552003121213,135.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],0,,_FOSBRETABULIN_DISODIUM,WO-2000048606-A1,Terminated,NCT00077103,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,32.7488,13.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,0,,_GRANISETRON,4845092,Terminated,NCT01275664,NAUSEA AND VOMITING|OVARIAN BRENNER TUMOR|OVARIAN CLEAR CELL CYSTADENOCARCINOMA|OVARIAN ENDOMETRIOID ADENOCARCINOMA|OVARIAN MUCINOUS CYSTADENOCARCINOMA|OVARIAN SEROMUCINOUS CARCINOMA|OVARIAN SEROUS CYSTADENOCARCINOMA|STAGE II OVARIAN CANCER|STAGE IIA FALLOPIAN TUBE CANCER|STAGE IIA OVARIAN CANCER|STAGE IIB FALLOPIAN TUBE CANCER|STAGE IIB OVARIAN CANCER|STAGE IIC FALLOPIAN TUBE CANCER|STAGE IIC OVARIAN CANCER|STAGE IIIA FALLOPIAN TUBE CANCER|STAGE IIIA OVARIAN CANCER|STAGE IIIA PRIMARY PERITONEAL CANCER|STAGE IIIB FALLOPIAN TUBE CANCER|STAGE IIIB OVARIAN CANCER|STAGE IIIB PRIMARY PERITONEAL CANCER|STAGE IIIC FALLOPIAN TUBE CANCER|STAGE IIIC OVARIAN CANCER|STAGE IIIC PRIMARY PERITONEAL CANCER|STAGE IV FALLOPIAN TUBE CANCER|STAGE IV OVARIAN CANCER|STAGE IV PRIMARY PERITONEAL CANCER|UNDIFFERENTIATED OVARIAN CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States|Women and Infants Hospital, Providence, Rhode Island, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,17.478798332614602,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,0,,_ESCITALOPRAM_OXALATE,WO-2003011278-A1,Terminated,NCT00387348,COLORECTAL CANCER|DEPRESSION|ESOPHAGEAL CANCER|EXTRAHEPATIC BILE DUCT CANCER|FATIGUE|GALLBLADDER CANCER|GASTRIC CANCER|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER,All,"35 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Massachusetts General Hospital, Boston, Massachusetts, United States",A61P25/24 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.Cl,0,,_EPIRUBICIN_HYDROCHLORIDE,5977082,Terminated,NCT00003852,CHILDHOOD GERM CELL TUMOR|EXTRAGONADAL GERM CELL TUMOR|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"15 Years to 120 Years   (Child, Adult, Older Adult)",Other,Primary Purpose: Treatment,"Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,57.95601552393271,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT03225781,PANCREATIC CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Verona Hospital, Verona, Italy",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3cc(O)c4c(c3)O[C@H](c3ccc(O)c(O)c3)CC4=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,0,,_ERIOCITRIN,4617293,Terminated,NCT03925909,PRE DIABETES,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sao Paulo State University ""Julio de Mesquita Filho"", Araraquara, SP, Brazil",C07H17/065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.715168689295396,42.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,0,,_CYPROHEPTADINE_HYDROCHLORIDE,4913865,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.39109632641321,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Terminated,NCT00652899,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,0,,_MK-2206,US-20080161317-A1,Terminated,NCT01243762,NEOPLASMS MALIGNANT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,, A61P11/06 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,20.468592784246,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,0,,_SECRETIN,,Terminated,NCT00587132,PANCREATIC CANCER,All,"35 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,0,,_SECRETIN,,Terminated,NCT00621556,INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Massachusetts General Hospital, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,0,,_SECRETIN,,Withdrawn,NCT01094626,PANCREATIC CANCER|INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00310050,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00864513,PANCREAS CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT00310050,PANCREATIC CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN,,Terminated,NCT00429403,BREAST CANCER,Female,"15 Years to 46 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States|St. Luke's International Hospital, Tokyo, Japan",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O,0,,_BROMOCRIPTINE_MESYLATE,4366145,Terminated,NCT00441363,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,18.135896014291802,74.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
CC[C@H](C)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CO)NC(=O)[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CS)C(C)C)C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)O)C(C)C)C(C)C)C(C)C)[C@H](C)O,0,,_THYMOSIN,,Terminated,NCT00598871,DIABETES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","United Medical Research Institute, Inglewood, California, United States|Doheny Eye Institute, Los Angeles, California, United States|Magruder Eye Institue, Orlando, Florida, United States|Southeast Retina Center, Augusta, Georgia, United States|Western Carolina Retinal Associates, PA, Asheville, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0
CCc1c(C)c2cc3nc(cc4nc(cc5cc(C)c(cc1[nH]2)[nH]5)C(C)=C4CCC(=O)O)C(CCC(=O)O)=C3C,0,,_PHOTOFRIN,,Terminated,NCT01966809,"BRAIN TUMOR, RECURRENT",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,0,,_MORPHINE_SULFATE,4083982,Terminated,NCT00660348,PAIN|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,0,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Terminated,NCT00324324,BREAST CANCER|CHRONIC MYELOPROLIFERATIVE DISORDERS|GESTATIONAL TROPHOBLASTIC TUMOR|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUROBLASTOMA|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00428597,"CARCINOMA, ISLET CELL|CARCINOMA, PANCREAS",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Peters, Missouri, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Georgetown, Texas, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Perth, Western Australia, Australia|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Paris, Be1 05677, France|Pfizer Investigational Site, Paris, Cedex, France|Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Clichy Cedex, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Rennes Cedex, France|Pfizer Investigational Site, Bad Berka, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Luebeck, Germany|Pfizer Investigational Site, Marburg, Germany|Pfizer Investigational Site, Ulm, Germany|Pfizer Investigational Site, Cremona, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Rozzano (MI), Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Kwei-Shan, Taoyuan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Leeds, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O,0,,_GALACTOSE,3933788,Terminated,NCT00427986,DIABETIC MACULAR OEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57,, Glostrup, Denmark",C12P21/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,30.817881270662603,12433.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)(CO)C(O)C(=O)NCCCO,0,,_PANTHENOL,4416873,Terminated,NCT01531517,DIABETIC FOOT ULCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alexandria University Hospitals, Alexandria, Egypt|Cairo University Hospitals, Alexandria, Egypt",A61Q19/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,11.3020801248485,2379.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0
COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,0,,_VOLINANSERIN,WO-1999046245-A2,Terminated,NCT00464061,SLEEP INITIATION AND MAINTENANCE DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Berlin, Germany|Anofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,80.0,32.7488,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1.C[C@H](O)C(=O)O.O,0,,_DOVITINIB_LACTATE,,Withdrawn,NCT02108782,GASTRINOMA|GLUCAGONOMA|INSULINOMA|PANCREATIC POLYPEPTIDE TUMOR|RECURRENT ISLET CELL CARCINOMA|SOMATOSTATINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1.C[C@H](O)C(=O)O.O,0,,_DOVITINIB_LACTATE,,Withdrawn,NCT02048943,"DUCT CELL ADENOCARCINOMA OF THE PANCREAS|RECURRENT PANCREATIC CANCER|STAGE III PANCREATIC CANCER|STAGE IV PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)C(c1ccc(F)cc1)c1ccc(F)cc1,0,,_DENAGLIPTIN,EP-1406873-B1,Withdrawn,NCT00387972,TYPE 2 DIABETES,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Clinical Trials Call Center, Tallassee, Alabama, United States|GSK Clinical Trials Call Center, Phoenix, Arizona, United States|GSK Clinical Trials Call Center, Tucson, Arizona, United States|GSK Clinical Trials Call Center, Beverly Hills, California, United States|GSK Clinical Trials Call Center, Carmichael, California, United States|GSK Clinical Trials Call Center, Concord, California, United States|GSK Clinical Trials Call Center, Torrance, California, United States|GSK Clinical Trials Call Center, Victorville, California, United States|GSK Clinical Trials Call Center, Wilmington, Delaware, United States|GSK Clinical Trials Call Center, Boynton Beach, Florida, United States|GSK Clinical Trials Call Center, Clearwater, Florida, United States|GSK Clinical Trials Call Center, Coral Gables, Florida, United States|GSK Clinical Trials Call Center, Hialeah, Florida, United States|GSK Clinical Trials Call Center, Hollywood, Florida, United States|GSK Clinical Trials Call Center, Melbourne, Florida, United States|GSK Clinical Trials Call Center, Miami, Florida, United States|GSK Clinical Trials Call Center, Opalocka, Florida, United States|GSK Clinical Trials Call Center, Plantation, Florida, United States|GSK Clinical Trials Call Center, Tampa, Florida, United States|GSK Clinical Trials Call Center, Calhoun, Georgia, United States|GSK Clinical Trials Call Center, Roswell, Georgia, United States|GSK Clinical Trials Call Center, Hayden Lake, Idaho, United States|GSK Clinical Trials Call Center, Chicago, Illinois, United States|GSK Clinical Trials Call Center, Chicago, Illinois, United States|GSK Clinical Trials Call Center, Lake Zurich, Illinois, United States|GSK Clinical Trials Call Center, Watseka, Illinois, United States|GSK Clinical Trials Call Center, Baton Rouge, Louisiana, United States|GSK Clinical Trials Call Center, Marrero, Louisiana, United States|GSK Clinical Trials Call Center, Oxon Hill, Maryland, United States|GSK Clinical Trials Call Center, Detroit, Michigan, United States|GSK Clinical Trials Call Center, Florissant, Missouri, United States|GSK Clinical Trials Call Center, St. Louis, Missouri, United States|GSK Clinical Trials Call Center, St. Peters, Missouri, United States|GSK Clinical Trials Call Center, Las Vegas, Nevada, United States|GSK Clinical Trials Call Center, Williamsville, New York, United States|GSK Clinical Trials Call Center, Charlotte, North Carolina, United States|GSK Clinical Trials Call Center, Morehead City, North Carolina, United States|GSK Clinical Trials Call Center, Fargo, North Dakota, United States|GSK Clinical Trials Call Center, Cincinnati, Ohio, United States|GSK Clinical Trials Call Center, Columbus, Ohio, United States|GSK Clinical Trials Call Center, Guthrie, Oklahoma, United States|GSK Clinical Trials Call Center, Norman, Oklahoma, United States|GSK Clinical Trials Call Center, Oklahoma City, Oklahoma, United States|GSK Clinical Trials Call Center, Oklahoma City, Oklahoma, United States|GSK Clinical Trials Call Center, Yukon, Oklahoma, United States|GSK Clinical Trials Call Center, Eugene, Oregon, United States|GSK Clinical Trials Call Center, Medford, Oregon, United States|GSK Clinical Trials Call Center, Beaver Falls, Pennsylvania, United States|GSK Clinical Trials Call Center, Fleetwood, Pennsylvania, United States|GSK Clinical Trials Call Center, Warminster, Pennsylvania, United States|GSK Clinical Trials Call Center, Anderson, South Carolina, United States|GSK Clinical Trials Call Center, Chattanooga, Tennessee, United States|GSK Clinical Trials Call Center, Johnson City, Tennessee, United States|GSK Clinical Trials Call Center, Cleburne, Texas, United States|GSK Clinical Trials Call Center, San Antonio, Texas, United States|GSK Clinical Trials Call Center, Seguin, Texas, United States|GSK Clinical Trials Call Center, Weber City, Virginia, United States",C07D207/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,63.01566767284739,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],0,,_FONDAPARINUX,,Withdrawn,NCT00659399,OVARIAN CARCINOMA,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute Clinical Cancer Center, New York, New York, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O.C[C@H](O)C(=O)O.O,0,,_SQUALAMINE_LACTATE,,Withdrawn,NCT02349516,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NJ Retina, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,0,,_DIPHENHYDRAMINE_HYDROCHLORIDE,3934576,Withdrawn,NCT00837941,PAINFUL DIABETIC NEUROPATHY,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M39/223,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,26.415326803425106,4425.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,,_FULVESTRANT,,Withdrawn,NCT03197584,OVARIAN CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1.O=S(=O)(O)O,0,,_BLEOMYCIN_SULFATE,,Withdrawn,NCT00027521,PANCREATIC CANCER,All,"Child, Adult, Older Adult",Industry|NIH,Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,0,,_OMEPRAZOLE,,Withdrawn,NCT01762644,TYPE 1 DIABETES,All,"10 Years to 20 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,0,,_OMEPRAZOLE,,Withdrawn,NCT03291249,NASH - NONALCOHOLIC STEATOHEPATITIS|NAFLD|T2DM (TYPE 2 DIABETES MELLITUS),All,"18 Years to 120 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Withdrawn,NCT02289144,"METASTATIC ANAPLASTIC THYROID CANCER|LOCALLY ADVANCED ANAPLASTIC, UNDIFFERENTIATED THYROID CANCER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,0,,_ENCLOMIPHENE_CITRATE,4729999,Withdrawn,NCT02160704,INFERTILITY,Male,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Baylor College of Medicine, Houston, Texas, United States",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,40.8386209162405,179.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,,_ERIBULIN,,Withdrawn,NCT03032614,BREAST CANCER STAGE IV|OVARIAN CANCER|BRCA1 MUTATION|BRCA2 MUTATION,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,0,,_LUNACALCIPOL,,Withdrawn,NCT01453634,STAGE 5 CHRONIC KIDNEY DISEASE (CKD)|SECONDARY HYPERPARATHYROIDISM (SHPT)|HEMODIALYSIS (HD),All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0
CCCCCC(=O)N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@H]3[C@](C)(C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](O)C[C@H]1OC[C@]13OC(C)=O,0,,_TAXOL_C,5475120,Withdrawn,NCT01606358,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"CHU de RENNES, Rennes, France",C07C69/00,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,13.3062280539641,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,1
CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1,0,,_IBIPINABANT,WO-2006045799-A2,Withdrawn,NCT00541567,OBESITY AND TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,53.0,32.7488,38.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
